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Abstract	
Background:	Traumatic	brain	injury	(TBI)	is	a	major	cause	of	psychological	and	
cognitive	disability	in	young	adults	in	the	developed	world.	The	prognosis	for	these	
patients	is	uncertain.	Neuroinflammation	may	be	an	important	underlying	
mechanism.	Growth	hormone	deficiency	(GHD)	is	a	recognised	consequence	of	TBI	
and	may	influence	recovery.	The	metabolic	syndrome,	a	state	of	insulin	resistance,	
may	also	influence	outcome	from	TBI.		
	
Objectives:	i)	To	study	the	prevalence	and	consequences	of	pituitary	dysfunction	in	
soldiers	who	have	suffered	a	blast	TBI	(bTBI)	ii)	To	investigate	the	effect	of	GH	
deficiency	and	serum	IGF-I	levels	on	recovery	from	TBI	iii)To	evaluate	a	new	positron	
emission	tomography	(PET)	radioligand	[18F]GE-180	purported	to	measure	TSPO	
neuroinflammation	in	the	healthy	human	brain	iv)	To	quantify	neuroinflammation	
using	[18F]GE-180	in	patient	following	TBI	and	correlate	with	metabolic	factors.		
	
Methods:	i)	Cross-sectional	comparative	study	of	19	soldiers	with	bTBI	vs.	39	civilians	
with	non-blast	TBI.	Full	endocrine	testing,	neuropsychological	testing,	diffusion	
tensor	imaging	(DTI)	ii)	Longitudinal	study	of	39	patients	following	TBI;	IGF-I	and	GHD	
testing	at	baseline,	DTI	and	neuropsychological	testing	at	two	study	visits	designed	
to	be	one	year	apart.	Intervention	study	of	10	patients	with	GHD	pre-	and	post-	1	
year	of	GH	replacement	therapy	iii)	Cross-sectional	PET	study	using	[18F]GE-180	in	10	
healthy	volunteers	iv)	Longitudinal	[18F]GE-180	PET	study	in	12	patients	following	
TBI:	MRI,	PET,	neuropsychological	and	metabolic	testing	at	two	visits	6	months	apart.	
	
Results:	i)	Higher	prevalence	of	pituitary	dysfunction	in	bTBI	(31.6%)	compared	to	
nbTBI	(2.6%),	P	=0.004	ii)	Greater	improvement	in	fractional	anisotropy	(FA)	in	
patients	with	a	higher	IGF-I	at	baseline,	in	the	splenium	of	the	corpus	callosum	
(SPCC)	and	in	logical	memory	scores;	no	effect	of	GH	replacement	per	se	seen	on	
WM	recovery	or	memory,	but	significant	improvement	in	QoL	and	depression	scores	
iii)	Low	brain	uptake	of	[18F]GE-180	in	healthy	volunteers,	two	compartmental	4K-fix	
(2TC)	model	provided	best	fit	of	the	data,	no	effect	of	TSPO	polymorphism	seen	iv)	
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no	significant	effect	of	genotype	seen	in	TBI	patients	or	in	outcome	measures	
between	patients	and	controls.	
	
Conclusions	
i)	Novel	finding	of	greater	prevalence	of	pituitary	dysfunction	in	patients	with	bTBI	ii)	
IGF-I,	irrespective	of	the	presence	of	GHD,	improves	WM	recovery	in	the	SPCC	and	
memory	iii)	GH	replacement	does	not	influence	cognition	or	brain	structure	in	this	
study	but	did	improve	quality	of	life	iv)	The	TSPO	ligand	[18F]GE-180	appears	to	be	
limited	by	poor	brain	uptake	v)	the	2TC-fix	model	provides	the	best	model	fit	iv)	
distribution	volumes	are	low	and	there	appears	to	be	no	effect	of	the	TSPO	
polymorphism	on	PET	outcome	measures	in	patients	with	TBI	and	controls.	
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1 Introduction		
1.1 Background		
1.1.1 Definition	of	traumatic	brain	injury	(TBI)	
	
The	most	recent	definition	of	TBI	was	formulated	by	the	Woking	Group	on	
Demographics	and	Clinical	Assessment	of	the	International	Interagency	Initiative	
toward	Common	Data	Elements	for	Research	in	TBI	and	Psychological	Health	in	2010	
(Menon,	Schwab,	Wright,	&	Maas,	2010).	Their	definition	is	as	follows:	
	
“An	alteration	in	brain	function	or	other	evidence	of	brain	pathology	
caused	by	an	external	force”	
	
Other	definitions	of	TBI	have	been	proposed	from	the	American	Congress	of	
Rehabilitation	Medicine	(ARCM)	(Medicine,	1993)	and	the	WHO	Task	Force	(Carroll,	
Cassidy,	Holm,	Kraus,	&	Coronado,	2004),	however	these	definitions	have	been	
criticised	for	focussing	on	mild	TBI	and	for	not	acknowledging	blast	injuries	as	an	
important	cause	of	TBI		(Roozenbeek,	Maas,	&	Menon,	2013).		
	
Hence	the	list	of	external	forces	defined	in	the	Common	Data	Elements	definition	
now	include:	‘the	head	being	struck;	the	head	striking	an	object;	the	brain	
undergoing	an	acceleration-deceleration	movement	without	direct	external	trauma	
to	the	head;	a	foreign	body	penetrating	the	brain;	forces	generated	from	events	such	
as	a	blast	or	explosion;	and	other	force	yet	to	be	defined.”	
	
An	“alteration	in	brain	function”	is	defined	as	1	of	the	following	clinical	signs:	
	
i) Any	period	of	loss	of	or	a	decreased	consciousness	level.	
ii) Any	loss	of	memory	for	events	immediately	before	(retrograde	
amnesia)	or	after	the	injury	(PTA).	
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iii) Neurologic	deficits	(weakness,	loss	of	balance,	change	in	vision,	
dyspraxia,	paresis/plegia,	sensory	loss,	aphasia)	
iv) Any	alteration	in	mental	state	at	the	time	of	the	injury	(confusion,	
disorientation,	slowed	thinking).	
	
The	definition	recognises	that	factors	other	than	TBI	may	be	responsible	for	
alterations	in	mental	state	at	the	time	of	the	injury	(e.g.	alcohol/recreational	drug	
use,	medication,	pain	and	post-traumatic	shock)	but	this	should	not	preclude	a	
diagnosis	of	TBI	(Menon	et	al.,	2010).	
	
1.1.2 Epidemiology	
	
TBI	is	global	public	health	problem	and	is	a	major	cause	of	death	and	lifelong	
disability	in	those	who	survive.	There	are	approximately	5.3	million	people	in	the	
USA	who	live	with	a	disability	related	to	TBI	(Langlois	&	Sattin,	2005)	and	
approximately	7	million	individuals	in	the	European	Union	(Brazinova	et	al.,	2015).	
This	accounts	for	approximately	15%	of	the	burden	of	death	and	disability	
worldwide.	The	World	Health	Organisation	(WHO)	projects	this	to	rise	to	20%	in	
2020	(Finfer	&	Cohen,	2001).	
	
The	incidence	of	TBI	(all	severity)	hospitalisations	in	England	in	2002	was	229	per	
100,000	(Tennant,	2005)	which	is	similar	to	the	incidence	of	stroke	in	European	
populations	(Carolei	et	al.,	1997).	The	incidence	was	found	to	vary	considerably	with	
age	and	geography.	31%	were	aged	between	0-15	yrs.;	56%	were	aged	16-74	and	
13%	were	aged	75	yrs.	and	over.	The	highest	incidence	was	found	in	Liverpool	(419	
per	100,000)	and	the	lowest	in	Brent	and	Harrow	(91	per	100,000)	(Tennant,	2005).		
	
Regarding	the	incidence	of	TBI	by	severity,	a	multicentre	study	in	Scotland	found	that	
90%	of	their	TBI	admissions	were	classified	as	‘mild’	(GCS	13-15),		5%	‘moderate’	
(GCS	9-12)	and	3%	‘severe’	(GCS	3-8).	However,	initial	severity	was	not	related	to	
disability	at	1	year	follow-up,		and	occurred	in	nearly	half	of	each	severity	group	
(mild	47%,	moderate	45%,	severe	48%)		(Thornhill	et	al.,	2000).	
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1.1.3 Aetiology		
Data	from	the	International	Mission	on	Prognosis	and	Analysis	of	Clinical	Trials	in	TBI	
(IMPACT)	database	gives	important	aetiological	information.	Road	traffic	accidents	
(RTA)	are	the	leading	cause	of	all	TBI	accounting	for	64.1%	of	cases,	followed	by	falls	
(19.3%),	‘other’	(6.9%),	assault	(5.1%),	work-related	(2.6%)	and	sports/recreation	
(2.0%).	RTA	included	all	accidents	on	the	street,	including	those	in	motor	vehicles,	on	
bicycles	and	as	pedestrians	and	the	group	‘falls’	included	those	that	had	taken	place	
in	a	domestic	setting	as	well	as	those	under	the	influence	of	alcohol	(Butcher	et	al.,	
2007).	Falls	were	associated	with	a	poorer	outcome	but	this	was	explained	by	the	
older	age	of	the	patients.	
	
Age	and	gender	are	other	important	aetiological	factors.	TBI	is	most	common	in	very	
young	children	(aged	0-4	yrs.)	and	in	adolescence	and	young	adulthood	(age	15-24	
yrs.)	with	a	subsequent	peak	in	incidence	in	older	adults	i.e.	over	65	yrs.	of	age	
(Thornhill	et	al.,	2000;	Thurman,	Branche,	&	Sniezek,	1998).	Older	people	have	the	
highest	rates	of	TBI-related	hospitalisations	and	deaths	.	Male	to	female	ratio	in	all	
subgroups	of	TBI	is	approximately	3:1	and	mortality	rates	and	complications	tend	to	
be	greater	in	men	compared	to	women	(Berry	et	al.,	2009).	
	
Alcohol	consumption	is	strongly	associated	with	TBI	occurrence.	Several	studies	
across	Europe	have	reported	alcohol	intoxication	to	be	a	factor	in	25-50%	of	TBI	
cases	and	the	association	is	stronger	in	males	versus	females	(Tagliaferri,	
Compagnone,	Korsic,	Servadei,	&	Kraus,	2006).		
	
Sports-related	injuries	account	for	a	significant	proportion	of	TBI	with	approximately	
300,000	of	these	types	of	injuries	in	the	United	States	each	year	(Thurman	et	al.,	
1998).	Blast	TBI	(bTBI)	from	improvised	explosive	devices	(IEDs)	also	contribute	
significantly	to	the	global	burden	of	TBI.	Estimates	of	bTBI	from	the	Iraq	and	
Afghanistan	conflicts	have	been	as	high	as	320,000	US	military	personnel	(Tanielian	
T,	2012).	
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1.1.4 Clinical	consequences	and	economic	impact	
	
TBI	is	a	heterogeneous	condition	that	can	lead	to	a	wide	variety	of	clinical	
consequences;	ranging	from	death	or	coma	to	disabling	neurological,	cognitive	and	
psychiatric	symptoms.	Pituitary	dysfunction	is	also	an	important	clinical	consequence	
that	will	be	discussed	later.	
	
In	survivors	of	TBI,	disability	is	reported	in	50%	at	one	year	with	similar	proportions	
at	5-7	years	after	TBI	and	12-14	years	(same	cohort)	(McMillan,	Teasdale,	&	Stewart,	
2012;	Thornhill	et	al.,	2000;	Whitnall,	McMillan,	Murray,	&	Teasdale,	2006).	The	
presence	of	reported	disability	at	one	year	is	a	particularly	bad	prognostic	factor	
with	80%	either	deceased	or	disabled	at	12-14	years.	These	three	observational	
studies	also	provide	evidence	for	change	in	disability	over	time	with	between	one	
quarter	and	a	third	reporting	an	improvement	in	disability	over	time.	
	
Neurological	consequences	(particularly	pertaining	to	moderate	and	severe	TBI)	
include	post-traumatic	epilepsy,	parkinsonism,	Dementia	of	the	Alzheimer’s	type,	
Dementia	pugilistica	(in	boxing	only),	Benign	Paroxysmal	Positional	Vertigo	(BPPV),	
anosmia	and	ocular/visual	motor	deterioration	(Bazarian,	Cernak,	Noble-Haeusslein,	
Potolicchio,	&	Temkin,	2009).	
	
In	patients	who	may	otherwise	have	a	full	neurological	they	may	still	suffer	from	
disabling	cognitive	symptoms.	Executive	functions	such	reasoning,	mental	flexibility,	
concept	formation	and	self-monitoring	are	particularly	vulnerable	in	TBI	due	to	the	
high	prevalence	of	frontal	lobe	injury	and	can	have	a	devastating	effect	on	job	
performance	activities	of	daily	living	(ADLs)	(McDonald,	Flashman,	&	Saykin,	2002).	
Impairments	in	short-term	memory	and	speed	of	information	processing	are	also	
commonly	reported	following	TBI	(Draper	&	Ponsford,	2008;	Kinnunen	et	al.,	2011;	
Scheid,	Walther,	Guthke,	Preul,	&	von	Cramon,	2006).	
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Patients	can	also	experience	troubling	neuropsychiatric	symptoms	following	a	TBI.	
Symptoms	of	anxiety	and	depression	are	common	along	with	personality	changes	
that	include	disinhibition,	aggression	and	apathy	(Arnould,	Rochat,	Azouvi,	&	Van	der	
Linden,	2015;	Fleminger,	2008).	Post-traumatic	stress	disorder	(PTSD),	substance	
abuse	and	even	psychosis	can	all	be	attributed	to	a	TBI	(Bryant	et	al.,	2010).	A	
multicentre	study	(n=592)	found	that	6	years	after	a	severe	injury	28%	of	patients	
met	criteria	for	at	least	1	psychiatric	disorder,	the	most	common	being	a	major	
depressive	episode	(11%)	followed	by	substance	use	disorder	(9%),	PTSD	(6%)	and	
generalised	anxiety	disorder	(6%)	(O'Donnell	et	al.,	2016).	
	
Hypopituitarism	is	also	a	recognised	phenomenon	following	TBI.	Initial	studies	
reported	prevalence	rates	of	up	to	90%	but	more	recent	studies	using	robust	testing	
approaches	and	stricter	inclusion	criteria	report	prevalence	rates	of	5-10%	(Klose	et	
al.,	2014;	Kokshoorn	et	al.,	2011).	Growth	hormone	deficiency	is	the	most	commonly	
reported	deficiency,	followed	by	ACTH	and	gonadotrophin	deficiencies.	TSH	
deficiency	is	very	unusual	and	permanent	diabetes	insipidus	is	also	rare	(Capatina,	
Paluzzi,	Mitchell,	&	Karavitaki,	2015;	Kokshoorn	et	al.,	2011).	Untreated	post-
traumatic	hypopituitarism	is	associated	with	impaired	lipid	profile,	unfavourable	
body	composition	and	decreased	quality	of	life	one	year	after	injury	(Klose,	Watt,	
Brennum,	&	Feldt-Rasmussen,	2007).	Growth	hormone	deficiency	in	particular	is	
associated	with	impaired	cognition	that	is	partially	reversible	with	GH	replacement	
(High	et	al.,	2010).	
	
The	economic	impact	of	TBI	is	considerable.	The	total	direct	and	indirect	costs	of	TBI	
in	2010	in	the	UK	was	approximately	5.5	billion	Euros	(Fineberg	et	al.,	2013)	and	in	
Europe	64	billion	Euros	(Gustavsson	et	al.,	2011).	Data	from	the	Trauma	Audit	
Research	Network	estimate	that	the	mean	cost	of	hospital	stay	per	patient	with	TBI	
was	£15,462	and	this	figure	varied	by	severity	of	injury,	associated	injuries,	patients	
aged	45-64	years,	length	of	stay	in	critical	care	and	overall	length	of	stay(Morris,	
Ridley,	Lecky,	Munro,	&	Christensen,	2008).	
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1.1.5 Pharmacotherapies	in	post-acute	TBI	
	
Since	this	thesis	deals	with	the	post-acute	(i.e.	>6	weeks	from	injury)	sequelae	from	
TBI,	I	shall	briefly	review	here	the	medical	therapies	used	to	treat	the	most	common	
symptoms	in	the	post-acute	phase	of	a	TBI	namely;	memory	and	attention	
impairment,	sleep	disturbance,	headache	and	depression.	(Bhatnagar,	Iaccarino,	&	
Zafonte,	2016).	The	evidence	base	for	cognitive	rehabilitation	and	other	non-medical	
interventions	will	not	be	reviewed	here.	Pituitary	dysfunction	and	its	treatment	will	
be	reviewed	separately	on	page	39.	
	
1.1.6 Sleep	disturbance		
The	sleep-wake	cycle	is	commonly	disturbed	following	a	TBI.	A	meta-analysis	
reported	that	25-29%	of	patients	have	a	diagnosed	sleep	disorder	(insomnia,	
hypersomnia,	apnoea)	and	50%	report	some	form	of	sleep	disturbance	(Mathias	&	
Alvaro,	2012).	Whilst	the	diagnosis	and	treatment	of	apnoea	is	a	separate	entity,	the	
management	of	sleep	disturbance	in	general	is	challenging.	Sleep	hygiene	
counselling	can	help	as	can	cognitive	behavioural	therapy.	
	
Melatonin	is	a	hormone	produced	by	the	pineal	gland	that	is	involved	in	the	
circadian	regulation	of	sleep-wakefulness.	Patients	with	TBI	have	significantly	lower	
levels	of	evening	melatonin	(Shekleton	et	al.,	2010)	and	in	a	single	cross-over	study,	
patients	reported	improved	day-time	alertness	on	melatonin,	and	increased	sleep	
duration	on	amitriptyline	(Kemp,	Biswas,	Neumann,	&	Coughlan,	2004).	Modafinil	
has	been	used	in	the	treatment	of	daytime	somnolence	and	has	shown	some	
efficacy	at	higher	doses	(250mg)	(Menn,	Yang,	&	Lankford,	2014).	The	mechanism	of	
action	is	not	clear.		
	
Other	drugs	such	as	benzodiazepines,	hypnotics,	trazadone	and	prazosin	have	
theoretical	applications	to	sleep	disturbance	following	TBI,	although	their	use	has	
not	been	well-studied	in	TBI	populations	and	may	be	limited	by	side-effects	such	as	
impaired	cognition	and	drowsiness.		
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1.1.7 Headache		
Headaches	are	very	common	following	a	TBI	and	can	take	various	forms	i.e.	
cervicogenic,	migraine-like,	tension-type	and	neuralgic	(related	to	the	greater	or	
lesser	occipital	nerves)	(A.	W.	Brown	et	al.,	2015).	Several	underlying	mechanisms	for	
the	development	of	headache	following	TBI	have	been	proposed	including	changes	
in	cerebral	blood	flow,	decrease	in	glucose	metabolism	and	disturbances	in	release	
of	inhibitory	neurotransmitters	(Solomon,	2009).		
	
Treatment	of	headache	following	TBI	is	similar	to	treatment	of	headache	more	
generally.	Symptomatic	treatment	includes	NSAIDs,	paracetamol,	triptan	medication	
and	antiemetic	medications	if	necessary.	To	avoid	headache	induction	by	medication	
over-use,	these	treatments	should	be	restricted	to	2-3	days	of	the	week	or	10	days	in		
month	(Bhatnagar	et	al.,	2016).	Headache	prophylaxis	in	the	form	of	beta-blockers,	
antiepileptic	and	antidepressant	agents	may	also	be	warranted.	Post-traumatic	
headache	may	also	be	treated	with	occipital	nerve	blocks	and	onabotulinum	toxin	A	
has	shown	some	efficacy	in	mild	bTBI	(Yerry,	Kuehn,	&	Finkel,	2015).	
	
1.1.8 Impaired	information	processing		
Deficits	in	information	processing	and	attention	are	common	consequences	
following	a	TBI	(Draper	&	Ponsford,	2008).	Dopamine,	noradrenaline	and	
acetylcholine	have	all	been	implicated	in	attentional	neural	pathways	and	have	all	
been	targets	for	therapeutic	intervention.	Methylphenidate	is	a	noradrenaline	and	
dopamine	reuptake	inhibitor	and	is	the	most	commonly	studied	therapy	in	this	
domain.	Several	studies	have	reported	benefit	in	processing	speed	following	TBI	but	
mixed	results	for	other	cognitive	domains	(McAllister	et	al.,	2016;	Sivan,	Neumann,	
Kent,	Stroud,	&	Bhakta,	2010;	Whyte	et	al.,	2004;	Willmott	&	Ponsford,	2009).	
Studies	to	evaluate	the	effect	of	bromocriptine,	atomoxetine,	amantadine	on	
information	processing	speed	have	shown	no	effect	(Ripley	et	al.,	2014;	Sivan	et	al.,	
2010;	Whyte	et	al.,	2008),	while	donepezil	and	lisdexamfetamine	dimesylate	(a	
neurostimulant)	have	demonstrated	a	positive	effect,	although	more	studies	are	
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needed	(Tramontana,	Cowan,	Zald,	Prokop,	&	Guillamondegui,	2014;	Whyte	et	al.,	
2004).	
	
1.1.9 Memory			
Targeted	pharmacotherapy	to	improve	memory	is	not	commonplace	in	the	TBI	clinic.		
Animal	studies	have	reported	mixed	effects	of	donepezil	on	memory	following	a	TBI	
(Shaw	et	al.,	2013;	Yu,	Kim,	&	Kernie,	2015).	In	humans,		a	small	trial	and	case	series	
of	donepezil	following	TBI	improved	measures	of	memory	(Trovato,	Slomine,	
Pidcock,	&	Christensen,	2006;	Zhang,	Plotkin,	Wang,	Sandel,	&	Lee,	2004)	and	a	
multicentre	placebo	controlled	study	to	evaluate	memory	remediation	following	TBI	
is	actively	recruiting	at	present.	Rivastigmine,	an	agent	used	in	AD,	has	shown	little	
promise	in	memory	impairment	following	TBI	(Silver	et	al.,	2009;	Tenovuo,	Alin,	&	
Helenius,	2009).	
	
1.1.10 	Depression			
There	is	a	30%	risk	of	developing	depression	for	up	to	5	years	following	TBI	and	
severity	of	injury	does	not	seem	to	be	a	particular	risk	factor	(Guillamondegui	et	al.,	
2011;	Osborn,	Mathias,	&	Fairweather-Schmidt,	2014).	Suicide	is	3-4	times	more	
common	than	in	the	general	population	(Gordon	et	al.,	2006).	Selective	serotonin	
reuptake	inhibitors	e.g.	citalopram	and	sertralline	are	considered	first	line	treatment	
for	depression	following	TBI	based	on	limited	but	supportive	evidence	in	the	
literature	(Ashman	et	al.,	2009;	Rapoport	et	al.,	2008;	Rapoport	et	al.,	2010).	In	the	
absence	of	TBI-specific	studies,	the	management	of	depression	beyond	first-line	
treatment	is	akin	to	the	general	management	of	depression	outside	of	TBI.	
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1.2 Pathophysiology	of	TBI	
	
There	are	a	variety	of	different	types	of	cellular	injury	following	TBI	that	can	broadly	
be	classified	into	focal	injuries	(contusions,	intraparenchymal	haematomas,	subdural	
and	epidural	haematomas).	Traumatic	subarachnoid	haemorrhage	(SAH)	can	also	be	
the	result	of	focal	damage.	Diffuse	axonal	injury	(DAI)	results	predominantly	from	
rapid	acceleration-deceleration	of	the	head	and	is	described	in	more	detail	below.	
	
1.2.1 Focal	injuries	
	
Focal	brain	damage	results	from	collision	forces	acting	on	the	skull,	causing	
compression	of	the	tissue	under	the	cranium.	Damage	can	occur	at	the	site	of	impact	
(coup)	or	opposite	to	site	of	impact	(contre-coup)	(Pudenz	&	Shelden,	1946).	The	
most	common	type	of	focal	brain	injury	is	a	contusion.	These	are	localised	areas	of	
damage	that	result	from	the	primary	traumatic	insult	followed	by	the	activation	of	
several	cellular	pathways	(dysregulation	of	cerebral	blood	flow,	reduction	in	nitric	
oxide,	accumulation	of	lactic	acid,	oedema	and	glutamate	release),	ultimately	
leading	to	neuronal	apoptosis	(Werner	&	Engelhard,	2007).	
	
1.2.2 Diffuse	injuries	
	
Diffuse	brain	injury	consists	of	widespread	damage	to	axons,	diffuse	vascular	injury	
(causing	microbleeds),	oedema	formation	and	hypoxic-ischaemic	injury.	It	is	thought	
to	result	from	rapid	acceleration	and	deceleration	forces,	typically	resulting	from	
high	speed	RTAs	(Gennarelli,	1983).	When	subjected	to	such	forces,	brain	segments	
move	at	variable	rates	causing	additional	shear	and	compressive	forces	within	the	
brain	parenchyma	(Gentry,	Godersky,	&	Thompson,	1988).	Axonal	injury	was	first	
reported	by	Strich	in	1956	and	described	as	the	diffuse	degeneration	of	the	white	
matter	of	the	cerebral	hemispheres	(Strich,	1956).	Later	the	term	‘diffuse	axonal	
injury’	was	defined	as	its	own	entity	with	three	grades	of	severity	relating	to	lobar	
injury	only	(grade	1),	additional	injuries	in	the	corpus	callosum	(grade	2)	and	further	
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additional	injuries	in	the	brainstem	(grade	3)	(Adams	et	al.,	1989).	Examples	of	focal	
and	diffuse	injuries	are	depicted	in	Figure	1-1	and	the	neuropathological	features	of	
DAI	in	Figure	1-2	.	
	
Figure	1-1	Focal	and	diffuse	TBI.	Examples	of	focal	and	diffuse	TBI	on	CT	(rows	1	
and	2)	and	MRI	(row	3).	
	
	
Focal	injury:	(A)	Left	frontal	contusion	with	midline	shift	to	the	right	and	compression	of	the	lateral	
ventricles.	(B)	Right	frontal	epidural	haematoma	with	midline	shift	to	the	left	and	compression	of	the	
anterior	part	of	the	lateral	ventricle.	(C)	Right	frontotemporoparietal	subdural	haematoma	with	a	
midline	shift	to	the	left.	Diffuse	injury:	(D)	Punctate	haemorrhage	within	the	right	posterior	limb	of	the	
internal	capsule,	a	sign	of	DAI;	(E)	Diffuse	SAH;	(F)	Diffuse	swelling	with	bilateral	compression	of	the	
basal	cisterns.	DAI	on	MRI:	Susceptibility	weighted	images	of	one	patient	revealing	punctate	
haemorrhages	(hypo-intense	foci)	within	(G)	the	right	frontal	hemisphere,	(H)	Splenium	of	the	corpus	
callosum,	and	(I)	mesencephalon,	corresponding	to	grade	3	DAI.	Reproduced	with	permission	from	
(Andriessen,	Jacobs,	&	Vos,	2010)	
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Figure	1-2	Typical	neuropathological	appearance	of	diffuse	axonal	injury.	
	
	
A)	Grade	2	DAI:	lesions	in	corpus	callosum	and	B)	Grade	3	DAI:	lesions	also	in	brain	stem	
(right	image).	Reproduced	with	permission	from	(Adams	et	al.,	1989)	
	
1.3 Structural	Imaging	Techniques	in	TBI		
	
This	section	of	the	Introduction	will	describe	the	principles	of	the	structural	imaging	
techniques	used	in	this	thesis.	
	
1.3.1 Principles	of	Magnetic	Resonance	Imaging	(MRI)		
MRI	provides	detailed	images	of	tissues	using	the	principle	of	nuclear	magnetic	
resonance	(NMR).	NMR	occurs	when	atomic	nuclei	are	absorbed	and	re-emit	
electromagnetic	radio	waves	when	placed	in	a	magnetic	field.	The	specific	resonance	
frequency	depends	on	the	strength	of	the	magnetic	field	and	the	properties	of	the	
atomic	isotope.	Only	isotopes	that	contain	an	odd	number	of	protons	have	the	
ability	to	produce	radio	waves	under	magnetic	conditions.		
	
The	isotope	of	choice	in	MRI	is	hydrogen	as	this	is	abundant	through	the	body	but	
varies	in	content	in	different	tissues.	MRI	allows	differentiation	of	tissues	based	on	
hydrogen	content	(e.g.	grey	and	white	matter	in	the	brain).	
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1.3.2 Summary	of	how	MRI	images	are	generated.	
	
Hydrogen	nuclei	with	lone	protons	carry	angular	momentum	or	‘spin’	as	it	is	
commonly	referred	to.	When	a	strong	magnetic	field	(B0)	is	applied	to	these	nuclei,	
they	reorder	themselves	with	respect	to	the	B0,	either	parallel	or	anti-parallel	to	it	
(‘low	energy’	or	‘high	energy’	atoms	respectively).	The	stronger	the	magnetic	field	
then	the	greater	the	number	of	parallel	atoms.	Once	aligned,	these	protons	precess	
around	the	B0	axis.		
	
When	excitatory	radiofrequency	pulses	are	applied	to	the	aligned	nuclei,	they	will	
‘flip’	from	low-energy	to	high-energy	states.	The	‘flip	angle’	is	the	degree	of	
displacement	of	protons	from	their	original	position	and	the	net	magnetisation	
vector	created	by	the	RF	pulse.	Increasing	the	strength	or	duration	of	the	excitatory	
RF	pulses	will	increase	the	flip	angle.	In	MRI,	the	source	of	RF	pulses	is	an	
electromagnetic	coil	around	the	magnetic	field.	
	
When	the	RF	pulse	ceases,	then	the	hydrogen	atoms	return	to	their	low-energy	state	
and	signal	is	emitted	which	is	dependent	on	the	flip	angle,	B0,	and	atomic	density.	A	
receiver	coil	around	the	tissue	of	interest	is	used	to	detect	this	electromagnetic	
signal.	Two	principal	components	of	this	signal	are	the	T1	and	the	T2	relaxation	
times.	The	T1	relaxation	time	is	the	time	taken	for	the	magnetisation	vector	to	
return	to	the	z-axis	and	the	T2	(or	transverse)	relaxation	time	is	the	rate	that	the	xy	
component	of	the	magnetisation	vector	decays.	Manipulation	of	the	magnetic	field	
can	be	applied	to	manipulate	these	relaxation	times.	T2*	accelerates	the	transverse	
decay	and	this	can	be	useful	for	some	MRI	images.	
	
	
1.3.3 T1	weighted-images		
These	image	reconstructions	use	the	T1	relaxation	time	to	make	contrasts	between	
tissues.	Grey	matter	has	a	significantly	longer	T1	time	than	white	matter	and	
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therefore	T1-weighted	images	provide	good	anatomical	information	and	contrast	
between	grey	and	white	matter.		
	
	
1.3.4 T2	weighted-images		
These	images	are	produced	using	the	T2	or	transverse	relaxation	times.	Grey	and	
white	matter	is	less	differentiated	this	way	because	the	T2	relaxation	times	are	not	
so	different.	However	fat	and	water	do	have	differences	in	the	T2	time	and	therefore	
is	useful	to	assess	pathological	states	such	as	oedema.	Figure	1-3	shows	axial	slices	
of	a	healthy	brain	to	demonstrate	contrast	differences	between	T1	and	T2	weighted	
images.	
	
Figure	1-3	MR	axial	images	of	a	healthy	brain.	T1	weighted	(left),	T2	weighted	
(right)	
	
	
	
1.3.5 Susceptibility-weighted	images	(SWI)	
	
These	images	are	constructed	differently	to	T1/T2	and	T2*.	SWI	uses	a	special	
gradient-recalled	echo	pulse	sequence	that	takes	advantage	of	the	magnetic	
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susceptibility	differences	between	tissues.	It	is	sensitive	to	venous	blood,	iron	and	
haemorrhage	in	the	brain	(Haacke,	Xu,	Cheng,	&	Reichenbach,	2004)	and	is	an	
effective	technique	to	identify	microhaemorrhages	from	TBI	(Barnes	&	Haacke,	
2009).	An	example	of	a	microbleed	visible	on	a	SWI	image	is	depicted	in	Figure	1-4.	
	
Figure	1-4	Single	microbleed	(overlaid	in	green)	visible	on	SWI	imaging	in	a	patient	
following	TBI		
	
	
1.3.6 Diffusion	tensor	imaging	(DTI)		
	
DTI	is	a	unique	MR	technique	that	measures	water	diffusion	in	the	brain	(Basser	&	
Jones,	2002)	and	is	usually	performed	in	research	settings.	In	tissues	where	there	is	
no	restriction	or	limited	restriction	to	water	diffusion	e.g.	cerebrospinal	fluid	(CSF),	
then	water	molecules	diffuse	in	a	random	fashion.	This	type	of	diffusion	is	called	
isotropic.	However,	in	a	white	matter	fibre,	water	will	preferentially	diffuse	along	the	
white	matter	tract	(where	there	is	less	restriction	to	movement)	rather	than	across	
it.	This	type	of	diffusion	is	called	anisotropic.	
	
DTI	can	tell	us	about	the	type	of	water	diffusion	in	brain	tissue	and	this	information	
can	be	useful.	In	brief,	the	application	of	multiple	gradient	fields	while	acquiring	MR	
	 36	
data,	followed	by	application	of	a	tensor	model	results	in	the	generation	of	an	
ellipsoid	tensor	at	each	voxel	Figure	1-5.		
	
Figure	1-5	Schematic	of	the	diffusion	tensor	ellipsoid		
	
	
	
A,	Schematic	drawing	showing	the	relationship	between	the	diffusion	tensor	ellipsoid	the	
underlying	white	matter	fibre	bundle.	The	direction	of	the	longest	axis	of	the	ellipsoid,	
mathematically	called	the	principal	eigenvector	of	the	diffusion	tensor	(e1),	corresponds	to	
the	major	fibre	direction	where	water	molecules	exhibit	the	fastest	diffusion	due	to	lack	of	a	
barrier.	B,	The	diffusion	tensor	ellipsoid	can	be	obtained	on	a	voxel-by-voxel	basis.	
Reproduced	with	permission	from	(Chung,	Chou,	&	Chen,	2011)	
	
	
The	ellipsoid	eigenvalues	vary	across	different	cell	types	in	the	brain	and	this	can	give	
important	information	regarding	the	underlying	structures.	For	example,	in	CSF,	the	
eigenvalues	are	large	as	there	is	predominantly	isotropic	diffusion	with	little	to	
constrain	the	movement	of	water	molecules.	There	is	more	constraint	of	water	
molecules	in	the	grey	matter,	but	eigenvalues	are	relatively	equal,	suggesting	that	
there	is	less	anisotropic	diffusion	but	no	net	direction	of	water	diffusion	within	
voxels.	White	matter	which	is	made	up	of	bundles	of	axons	does	have	high	
constraint	of	water	molecules	along	them	and	therefore	DTI	is	a	useful	modality	to	
study	white	matter	in	particular.	
	
There	are	two	principal	ways	in	which	DTI	can	be	useful.	Tractography	is	a	technique	
which	uses	the	eigenvectors	to	map	out	pathways	of	white	matter	fibres	in	the	brain	
(Figure	1-6)		
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Figure	1-6	Principles	of	tractography	
	
	
Diffusion	ellipsoid	map	with	two	regions	of	interest.	B)	Schematic	representation	of	
diffusion	tensors	in	a	5x5	grid,	with	seed	ROI	in	dark	blue	and	termination	ROI	in	red.	
The	black	line	represents	the	propagation	of	the	deterministic	tractography	
streamline	in	the	direction	of	principal	eigenvector.	C)	Probabilistic	tractography	
produces	a	likelihood	map	of	the	diffusion	path	between	two	ROIs.	Rather	than	
delineating	a	single	best	path,	the	likelihood	map	shows	the	probability	that	a	
particle	diffusing	between	ROIs	traverses	each	voxel.	D)	Resulting	tract	connecting	
the	two	ROIs.	Adapted	with	permission	from	(Nucifora,	Verma,	Lee,	&	Melhem,	2007)	
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Eigenvalues	and	eigenvectors	can	also	be	used	to	generate	diffusivity	measures	that	
can	describe	the	direction	and	quantity	of	diffusion	within	an	individual	voxel	(Basser	
&	Pierpaoli,	1996).	Fractional	Anisotropy	(FA)	describes	the	overall	constraint	of	
water	diffusion	within	a	voxel	and	is	represented	by	the	equation	here:		
	
	
	
	
FA	values	close	to	1	suggest	that	diffusion	is	highly	anisotrophic	(constrained)	and	
values	close	to	0	imply	that	diffusion	is	isotropic.	Mean	diffusivity	(MD)	describes	the	
overall	amount	of	water	diffusion	in	a	molecule.	When	MD	is	low	there	is	little	water	
movement	and	when	it	is	high	there	is	high	diffusivity	of	water.	MD	does	not	
however	tell	us	about	the	directionality	of	water	diffusion.	Axial	(AD)	and	radial	
diffusivity	(RD)	are	the	other	diffusivity	measures	that	represent	the	degree	of	water	
restriction	in	the	axial	and	radial	planes	of	the	ellipsoid:	
	
Radial	diffusivity=	½	(λ1	+	λ3)	
	
Axial	Diffusivity	=	λ1	
	
In	white	matter,	FA	is	generally	thought	to	reflect	loss	of	white	matter	integrity	
either	reflecting	damage	to	myelin	or	axon	membrane,	reduced	axonal	packing	
density	or	reduced	axonal	coherence.	There	may	be	limitations	to	the	biological	
interpretation	of	DTI,	however,	it	is	still	considered	a	useful	imaging	modality	for	
investigation	of	white	matter	pathology	in	stroke,	multiple	sclerosis	(MS),	
Alzheimer’s	(AD)	and	psychiatric	disorders	as	well	as	TBI	(Assaf	&	Pasternak,	2008;	
Kinnunen	et	al.,	2011;	Kou	et	al.,	2010).	
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1.4 Pituitary	dysfunction	following	TBI		
	
The	pituitary	gland	is	a	small	endocrine	gland,	weighing	approximately	0.5	g	that	sits	
in	the	sella	turcica	at	the	base	of	the	brain	as	is	connected	to	the	hypothalamus	via	
the	pituitary	stalk	(Figure	1-7)	The	gland	itself	is	composed	of	two	embryologically		
and	functionally	distinct	structures;	the	adenohypophysis	(anterior	pituitary)	and	the	
neurohypophysis	(posterior	pituitary).	The	anterior	pituitary	gland	releases	6	
principal	hormones	and	the	posterior	pituitary	secretes	2	(Table	1-1).	
	
Figure	1-7	T2	MRI	coronal	pituitary	view	with	gadolinium	enhancement	
		
	(P=pituitary,	s=pituitary	stalk,	c=corpus	callosum,	3rd=third	ventricle)												
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Table	1-1	Anterior	and	posterior	pituitary	hormones	and	their	
downstream	effectors	
	
	
Pituitary	dysfunction	secondary	to	TBI	was	considered	rare	prior	to	2000.	It	was	first	
described	in	1918,	but	only	became	more	widely	appreciated	until	two	
prevalence	studies	were	published	in	2000	(Benvenga,	Campenni,	Ruggeri,	&	
Trimarchi,	2000;	E,	1918;	Lieberman,	Oberoi,	Gilkison,	Masel,	&	Urban,	2001).	
Pituitary	dysfunction	in	the	context	of	TBI	refers	to	hypofunction	of	the	pituitary	
gland	(usually	anterior)	i.e.	hypopituitarism	or	panhypopituitarism,	or	abnormal	
prolactin	measurements.	Excess	anterior	pituitary	hormone	production	is	not	
described	following	TBI.	
	
Here	I	describe	the	prevalence,	consequences	and	treatment	of	pituitary	dysfunction	
following	TBI.	Please	note	that	additional	introductory	material	on	this	subject	is	
provided	at	the	beginning	of	Chapters	3,	4,	and	5.	
	 	
Anterior(pituitary(gland Cell(type Principal(target
Principal(downstream(
mediator( Effect
Growth'hormone'(GH) Somatotroph Liver Insulin8like'growth'
factor'(IGF8I)
Growth/metabolism
Prolactin'(PRL) Lactotroph Mammary'glands n/a Lactation
Adrenocorticotropic'
hormone'(ACTH)
Corticotroph Adrenal'cortex Cortisol' Secretion'of'stress'
hormones
Thyroid'stimulating'
hormone'(TSH)
Thyrotroph Thyroid'gland Thyroxine'(T4) Energy'metabolism
Follicle'stimulating'
hormone'(FSH)
Gonadotroph Ovaries/testes Oestrogen'
/testosterone
Regulation'of'
reproduction
Lutenising'hormone'(LH) Gonadotroph Ovaries/testes
Progesterone/''''
testosterone
Production'of'sex'
hormones
Posterior(pituitary(gland
Antidiuretic'hormone'
(ADH)
n/a Kidneys/arterioles n/a Water'retention'and'
blood'pressure'
Oxytocin n/a
Uterus/mammary'
glands n/a
Uterine'contractions'
and'lactation
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1.4.1 Prevalence	of	chronic	post-traumatic	anterior	pituitary	
dysfunction	following	TBI		
The	first	systematic	review	on	the	prevalence	of	pituitary	dysfunction	following	TBI	
suggested	that	this	condition	was	common	(27.5%)	and	even	more	so	following	SAH	
(47%)	(Schneider,	Kreitschmann-Andermahr,	Ghigo,	Stalla,	&	Agha,	2007).	However	
more	recent	studies	have	reported	much	lower	prevalence	rates	(Kokshoorn	et	al.,	
2011).	There	are	several	reasons	that	could	explain	this	variability	including	the	
choice	of	dynamic	endocrine	tests	and	cut-offs	particularly	for	growth	hormone	
deficiency	(GHD),	use	of	confirmatory	testing	(Klose	et	al.,	2007;	Kokshoorn	et	al.,	
2010),	time	since	TBI	to	endocrine	testing	and	severity	of	injury.	A	recent	systematic	
review	attempts	to	control	for	these	factors	(Tanriverdi	et	al.,	2015).	1203	patients	
were	analysed	across	14	studies.	28%	were	found	to	have	at	least	one	hormone	
deficiency	and	6%	were	found	to	have	multiple	deficiencies.	The	frequencies	of	
hypopituitarism	following	TBI	are	displayed	in	Table	1-2.		
	
Table	1-2	Frequencies	of	anterior	hypopituitarism	in	the	chronic	phase	following	
TBI.		
	
	
Abbreviations:	ND=not	defined.	Adapted	from	(Tanriverdi	et	al.,	2015)	
	
	
First&Author,&Year& N GH LH/FSH ACTH TSH Hypopituitarism Multiple&Deficiencies
Bondanelli,*2004 50 4 7 0 5 14 6
Aimaretti,*2005 70 14 8 4 5 16 7
Agha,*2004 102 18 12 23 1 29 6
Popovic,*2004 67 10 6 5 3 23 7
Agha,*2005 48 5 6 9 1 ND ND
Schnieder,*2006 70 7 14 6 2 25 3
Tanriverdi,*2006 52 17 4 10 3 26 5
Klose,*2007 104 18 2 5 2 18 6
Bushnik,*2007 64 23 7 39 12 58 ND
Bavisetty,*2008 70 11 7 0 0 15 5
Kleindienst,*2009 23 9 0 11 0 ND ND
Srinivasan,*2009 18 4 0 9 4 10 5
Van*der*Eerden,*2010 107 1 7 6 1 15 0
Kokshoorn,*2011 112 3 1 2 ND 6 0
LealKCerro,*2005 170 6 29 11 10 42 15
Hermann,*2006 76 6 13 2 2 18 5
Total*TBI,*n 1203 156 123 142 51 315 70
Total*TBI,*% 100% 13.0% 10.2% 11.8% 4.2% 27.8% 6.2%
Total*TBI*all*GCS,*n 957 144 81 129 39 255 50
Total*TBI*all*GCS,*% 100% 15.0% 8.5% 13.5% 4.1% 28.8% 5.6%
Total*TBI*GCS*≤8,*n 246 12 42 13 12 60 20
Total*TBI*GCS*≤8,*% 100% 4.9% 17.1% 5.3% 4.9% 24.4% 8.1%
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However,	when	using	an	additional	confirmatory	test	at	least	three	months	after	a	
TBI,	15%	were	found	to	have	any	hormone	deficiency	and	4%	had	multiple	hormone	
deficiencies	(n=313).	Consistent	with	other	studies,	GHD	was	the	most	common	
deficit	(9%),	followed	by	ACTH	(6%),	LH/FSH	(5%)	and	TSH	(1%).	Frequencies	of	
hypopituitarism	in	the	chronic	phase	(at	least	3	months	after	TBI)	and	studies	only	
with	confirmatory	tests	are	shown	in	Table	1-3.	
	
Table	1-3	Frequencies	of	hypopituitarism	in	the	chronic	phase	(at	least	3	months	
after	TBI)	and	studies	only	with	confirmatory	tests		
	
Adapted	from	(Tanriverdi	et	al.,	2015)	
	
	
1.4.2 Prevalence	of	pituitary	dysfunction	in	the	multidisciplinary	TBI	
clinic	at	Imperial	Healthcare	NHS	Trust		
	
A	weekly	multidisciplinary	TBI	clinic	was	set	up	in	2009	to	provide	neurological,	
endocrine,	cognitive	and	psychological	support	to	patients	in	the	chronic	phase	
following	a	TBI.	From	April	2012	to	March	2016	I	have	assisted	Dr	Tony	Goldstone	in	
providing	the	neuroendocrine	care	for	these	patients.	I	have	seen	approximately	470	
new	and	follow-up	patients	in	this	clinic.	Our	preference	has	been	to	perform	two	
dynamic	tests	of	pituitary	function	before	confirming	the	diagnosis	of	either	GH	or	
ACTH	deficiency.	
	
In	our	cohort	of	TBI	patients	seen	at	Imperial	College	Healthcare	Trust	between	2009	
and	2012,	93	out	of	248	(37.5%)	had	a	sub-optimal	GH	response	to	glucagon	testing	
(peak	GH	<5	mcg/L).	However	the	final	prevalence	of	GHD	was	only	7.4%	(13/176	
patients)	defined	through	inadequate	GH	response	during	2	dynamic	tests:	glucagon	
First&Author,&Year&(Ref) N GH LH/FSH ACTH TSH Hypopituitarism Multiple&Deficiencies
Pathological*screening*tests
Agha,*2004 102 18 12 23 1 29 6
Klose,*2007 104 18 2 5 2 18 6
Van*der*Eerden,*2010 107 1 7 6 1 15 0
Total*N 313 37 21 34 4 62 12
Total*% 100% 11.8% 6.7% 10.9% 1.3% 19.8% 3.8%
Pathological*confirmatory*tests*
Agha,*2004 102 11 12 13 1 29 6
Klose,*2007 104 16 2 5 2 16 6
Van*der*Eerden,*2010 107 0 0 1 0 1 0
Total*N 313 27 14 19 3 46 12
Total*% 100% 8.6% 4.5% 6.1% 1.0% 14.7% 3.8%
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test	followed	by	GHRH-Arginine	test.	We	found	the	glucagon	test	alone	to	have	a	
relatively	poor	specificity	and	sensitivity	in	the	diagnosis	of	GHD	after	TBI	when	
compared	to	the	GHRH-Arginine	test	(using	age-	and	BMI-	adjusted	cut-offs).	At	<5	
mcg/L	GH	cut-off	in	the	glucagon	test	sensitivity	was	86.7%	and	specificity	14.3%,	
while	at	<3	mcg/L	sensitivity	was	66.7%	and	specificity	60.0%	(n=49)	(Zaw-Linn	J,	
Feeney	C,	Goldstone	AP.	BSc	Project	2013).	
	
1.4.3 Proposed	pathophysiological	mechanisms	for	developing	TBI-
induced	chronic	hypopituitarism	
	
It	is	not	completely	clear	how	post-traumatic	hypopituitarism	develops	following	TBI;	
although	several	hypotheses	have	been	proposed	including	direct	damage	to	the	
pituitary,	hypothalamus	or	stalk;	vascular	damage	to	the	long	hypophyseal	vessels;	
autoimmunity	and	genetic	factors.	
	
Supporting	a	vascular	hypothesis,	in	one	study,	80%	of	patients	with	traumatic	
hypopituitarism	had	at	least	one	radiological	abnormality	of	the	sella	(including	loss	
of	volume	or	empty	sella,	signal	inhomogeneities,	perfusion	deficit,	and	lack	of	
neurohypophyseal	signal)	compared	to	29%	of	those	without	hypopituitarism	
(P=0.032)	(Schneider,	Samann,	et	al.,	2007).	In	the	acute	phase	following	a	moderate	
or	severe	TBI,	another	study	found	that	30%	of	patients	had	pituitary	gland	
enlargement	or	evidence	of	haemorrhage/infarction	or	signal	abnormalities	on	MRI	
(Maiya	et	al.,	2008).	The	commonly	observed	pattern	of	GH,	followed	by	
gonadotrophin	deficiencies	following	TBI	may	also	be	explained	by	the	somatotrophs	
and	gonadotrophs	being	located	in	the	area	of	the	pituitary	perfused	by	the	long	
hypophyseal	vessels,	although	this	is	purely	speculative.		
	
Autoimmunity	has	also	been	proposed	as	a	potential	mechanism.	Pituitary	
antibodies	may	develop	after	blood-brain	barrier	(BBB)	disruption	allows	leakage	of	
pituitary	proteins	into	the	circulation	which	in	turn	induces	an	immune	response	
(Papa	et	al.,	2012;	Tanriverdi	et	al.,	2010).	One	study	has	reported	a	prevalence	of	
45%	of	antipituitary	antibodies	(APAs)	following	TBI	(compared	to	0%	in	controls)	
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and	this	was	associated	with	the	development	of	hypopituitarism	(Tanriverdi,	De	
Bellis,	et	al.,	2008).	This	finding	has	also	been	replicated	in	boxers	who	have	been	
exposed	to	repetitive	head	trauma	(Tanriverdi	et	al.,	2010).		
	
Genetic	factors	have	also	been	implicated	as	contributory	mechanisms.	
Apolipoprotein	(APOE)	is	a	key	protein	which	has	a	role	in	neuronal	repair	and	is	
heavily	expressed	in	the	hypothalamo-pituitary	area	(Nishida,	Yoshioka,	&	St-Amand,	
2005).	The	E4	allele	is	thought	to	be	a	strong	risk	factor	for	the	development	of	
Alzheimer’s	disease	(AD)	(Welsh-Bohmer,	Gearing,	Saunders,	Roses,	&	Mirra,	1997),	
but	the	E3	allele	can	inhibit	the	neuroinflammatory	response	(Laskowitz	et	al.,	2001).	
A	preliminary	study	has	found	pituitary	dysfunction	was	significantly	lower	in	those	
with	APOE	E3/E3	genotype	(17.7%	in	those	with	the	E3	allele	vs.	42%	without	
P=0.01)	(Tanriverdi,	Taheri,	et	al.,	2008).	
	
1.4.4 Clinical	consequences	of	TBI-induced	chronic	hypopituitarism	
	
The	clinical	consequences	of	post-traumatic	hypopituitarism	can	be	divided	into	
metabolic	(body	fat	composition,	body	mass	index	(BMI),	hypertension,	glucose	
metabolism,	lipid	profile,	bone	metabolism)	and	cognitive/psychological.	These	shall	
be	addressed	in	turn.	
	
Metabolic	consequences	
Outside	of	TBI,	untreated	hypopituitarism	can	lead	to	a	number	of	metabolic	
abnormalities.	Growth	hormone	deficiency	in	particular	induces	truncal	obesity,	
reduces	lean	body	mass	and	bone	mass	that	reverse	on	treatment	(Mukherjee,	
Murray,	&	Shalet,	2004).	GHD	also	contributes	to	an	adverse	cardiovascular	risk	
profile,	including	dyslipidaemia,	hypertension	and	increased	mortality	from	
cardiovascular	causes	(Verhelst	&	Abs,	2009).	Untreated	hypogonadism	i.e.	
testosterone	deficiency	can	other	induce	a	averse	metabolic	profile	as	well	as	
thyroid	and	ACTH	deficiencies	(although	the	latter	two	deficiencies	are	usually	
immediately	treated,	leaving	less	scope	for	metabolic	abnormalities	to	develop).	
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TBI	patients	who	developed	hypopituitarism	following	injury	were	more	insulin	
resistant,	had	worse	lipid	profile	and	had	altered	glucose	metabolism,	that	was	not	
explained	by	an	increase	in	BMI	(Prodam	et	al.,	2013).	Another	study	also	confirmed	
higher	waist	circumference,	total	fat	mass	and	low-density	lipoprotein-cholesterol	
(LDL)	in	patients	with	hypopituitarism	at	12	month	follow-up	after	TBI	(Klose	et	al.,	
2007).	
	
Cognitive/psychological	consequences			
There	are	several	targets	for	GH	and	its	downstream	mediator	IGF-I	throughout	the	
brain	(Lobie	et	al.,	1993).	GH	and	IGF-I	are	thought	to	have	neuroprotective	effects	
and	influence	cognitive	domains	relating	to	learning	and	memory	(Nyberg	&	
Hallberg,	2013).	The	influence	of	GHD	and	GH	replacement	will	be	discussed	in	more	
detail	in	the	introductory	sections	of	Chapter	4	and	5	respectively.	In	gonadotrophin	
deficiency,	testosterone	replacement	has	been	shown	to	have	positive	effect	on	
spatial	and	verbal	memory;	an	effect	also	seen	in	healthy	older	males	and	those	with	
AD	who	are	not	hypogonadal	(Cherrier,	2009;	Cherrier	et	al.,	2001;	Cherrier,	Craft,	&	
Matsumoto,	2003).	The	effect	of	ACTH/cortisol/thyroxine/prolactin	(Cherrier,	2009;	
Cherrier	et	al.,	2001;	Cherrier	et	al.,	2003)	on	cognition	is	not	clearly	delineated.		
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1.4.5 Diagnostic	tests	and	treatment	of	TBI-induced	chronic	
hypopituitarism	
	
Diagnosis	
The	diagnosis	of	thyroid,	prolactin,	LH,	FSH	abnormalities	is	generally	straightforward	
and	can	be	diagnosed	on	single	or	multiple	serum	samples.	However	the	diagnosis	of	
ACTH	and	GH	deficiency	is	more	complicated	due	to	the	pulsatile	release	and	diurnal	
profile	of	these	hormones.	For	this	reason,	dynamic	function	tests	are	required	
whereby	the	pituitary	is	stimulated	by	some	means	(e.g.	hypoglycaemic	stress,	
glucagon)	and	measurements	of	cortisol	and	GH	taken	thereafter.	These	
measurements	are	then	analysed	against	cut-off	thresholds	to	determine	whether	
ACTH	or	GH	deficiency	is	present.	Examples	of	these	dynamic	function	tests	include	
the	insulin	tolerance	test	(ITT)	and	the	glucagon	stimulation	test	(GST).	Diagnostic	
testing	for	hypopituitarism	following	TBI	will	be	explained	in	more	detail	in	Chapter	
3.		
	
Treatments	
The	most	commonly	diagnosed	pituitary	hormone	abnormality	following	TBI	is	GHD	
and	criteria	for	starting	recombinant	GH	replacement	is	generally	governed	by	
guidelines	produced	by	the	National	Institute	for	Health	and	Care	Excellence	(NICE).	
There	are	six	manufacturers	that	produce	somatrophin	and	is	usually	administered	
once	a	day,	subcutaneously,	via	a	pen	device.	The	current	NICE	guideline	
recommends	that	treatment	should	only	be	considered	in	those	with	severe	GHD	
(i.e.	peak	GH	<9	mU/L	on	an	ITT	or	another	reliable	test)	and	impaired	quality	of	life	
(<11/25	on	the	Assessment	of	GH	Deficiency	in	Adults	questionnaire	(AGHDA)	(QoL-
AGHDA)).	NICE	also	suggests	that	QoL	should	be	reassessed	at	9	months	and	if	it	has	
not	improved	by	7	points	then	consideration	should	be	given	to	stopping	treatment	
(guideline,	2003).	In	the	case	of	multiple	hormone	deficiencies	it	is	generally	
accepted	practice	to	replace	other	hormones	prior	to	GH	and	reassess	QoL	
thereafter.	In	the	case	of	GHD	following	TBI	it	is	not	recommended	to	start	GH	less	
than	a	year	after	injury,	in	case	of	resolution	of	the	condition.	The	effect	of	GH	
replacement	on	cognition	and	recovery	from	TBI	will	be	discussed	in	Chapter	5.	
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TSH	deficiency	following	TBI	is	extremely	rare	(Tanriverdi	et	al.,	2015).	Indeed	in	our	
cohort	of	patients	at	Imperial	Healthcare	NHS	Trust,	we	have	not	diagnosed	a	single	
case	since	2009.	However	if	present,	thyroxine	replacement	should	be	implemented	
in	the	standard	manner.	ACTH	deficiency,	once	confirmed,	necessitates	prompt	
replacement	with	replacement	doses	of	glucocorticoid	(usually	hydrocortisone	20mg	
in	divided	doses	per	day),	including	education	on	doubling	dosage	in	intercurrent	
illness	and	seeking	prompt	medical	attention	in	case	of	vomiting.	Usually	patients	
carry	a	steroid	card	or	a	medialert	bracelet.	Testosterone	replacement	in	males	will	
depend	on	a	variety	of	factors	including	reported	sexual	symptoms	and	reduced	
bone	mineral	density.	When	instigated,	replacement	can	take	various	forms.	Our	
preference	is	to	initiate	3	monthly	depot	injections.	There	are	limited	data	available	
to	draw	conclusions	about	the	effect	of	ACTH/FSH/LH	and	TSH	deficiencies	following	
TBI.		
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1.5 Neuroinflammation	following	TBI	
	
The	second	half	of	this	thesis	(Chapters	6	and	7)	addresses	a	different	theme;	
neuroinflammation	following	TBI.	I	shall	describe	here	why	neuroinflammation	in	TBI	
is	an	important	area	of	research	and	how	metabolic	factors	may	map	onto	this.	
	
1.5.1 Definition	
	
Inflammation	in	general	terms	is	the	body’s	response	to	injury.	Outside	of	the	CNS	it	
is	easier	to	describe	where	blood	borne	cytokine	and	chemokines	facilitate	
recruitment	of	monocytes,	neutrophils	and	macrophages	to	the	site	of	injury	with	
the	goal	of	repairing	injurious	damage	to	the	body.	Within	the	CNS,	this	traditional	
role	has	been	extended	to	include	the	activation	of	microglia	and	astroglia.	These	
brain	glial	cells	are	both	sources	and	targets	of	inflammatory	mediators	and	their	
activation	is	a	central	response	to	a	variety	of	CNS	injury;	including	trauma,	infection,	
drugs,	and	various	disease	processes	(O'Callaghan,	Sriram,	&	Miller,	2008).	Given	
that	microglial	are	the	dominant	immune	cell	and	can	be	studied	with	positron-
emission	tomography,	this	thesis	will	focus	on	microglial	activation	following	TBI.		
	
1.5.2 The	role	of	microglia	in	mediating	the	neuroinflammatory	
response	
	
Microglia	are	the	brain’s	resident	macrophages	(representing	up	to	10%	of	the	total	
cell	population	of	the	brain)	and	are	key	orchestrators	in	the	brain’s	inflammatory	
processes.	Microglia	are	thought	to	be	mobile	and	have	a	highly	branched	
morphology	allowing	constant	surveillance	of	their	environment	(Morganti-
Kossmann,	Satgunaseelan,	Bye,	&	Kossmann,	2007).	In	their	quiescent	state,	they	
may	exert	a	role	in	synaptic	pruning.	When	microglia	become	activated	in	response	
to	injury,	they	rapidly	change	their	morphology	and	upregulate	a	number	of	cell-
surface	and	intracellular	antigens	(Finnie,	2013).	
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In	their	activated	state,	microglia	release	a	variety	of	pro-inflammatory	cytokines	
including	IL-1B	and	TNF-alpha	which	can	cause	damage	by	the	production	of	
superoxide	free	radicals	(Koshinaga	et	al.,	2000).	However	they	can	also	serve	
neuroprotective	functions	e.g.	clearing	toxic	debris	by	phagocytosis,	release	of	
trophic	factors	and	recruiting	new	stem	cells	to	the	site	of	injury	(Colton,	2009)	
	
The	ability	of	microglia	to	exert	both	beneficial	and	harmful	effects	is	due	to	their	
ability	to	adopt	different	phenotypes	under	different	conditions.	The	M1,	or	
‘classically	activated’	phenotype	is	pro-inflammatory	and	destructive,	marked	by	
production	of	high	levels	of	TNF-alpha,	interferon	gamma,	IL-1B,	IL-12	and	low	levels	
of	IL-10.	Conversely,	the	M2	or	‘alternatively	activated’	phenotype	releases	anti-
inflammatory	cytokines	such	as	IL-4,	TGF-beta	and	IL-10	and	promotes	tissue	
remodelling	and	angiogenesis	(Nimmerjahn,	Kirchhoff,	&	Helmchen,	2005).	It	is	well	
recognised	however	that	the	M1/M2	dichotomy	of	microglial	differentiation	is	likely	
to	be	an	oversimplification	and	instead	represent	2	extremes	of	phenotypic	variation	
in	vivo.	
	
How	exactly	microglia	can	alter	their	phenotype	following	CNS	injury	is	dependent	
on	a	variety	of	different	factors	within	the	neural	microenvironment,	including	
variation	of	microglial	populations	within	the	cortex,	variation	in	neurotransmitter	
signalling	and	differences	in	complement	production	and	leucocyte	infiltration	
(Nimmerjahn	et	al.,	2005)	
	
Increasing	evidence	suggest	that	microglia	can	also	be	influenced	by	signals	outside	
the	CNS.	Systemic	inflammation,	for	example,	can	invoke	microglial	activation	
through	signalling	pathways	that	are	not	completely	understood	(Perry,	
Cunningham,	&	Holmes,	2007).	
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1.5.3 Neuropathological	evidence	for	chronic	microglial	activation	
following	TBI	
	
	
Pathological	markers	for	microglial	activation	(CD68,	CR3/43)	appear	to	be	present	
peri-lesionally	following	an	acute	TBI	but	there	is	also	evidence	for	a	long-term	
microglial	response	that	may	be	harmful	(Gentleman	et	al.,	2004;	Johnson	et	al.,	
2013;	Shitaka	et	al.,	2011).	In	one	study	of	head-injured	patients	who	survived	at	
least	a	year	following	their	head	injury,	CD68	immunoreactivity	was	greater	in	both	
parasagittal	and	hippocampal	white	matter	up	to	4	years	following	injury	and	CR3/43	
mmunoreactivity	was	greater	in	both	parasagittal	and	hippocampal	white	matter	up	
to	16	years	following	the	injury.	This	appeared	not	to	be	influenced	by	age	
(Gentleman	et	al.,	2004).	
	
Another	study	also	replicated	these	findings	by	reporting	on-going	pathological	
evidence	of	neuroinflammation,	especially	in	the	corpus	callosum,	up	to	18	years	
after	a	single	moderate-severe	TBI	in	humans	(Johnson	et	al.,	2013).	However	they	
also	described	an	association	of	chronic	microglial	activation	with	on-going	axonal	
degeneration	consistent	with	other	animal	models	that	demonstrate	white	matter	
degeneration	following	TBI	(X.	H.	Chen	et	al.,	2004;	Gale,	Johnson,	Bigler,	&	Blatter,	
1995).		
	
1.5.4 Microglia	in	neurodegeneration		
	
In	addition	to	their	phagocytic	role	(neuroprotective	role),	activated	microglia	
synthesize	and	secrete	potential	neurotoxins	that	may	cause	or	aggravate	CNS	
pathology.	These	toxins	include	free	radicals,	nitric	oxide,	IL-1,	IL-6,	TNF α, among	
others	(Chao,	Hu,	Molitor,	Shaskan,	&	Peterson,	1992;	Chao,	Hu,	&	Peterson,	1995;	
Chao,	Hu,	Sheng,	&	Peterson,	1995;	Giulian,	Baker,	Shih,	&	Lachman,	1986;	Righi	et	
al.,	1989).	For	example,	in	AD,	a	classical	neurodegenerative	disease,	microglial	
activation	has	been	shown	in	regions	associated	with	amyloid	β deposition	(Edison	
et	al.,	2008).	
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TBI	is	now	considered	to	have	a	neurodegenerative	component	and	is	a	risk	factor	
for	the	development	of	dementia	(D.	H.	Smith,	Johnson,	&	Stewart,	2013).	
Neurodegeneration	may	be	an	underlying	mechanism	that	could	explain	the	variable	
recovery	from	TBI	over	the	long-term	(McMillan	et	al.,	2012).	Recently,	amyloid	
pathology	has	been	shown	to	correlate	with	axonal	injury	following	TBI	(Scott	et	al.,	
2016).		
	
1.5.5 Therapies	targeted	at	reducing	microglial	activation		
Minocycline,	a	tetracycline	antibiotic,	inhibits	microglial	activation	and	has	other	
neuroprotective	effects	at	an	experimental	level.	It	is	the	most	widely	studied	agent	
specifically	targeting	neurological	conditions	that	have	a	neuroinflammatory	
component	(Plane,	Shen,	Pleasure,	&	Deng,	2010).	Human	clinical	studies	of	
minocycline	have	had	positive	and	negative	effects	on	disease	outcomes	in	stroke		
(Lampl	et	al.,	2007),	multiple	sclerosis	(Metz	et	al.,	2009),	Parkinson’s	disease	("A	
pilot	clinical	trial	of	creatine	and	minocycline	in	early	Parkinson	disease:	18-month	
results,"	2008),	Huntington’s	disease	(Thomas,	Ashizawa,	&	Jankovic,	2004).	Results	
from	a	clinical	trial	in	TBI	are	awaited	(Scott	G,	Sharp	DJ	et	al.).		
	
1.5.6 The	Translocator	Protein	(TSPO)			
The	18	kDA	TSPO	protein	(formerly	known	as	the	benzodiazepine	receptor)	is	
present	in	the	outer	mitochondrial	membrane	of	cells	and	is	thought	to	play	a	crucial	
role	in	cholesterol	transport	across	cells;	the	first	step	in	steroidogenesis	(R.	C.	
Brown	&	Papadopoulos,	2001).	However	this	traditional	view	of	TSPO	function	has	
recently	been	challenged	by	a	number	of	experimental	studies	(for	review	see	
(Selvaraj,	Stocco,	&	Tu,	2015).	TSPO	has	a	number	of	other	roles	related	to	
mitochondrial	function	including	immune	modulation,	apoptosis,	cell	proliferation,	
protein	import,	porphyrin	transport,	haem	biosynthesis,	ion	transport,	cellular	
respiration	and	oxidative	processes	(Girard	et	al.,	2012).	
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There	are	low	levels	of	TSPO	in	the	healthy	nervous	system	but	are	then	rapidly	up-
regulated	in	microglia	and	astrocytes	in	the	context	of	disease	or	injury	(M.	K.	Chen	
&	Guilarte,	2008;	Cosenza-Nashat	et	al.,	2009).	TSPO	has	therefore	become	a	target	
for	measuring	microglial	activation	via	positron-emission	tomography	(PET).	
	
1.5.7 TSPO	PET	Imaging	
	
PET	is	a	functional	imaging	technique	where	radiotracers	labelled	with	a	positron-
emitter	are	injected	into	the	body	to	measure	a	biological	process.	A	positron	is	the	
antiparticle	of	the	electron	and	has	a	positive	charge.	Unstable	radioisotopes	(i.e.	
chemical	elements	with	varying	number	of	neutrons)	are	able	to	emit	positrons	
when	they	undergo	decay.	The	radiotracer	will	concentrate	around	the	receptor	or	
metabolic	process	of	interest.	
	
Once	a	positron	is	emitted	it	will	travel	a	short	distance	(1-3mm)	before	it	collides	
with	an	electron.	This	collision	is	known	as	annihilation	and	once	it	occurs	two	
gamma	rays	are	produced	at	180	degree	angles	to	one	another.	These	gamma	rays	
are	detected	by	a	gamma	counter	which	allows	3D	images	to	be	reconstructed.		
	
A	number	of	radioligands	have	been	developed	to	measure	the	TSPO	receptor.	The	
first	ligand	developed	for	this	purpose	was	[11C]PK-11195	and	has	been	used	widely	
to	measure	microglial	activation	in	AD,	mild	cognitive	impairment,	Huntington’s	
disease,	Parkinson’s	disease,	multiple	sclerosis,	schizophrenia,	fronto-temporal	
dementia,	multiple	system	atrophy,	ischaemic	stroke	and	TBI	(Ramlackhansingh	et	
al.,	2011;	Schweitzer,	Fallon,	Mann,	&	Kumar,	2010).	
	
Although	[11C]PK-11195	has	some	utility	in	measuring	neuroinflammation	in	a	wide	
variety	of	neurological	and	psychiatric	disease,	there	are	certain	limitations	to	its	
use.	The	kinetics	of	the	molecule	are	highly	variable	in	part	due	to	high	plasma	
protein	binding,	high	non-specific	binding	due	to	the	lipophilicity	of	the	molecule	and	
low	brain	uptake	(Ching	et	al.,	2012).	As	a	result	of	these	factors,	there	is	no	
standardised	approach	to	analysis	and	interpretation.	Practically-speaking,	the	half	
	 53	
life	of	carbon-11	(20.38	mins)	necessitates	the	availability	of	an	onsite	cyclotron	to	
manufacture	the	molecule	and	this	can	restrict	its	use	increase	its	cost.	
	
Over	the	last	decade,	approximately	20	new	ligands	for	TSPO	have	been	developed	
and	evaluated	in	imaging	studies	with	the	hope	of	addressing	some	of	the	limitations	
outlined	with	[11C]PK-11195	(Chauveau,	Boutin,	Van	Camp,	Dolle,	&	Tavitian,	2008).	
Several	second-generation	TSPO	ligands	including	[11C]PBR-28,	[11C]DAA1106,	
[11C]DPA713,	[18F]PBR06,	[18F]FEPPA	and	[18F]PBR111	with	improved	signal-noise	
ratio	have	been	investigated	in	humans.	
	
A	major	observation	with	these	ligands	was	that	there	was	considerable	
interindividual	variability	in	their	affinity	for	TSPO	(Owen	et	al.,	2011;	Owen	et	al.,	
2010).	It	seemed	that	these	ligands	bound	with	a	trimodal	distribution:	either	high,	
low	or	mixed	affinity	depending	upon	the	subject.	Subsequently,	it	was	found	that	a	
Ala147Thr	polymorphism	for	the	TSPO	receptor	is	responsible	for	this	trimodal	
distribution	(Owen	et	al.,	2012).	
	
	
1.5.8 	[18F]GE-180	
	
The	TSPO	ligand	of	choice	for	this	thesis	(chapters	6	and	7)	is	a	novel	fluorinated	
tracer,	[18F]GE-180	(S-N,N-diethyl-	9-2-18F-fluoroethyl]-5-methoxy	2,3,4,9-
tetrahydro-1H-carba-	zole-4-carboxamide)	(Figure	1-8).	This	ligand	was	identified	as	
the	lead	compound	from	series	of	85	tricyclic	indoles	all	assessed	for	binding	affinity,	
brain	uptake	and	specific	binding	in	an	established	neuroinflammation	model	
(Wadsworth	et	al.,	2012).	A	fluorinated	molecule	with	a	half	life	of	109.7	minutes	has	
advantages	over	carbon-11	in	terms	of	obviating	requirement	for	on-site	cyclotron	
and	cost.		
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Figure	1-8	Chemical	structures	of	[11C]PK-11195	and	[18F]GE-180	
	
	
	
	
		
	
	
	
	[18F]GE-180	was	able	to	identify	sites	of	microglial	activation	by	in	vivo	PET	imaging	
that	was	confirmed	with	immunohistochemistry	in	an	acute	model	of	
neuroinflammation	and	appeared	to	have	superior	binding	to	[11C]PK-11195	(Dickens	
et	al.,	2014).	This	pattern	was	maintained	in	a	preclinical	model	of	stroke,	where	
[18F]GE-180	demonstrated	better	signal	to	noise	ratio	compared	to	[11C]PK-11195	
Figure	1-9	(Boutin	et	al.,	2015).	Not	only	did	[18F]GE-180	have	greater	signal	at	infarct	
site,	the	level	of	non-specific	binding	in	healthy	tissue	was	lower	when	compared	to	
[11C]PK-11195.	
	
	
	
	
	
	
		
	
	
	 55	
Figure	1-9	[11C]PK-11195	vs.	[18F]GE-180	in	an	animal	mode	of	stroke	
	
 
	
a)	Infarct	volumes	(red	points-excluded	animals	due	to	very	small	infarcts)	b)	Representative	
T2	MR	image	in	a	rat	showing	visible	infarct	(Str	striatum,	Cx	cortex)	c)	3D	rendering	of	
infarct	areas	d)e)	coregistered	quantitative	PET/CT	images	(40-60min	summed	image	after	
injection).	Reproduced	with	permission	from	(Boutin	et	al.,	2015)	
	
One	of	the	first	clinical	studies	using	[18F]GE-180	is	described	in	Chapter	6.	
	
1.5.9 TSPO	imaging	in	TBI	
	
The	role	of	neuroinflammation	in	the	pathophysiology	of	TBI	has	been	purported	as	
a	potential	mechanism	to	explain	the	variable	recovery	from	TBI	as	well	as	the	
development	of	de	novo	diseases	including	post-traumatic	epilepsy	and	dementia	.	
(Annegers,	Hauser,	Coan,	&	Rocca,	1998;	Z.	Guo	et	al.,	2000;	McMillan,	Teasdale,	
Weir,	&	Stewart,	2011).	Animal	models	have	demonstrated	that	the	initial	
inflammatory	process	can	continue	for	a	year	following	TBI,	especially	in	the	
thalamus	(Nagamoto-Combs,	McNeal,	Morecraft,	&	Combs,	2007).	Human	post-
mortem	studies	have	also	shown	microglial	activation	in	long-term	survivors	of	TBI	
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(Gentleman	et	al.,	2004)	and	sites	of	activation	coincide	with	Wallerian	degeneration	
(Wilson	et	al.,	2004).		
	
In	a	TSPO	PET	study	using	[11C]PK-11195	in	ten	patients	at	least	11	months	after	
moderate-severe	TBI,	all	patients	had	increased	thalamic	binding	compared	to	
controls.	This	effect	seemed	to	be	present	even	in	patients	who	had	a	very	long	time	
since	injury	(Figure	1-10).	
	
Figure	1-10	[11C]PK-11195	images	of	TBI	patients	overlaid	on	T1	transverse	images	
at	the	level	of	the	thalamus.	
	
	
Numbers	indicate	time	from	TBI	to	time	of	PET	scan.	Reproduced	with	permission	from	
(Ramlackhansingh	et	al.,	2011)	
	
[11C]PK-11195	binding	varied	between	regions	with	highest	binding	in	the	thalamus,	
putamen	and	posterior	limb	of	the	internal	capsule	(PLIC)	(Figure	1-11).	[11C]PK-
11195	in	the	thalamus	was	associated	with	greater	cognitive	impairment.	Increased	
binding	was	not	found	at	the	sites	of	focal	damage,	but	more	distant	subcortical	
areas	which	may	reflect	the	dense	connectivity	of	these	structures.	
	
In	Chapters	6&7	I	will	be	expanding	on	our	group’s	TSPO	research	by	using	the	tracer	
[18F]GE-180	in	patients	following	a	TBI.	I	will	be	investigating	whether	the	Metabolic	
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Syndrome	(MetS)	correlates	with	TSPO	neuroinflammation	and	recovery	following	a	
TBI.	
	
Figure	1-11.	[11C](R)PK11195	binding	in	the	regions	of	interests	investigated.	
	
	
	
Individual	subjects'	binding	potentials	are	plotted	with	patients	in	blue	and	control	subjects	in	
red.	PET	=	positron	emission	tomography;	AC	=	anterior	cingulate;	PC	=	posterior	cingulate;	
Caud	=	caudate;	Puta	=	putamen;	Thal	=	thalami;	Hippo	=	hippocampus;	OL	=	occipital	lobe;	
IFG	=	inferior	frontal	gyrus;	SFG	=	superior	frontal	gyrus;	Cere	=	cerebellum;	PIC	=	posterior	
limb	of	internal	capsule;	AIC	=	anterior	limb	of	internal	capsule;	BS	=	brainstem;	CC	=	corpus	
callosum.	*p	<	0.05	significance;	**survives	Bonferroni	multiple	comparison	correction.		
Reproduced	with	permission	from	(Ramlackhansingh	et	al.,	2011)	
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1.6 The	Metabolic	Syndrome	(MetS)		
1.6.1 Definition		
MetS	is	the	name	given	to	a	group	of	disorders	,	which,	when	occurring	together,	
significantly	increases	the	risk	of	developing	cardiovascular	disease	and	diabetes.	
This	condition	exists	in	approximately	20-25%	of	adults	in	the	developed	world	
(Cameron,	Shaw,	&	Zimmet,	2004;	Ford,	Giles,	&	Dietz,	2002).	
	
There	are	several	definitions	of	MetS	based	on	consensus	statements	from	
worldwide	organisations	such	as	the	International	Diabetes	Federation	(IDF)	
(Cameron	et	al.,	2004),	the	World	Health	Organisation	(WHO)	(Alberti	&	Zimmet,	
1998)	and	the	US	National	Cholesterol	Education	Program	Adult	Treatment	Panel	III	
(NCEP)	("Executive	Summary	of	The	Third	Report	of	The	National	Cholesterol	
Education	Program	(NCEP)	Expert	Panel	on	Detection,	Evaluation,	And	Treatment	of	
High	Blood	Cholesterol	In	Adults	(Adult	Treatment	Panel	III),"	2001).	All	incorporate	
the	core	elements	of	abdominal	obesity,	hypertension,	impaired	glucose	metabolism	
and	dyslipidaemia,	but	differ	in	the	exact	cut-offs	or	scoring	criteria.	
	
1.6.2 MetS	and	the	brain		
The	link	between	MetS	and	cardiovascular	decline	is	well	established,	but	there	may	
also	be	an	important	association	with	neurodegenerative	processes.	Type	2	diabetes	
is	a	strong	risk	factor	for	the	development	of	AD	(Ballard	et	al.,	2011)	and	can	delay	
recovery	from	stroke	(Kissela	&	Air,	2006)	and	peripheral	nerve	injuries	(Kennedy	&	
Zochodne,	2000).	
	
Several	longitudinal	studies	have	linked	MetS	with	cognitive	impairment	and	
interestingly	more	so	in	those	who	had	raised	markers	of	systemic	inflammation	e.g.	
CRP,	IL-6	and	antichymotrypsin	(Dik	et	al.,	2007;	Yaffe	et	al.,	2007;	Yaffe	et	al.,	2004).	
The	Framingham	study	demonstrated	that	cognition	was	inversely	associated	with	
blood	pressure	and	type	2	diabetes	(Elias,	Wolf,	D'Agostino,	Cobb,	&	White,	1993)	
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and	another	study	suggested	that	the	presence	of	MetS	confers	a	74%	risk	of	
cognitive	impairment	(Whitmer,	Gunderson,	Barrett-Connor,	Quesenberry,	&	Yaffe,	
2005).		
	
Metformin	is	a	biguanide	drug	which	counteracts	the	effects	of	MetS	and	increases	
insulin	sensitivity.	In	animals,	metformin	has	been	shown	to	improve	learning	and	
memory	impairment	in	High	Fat	Diet	(HFD)-fed	rats	(Pintana,	Apaijai,	Pratchayasakul,	
Chattipakorn,	&	Chattipakorn,	2012).	
	
1.6.3 MetS	and	TBI			
In	the	case	of	TBI,	type	2	diabetes	increases	mortality	acutely	(Ley	et	al.,	2011),	but	
the	long	term	effects	of	metabolic	abnormalities	on	brain	repair	are	less	clear.	Some	
animal	studies	however	suggest	that	MetS	and	a	neurodegenerative	process	
following	TBI	may	be	linked.	Insulin	resistant	diabetic	rats	or	rats	fed	a	HFD	had	
worse	cognition	function,	greater	neurodegeneration	and	abnormal	neural	plasticity	
after	a	cortical	contusion	injury	(Hoane,	Swan,	&	Heck,	2011).	Another	study	
demonstrated	that	hippocampal	brain-derived	neurotrophic	factor	(BDNF)	was	
reduced	and	cognition	was	worse	in	rats	fed	a	high-fat	sucrose	diet	following	a	TBI	
(A.	Wu,	Molteni,	Ying,	&	Gomez-Pinilla,	2003).		
	
MetS	is	a	potentially	reversible	condition	either	by	lifestyle	interventions	(diet,	
exercise)	or	by	medications,	or	both.	Simple	exercise	has	been	found	to	improve	
brain	plasticity	and	neurocognitive	performance	after	a	TBI	and	improves	features	of	
the	MetS	(Archer,	2012).	In	vitro	and	an	in	vivo	work	has	demonstrated	that	
metformin	has	been	shown	to	enhance	neurogenesis	especially	in	the	hippocampus	
and	olfactory	bulb	and	enhances	spatial	memory	following	a	TBI(Wang	et	al.,	2012).	
Finally,	statin	therapy	has	been	shown	to	reduce	axonal	injury,	enhance	neurite	
outgrowth	and	promote	neurological	functional	recovery	after	experimental	TBI	(H.	
Wu,	Mahmood,	Qu,	Xiong,	&	Chopp,	2012).	Statins	may	exert	their	effects	by	
reducing	neuroinflammation.	Simvastatin	has	been	shown	to	inhibit	microglial	and	
astrocytic	activation	and	reduce	IL-1β	following	a	TBI	(Li	et	al.,	2009).	
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Glucagon-like	peptide-1	(GLP-1)	agonists	are	another	class	of	drugs	which	counteract	
the	effect	of	MetS.	They	are	licensed	treatments	for	type	2	diabetes	and	act	to	
induce	glucose-dependent	insulin	secretion.	As	GLP-1	receptors	are	distributed	
widely	in	the	brain,	these	drugs	are	likely	to	have	a	central	mode	of	action	as	well	
(Alvarez	et	al.,	2005;	Blazquez	et	al.,	1998).	Exendin-4	(a	GLP-1	agonist)	treatment	
produced	neuroprotective	effects	in	vitro	and	improved	cognitive	function	in	an	
animal	model	of	TBI	(Eakin	et	al.,	2013).	Pioglitazone,	a		thiazolidinedione,	acting	
through	the	PPAR-ϒ	receptor	has	shown	some	promise	in	reducing	histological	
damage	and	inflammation	in	the	acute	phase	following	TBI	(Thal	et	al.,	2011).	
	
	
1.6.4 Prevalence	of	MetS	in	TBI	patients	at	Imperial	Healthcare	NHS	
Trust		
	
I	investigated	the	prevalence	of	metabolic	abnormalities	in	241	patients	attending	
the	TBI	clinic.	A	high	proportion	of	these	patients	had	features	of	MetS	(Figure	1-12):	
18%	had	insulin	resistance	using	a	Homeostatic	Model	Assessment	Score	(HOMA)	of	
>3,	18%	obesity	(BMI>30	kg/m2),		16%	elevated	fasting	glucose	(>5.6	mmol/L),	3.4	%	
had	diagnosed	type	2	diabetes,	18%	hypertriglyceridemia,	and	50%	low	HDL-
cholesterol.	
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Figure	1-12	Prevalence	MetS	variables	in	patients	attending	the	multidisciplinary	
TBI	clinic	(n=241).	
	
TG=Triglyceride,	HDL=High	Density	Lipoprotein,	FBG	=	Fasting	Blood	Glucose			
1.6.5 MetS	and	systemic	inflammation	
	
There	is	evidence	to	suggest	that	MetS	increases	systemic	inflammation.	MetS	
principally	results	from	a	combination	of	poor	diet,	lack	of	physical	exercise	and	
genetic	factors.	Under	normal	physiology,	excess	glucose	and	free	fatty	acids	(FFA)	
are	taken	up	from	the	circulation	by	adipose	tissue,	liver	and	skeletal	muscle	by	
insulin.	They	are	then	converted	to	glycogen	or	triglycerides	where	they	are	stored	
for	future	use.		
	
In	a	state	of	chronic	over-nutrition,	these	storage	tissues	exceed	their	capacity	to	
store	excess	energy.	Adipocytes	hypertrophy	and	free	fatty	acids	(FFA)	in	the	
circulation	multiply.	These	two	processes	ultimately	activate	M1	macrophages	in	the	
adipose	tissue	which	then	release	pro-inflammatory	cytokines	such	as	IL-β,	TNF-α	
and	IL-6	(Hotamisligil	et	al.,	1996).	This	exacerbates	adipocyte	insulin	resistance	and	
Insulin resistance 
18%
High TG
18%
obesity 
18%
Raised FBG
16%
Type 2 diabetes
4%
Low HDL
50%
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further	recruits	further	macrophages	(Xu	et	al.,	2003).	In	addition,	excess	FFA	and	
adiopcytokines	pass	directly	to	the	liver	impairing	insulin	action	and	promoting	
visceral	adiposity.	Visceral	adiposity	in	itself	is	associated	with	a	pro-inflammatory	
state	with	high	plasminogen	activator	inhibitor-1	(PAI-1)	and	low	adiopnectin	(Amato	
et	al.,	2014).	
	
This	smouldering	inflammatory	response	in	the	periphery	is	now	thought	to	drive	the	
cardiovascular	disease	seen	in	MetS	and	the	efficacy	of	treatments	such	as	aspirin	
and	statins	are	thought	to	be,	at	least	in	part,	mediated	by	their	anti-inflammatory	
effects	(Rocha	&	Libby,	2009)	
	
1.6.6 Link	between	systemic	inflammation	and	neuroinflammation		
It	has	long	been	observed	that	systemic	infections	can	induce	a	flare	of	multiple	
sclerosis	(MS)	for	example.	Microglial	activation	appears	to	be	a	mechanism	through	
which	this	occurs.	Markers	of	inflammation	in	the	systemic	circulation	can	signal	to	
microglia	in	a	number	of	ways	(Perry	et	al.,	2007).	
	
Firstly,	damage	from	TBI	could	disrupt	the	blood	brain	barrier	(BBB)	to	the	extent	
that	cytokines	and	inflammatory	mediators	in	the	blood	are	able	to	communicate	
directly	with	macrophages.	The	signal	is	then	communicated	to	the	microglia	and	
spreads	though	the	CNS.	
	
Alternatively,	systemic	inflammatory	mediators	may	interact	directly	with	the	brain	
endothelium,	communicating	across	the	BBB	via	perivascular	macrophages,	possibly	
through	induction		of	lipid	mediators	e.g.	prostaglandin	E2.	Finally,	direct	signalling	
can	also	occur	from	the	abdominal	cavity	to	the	brain	via	the	vagus	nerve.		
	
In	AD,	factor	such	as	systemic	inflammation	and	obesity	appear	to	promote	disease	
progression	(Heneka	et	al.,	2015).	MetS,	diabetes	and	obesity	all	invoke	a	state	of	
low	grade	peripheral	inflammation	and	it	may	be	this	pathway	that	could	promote	a	
harmful	neuroinflammatory	process.		
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Given	that	TBI	can	induce	neuroinflammation	and	neurodegeneration,	it	may	be	that	
peripheral	factors	such	as	MetS,	diabetes	and	obesity	could	modulate	the	long	term	
outcome	from	TBI	in	much	the	same	way	as	AD	and	other	neurodegenerative	
diseases.		
	
1.7 Thesis	overview		
1.7.1 Chapter	1.	Introduction	
	
In	this	chapter	I	define	TBI,	review	the	epidemiology,	aetiology	and	its	clinical	
consequences,	economic	impact	and	treatments.		I	then	describe	the	typical	
pathophysiological	features	of	TBI.	I	then	introduce	the	reader	to	a	clinical	
consequence	that	is	a	major	theme	in	this	thesis;	namely	pituitary	dysfunction	
following	TBI	and	its	metabolic	and	psychological	consequences.	Neuroinflammation	
is	then	introduced	as	another	major	theme	in	this	thesis.	I	discuss	its	significance	in	
TBI,	how	it	is	quantified	and	how	it	may	be	influenced	by	the	metabolic	syndrome.	
	
1.7.2 Chapter	2.	Methods		
This	chapter	describes	the	study	designs,	patient	recruitment	and	data	collection	for	
each	chapter.	Neuroimaging	techniques	used	in	this	study	are	introduced	including	
DTI	and	tract	based	spatial	statistics.	PET	methodology	is	presented	including	an	
overview	of	kinetic	compartmental	modelling,	generation	of	an	arterial	input	
function	and	the	analysis	processing	steps.	Methods	for	diagnosing	endocrine	
dysfunction	and	metabolic	impairments	are	also	presented	here.	
	
1.7.3 Chapter	3.	Pituitary	Dysfunction	following	Blast	Traumatic	Brain	
Injury			
Here	I	describe	the	high	prevalence	of	pituitary	dysfunction	in	19	soldiers	with	blast	
TBI	(bTBI)	compared	to	39	patients	with	non-blast	TBI	(nbTBI).	I	present	the	
endocrine	analyses	I	performed,	quality	of	life	(QoL)	scores,	cognitive	outcome	and	
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diffusion	tensor	imaging	(DTI)	results	in	soldiers.	This	work	has	already	been	
published	in	Annals	of	Neurology	(Baxter	et	al.,	2013).	
	
1.7.4 Chapter	4:	Association	of	serum	IGF-I	with	white	matter,	
neuropsychological	and	cognitive	recovery	following	traumatic	
brain	injury		
Here	I	present	a	longitudinal	DTI	and	cognitive	study	in	39	patients	following	TBI.	I	
use	baseline	serum	IGF-I	measurements	and	compare	outcome	measures	for	
patients	with	an	IGF-I	above	the	median	for	the	whole	group	compared	to	those	with	
an	IGF-I	below	the	median	value.	I	present	whole	brain	and	ROI	FA	results	and	
cognitive/QoL	analyses.	
	
1.7.5 Chapter	5:	The	effect	of	GH	replacement	therapy	on	the	recovery	
from	TBI			
In	this	chapter	I	present	the	whole	brain	and	ROI	FA	results	for	10	patients	who	
received	growth	hormone	replacement	(GHR)	for	a	median	duration	of	14	months	
following	TBI	compared	to	a	group	of	TBI	patients	who	did	not	receive	this	
treatment.	I	present	the	patient	characteristics,	whole	brain	and	ROI	FA	results,	
cognitive	QoL	analyses	and	show	the	effect	of	GHR	on	metabolic	impairment.		
	
1.7.6 Chapter	6:	Neuroinflammation	in	TBI:	A	kinetic	analysis	of	the	
translocator	protein	(TSPO)	positron-emission	tomography	
ligand	[18F]GE-180	in	the	human	brain	
	
In	this	chapter	I	present	a	PET	study	using	the	novel	TSPO	ligand	[18F]GE-180	in	
healthy	volunteers.	I	present	the	blood	and	imaging	data	and	kinetic	modelling.	I	also	
investigate	whether	there	is	an	effect	of	the	TSPO	polymorphism	on	outcome	
measures	as	has	been	seen	with	other	TSPO	tracers.	This	work	has	been	accepted	for	
publication	in	the	European	Journal	of	nuclear	medicine	and	molecular	imaging.	
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1.7.7 Chapter	7:	Analysis	of	neuroinflammation	in	TBI	using	the	novel	
PET	radioligand	[18F]GE-180	and	its	relationship	with	the	
metabolic	syndrome		
In	this	chapter	I	present	the	[18F]GE-180	PET	data	in	TBI	patients	at	baseline	and	
follow-up	six	months	later.	I	examine	for	an	effect	of	the	TSPO	polymorphism	(high	
affinity	and	mixed	affinity	binders).	I	also	investigate	for	a	influence	of	metabolic	
syndrome	on	[18F]GE-180	outcome	measures.	
	
1.7.8 Chapter	8:	Discussion		
In	this	final	chapter	I	summarise	the	results	from	all	the	chapters,	discuss	their	
significance	and	limitations.		
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2 Methods	 	
This	chapter	will	provide	a	broad	overview	of	the	participants,	materials,	methods	
and	analyses	used	in	this	thesis.	Please	note	that	each	chapter	has	its	own	methods	
section	and	will	refer	to	sections	in	this	chapter	where	necessary.		
2.1 Participants			
2.1.1 Recruitment	for	Chapter	3		
19	military	bTBI	patients	were	recruited	using	the	Academic	Department	of	Military	
Emergency	Medicine	(Birmingham,	UK)	trauma	database	to	identify	soldiers	injured	
between	December	2009	and	March	2012.	This	part	of	the	recruitment	process	was	
carried	out	by	D	Baxter.	Comparison	was	made	with	an	age-	and	gender-matched	
control	group	of	39	patients	who	had	suffered	a	non-blast	TBI	and	who	were	seen	in	
the	multidisciplinary	TBI	clinic	at	Charing	Cross	Hospital	between	August	2009	and	
March	2012,	met	the	inclusion	and	exclusion	criteria	and	were	within	age	range	of	
the	bTBI	group.	Soldiers	were	scanned	on	a	3	Tesla	(Phillips	Achieva	scanner,	Phillips	
Medical	Systems,	Netherlands)	in	the	Robert	Steiner	Unit	at	Hammersmith	Hospital	
London.	
	
2.1.2 Recruitment	for	Chapter	4		
39	patients	with	a	history	of	TBI	were	recruited	from	the	multidisciplinary	TBI	clinic	
at	Charing	Cross	and	St	Mary’s	Hospitals	or	via	Richard	Greenwood’s	clinic	at	
Homerton	Hospital.	Endocrine	testing	was	performed	as	part	of	routine	clinical	care	
at	either	Charing	Cross	or	St	Mary’s	Hospital.	
	
Inclusion	criteria	were	as	follows:	
i) On-going	cognitive	or	psychological	symptoms	following	TBI	
ii) Aged	18-80	
iii) Capacity	to	give	informed	consent	
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Exclusion	criteria	were	as	follows:	
i) History	of	neurosurgery	or	craniotomy	
ii) History	of	psychiatric	or	neurological	illness	prior	to	TBI	
iii) History	of	significant	previous	TBI	
iv) Current	or	previous	drug	or	alcohol	abuse	
v) Completion	of	endocrine	testing	
vi) Contraindication	to	MRI	scanning		
	
Research	ethics	approval	was	obtained	from	the	Ealing	and	West	London	Research	
Ethics	Committee	REC	09/H0707/82.	A	control	group	of	35	age	and	gender	matched	
healthy	volunteers	was	recruited	from	various	sources	and	had	been	collected	by	the	
group	over	the	last	few	years.	All	controls	had	no	history	of	neurological	or	
psychiatric	illness	and	were	not	taking	any	medication.		Patients	were	scanned	on	a	3	
Tesla	(Phillips	Achieva	scanner,	Phillips	Medical	Systems,	Netherlands)	in	the	Robert	
Steiner	Unit	at	Hammersmith	Hospital	London.		
2.1.3 Recruitment	for	Chapter	5			
14	patients	with	confirmed	growth	hormone	deficiency	(GHD)	were	recruited	from	
the	multidisciplinary	TBI	clinic	at	Charing	Cross	and	St	Mary’s	Hospitals	under	the	
same	ethics	as	for	Chapter	4.	10	of	these	patients	were	scanned	prior	to	starting	GH	
and	10	one	year	afterwards.	The	4	other	patients	with	GHD	were	either	not	started	
on	GH	(n=3,	1	due	to	bladder	carcinoma,	1	asymptomatic,	1	requiring	investigation	
for	nasal	polyps)	or	lost	to	follow-up	(n=2).	This	group	was	compared	to	a	control	
group	of	23	patients	with	TBI	(but	no	GHD)	and	who	were	age	and	gender	matched.			
2.1.4 Recruitment	for	Chapter	6		
	
10	healthy	controls	were	recruited	via	various	routes	including	word	of	mouth,	
existing	volunteer	databases	and	advertisements	on	noticeboards.	Inclusion	criteria	
were	as	follows:	
	
i) age	between	20	and	65	years	
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ii) in	good	general	health	
iii) no	significant	current	or	previous	neurological	or	psychiatric	illness	
iv) capable	of	giving	written	informed	consent	
v) not	currently	on	any	medication	that	would	interfere	with	the	study	
or	compromise	participant	safety.	
 
Exclusion	criteria	were	as	follows:		
	
i) unwillingness	or	inability	to	follow	the	procedures	required	
ii) significant	prior	neurological	or	psychiatric	illness	
iii) history	of	a	drug	or	other	allergy	that,	in	the	opinion	of	the	
investigators,	contraindicates	their	participation	in	the	study	
iv) use	of	any	medication	or	substance	that,	in	the	opinion	of	the	
investigators,	would	interfere	with	the	study	or	compromise	
participant	safety		
v) contraindication	to	MRI	scanning,	assessed	by	a	standard	pre-MRI	
questionnaire	(e.g.	presence	of	ferromagnetic	implants,	
claustrophobia,	pregnancy)	
vi) contraindication	to	PET-CT	scanning	(e.g.	pregnancy)	
vii) contraindication	to	arterial	line	insertion	(e.g.	positive	Allen’s	test	
indicating	ulnar	arterial	insufficiency,	prolonged	PT)	
viii)	contraindication	to	receiving	contrast	e.g.	previous	allergy	or	chronic	
renal	impairment	
ix) Exposure	to	ionising	radiation	(above	normal	background	levels)	in	
the	last	two	years.	
x) Low	affinity	binders	(LABs)	were	excluded	(see	section	2.6.1	TSPO	Genotyping	page	80).	
	
The	study	was	approved	by	the	Westminster	Research	Ethics	committee	(Project	ref	
no:	13/LO/1596	version	2.0	date	3.12.13)	and	by	the	Administration	of	Radioactive	
Substances	Advisory	Committee	(ARSAC).	
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2.1.5 Recruitment	for	Chapter	7	
 
28	patients	were	recruited	from	the	multidisciplinary	TBI	clinic	at	St	Mary’s	Hospital.	
They	then	had	either	a	face	to	face	or	telephone	consultation	to	screen	for	the	
inclusion	and	exclusion	criteria	and	to	ensure	they	had	read	the	patient	information	
leaflet.	They	were	then	invited	to	come	for	an	initial	visit	to	have	a	metabolic	
assessment	and	a	genetic	test	to	screen	for	the	TSPO	polymorphism.	From	this	point	
12	patients	were	suitable	for	inclusion	into	the	scanning	part	of	the	study.	Of	these	
10	completed	a	follow-up	scanning	session	6	months	later.	A	proportion	of	these	
patients	were	selected	because	they	had	confirmed	Metabolic	syndrome	(MetS)	
	
Inclusion	criteria	were	as	follows:		
i) age	between	20	and	65	years	
ii) a	diagnosis	of	traumatic	brain	injury	(TBI)	
iii) no	significant	neurological	or	psychiatric	illness	prior	to	TBI	
iv) capable	of	giving	written	informed	consent	
v) not	currently	on	any	medication	that	would	interfere	with	the	study	
or	compromise	participant	safety.	
	
Additional	inclusion	criteria	for	TBI	patients	with	MetS		
i) Raised	waist	circumference	i.e.	Male	≥	94	cm,	Female	≥	80cm	
(European	measurements,	other	ethnic	specific	measurement	apply).	
If	body	mass	index	(BMI)	>30	kg/m2	then	waist	circumference	criteria	
can	be	assumed.	
Plus	TWO	or	more	of:	
ii) Fasting	hypertriglyceridemia	(≥1.7	mmol/L	or	on	specific	treatment	
for	this	lipid	abnormality)	
iii) Hypertension	(systolic	≥130mmHg,	diastolic	≥85	or	on	anti-
hypertensive	drugs)	
iv) Raised	fasting	glucose	(≥5.6	mmol/L	or	previously	diagnosed	Type	2	
Diabetes,	or	on	anti-diabetic	medication).	
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v) Low	HDL-cholesterol	(males	<1.03	mmol/L,	females	<1.29	mmol/L,	or	
on	specific	treatment	for	this	lipid	abnormality).	
Exclusion	criteria	were	as	follows:	
i) unwillingness	or	inability	to	follow	the	procedures	required	
ii) significant	prior	neurological	or	psychiatric	illness	
iii) history	of	a	drug	or	other	allergy	that,	in	the	opinion	of	the	
investigators,	contraindicates	their	participation	in	the	study	
iv) use	of	any	medication	or	substance	that,	in	the	opinion	of	the	
investigators,	would	interfere	with	the	study	or	compromise	
participant	safety		
v) contraindication	to	MRI	scanning,	assessed	by	a	standard	pre-MRI	
questionnaire	(e.g.	presence	of	ferromagnetic	implants,	
claustrophobia,	pregnancy)	
vi) contraindication	to	PET-CT	scanning	(e.g.	pregnancy)	
vii) contraindication	to	arterial	line	insertion	(e.g.	positive	Allen’s	test	
indicating	ulnar	arterial	insufficiency,	prolonged	PT)	
viii)Contraindication	to	receiving	contrast	e.g.	previous	allergy	or	chronic	
renal	impairment	
	
The	study	was	approved	by	the	Westminster	Research	Ethics	committee	(Project	ref	
no:	13/LO/1596	version	2.0	date	3.12.13)	and	by	the	Administration	of	Radioactive	
Substances	Advisory	Committee	(ARSAC).	A	high-level	overview	of	the	study	design	is	
depicted	in	Figure	2-1	
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Figure	2-1	High	level	overview	of	study	design	(PET	studies).	
	
My	studies	accounted	for	n=12	TBI	patients	and	n=10	healthy	volunteers.	TSPO=translocator	
protein.			
2.2 TBI	severity	classification		
For	all	chapters,	TBI	severity	was	assessed	according	to	the	Mayo	Classification	
system	(Malec	et	al.,	2007).	These	scoring	criteria	integrate	post-traumatic	amnesia	
(PTA);	lowest	Glasgow	Coma	Scale	(GCS)	score	in	the	first	24	hours,	duration	of	loss	
of	consciousness	and	neuroimaging	findings.	Criteria	are	shown	below	in	Table	2-1.	
	
	
	
	
	
	
	
	
	
Recruitment 
Consent and 
Screening              
Visit 
6 month 
Follow-up Visit 
TBI patients 
n ≈ 40 
Baseline Visit 
Metabolic 
assessment; 
cognitive 
assessment; MRI; 
1× GE-180 PET-CT 
Healthy volunteers 
n ≈ 15 
Cognitive 
assessment;  
MRI 
Chronic neuroinflammation after TBI - Study Design 13/LO/1596 v1.0 (4/10/2013) 
Metabolic assessment;  
Genetic analysis; MRI; 
 Cognitive assessment; 
1× GE-180 PET-CT 
n=40 
Metabolic assessment;  
Genetic analysis; MRI; 
 Cognitive assessment; 
1× GE-180 PET-CT 
N=15 
Consent; Clinical 
assessment; 
screening bloods; 
TSPO analysis 
Consent; Clinical 
assessment; 
screening bloods; 
TSPO analysis 
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Table	2-1	TBI	Mayo	classification	severity	score	adapted	from	(Malec	et	al.,	2007)	
	
Injury	Severity	 Diagnostic	criteria	
Moderate	to	severe	TBI	 If	one	of	more	of	the	following	criteria	apply:		
i) Death	Secondary	to	TBI	
ii) LOC	30	mins	or	greater	
iii) PTA	24	hours	or	greater	
iv) GCS<13/15	in	the	first	24	hours	
after	injury	(attributable	to	TBI,	
not	other	causes)	
v) One	of	the	following	imaging	
findings:	
-Intracerebral,	subdural	or	
epidural	haematoma	
-cerebral	contusion	
-penetration	of	the	dura	
-subarachnoid	haemorrhage	
-brainstem	injury	
Probable	(Mild)	TBI	 If	none	of	the	above	apply	but	patients	have	
one	or	more	of	the	following:	
i) LOC	<30	mins	
ii) PTA	<24	hours	
iii) Depressed	basilar	or	linear	skull	
fracture	with	intact	dura.	
Possible	(Symptomatic)	TBI	 If	none	of	the	above	apply,	but	patients	
report	one	or	more	of	the	following	
symptoms:	
i) Blurred	vision	
ii) Headache	
iii) Focal	neurological	symptoms	
iv) Dazed	
v) Dizziness	
vi) Nausea	
vii) Confusion		
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2.3 Study	visit	at	Robert	Steiner	MRI	Unit	(Chapter	3,	4	and	5)	
 
All	participants	were	sent	a	patient	information	leaflet	and	screened	for	inclusion	or	
exclusion	criteria	either	in	clinic	or	over	the	telephone	prior	to	arrival	on	the	study	
day.	Consent	forms	were	signed	at	the	study	visit.	A	full	clinical	assessment	was	
carried	out	including	recording	of	symptoms	and	medications.	A	cognitive	
assessment	was	carried	out.	Quality	of	life	questionnaires	were	filled	out.	Following	
this,	brain	MRI	scans	were	acquired.	
	
At	the	follow-up	visit,	the	same	study	protocol	was	applied.	A	clinical	assessment	
was	taken	to	assess	on-going	symptoms	and	medication	changes.	In	the	case	of	
those	patients	on	GH,	enquiry	was	made	as	to	current	dosing,	dose	changes	during	
the	year	and	any	periods	off	treatment.		
	
2.3.1 Quality	of	Life	(QoL)	assessments		
Questionnaires	were	given	to	the	participants	to	fill	out	under	supervision.	These	
questionnaires	were	chosen	to	reflect	some	of	the	common	symptoms	reported	by	
patients	following	a	TBI,	including	depression	and	sleep	disturbance	and	included:	
	
i) Quality	of	Life.	Assessment	of	GH	deficiency	in	Adults	(AGHDA)	(QoL-
AGHDA)	
ii) Beck	Depression	Inventory-II	(BDI-II)	(Beck,	Steer,	Ball,	&	Ranieri,	1996)	
iii) Short	Form-36	Survey	(SF-36)	(Ware	&	Sherbourne,	1992)	
iv) Nottingham	Health	Profile	(NHP)	(Hunt,	McEwen,	&	McKenna,	1985)	
v) Pittsburgh	Sleep	Quality	Index	(Buysse,	Reynolds,	Monk,	Berman,	&	
Kupfer,	1989)	
vi) Epworth	sleepiness	scale	(Johns,	1991)								
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2.3.2 Neuropsychological	assessment		
All	patients	underwent	a	standardised	neuropsychological	battery	of	tests	which	our	
group	has	used	previously	in	TBI	(Bonnelle	et	al.,	2012;	Kinnunen	et	al.,	2011).		
	
i) The	Wechsler	Test	of	Adult	Reading	(WTAR)	(Wechsler,	1997b)	was	used	
to	assess	pre-morbid	intellectual	functioning.	
ii) The	Wechsler	Abbreviated	Scale	of	Intelligence	(WASI)	Similarities	and	
Matrix	Reasoning	subtests	were	used	to	assess	current	non-verbal	and	
verbal	reasoning	ability	(Wechsler,	1999)	
iii) Wechsler	Memory	Scale-Third	Edition	(WMS-III)	subtest	Digit	Span,	was	
used	to	assess	working	memory	(Wechsler,	1997b)	
iv) Wechsler	Memory	Scale-Third	Edition	(WMS-III)	subtest	Logical	Memory	I	
and	II,	was	used	to	measure	immediate	and	delayed	memory	recall	of	
structured	verbal	material	(Wechsler,	1997a)	
v) The	Peoples’	test	from	the	Doors	and	People	Test	to	assess	associative	
learning	and	recall	(immediate	and	delayed)	(Baddeley,	1994).	
vi) The	Delis-Kaplan	Executive	Function	System	(D-KEFS)	subtests	Verbal	
Fluency	(F-A-S)	and	Colour-Word	Interference	(Stroop)	to	assess	word	
generation	fluency,	cognitive	flexibility	and	set-shifting	and	information	
processing	speed	(Delis,	2001).	
vii) The	Trail	Making	Test	(Forms	A	and	B)	was	used	to	further	assess	
executive	functions	(R,	1958)	
	
2.3.3 MRI	brain	acquisition		
Each	participant	had	standard	high-resolution	T1	and	gradient-echo	(T2*)	
(1.75x1.75x2mm3)	imaging	to	assess	focal	brain	injury	and	evidence	of	microbleeds,	
superficial	siderosis,	presence	and	location	of	contusions	and	gross	pituitary	injury.	
All	structural	MR	scans	were	reviewed	by	a	single	experienced	consultant	
neuroradiologist,	Dr	Manesh	Patel	(Hammersmith	Hospital,	London).	
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MRI	was	performed	on	3T	Achieva	scanner	(Philips	Medical	Systems,	Netherlands)	
using	an	8	channel	head	coil.	The	T1	and	T2*-weighted	images	were	obtained	prior	
to	DTI.	For	DTI,	diffusion-weighted	volumes	with	gradients	applied	in	16	non-
collinear	directions	were	collected	in	each	of	the	four	DTI	runs,	resulting	in	a	total	of	
64	directions.	The	following	parameters	were	used:	73	contiguous	slices,	slice	
thickness	2mm,	field	of	view	224mm,	matrix	128	x	128	(voxel	size	1.75x1.75x2	mm3),	
b	value	1000	and	four	images	with	no	diffusion	weighting	(b=0s/mm2).		
	
2.3.4 Generation	of	FA	maps			
The	images	were	registered	to	the	b0	image	by	affine	transformations	to	minimize	
distortion	due	to	motion	and	eddy	currents	and	then	brain-extracted	using	Brain	
Extraction	Tool	(S.	M.	Smith,	2002)	from	the	FMRIB	Software	Library	image	
processing	toolbox	(S.	M.	Smith	et	al.,	2004;	Woolrich	et	al.,	2009).	FA	maps	were	
generated	using	the	Diffusion	Toolbox	(Behrens	et	al.,	2003).	
	
2.3.5 Tract	based	spatial	statistics	(TBSS)		
TBSS	is	a	voxel-wise	approach	to	analysing	FA	maps	(and	other	DTI	metrics).	Given	
that	there	is	significant	inter-individual	variability	in	brain	structure	and	volume,	DTI	
data	is	particularly	vulnerable	to	partial	volume	effects.	TBSS	is	a	method	of	tackling	
this	problem	by	reducing	white	matter	(WM)	structure	to	smaller	regions	of	brain	
tracts’	where	the	WM	alone	is	consistent	across	groups	(S.	M.	Smith	et	al.,	2006)	
	
TBSS	was	carried	out	using	the	FMRIB	Software	Library	(S.	M.	Smith	et	al.,	2006;	S.	
M.	Smith	et	al.,	2004)	and	involved	a	number	of	steps:		
	
(i) Non-linear	alignment	of	all	subjects’	FA	images	into	common	FMRIB58	FA	
template	space;		
(ii) Affine-transformation	of	the	aligned	images	into	standard	MNI152	1mm	
space;		
(iii) Averaging	of	the	aligned	FA	images	to	create	a	4D	mean	FA	image;		
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(iv) Thinning	of	the	mean	FA	image	to	create	a	mean	FA	‘skeleton’	
representing	the	centre	of	all	white	matter	tracts,	and	in	this	way	
removing	partial-volume	confounds	
(v) Thresholding	of	the	FA	skeleton	at	FA	0.2	to	suppress	areas	of	extremely	
low	mean	FA	and	exclude	those	with	considerable	inter-individual	
variability.		
(vi) Non-parametric	permutation-based	statistics	were	employed	using	
randomize	with	threshold-free	cluster	enhancement	and	5000	
permutations	(Nichols	&	Holmes,	2002;	S.	M.	Smith	&	Nichols,	2009)	
(vii) A	threshold	of	P<0.05	was	then	applied	on	the	results,	corrected	for	
multiple	comparisons.	
	
2.3.6 Longitudinal	TBSS	analyses		
An	interaction	design	matrix	was	set	up	in	a	GLM	framework	and	is	depicted	in	
Figure	2-2.	This	matrix	was	able	to	examine	for	an	effect	of	time	and	an	interaction	
on	time	of	our	chosen	variable	(e.g.	IGF-I,	GHD),	but	was	unable	to	examine	for	an	
effect	of	group	due	to	‘rank	deficiency’.	Covariates	could	not	be	added	to	this	model	
for	this	reason	also.	To	examine	for	an	effect	of	group	a	subtraction	design	was	set	
up	whereby		the	two	FA	maps	per	subject	were	subtracted	from	one	another	and	
TBSS	performed	on	the	resulting	image.		
	
Figure	2-2	Longitudinal	TBSS	design	matrix	
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2.4 Endocrine	methods		
The	same	method	to	diagnose	pituitary	dysfunction	was	used	for	chapter	3,4	and	5.	
The	diagnostic	algorithm	and	details	of	the	endocrine	tests	used	can	be	found	in	
3.2.4	Tests	for	pituitary	dysfunction	page	102.	These	tests	were	performed	as	
part	of	routine	clinical	care	under	the	supervision	of	Dr	Tony	Goldstone	(Consultant	
Endocrinologist).	Pituitary	hormone	deficiencies	were	treated	when	appropriate.	GH	
treatment	was	administered	by	the	patients	themselves	following	education	from	
our	endocrine	specialist	nurse,	Debbie	Peters,	at	Charing	Cross	Hospital.	Patients	
were	followed	up	in	the	multidisciplinary	TBI	clinic	at	either	Charing	Cross	or	St	
Mary’s	Hospitals.			
2.5 Methods	for	assessing	insulin	resistance	(IR)	and	the	metabolic	
syndrome		
2.5.1 Criteria	for	diagnosing	the	metabolic	syndrome	in	this	study	
	
The	method	for	diagnosing	the	metabolic	syndrome	in	this	study	was	using	the	
criteria	from	the	International	Diabetes	Federation	(Alberti,	Zimmet,	&	Shaw,	2006).	
I	chose	this	criteria	as	it	has	ethnic	specific	cut-offs	for	waist	circumference.	Criteria	
are	displayed	in	Table	2-2.	
	
Table	2-2	IDF	criteria	for	diagnosing	the	metabolic	syndrome	
	
*	If	BMI	is	>30kg/m2,	central	obesity	can	be	assumed	and	waist	circumference	does	
not	need	to	be	measured.		
Central	obesity	(defined	as	waist	circumference*	with	ethnicity	specific	values)	
plus	any	two	of	the	following	four	factors:	
Raised triglycerides ≥ 150 mg/dL (1.7 mmol/L)
or specific treatment for this lipid abnormality 
Reduced HDL cholesterol < 40 mg/dL (1.03 mmol/L) in males 
< 50 mg/dL (1.29 mmol/L) in females 
or specific treatment for this lipid abnormality 
Raised blood pressure systolic BP ≥ 130 or diastolic BP ≥ 85 mm Hg
or treatment of previously diagnosed hypertension 
Raised fasting plasma glucose (FPG) ≥ 100 mg/dL (5.6 mmol/L),
or previously diagnosed type 2 diabetes 
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Cut-offs	for	ethnic	specific	waist	circumference	are	displayed	in	Table	2-3.	
For	patients	who	I	did	not	have	a	waist	circumference	measurement	(Chapter	5),	I	
calculated	a	‘metabolic	score’,	assigning	a	single	point	(out	of	4)	for	each	of	the	
categories	in	Table	2-2	excluding	BMI	and	waist	measurement.	
	
Table	2-3	Table	showing	cut	offs	for	waist	circumference	for	different	ethnic	groups		
	
	
2.5.2 Sex-hormone	binding	globulin	(SHBG)			
SHBG	is	a	specific	steroid-binding	globulin	which	is	mainly	derived	from	the	liver	
(Selby,	1990).	It	binds	testosterone	with	high	affinity	and	oestrogens	with	lower	
affinity.	Its	function	is	a	modulate	androgen	delivery	to	tissues.	Insulin	appears	to	
have	a	modulatory	effect	on	SHBG	levels	and	therefore	diseases	characterised	by	IR	
affect	serum	concentrations	of	SHBG.	For	example	lower	SHBG	level	has	been	
reported	in	obesity	(Pasquali	et	al.,	1991)	and	polycystic	ovarian	syndrome	(PCOS)	
(Meirow	et	al.,	1995).	In	addition,	low	SHBG	levels	are	an	independent	risk	factor	for	
developing	type	2	diabetes	(Lindstedt	et	al.,	1991).	SHBG	was	measured	on	a	single	
blood	samples	on	all	participants	as	part	of	a	metabolic	assessment.	
	
2.5.3 The	Homeostasis	Model	Assessment	(HOMA)			
The	gold	standard	for	measuring	insulin	resistance	is	the	hyperinsulinaemic	
euglycaemic	clamp	which	measures	the	amount	of	infused	glucose	require	to	
maintain	euglycaemia	in	a	state	of	excess	insulin	(DeFronzo,	Tobin,	&	Andres,	1979).	
However	this	method	is	time-consuming	and	not	practical	to	perform	in	large	clinical	
populations.	However	the	HOMA,	which	estimates	steady	state	beta	cell	function	
Country/Ethinc	Group Waist	circumference
Eurpoids Female	≥	80	cm	Male	≥	94	cm	
South	Asians	 Female	≥	80	cm	Male	≥	90	cm	
Chinese Female	≥	80	cm	Male	≥	90	cm	
Japanese Female	≥	80	cm	Male	≥	90	cm	
Ethnic	South	and	Central	Americans	 Use	South	Asian	recommendations	until	more	specific	data	are	available	
Sub-Saharan	Africans	 Use	European	data	until	more	specific	data	are	available	
Eastern	Mediterranean	and	Middle	East	(Arab)	populations	Use	European	data	until	more	specific	data	are	available	
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(%B)	and	insulin	sensitivity	(%S)	correlates	well	with	the	gold	standard	and	is	
therefore	widely	accepted	as	a	measure	of	IR	(HOMA	IR	is	the	reciprocal	of	%S).	
In	order	to	calculate	HOMA-IR,	a	fasting	insulin	and	glucose	sample	was	taken	on	
participants.	I	downloaded	the	model	from	(https://www.dtu.ox.ac.uk/homacalculator/)	
used	this	to	calculated	a	HOMA	IR	value	for	each	individual.	
	
2.5.4 C-peptide		
C-peptide	is	the	connecting	molecule	of	the	insulin	A	and	B	chain	in	the	proinsulin	
molecule.	Measurements	of	this	peptide	were	taken	in	the	fasted	state	in	the	
morning.	20/(fasting	blood	glucose	x	c-peptide)	was	calculated;	a	model	which	has	
been	shown	to	be	an	effective	measure	of	IR	(Ohkura	et	al.,	2013)	
	
2.5.5 Glycosylated	Haemoglobin	(HbA1c)		
Non-fasted	blood	measurements	were	taken	of	HbA1c	to	test	for	type	2	diabetes	
(>48	mmol/mol)	and	to	provide	a	measure	of	dysglycaemia.		
	
2.5.6 %	body	and	%	visceral	fat			
Where	possible,	measurements	of	body	fat	composition	were	taken	on	a	BC-418	
Segmental	Body	Composition	Analyser	(Tanita).	
		
2.6 PET	Screening	Visit	(Chapters	6	and	7)		
For	this	initial	visit	patients	arrived	fasted	at	the	Clinical	Research	Facility	(CRF)	on	
the	Hammersmith	campus.	In	summary,	the	following	would	be	performed:	
	
i) Signing	of	consent	form	
ii) Detailed	history	and	clinical	examination	
iii) BP,	waist	circumference,	height,	weight,	%	body	fat,	electrocardiogram	
(ECG)	
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iv) Screening	bloods	for	FBC,	clotting,	renal	profile,	HbA1c,	lipids,	sex-
hormone	binding	globulin	(SHBG),	glucose,	insulin,	c-peptide	
v) Bloods	for	TSPO	genotyping.	
vi) Structured	Clinical	Interview	for	DSM-IV	Axis	1	disorders	(SCID-I)	to	screen	
for	current	psychiatric	disorders.		
vii) Allen’s	test	to	test	for	patency	of	the	ulnar	artery		
	
2.6.1 TSPO	Genotyping			
All	patients	had	TSPO	genotyping	at	screening	visits	to	establish	number	of	alleles	for	
the	Ala147Thr	polymorphism.	Venepuncture	was	performed	and	a	single	blood	
sample	was	sent	to	the	pathology	laboratory	at	Hammersmith	Hospital.	DNA	was	
extracted	using	the	Qiagen	QIAmp	DNA	blood	mini	kit	and	genotyping	was	
performed	using	a	TaqMan	Allelic	Discrimination	assay.	Those	individuals	with	two	
alleles	for	the	Ala147Thr	polymorphism,	were	labelled	‘low-affinity	binders’	(LABs)	
and	were	excluded	from	the	study.	This	is	because	we	expected	there	to	be	minimal	
binding	in	LABs	and	therefore	did	not	justify	the	radiation	exposure	for	these	
individuals.	Mixed	affinity	binders	(MABs)	had	one	allele	for	the	polymorphism	and	
high	affinity	binders	(HABs)	had	none.	These	individuals	were	included	in	the	study.	
	
Analyses	for	chapter	6	and	7	were	separated	according	to	HAB	or	MAB	status	as	we	
expected	our	TSPO	tracer	to	show	differentiation	between	the	two	such	that	MABs	
would	show	50%	binding	compared	to	HABs	(Owen	et	al.,	2011;	Owen	et	al.,	2012).	
	
2.7 PET	scanning	visit		
Prior	to	PET	scanning,	participants	had	vital	signs	checked,	venous	cannula	inserted	
and	all	females	had	a	urinary	pregnancy	test.	Blood	samples	are	taken	at	this	point	
for	markers	of	inflammation,	CRP,	ESR,	IL-6,	TNF-	α,	CRP,	HsCRP,	MCP-1,	IP-10,	MIP	
1-	β,	SB100β.	An	arterial	line	was	inserted	(where	possible)	to	enable	blood	
monitoring	of	the	tracer.	This	was	performed	by	external	medical	professionals	
trained	in	the	procedure.	A	10	cm	line	was	inserted	using	2%	lidocaine	(seldinger	
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technique).	Verbal	consent	was	taken	separately	for	this	procedure	and	recorded	in	
the	medical	notes.	
	
[18F]GE-180	was	manufactured	at	GE	Healthcare’s	Amersham	site	and	transported	to	
the	CIF	according	to	local	standard	operating	procedures	(SOPs).	It	was	used	within	
12	hours	of	manufacture.	
	
2.8 Dynamic	PET	acquisition		
Patients	were	positioned	supine	in	the	PET-CT	scanner	(Biograph	6).	The	arterial	line	
was	connected	to	continuous	blood	monitoring	machine	via	1.5	m	tube	after	being	
flushed	with	saline.	CT	topogram	was	performing	for	positioning	followed	by	low-
dose	CT	scan	for	attenuation	correction	5-10	minutes	before	tracer	injection.	PET	
scanner	started	at	30	seconds	prior	to	injection	to	ensure	machinery	operation	prior	
to	injecting	the	tracer.	Clocks	were	synchronised	to	the	PET	scanner	clock	and	quality	
checks	carried	out	in	accordance	with	local	SOPs.	Approximately	185	MBq	of	
[18F]GE-180	(drawn	up	in	10mL	of	normal	saline)	was	administered	as	a	stat	bolus	
followed	by	a	20	mL	flush	of	normal	saline	at	the	same	time	as	the	90	minute	PET	
acquisition	(list	mode)	started.	Frames	time	are	outlined	in	Table	2-4	below:	
	
Table	2-4	Frame	times	for	the	90min	dynamic	PET	acquisition	
No.	 Duration	(sec)	 Frames	 Time	(cumulative	
secs)	
0	 30	 0	 30	
1-6	 15	 6	 90	
7-9	 60	 3	 180	
10-14	 120	 5	 600	
15-19	 300	 5	 1500	
20-24	 600	 5	 3000		
Patients	were	checked	for	head	position	every	15	minutes	and	remained	in	the	
scanner	for	the	90	minutes	duration.	At	the	end	of	the	scan,	the	arterial	line	was	
removed	and	pressure	applied	for	20	minutes	followed	by	a	pressure	dressing.	The	
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venous	cannula	was	also	removed	and	vital	signs	taken	before	participant	allowed	to	
go	home.	
	
2.9 Acquisition	Procedure-Blood	and	metabolites			
Continuous	blood	sampling	was	taken	for	the	first	15	minutes	(withdrawal	rate	2.5	
mL/min)	and	discrete	blood	samples	taken	at	the	following	times	following	scan	
start:	0,	5,	10,	15,	30,	50,	70,	90	mins.	Whole	blood	and	plasma	radioactivity	readings	
were	taken.	The	parent	fraction	of	[18F]GE-180	was	measured	by	high-performance	
liquid	chromatography	(HPLC)	of	discrete	plasma	samples.	Further	details	on	these	
methods	can	be	found	in	6.2.5	Whole	Blood,	Plasma	Activity	and	Parent	Fraction	of	[18F]GE-180	page	181.	
	
2.10 PET	data	reconstruction		
Data	was	reconstructed	as	24	temporal	frames.	Filtered	back	projection	(matric	size	
168x168,	zoom	2.6,	5	mm	Gaussian	filter,	pixel	size	1.56	x	1.56,	slice	thickness	3	mm)	
was	the	method	used	for	data	reconstruction	with	and	without	attenuation	
correction.	The	standard	corrections	for	scatter,	decay	and	randoms	were	applied.		
	
A	diagrammatic	overview	of	the	processes	involved	in	PET	acquisition	for	this	study	
is	seen	in	Figure	2-3.	
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Figure	2-3	An	overview	of	the	processes	involved	in	acquiring	PET	data	
	
HPLC=High	performance	liquid	chromatography	
	
	
2.11 MRI	acquisition		
All	participants	had	high	resolution	T1-weighted	structural	MRI.	Participants	were	
scanned	on	a	Siemens	3T	Verio	system	(Siemens	Healthcare,	Germany).	An	MPRAGE	
sequence	was	acquired	with	the	following	parameters:	repetition	time	=	2300	ms;	
echo	time	=	2.98	ms	;	flip	angle	=	9°;	field	of	view	=	25.6	cm	x	24	cm;	matrix	=	256	x	
240;	number	of	slices	=	160,	slice	thickness	=	1	mm;	yielding	final	voxel	dimensions	
of	1	mm3.	
	
In	addition	to	standard	T1	imaging	required	for	PET	analysis,	the	following	sequences	
were	acquired;	SWI,	T2	Flair,	arterial	spin	labelling	(ASL),	DTI,	Magnetic	Resonance	
Spectroscopy	(MRS)	and	resting	state	fMRI.	Three	fMRI	tasks	were	performed	during	
acquisition,	including	a	memory	task	where	patients	were	shown	abstract	art	
pictures	and	tested	on	recall	in	the	break,	the	Choice	Reaction	Time	task	(CRT)	and	a	
11C,	18F,	13N,	15O	
Isotope	produc5on	
Radiochemistry		
Injec5on	of	Radioligand	
TRACER	CONCENTRATION	
-  [WHOLE	BLOOD]-
discrete	and	con5nuous	
-  [PLASMA]	
-  [METABOLITES]	
Arterial	Input	Func5on	
HPLC	
Arterial	line	sampling	
	
Dynamic	PET	data	 +	 +	Structural	MRI	
PET	reconstruc5ons	
FBP,	AC,	SC	
	 84	
Breath	Hold	task.	Were	possible	a	venous	cannula	was	inserted	and	gadolinium	
contrast	given.	Delayed	images	were	taken	5	minutes	after	injection.		
	
2.12 PET	Analysis-basic	principles		
A	‘perfect’	PET	radioligand	would	be	one	where	once	injected	into	the	circulation	all	
of	the	free	tracer	is	delivered	to	the	brain	and	binds	only	to	the	receptor	of	interest	
and	concentrates	in	the	most	receptor	dense	areas.	In	this	situation	it	would	not	be	
of	interest	what	was	happening	in	the	circulation	and	analysis	could	be	performed	
using	tissue	counts	only.	
	
However	this	ideal	scenario	is	never	played	out.	Once	a	radioligand	is	injected	into	
the	circulation	it	undergoes	metabolism,	decay,	it	binds	to	plasma	proteins	and	can	
enter	into	cells	where	it	can	become	involved	in	a	variety	of	cellular	processes.	When	
a	proportion	of	the	free	tracer	enters	the	brain	it	binds	to	the	receptor	of	interest	
but	also	binds	to	non-specific	receptors,	so	called	specific	and	non-specific	binding.	
(Figure	2-4).	
	
Measurement	of	tracer	metabolites,	whole	blood	vs.	plasma	tracer	and	parent	
fraction	(proportion	of	unchanged	tracer	in	the	circulation)	is	useful	information	as	
this	determines	how	much	tracer	the	brain	‘sees’.	Kinetic	modelling	explores	the	
relationship	seen	in	the	blood	vs.	brain	tissue.	Mathematical	equations	are	applied	
to	describe	the	observed	data.		
	
Sometimes	blood	measurements	are	not	required.	For	example,	if	there	has	been	a	
lot	of	experience	with	a	tracer,	there	may	be	a	consensus	on	an	analysis	approach	
using	a	reference	or	pseudo-reference	tissue	approach.	A	reference	tissue	is	a	region	
where	there	are	no	receptors	for	the	ligand	of	interest.	A	pseudo	reference	tissue	is	
one	where	binding	exists	but	is	low	and	used	consistently	across	analyses.	Analysis	
approaches	like	this	mean	that	blood	measurements	are	not	required	and	tissue	
data	alone	can	be	used.	This	has	advantages	in	terms	of	patient	comfort,	resources,	
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cost	and	speed	of	analysis	but	can	overlook	issues	such	as	variability	in	non-specific	
binding	and	radioactive	metabolites.		
	
Figure	2-4	Schematic	overview	of	ligand-receptor	binding	model	
	
	
In	my	PET	studies,	given	that	we	were	using	a	novel	tracer,	we	decided	to	perform	
blood	measurements	and	perform	full	kinetic	modelling.	This	section	will	describe	
the	common	models	used,	define	the	outcome	measures	and	describe	the	analysis	
pipeline	used	for	chapters	7	and	8.	
	
2.13 Compartmental	Modelling	(CM)		
A	compartment	is	an	idealised	container	of	a	chemical	substance	and	they	may	not	
be	spatially	distinct.	CM	is	used	in	PET	to	describe	the	behaviour	of	the	tracer.	It	
enables	quantification	of	the	underlying	physiological,	biochemical	and	
pharmacological	processes.	It	also	enables	estimation	of	parameters	at	equilibrium	
when	in	reality	most	experiments	cannot	continue	until	that	point.	CMs	can	be	
Reference 
Tissue 
Blood Target 
Tissue 
Speciﬁc	binding		
	
Non-	Speciﬁc	
binding		
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described	in	terms	of	linear,	first-order,	constant-coefficient,	ordinary	differential	
equations.	However	certain	assumptions	are	made	regarding	the	tracer:	
	
i) TRACER:	Labelled	compound	is	in	tracer	amounts	(i.e.	so	as	not	to	perturb	
the	physiology	of	the	system)	
ii) MIXING:	Instant	mixing	i.e.	homogeneous	concentration	in	each	
compartment.	
iii) EXCHANGE:	The	exchange	rate	of	labelled	compound	among	the	
compartments	is	related	to	the	concentration	within	them.	
	
By	convention,	the	first	compartment	is	the	concentration	of	the	tracer	in	the	blood.	
This	is	known	as	the	arterial	input	function	and	this	is	what	drives	the	system.		
	
2.13.1 	Arterial	Input	Function	
	
The	arterial	input	function	describes	the	concentration	of	the	unchanged	(non-
metabolised)	compound	in	arterial	plasma	as	a	function	of	time.	It	describes	how	
much	tracer	is	available	for	delivery	to	tissue	over	the	duration	of	the	scan.	Broadly	it	
can	be	generated	by	following	these	steps:		
i) Continuous		arterial	blood	sampling	and/or	discrete	blood	sampling	from	
tracer	administration	to	the	end	of	the	PET	scan.	
ii) Centrifugation	of	blood	to	separate	plasma	
iii) Plasma	radioactivity	measurement.	
iv) Radioactivity	divided	by	sample	mass	or	volume.	
v) Decay	correction	to	the	time	of	injection	
vi) Metabolite	correction	
vii) Dispersion	correction	(where	necessary)	
viii) Time	delay	correction	(to	account	for	tubing	delay	and	delay	from	brain	
to	source	of	blood	sample)	
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2.13.2 	One	tissue	compartmental	model	(1TCM)		
This	is	the	simplest	compartmental	model	and	shown	in		
Figure	2-5.	The	first	compartment	is	the	arterial	input	function.	The	second	compartment	is	
the	radioligand	in	tissue.	Models	can	be	irreversible	of	reversible.	Irreversible	model	permit	
tracer	extraction	in	one	direction	only	(K1),	whereas	a	reversible	model	allows	exchange	in	
the	other	direction	and	therefore	has	a	second	rate	constant	(K2).	Both	these	models	are	
described	by	differential	equations.	
	
Figure	2-5	Schematic	demonstrating	1TCM	models	(reversible	and	irreversible)	
		
A	1TC	model	is	the	simplest	model	to	apply	to	PET	data	but	is	often	too	simple	to	
describe	the	behaviour	of	most	tracers.		
	
	
	
	
	
K1	
K1	
k2	
CP	
CP	
C1	
C1	
One	compartment	model	(irreversible)	
One	compartment	model	(reversible)	
dC1(t)				=K1CP	(t)	
				dt	
	
dC1(t)				=K1CP	(t)-k2C1(t)	
				dt	
	
K1=	ﬂow	x	extrac?on	of	tracer	
k2=	second	rate	constant	
CP=concentra?on	of	tracer	in	plasma	(arterial	input	func?on)	
C1=concentra?on	of	tracer	in	?ssue	(bound	and	unbound)	
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2.13.3 	Two	tissue	compartment	model	(2TC)	
	
This	is	the	commonest	model	used	for	PET	tracers.	The	compartments	generally	
refer	to	the	concentration	of	the	tracer	in	the	plasma	(as	with	1TC),	tracer	that	is	
specifically	bound	and	tracer	that	is	non-specifically	bound.	The	amount	of	tracer	in	
the	blood	volume	within	the	tissue	should	be	added	as	a	fixed	amount	(5%	in	brain)	
or	fitted	blood	volume	could	be	used.	Alternatively,	blood	volume	in	tissue	could	be	
considered	as	another	compartment.	Two	differential	equations	are	used	to	describe	
these	models	and	again	can	be	reversible	of	irreversible.	The	classic	irreversible	2TC	
tracer	is	labelled	Fludeoxyglucose	(FDG).	These	models	are	shown	Figure	2-6.	
	
Figure	2-6	Schematic	demonstrating	1TCM	models	(reversible	and	irreversible)	
							
K1	
K1	
k2	
CP	
CP	
C1	
C1	
Two	compartment	model	(irreversible)	
Two	compartment	model	(reversible)	
k2	
C1	
C2	
C2	k4	
	
k3	
	
k3	
	
Two	compartment	model	(irreversible)	 Two	compartment	model	(reversible)	
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2.13.4 	Volume	of	Distribution	(VT)		
VT		is	defined	as	the	ratio	of	the	radioligand	concentration	in	tissue	target	region	(CT)	
to	that	in	plasma	(CP)	at	equilibrium.	The	equation	for	this	is	simply	CT/	CP.	
Equilibrium	is	when	a	steady	state	concentration	of	the	tracer	is	achieved	in	tissue	
(i.e.	flux	into	and	out	of	tissue	is	the	same).	As	a	rule	of	thumb,	VT	of	10	mL/cm3	is	
being	concentrated	in	the	tissue	at	a	ratio	of	10:1.	
	
If	a	CM	appropriately	describes	the	tracer	kinetics	then	is	possible	to	calculate	the	
volume	of	distribution	(VT)	in	a	volume	or	interest	or	at	a	voxel	level.	VT	can	be	
derived	from	any	CM,	as	long	as	there	is	no	irreversible	uptake.		
	
VT	is	proportional	to	both	receptor	density	and	binding	affinity	of	the	tracer.	VT		does	
not	account	for	plasma	protein	binding	(as	this	is	not	corrected	for	in	the	arterial	
input	function)	and	does	not	differentiate	between	specific	and	non-specific	binding.	
Therefore	binding	potentials	are	used	differentiate	between	specific	and	non-specific	
binding.	However	in	order	to	calculate	this	without	a	reference	region	approach	then	
Bmax	(total	density	of	receptors)	and	KD	(equilibrium	dissociation	constant)	need	to	be	
known	and	this	can	only	be	confirmed	with	a	2nd	receptor	blocking	PET	study.	
	
2.13.5 	Simplified	reference	tissue	model	(SRTM)	
	
This	model	can	be	used	when	a	1TC	model	could	describe	the	kinetics	of	the	tracer	
and	a	reference	tissue	(i.e.	one	with	no	specific	binding)	is	known	(Lammertsma	&	
Hume,	1996).	It	does	not	require	an	arterial	input	function.	Here	BPND	(i.e.	specific	
binding)	can	be	calculated	by	solving	the	differential	equation	below	(Figure	2-7).	It	
can	also	be	solved	by	linearised	methods	which	makes	it	possible	to	produce	
parametric	images	of	model	parameters.	
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Figure	2-7	Schematic	demonstrating	the	simplified	reference	tissue	model	(SRTM)	
	
	
2.13.6 	Akaike	information	criterion	(AIC)	(Akaike,	1974)		
AIC	is	founded	in	information	theory.	It	is	a	method	of	comparing	model	fits	for	a	
given	set	of	data.	The	lower	the	number	then	the	better	the	fit.	In	the	case	of	two	
model	fits	being	equally	suitable	to	describe	the	data	then	the	model	with	the	least	
number	of	parameters	is	deemed	to	be	most	parsimonious.	
	
2.13.7 	Standardised	uptake	values	(SUV)	
	
SUV	is	another	method	of	PET	quantification	that	is	used	widely	especially	in	clinical	
imaging.	It	is	simply	a	ratio	of	measured	radioactivity	in	tissue	at	certain	time	divided	
by	body	weight	and	injected	dose	of	radioligand.	It	does	not	require	dynamic	PET	
acquisition,	but	relies	on	a	single	image,	usually	a	‘summed’	image	at	late	time	point.	
SUV	calculations	do	not	require	arterial	blood	sampling.	However,	using	tracer	dose	
per	unit	of	body	weight	is	a	crude	approximation	for	tracer	delivery	to	tissue.	A	
K1	
K1	
k2	
CP	
CFT	+	CNS	+	CS	
Simpliﬁed	reference	8ssue	model	(SRTM)		
k2	
CFT	+	CNS		
Reference	
8ssue	
ROI	
CP		=	[tracer	in	plasma]	CFT	=	[free	tracer]	CNS	=[non-speciﬁcally	bound	tracer		CS	=	[speciﬁcally	bound	tracer]	
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reference	tissue	can	also	be	used	to	cancel	out	effect	of	non-specific	binding	and	this	
is	called	SUVR.		
2.13.8 	Logan	graphical	analysis		
Logan	graphical	analysis	(or	Logan	plot)	is	a	technique	that	simplifies	the	
compartmental	modelling	approach	by	transforming	the	model	equations	into	a	
linear	equation	evaluated	at	specific	time	points.	This	reduces	the	number	of	
parameters	to	a	slope	and	intercept.	The	slope	is	applied	to	the	most	linear	portion	
of	the	curve.	This	method	can	be	used	for	tracers	with	reversible	uptake.	For	
irreversible	tracers,	Patlak	graphical	analysis	can	be	used.	
	
2.13.9 	Distribution	volume	ratios	(DVR)		
This	is	the	ratio	of	the	DV	of	a	receptor-containing	region	to	a	non-receptor	region.	It	
usually	requires	an	arterial	input	function	to	calculate	but	can	also	be	derived	from	
graphical	analysis	methods.	
	
2.14 PET	analysis	pipeline		
MIAKATTM	(Molecular	Imaging	And	Kinetic	Analysis	Toolbox)	was	used	for	the	PET	
analysis	in	this	thesis.	The	first	version	was	developed	in	2015	and	was	used	to	do	
the	analysis	for	the	published	study	in	Chapter	6.	An	updated	version	was	used	for	
the	analysis	in	Chapter	7.	It	is	freely	available	and	was	developed	by	Professor	Roger	
Gunn,	Graham	Searle	and	Christopher	Coello	who	work	at	Imanova	and	Imperial	
College,	London.	
	
MIAKATTM	contains	software	for	the	quantitative	analysis	of	PET	neuroimaging	data	
an	is	presented	in	a	pipeline	format.	The	three	main	inputs	to	the	pipeline	are	i)	
dynamic	PET	ii)	structural	MRI	and	ancillary	blood	data).	Broadly	speaking	the	
pipeline	follows	the	sequence	below:	
	
1) Brain	Extraction	
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2) Brain	Tissue	Segmentation	(GM/WM/CSF)	
3) Motion	Correction	
4) Region	of	interest	definition	via	a	neuroanatomical	atlas	
5) Blood/plasma	kinetic	modelling	
6) ROI	tracer	kinetic	modelling		
7) Parametric	imaging	
	
The	outputs	from	this	pipeline	are	quantitative	outcome	measures	extracted	from	
various	CM	on	a	regional	or	voxel-wise	basis.	The	software	uses	code	from	the	
FMRIB	Software	Library	(FSL)	and	Statistical	Parametric	Mapping	(SPM).	Matlab	(with	
the	Optimisation	Toolbox)	is	required	for	running	the	pipeline.	However	there	is	also	
a	graphical	user	interface	(GUI).	
	
2.14.1 	Inputs	to	MIAKATTM	
	
Dynamic	PET	data	(attenuated	and	non-attenuated	corrected)	and	structural	T1	MRI	
image	were	required	in	nifti	pair	format.	Blood	data	collected	in	the	CIF	was	
converted	into	ancillary	file	format	by	hand.	This	data	file	contained	15	minutes	of	
continuous	whole	blood	radioactivity	readings,	discrete	plasma	and	whole	blood	
readings	and	parent	fraction.	All	data	was	decay	corrected	to	the	start	of	the	
injection	time.	A	schematic	of	the	inputs	and	outputs	to	the	MIAKATTM	pipeline	is	
shown	in	Figure	1-1.	
	
An	AnalysisManager	data	structure	was	used	to	gather	the	output	of	any	given	
examination.	This	involved	generating	a	binary	.mat	file		from	a	template	which	
contained	information	regarding	i)	the	examinations	and	processes	to	be	performed	
ii)	configuration	options	for	each	process	iii)	progress	of	the	analysis	throughout	the	
pipeline	iv)	paths	to	input/output	data	and	v)	references	to	all	relevant	analysis	data	
structure	mat-files.	The	template	could	be	customised	to	include	different	CMs,	
reference	models	and	different	blood	volume	corrections.	
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2.14.2 	Summary	of	structural	MRI	processing	steps		
Preprocess	images	
This	step	creates	a	back-up	of	the	images,	strips	information	in	the	header	and	
converts	the	units	of	the	dynamic	PET	AC	image	to	kBq/ml.	
	
Make	isotropic	
This	step	transforms	a	3D	volume	with	any	voxel	size	to	a	3	volume	with	isotropic	
voxel	with	a	chosen	size	(default	2	mm).		
	
Brain	extraction	 	
This	process	uses	the	FSL	toolbox	(FSL	Brain	Extraction	Tool)	to	perform	brain	
extraction.	
	
Brain	segmentation	 	
This	process	uses	a	specified	tool	(usually	FSL	or	SPM)	to	segment	the	brain	MRI	
creating	a	selection	of	output	images:	grey	matter	image,	white	matter	image	and	
csf	image.																		
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Figure	2-8	Overview	of	the	PET	analysis	pipeline	
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Rigid	registration	to	template		
This	step	rigidly	registers	(6	degrees	of	freedom)	the	brain	MRI	to	a	template.	The	
transformation	matrix,	is	saved	in	the	Analysis	data	structure	and	applied	to	the	
brain	tissue	probability	maps	from	the	previous	steps.	The	default	options	are	to	use	
SPM	co-registration	and	realignment	functions.	
	
Nonlinear	registration	of	template	
Using	SPM	as	a	default,	this	steps	nonlinearly	registers	the	template	MRI	to	the	
subject’s	rigidly	registered	brain	MRI	and	saves	the	deformation	field.		
	
Define	ROIs	
ROIs	are	defined	during	this	process	but	not	applied	to	this	examination;	they	are	
applied	to	the	PET	pre-processing.		The	standard	neuroanatomical	atlas	used	is	the	
CIC	atlas	version	2.0,	defined	on	the	nonlinear	ICBM152	template	and	developed	
using	the	region	of	interest	definitions	defined	by	Tziorti	et	al.	2011	(Tziortzi	et	al.,	
2011).			
Make	into	final	space	
This	process	reslices	any	specified	volume	to	the	final	space.	This	means	that	they	
will	be	registered	with	PET	dynamic	image	from	which	time	activity	curves	(TACs)	will	
be	extracted.				
2.14.3 	Summary	of	PET	pre-processing	steps			
Review	ANC	file	
This	process	checks	that	this	file	is	present	and	that	the	content	matches	pre-defined	
criteria.	
	
Motion	correction	
This	step	realigns	the	dynamic	PET	data	using	a	frame-to-frame	rigid	registration.	
One	frame	from	the	PET	data	is	selected	as	reference	and	all	other	frames	are	
registered	to	this.	Frame	16	was	chosen	for	these	studies.	Additionally	this	step	
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rigidly	registers	the	dynamic	PET	to	the	MRI	(brain-extracted	MRI	registered	to	MNI	
space)	of	the	same	subject.	
	
Make	integral	images	
This	step	makes	one	or	several	static	or	‘summed’	images	where	each	voxel	is	the	
average	value	of	that	voxel	over	a	selected	interval	of	time.		
	
Check	LR	Flip	
This	step	evaluates	the	left-right	orientation	match	between	PET	and	MRI	images.	If	
the	cost	function	of	the	non-flipped	is	better	than	the	flipped,	the	output	is	labelled	
‘probably	OK’.	If	the	cost	function	of	the	flipped	is	better	than	the	non-flipped	then	
the	output	is	labelled	‘Probably	failed’.	If	they	are	similar	the	output	is	labelled	‘Not	
determined’.	
	
Generate	time	activity	curves	(TACs)	
This	process	generates	TACs	for	all	regions	of	interest	and	stores	them	in	the	Analysis	
data	structure.		
	
Make	input	function	
Continuous	and	discrete	whole	blood	data	are	merged	to	form	a	whole	blood	TAC	
for	the	duration	of	the	dynamic	PET	scan.	A	plasma-over-blood	(POB	model)	is	fitted	
to	the	ratios	of	discrete	plasma	and	whole	blood	samples	to	generate	a	plasma	TAC	
with	the	same	temporal	resolution	as	the	whole	blood	curve.	A	parent	fraction	
model	is	fitted	to	the	parent	fraction	data	and	then	applied	to	the	plasma	TAC	to	
produce	a	parent	in	plasma	TAC	which	serves	as	the	arterial	input	function	for	the	
kinetic	modelling	stage.	
	
Usually	there	will	be	a	temporal	delay	between	tissue	TAC	and	parent	in	plasma	TAC	
due	to	delay	in	tubing	connecting	to	the	continuous	blood	monitoring	machine	and	
delay	in	vasculature	from	brain	to	radial	artery.	In	our	examinations	this	delay	was	
greater	than	usually	expected	due	to	the	use	of	a	1mmx1.5m	tube	(withdrawal	rate	
2.5	mL/min).	Therefore	we	applied	a	+30	second	delay	correction	at	this	step.	
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Kinetic	modelling		
The	principles	of	kinetic	modelling	have	already	been	discussed	on	page	85	section	2.13.	This	
step	applies	models	that	have	been	selected	in	the	AnalysisManager.	Models	available	are:	
Blood	Volume,	1TC	irreversible,	1TC	reversible,	2TC	irreversible,	2TC	reversible,	Logan,	
Patlak,	simplified	reference	tissue	model	(SRTM),	RefLogan,	RefPatlak	among	others.			
Parametric	Images	
Generation	of	parametric	images	involved	fitting	a	model	to	a	TAC	for	each	voxel	in	
the	image.		
	
Data	Extraction	
Individual	parameters	for	rate	constants	and	outcome	measures	were	extracted	
using	a	matlab	script	enabling	statistical	analyses.	Voxel-wise	analyses	using	
parametric	maps	were	performed	in	FSL.	 	
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2.15 Data	management	
Neuroimaging	data	was	stored	on	the	Computational,	Cognitive	and	Clinical	
Laboratory	computer	server	based	at	Imperial	College	London.	All	patient	
identifiable	information	was	stored	on	NHS	computer	that	were	password	protected.	
No	such	data	was	stored	on	Imperial	College	or	personal	computer.	Blood	and	
genetic	samples	were	anonymously	coded.	Each	participant	was	assigned	a	file	
containing	consent	form,	case	report	form	and	all	documentation	arising	from	the	
study.	These	files	are	stored	in	a	lockable	room	in	the	C3NL	laboratory.	Separate	
medical	notes	are	stored	in	the	ICCRF.	
	
2.16 Statistical	packages	
Any	statistical	packages	used	for	data	analysis	will	be	highlighted	in	each	chapter.	
SPSS	v21	and	v22	were	used	consistently.	Graphpad	v	6.0	and	MATLAB	R2015b	were	
used	to	generate	figures	in	the	results	sections.	
	
2.17 Ethical	issues	arising		
Full	ethical	approval	was	obtained	for	all	studies.	Amendments	were	sought	where	
necessary.	Yearly	reports	were	filed	and	sent	back	to	the	ethics	committees.	Reports	
of	adverse	events	(n=1)	were	dealt	with	according	to	good	clinical	practice	(GCP)	and	
recorded	in	the	medical	notes.	Incidental	findings	of	abnormalities	detected	on	
clinical	examination	and	blood	work	were	communicated	to	the	patient	and	details	
send	to	the	general	practitioner	(n=2).		 	
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3 Pituitary	Dysfunction	after	Blast	Traumatic	Brain	Injury	
(bTBI)			
3.1 Introduction		
The	prevalence	of	bTBI,	from	the	use	of	improvised	explosive	devices	(IEDs)	has	
increased	considerably	since	the	Iraq	and	Afghanistan	conflicts	(Benzinger	et	al.,	
2009).	Approximately	400	soldiers	in	the	UK	and	2,000	soldiers	in	the	UK	have	been	
fatally	injured	by	blast	injuries	since	2001	(SG,	2012).	Injuries	can	result	directly	from	
the	blast	wave	(primary),	from	missiles	propelled	by	the	blast	force	(secondary),	or	
from	impact	with	another	object	(tertiary)	(Cernak	&	Noble-Haeusslein,	2010).	Of	
those	who	have	survived	a	blast	impact,	approximately	300,000	US	soldiers	have	
suffered	at	least	a	probable	bTBI	(Tanielian	T,	2012).	These	individuals	are	usually	
young	and	of	peak	physiological	fitness	which	means	that	the	potential	long	term	
impact	of	subsequent	physical,	psychological	and	cognitive	impairments	is	
considerable.	The	mainstay	of	treatment	is	supportive;	intensive	rehabilitation	can	
help,	but	there	are	no	targeted	pharmacological	interventions	available	to	improve	
prognosis	for	these	individuals	(Ruff	&	Riechers,	2012).	
	
Pituitary	dysfunction,	especially	growth	hormone	deficiency	(GHD),	is	a	well-
recognised	consequence	of	non-blast	TBI	(nbTBI).	Initial	prevalence	studies	reported	
pooled	prevalence	of	hypopituitarism	of	23-30%	in	the	chronic	phase	following	a	TBI	
(Schneider,	Kreitschmann-Andermahr,	et	al.,	2007).	However	more	recent	studies	
report	a	consistently	lower	prevalence	at	approximately	5%	(Kokshoorn	et	al.,	2011).	
Reasons	for	this	discrepancy	include	differences	in	the	dynamic	tests	selected,	
number	of	testing	points	and	differences	in	normal	reference	ranges	(Kokshoorn	et	
al.,	2010).		
	
Hypopituitarism	can	have	metabolic	consequences	such	as	increased	insulin	
resistance	and	reduction	in	bone	mineral	density	as	well	as	a	deleterious	effect	on	
cognitive	capabilities	and	psychological	well	being	(Cherrier,	2009;	Molitch,	
Clemmons,	Malozowski,	Merriam,	&	Vance,	2011).	Therefore,	growth	hormone,	
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testosterone	and	cortisol	replacement	strategies	offer	welcome	therapeutic	options	
for	these	individuals	(Cherrier,	2009;	Molitch	et	al.,	2011;	Salvatori,	2005).	What	is	
not	known	however	is	the	prevalence	of	pituitary	dysfunction	following	bTBI.	
	
Diffusion	tensor	imaging	(DTI)	is	an	advanced	imaging	technique,	that	can	be	used	to	
study	white	matter	damage	following	TBI	(see	Introduction:	Diffusion	tensor	imaging	(DTI)	1.3.6	page	35).		By	using	diffusivity	measures	such	as	fractional	
anisotropy	(FA).	Even	in	mild,	uncomplicated	bTBI,	marked	DTI	abnormalities	have	
been	seen	in	multiple	brain	regions	(Mac	Donald	et	al.,	2011).		
	
The	primary	objective	of	this	study	was	to	investigate	the	prevalence	and	associated	
features	of	pituitary	dysfunction	following	moderate-severe	bTBI	compared	to	an	
age	and	gender	matched	control	group	of	nbTBI.	The	secondary	objective	was	to	test	
the	hypothesis	that	DTI	would	show	differences	between	those	soldiers	with	and	
without	pituitary	dysfunction.	Finally,	the	third	objective	was	to	investigate	whether	
certain	cognitive	domains	were	impaired	in	those	soldiers	with	vs.	those	without	
pituitary	dysfunction.		
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3.2 Methods		
3.2.1 Participants		
Nineteen	UK	soldiers	who	had	sustained	a	moderate-severe	bTBI	in	Afghanistan	
between	December	2009-March	2012	were	recruited	by	D	Baxter	using	the	
Academic	Department	of	Military	Emergency	Medicine	(Birmingham,	UK)	trauma	
database.	Research	ethics	approval	was	obtained	from	the	Ealing	and	West	London	
Research	Ethics	Committee	(09/H0707/82)	and	informed	consent	was	obtained	from	
all	individuals.	
	
A	control	group	of	39	patients	with	non-blast	TBI	was	selected	from	a	clinical	
database	of	all	patients	seen	in	the	multidisciplinary	TBI	clinic	at	Imperial	Healthcare	
NHS	Trust	from	August	2009	though	to	March	2012.	Patients	were	selected	if	they	
met	the	inclusion/exclusion	criteria	and	if	they	fell	within	the	same	age	group	of	the	
bTBI	group.	
	
All	participants	had	a	full	clinical	assessment	to	include	recording	of	the	following	
variables	if	available:	time	since	injury,	Injury	Severity	Score	(ISS)	(Baker,	O'Neill,	
Haddon,	&	Long,	1974),	Abbreviated	Injury	Scale	(AIS)	Glasgow	Coma	Score	(GCS),	
post-traumatic	amnesia	(PTA),	BMI,	Limb	amputation,	skull/facial	fractures,	post-
traumatic	epilepsy	and	full	medication	history.		
	
3.2.2 Inclusion/exclusion	criteria	for	bTBI	group		
Inclusion:	A	primary	moderate-severe	brain	injury	caused	by	a	single	exposure	to	a	
blast.	
Exclusion:		1)	Requirement	for	massive	blood	transfusion	indicating	severe	
hypovolaemic	shock	at	scene	2)	Intracranial	lesions	causing	mass	effect	3)	Post-
traumatic	stress	disorder	(PTSD)	
(	1)+2)	so	as	to	constrain	our	findings	to	that	of	a	primary	blast	wave	only	and	3)	as	
PTSD	itself	has	been	linked	with	endocrine	disturbance	(Pervanidou	&	Chrousos,	
2010)).	
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3.2.3 Inclusion/exclusion	criteria	for	bTBI	and	nbTBI	group		
Inclusion:	1)	Males	2)	>2	and	<48	months	from	a	single	TBI	3)	Moderate-severe	injury	
based	on	the	Mayo	criteria	(Malec	et	al.,	2007)	4)	Psychological	or	cognitive	
symptoms	5)	Completion	of	all	pituitary	endocrine	testing.	
	
Exclusion:	1)	Prior	history	of	neurological	and/or	psychiatric	disorder	2)	Current	or	
previous	recreational	drug	use	3)	Alcohol	consumption	above	the	recommended	
weekly	amount	of	21	units	4)	Diabetes	mellitus	in	case	of	interference	with	
endocrine	tests	and	potential	effects	on	brain	structure	and	function	5)	Reversed	
sleep-wake	cycle	indicating	disturbed	diurnal	rhythm	with	effects	on	hormonal	
pulsatility	5)	Craniotomy	following	injury	to	avoid	brain	imaging	registration	
difficulties	from	such	gross	changes	in	brain	structure.		
	
3.2.4 Tests	for	pituitary	dysfunction		
All	patients	had	measurements	of	basal	anterior	pituitary	hormone	levels	(GH,	IGF-I	
(Immulite® 2000),	TSH,	free	T4,	free	T3,	LH,	FSH,	testosterone	(Abbott	Architect	
Ci8200),	prolactin,	ACTH,	cortisol	and	sex	hormone	binding	globulin	(SHBG)).	Free	
androgen	index	(FAI)	was	calculated	as	100	x	total	testosterone/SHBG.	All	patients	
went	on	to	have	full	dynamic	endocrine	testing.	Criteria	for	diagnoses	of	pituitary	
dysfunction	were	as	follows:	
	
i) Hyperprolactinaemia:	two	consecutively	raised	prolactin	readings	(above	
the	upper	reference	range)	and	negative	macroprolactin	which	is	an	
immunological	artefact	leading	to	artificially	raised	prolactin	levels	(T.	P.	
Smith,	Kavanagh,	Healy,	&	McKenna,	2007).	In	subjects	with	confirmed	
biochemical	hyperprolactinaemia,	an	MRI	of	the	pituitary	(with	
gadolinium	contrast)	was	performed	and	reviewed	by	an	experienced	
neuroradiologist	to	rule	out	an	incidental	pituitary	tumour	
ii) Gonadotrophin	deficiency	was	defined	as	a	low	morning	testosterone	
(<10	nmol/L)	with	low	or	non-elevated	LH	(NR	1.7-12.0	iu/L)	and	FSH	(NR	
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1.7-8.0	iu/L)	given	only	males	were	studied.	As	SHBG	affects	the	
bioavailability	of	circulating	sex	hormones,	if	the	SHBG	level	was	low	(i.e.	
below	lower	reference	limit	of	15	nmol/L),	then	FAI	needed	to	be	<30	for	
the	diagnosis.	Primary	hypogonadism	was	diagnosed	using	s	standard	
approach	of	low	morning	testosterone	(accounting	for	SHBG	using	FAI)	
with	elevated	FSH	and/or	LH.	
iii) GH	deficiency	was	diagnosed	following	failure	of	two	dynamic	pituitary	
tests	carried	out	in	the	morning.	The	glucagon	stimulation	test	(GST)	was	
used	as	an	initial	screening	test	followed	by	either	the	GHRH-Arginine	test	
or	Insulin	Tolerance	Test	(ITT)	
iv) ACTH	deficiency	was	diagnosed	on	the	basis	of	failure	of	two	dynamic	
pituitary	tests	carried	out	in	the	morning.	All	patients	had	a	GST	followed	
by	an	ITT	or	overnight	Metyrapone	Stimulation	Test	(MST).	A	Cortisol	Day	
Curve	(CDC)	was	used	to	help	confirm	the	diagnosis	where	necessary	and	
assess	the	need	for	maintenance	hydrocortisone	replacement.	
	
Although	the	ITT	is	considered	the	‘gold	standard’	dynamic	test	for	ACTH	and	GH	
deficiency	it	was	not	routinely	performed	here	because	of	the	high	prevalence	or	
absolute	and	relative	contraindications	in	TBI	populations.	10.5%	of	the	bTBI	group	
and	10.3%	of	the	nbTBI	group	had	an	absolute	contraindication	(history	of	seizures,	
ischaemic	heart	disease/abnormal	ECG/cardiac	arrhythmias)	and	a	further	21.1%	and	
53.8%	had	what	we	considered	to	be	a	relative	contraindication	(Intracranial	post	
traumatic	lesion)	in	the	bTBI	and	nbTBI	groups	respectively.	We	therefore	restricted	
the	use	of	the	ITT	to	those	cases	where	there	was	an	equivocal	second	test	result	
e.g.	difficultly	adjusting	for	BMI	in	light	of	bilateral	lower	limb	amputations	and	we	
had	carefully	excluded	any	contraindications	that	may	have	compromised	patient	
safety.	
	
Posterior	Pituitary	Function	
Diabetes	insipidus	was	screened	for	on	the	basis	of	symptoms	(polyuria	and	
polydipsia)	and	paired	urine	and	plasma	osmolalities.	If	thought	to	be	clinically	
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indicated	by	the	attending	physician	a	water	deprivation	test	was	carried	out,	
although	this	was	not	done	routinely	(n	=1	in	bTBI	and	n=6	in	nbTBI	group).		
	
Oxytocin	was	not	measured.	
	
All	dynamic	endocrine	testing	was		carried	out	either	in	a	day	ward	at	Charing	Cross	
Hospital	or	St	Mary’s	Hospital,	London.	A	summary	of	the	algorithm	used	to	define	
pituitary	dysfunction	can	be	seen	in	Table	3-1.	
	
Table	3-1	Summary	table	showing	diagnostic	algorithm	for	pituitary	dysfunction		
	
Abbreviations:	BMI	(body	mass	index),	FAI	(free	androgen	index	=(testosterone/SHBG)	x	
100,	NR	(normal	range)	
	
3.2.5 Glucagon	Stimulation	test	(GST)		
Following	an	overnight	fast,	basal	blood	samples	were	taken	and	Glucagon	
(GlucaGenTM	Novo	Nordisk	Pharmaceuticals	1mg	or	1.5	mg	if	weight	>90kg)	was	
administered	by	IM	injection.	Blood	samples	for	glucose,	serum	cortisol	and	GH	were	
taken	at	90,	120,	150	and	180	minutes	after	glucagon	was	given	via	an	IV	cannula.	
The	majority	of	subjects	(89%	bTBI	and	70%	nbTBI)	also	had	samples	taken	at	210	
and	240	minutes.	“Failure”	on	the	test	was	defined	as	a	peak	GH	<5	μg/L	and	cortisol	
<350	nmol/L	(Cegla	et	al.,	2013)	
	
Pituitary Axis 1st Test Confirmatory test
GH Deficiency Glucagon Stimulation Test: peak GH < 5µg/L GHRH-Arginine Test: 
  GH < cut off based on age and BMI{Colao};
  OR ITT: peak GH <3 µg/L
ACTH Deficiency Glucagon Stimulation Test: Metyrapone Test: 11-DOC <200 nmol/L (<6.9 µg/dL)
 peak cortisol <350 nmol/L (<12.7 µg/dL)   OR if unavailable ACTH <60 ng/L 
  despite cortisol < 200nmol/L (<7.2 µg/dL);
OR ITT: peak cortisol <450 nmol/L (<16.3 µg/dL)
Supported by AM cortisol <100 nmol/L (<3.62 µg/dL)
Hyperprolactinemia Prolactin >375 mU/L (NR 75-375) Repeat prolactin >375 mU/L 
  AND negative Macroprolactin 
  AND normal MRI pituitary with contrast
Gonadotrophin Deficiency Random testosterone <10 nmol/L (<2.9 ng/mL) Repeat abnormal basal levels 
  OR if SHBG low (<15 nmol/L) FAI <30,   using morning (9-10am) sample
  AND non-elevated LH (NR 1.7-12.0 IU/L)
  and FSH (NR 1.7-8.0 IU/L) 
TSH Deficiency Free T4 <9.0 pmol/L (<0.70 ng/dL) Repeat abnormal basal levels 
  OR free T3 <2.5 pmol/L (<0.16 ng/dL),
  AND non-elevated TSH (NR 0.30-4.22 mU/L)
ADH (Vasopressin) Deficiency Symptoms of polyuria or polydipsia Water Deprivation Test 
(Diabetes Insipidus)
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During	the	course	of	data	collection	the	assay	for	cortisol	measurements	changed	in	
August	2010	from	the	Immulite®2000	to	the	Architect	i2000.	To	ensure	
comparability,	linear	regression	was	performed	(not	shown)	to	show	coefficients	of	
variation	of	<10%	for	cortisol	levels	83-967	nmol/L.		
	
3.2.6 GHRH-Arginine	Test		
In	the	fasted	state,	patients	had	blood	samples	taken	for	GH	and	IGF-I	measurement	
at	0	minutes.	GHRH	(Somatorelin,	Ferring)	1	μg/kg	was	given	as	a	bolus	IV	injection	
into	one	arm	followed	by	the	IV	infusion	0.5g/kg	L-arginine	monohydrochloride	
(Stockport	Pharmaceuticals)	as	a	10	%	solution	(30g/300mL	up	to	a	maximum	of	30g)	
in	normal	saline	over	30	minutes.	Further	blood	samples	for	GH	estimation	were	
taken	at	+30,	60,90	120	and	150	minutes	after	the	start	of	the	arginine	infusion.	
“Failure”	on	this	test	was	defined	using	published	age	and	BMI	criteria	(Colao	et	al.,	
2009).	If	BMI	could	not	be	calculated,	in	amputees	for	example,	then	BMI	cut	offs	in	
the	overweight	range	were	used.	
	
3.2.7 Insulin	Tolerance	Test	(ITT)			
In	the	fasted	state,	IV	insulin	Actrapid	(NovoNordisk)	was	administered	(0.1	U/kg)	
though	an	IV	line	by	an	endocrine	specialist	nurse	or	physician.	Blood	samples	were	
taken	for	GH,	cortisol	and	glucose	at	0,30,60,90	and	120	mins.	Once	target	
hypoglycaemia	of	<2.2	mmol/L	was	achieved,	hypoglycaemia	was	reversed	with	oral	
glucose.	Abnormal	cortisol	response	was	defined	as	peak	cortisol	of	<450	nmol/L.	
Severe	GH	deficiency	was	defined	as	a	peak	GH	<3	μg/L	(Molitch	et	al.,	2011).	
	
3.2.8 Other	pituitary	function	tests		
A	cortisol	day	curve	(blood	samples	of	serum	cortisol	at	0900h,	1200h,	1500h,	1800h	
and	2100h)	was	carried	in	in	cases	of	diagnostic	uncertainty.	The	MST	works	on	the	
principle	that	metyrapone	causes	inhibition	of		11	β-hydroxylase	(used	in	the	
conversion	of	11-deoxycortisol	to	cortisol)	which	suppresses	cortisol.	Once	a	desired	
threshold	of	<200	nmol/L	is	reached,	this	is	thought	to	stimulate	an	ACTH	drive.	
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Where	carried	out,	this	test	was	conducted	in	line	with	accepted	practice	(Steiner,	
Bahr,	Exner,	&	Oelkers,	1994).	Subjects	were	considered	to	be	ACTH	sufficient	if	11-
DOC	was	>200	nmol/L	or	where	11-DOC	unavailable,	ACTH	to	above	60	ng/L.	Where	
indicated	a	two	stage	water	deprivation	test	was	carried	out	in	non-fasted	subjects	
using	widely	accepted	methodology	(Vokes	&	Robertson,	1988).	
	
3.2.9 Quality	of	Life	(QoL)	assessments		
Quality	of	Life	(QoL)	assessments	were	carried	out	in	all	individuals	in	both	the	bTBI	
and	nbTBI	groups.	These	assessments	included	the	Assessment	of	GH	Deficiency	in	
Adults	(AGHDA	scale),	Beck	Depression	Inventory	Score	(BDI-II),	Epworth	Sleepiness	
Scale,	Pittsburgh	Sleep	Index,	Nottingham	Health	Profile	(NHP)	and	the	Short	Form	
Survey	(SF-36).	Please	see	Methods	section	Quality	of	Life	(QoL)	assessments	2.3.1	
page	73.	for	more	detailed	information.	
	
3.2.10 	Neuropsychological	Assessments		
Each	soldier	completed	a	standardised	battery	of	neuropsychological	tests	previously	
shown	in	our	group	to	detect	to	cognitive	impairment	following	TBI	(Kinnunen	et	al.,	
2011).	For	more	detailed	explanation	please	see	Neuropsychological	assessment	
2.3.2	page	74.	In	summary	these	tests	included:	
	
i) The	Wechsler	Test	of	Adult	Reading	(WTAR)	to	assess	pre-morbid	
intelligence		(green)	
ii) The	People	test	from	the	Doors	and	People	Test	(Baddeley	2010)	to	
measure	associative	learning	and	memory	
iii) The	Trail	Making	Test		to	assess	executive	functions	of	set-shifting,	
inhibitory	control	and	cognitive	flexibility.	
iv) Verbal	and	non-verbal	reasoning	ability	via	the	Wechsler	Abbreviated	
Scale	of	Intelligence	Similarities	and	Matrix	Reasoning	subtests	
(Wechsler	1999).	
v) The	Colour-Word	subtest	and	Letter	fluency	from	the	Delis-Kaplan	
Executive	Function	System.	
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vi) Median	reaction	time	for	accurate	responses	on	a	simple	
computerised	choice	reaction	task.	
	
3.2.11 	Structural	Imaging		
Each	soldier	had	standard	high-resolution	T1	and	gradient-echo	(T2*)	
(1.75x1.75x2mm3)	imaging	to	assess	focal	brain	injury,	evidence	of	microbleeds,	
superficial	siderosis,	presence	and	location	of	contusions	and	gross	pituitary	injury.	
All	structural	MR	scans	were	reviewed	by	a	single	experienced	consultant	
neuroradiologist.		
	
Contusion	volume	was	calculated	by	converting	the	T1	images	into	standard	1mm	
MNI	brain	space	using	FLIRT	(FMRIB,	University	of	Oxford,	UK)	and	manually	drawing	
a	mask	in	the	z	plane.		
	
3.2.12 	DTI	Analysis		
Using	individual	FA	maps,	TBSS	(see	Methods:	Tract	based	spatial	statistics	(TBSS)	
2.3.5	page	75)	was	used	to	look	for	whole	brain	difference	between	those	with	and	
those	without	pituitary	dysfunction.	An	FA	region	of	interest	analysis	was	also	
carried	out	using	the	John	Hopkins	University	(JHU)	white	matter	atlas.	Ten	regions	
were	selected	that	have	previously	been	shown	to	be	damaged	in	nbTBI	(Kinnunen	
et	al.,	2011)	as	well	as	mild	bTBI		(Mac	Donald	et	al.,	2011).		
	
These	regions	were:	anterior	and	posterior	internal	capsules,	cingulum,	body/genu	
and	splenium	of	the	corpus	callosum,	cerebral	peduncles,	middle	cerebellar	
peduncles,	and	uncinate	fasciuli	(Figure	3-1).	In	addition	a	cerebellum	ROI	mask	
was	drawn	manually	and	an	orbitofrontal	white	matter	ROI	mask	made	using	the	
Washington	University,	St	Louis	criteria	from	the	standard	MNI152	1mm	T1	brain	
(Mac	Donald	et	al.,	2011).	A	repeated	measures	ANOVA	was	performed	to	assess	the	
overall	significance	effect	of	pituitary	dysfunction	on	FA,	including	group,	ROI	and	
group	x	ROI	interaction	as	independent	variables,	with	post-hoc	2-tailed	t-tests	for	
comparison	of	FA	in	individual	ROIs	between	groups.	
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Figure	3-1	White	matter	tract	regions	of	interest	
	
Regions	of	interest	(ROIs)	used	for	determination	of	fractional	anisotropy	(FA)	in	
soldiers	after	blast	traumatic	brain	injury	(bTBI).	Individual	color	masks	overlaid	onto	
group	average	FA	map	for	soldiers	with	bTBI	(n=19)	registered	into	standard	MNI	
space	(using	MNI	co-ordinates).	ROIs	are:	(A)	anterior	internal	capsule,	(B)	posterior	
internal	capsule,	(C)	cingulum,	(D)	corpus	callosum,	(E)	cerebral	peduncles,	(F)	middle	
cerebellar	peduncles,	(G)	orbitofrontal	white	matter,	(H)	uncinate	fasciculi.	FA	was	
sampled	from	areas	within	a	white	matter	skeleton	(not	shown)	produced	by	tract	
based	spatial	statistics	(TBSS).	(Figure	produced	by	D.	Baxter)	
	
3.2.13 	Statistical	Analyses		
Comparisons	between	groups	(nbTBI	vs.	bTBI;	and	bTBI	with	pituitary	dysfunction	vs.	
bTBI	without	pituitary	dysfunction)	were	made	using	Fisher’s	exact	test	for	
prevalence	data	and	unpaired	Student	t	test	(FA	and	neurocognitive	variables)	or	
Mann-Whitney	U	test	(other	variables)	for	continuous	data	(SPSS	v	19.0).	
Significance	was	defined	as	p<0.05.	A	group	x	ROI	repeated	measure	ANOVA	was	
performed	to	assess	the	overall	effect	of	pituitary	dysfunction	on	FA.	
	
	 109	
3.3 Results		
3.3.1 Patient	Characteristics		
All	soldiers	with	bTBI	had	sustained	their	injuries	by	proximity	to	IED	exposure	in	
Afghanistan.	All	had	been	wearing	full	personal	protective	equipment.	In	the	control	
nbTBI	group,	injuries	were	secondary	to	road	traffic	accidents	(RTAs;	34%)	assaults	
(32%),	falls	(23%)	and	sporting	injuries	(2%).	There	was	a	history	of	previous	mild	TBI	
in	the	nbTBI	group,	but	not	in	the	bTBI	group.	
	
The	bTBI	and	nbTBI	groups	were	generally	well-matched	in	age,	gender,	ISS	whole	
body	injury	severity,		presence	of	skull	or	facial	fractures	(15.8	vs.	15.4%)	and	post-
traumatic	seizures	(10.5	vs.	7.7%).	The	bTBI	group	had	a	significantly	longer	post-	
traumatic	amnesia	duration	(PTA	median	5.5	days	vs.	0.5	days,	p	=	0.01);	more	
injuries	requiring	surgery	to	or	loss	of	function	of	major	extracranial	organs	(57.9	vs.	
7.7%,	p	=	0.002);	more	amputations	(36.8	vs.	0%,	p	<	0.001);	and	greater	use	of	
strong	prescription	opiates	(47.3	vs.	7.7%,	p	<0.001).	The	time	from	TBI	to	endocrine	
testing	was	significantly	longer	in	the	bTBI	group	(median	15.2	vs.	5.8	months,	p	
<0.001).	Demographic	data	are	displayed	in	Table	3-2.	
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Table	3-2	Patient	Characteristics	 	
  units 
/ max 
score 
All nbTBI  All bTBI P value bTBI: No Pituitary 
Dysfunction 
bTBI: 
Pituitary 
Dysfunction 
P 
value 
n   39 19   13 6   
Age at TBI         yr. 31.3 [22.5-
35.7] 
26.7 [26.1-30.9] 0.40 26.6 [24.6-30.6] 29.3 [25.8-
36.6] 
0.48 
    17.2 - 44.8 19.0 - 43.5   19.0 - 36.3 25.0 - 43.5   
Age at testing  yr. 32.3 [23.1-
36.7] 
28.3 [26.8-32.2] 0.40 28.0 [25.3-31.4] 30.3 [27.4-
38.3] 
0.32 
    19.9 - 45.1 19.6 - 44.7   19.6 - 37.6 26.3 - 44.7   
Time since TBI mo 5.8 [3.1-
11.0] 
15.2 [10.8-19.3] 0.001 15.2 [8.8-16.6] 17.6 [12.3-
20.2] 
0.32 
    1.9-41.2 4.1 - 23.7   4.1-23.7 4.9-21.9   
ISS  75 25.0 [16.0-
32.0] 
33.0 [20.0-45.0] 0.17 24.0 [14.5-40.5] 35.5 [27.0-
51.3] 
0.24 
    1-75 9-70   9-45 9-70   
AIS Head  6 5.0 [4.0-5.0] 4.0 [3.0-5.0] 0.04 4.0 [2.5-4.0] 5.0 [3.0-5.3] 0.06 
    1-6 0-6   0-5 0-6   
AIS Chest  6 0 [0-0] 0 [0-2] 0.11 0 [0-3] 0.5 [0-2.3] 0.83 
    0-6 0-4   0-4 0-3   
AIS Abdomen  6 0 [0-0] 0 [0-2] 0.02 0 [0-2] 0 [0-2.3] 0.97 
    0-3 0-3   0-2 0-3   
GCS 15 14.0 [6.0-
14.0] a 
3.0 [3.0-14.5] b 0.24 14.0 [3.0-15.0] c 3.0 [3.0-3.0] d 0.19 
    3-15 3-15   3-15 3-3   
PTA  days 0.5 [0-7.3] e 5.5 [0.8-22.8] 0.01 3.0 [0-19.3] 15.5 [6.3-31.5] 0.10 
    0-42  0-84   0-84 4-42   
PTA>24 hrs   20 (51.3%) 13 (68.4%) 0.27 7 (58.3%) 6 (100%) 0.11 
BMI  kg/m2 24.7 [22.4-
29.4] 
26.7 [24.5-28.9] 0.28 26.6 [24.5-28.7] f 25.5 [22.4-
32.0] g 
0.79 
    17.0-33.4 21.7-33.7   23.6-29.4 21.7-33.7   
Limb amputation   0 (0%) 8 (42.1%) <0.001 6 (46.1%) 2 (33.3%)  1.00 
Major organ 
damage 
  3 (7.7%) 11 (57.9%) <0.001 7 (53.9%) 4 (66.7%) 1.00 
Skull/facial 
fracture 
  6 (15.4%) 3 (15.8%) 1.0 0 (0%) 3 (50.0%)  0.02 
Opiate use   3 (7.7%) 9 (47.3%)  0.001 6 (46.2%) 3 (50.0%) 1.00 
Anti-depressant 
use 
  5 (12.8%) h 10 (52.7%) i 0.003 7 (53.8%) j 3 (50.0%) k 1.00 
Seizures post 
TBI 
  3 (7.7%) l 2 (10.5%) m 1.0 1 (7.7%) n 1 (16.7%) o 1.00 
Primary 
hypogonadism 
  1 (2.6%) p 4 (21.1%) q 0.04 4 (30.8%) q 0 (0%) q 0.26 
	
	
Data	are	expressed	as	median	[interquartile	range],	range,	or	No.	(%).	Probability	values	are	
from	Mann–Whitney	U	test	or	Fisher	exact	test	between	groups.	aStatistically	significant;	p	<	
0.05.	Data	available	for	bn	5	16,	cn	5	9,	dn	5,	en	5	4,	fn	5	38,	and	due	to	amputations:	gn	5	7,	
hn	5	4.	For	analgesic	purposes	only	in:	in	5	5	(12.8%),	jn	5	6	(31.6%),	kn	5	4	(30.8%),	ln	5	2	
(33.3%).	For	depression	itself	in:	in	5	0	(0%),	jn	5	4	(21.1%),	kn	5	3	(23.1%),	ln	5	1	(16.7%).	On	
antiepileptic	drugs	in	mn	5	3,	nn	5	1,	on	5	0,	pn	5	1.	qNot	due	to	trauma.	rDue	to	perineal	
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trauma.	AIS	5	Abbreviated	Injury	Score;	BMI	5	body	mass	index;	bTBI	5	blast	traumatic	brain	
injury;	GCS	5	Glasgow	Coma	Scale;	ISS	5	Injury	Severity	Score;	nbTBI	5	nonblast	TBI;	PTA	5	
post-traumatic	amnesia.	
	
3.3.2 Prevalence	of	Pituitary	Dysfunction	in	bTBI			
Six	of	19	soldiers	with	bTBI	(31.6%)	had	confirmed	anterior	pituitary	dysfunction.	Of	
these,	two	soldiers	(10.5%)	had	hyperprolactinaemia,	2	(10.5%)	had	isolated	GH	
deficiency,	1	(5.3%)	had	isolated	ACTH	deficiency	and	1	(5.3%)	had	combined	ACTH,	
GH	and	gonadotrophin	deficiencies.	Within	the	nbTBI	control	group,	only	1	of	39	
subjects	had	pituitary	dysfunction	(isolated	GH	deficiency)	(p=0.004	in	bTBI	vs.	
nbTBI).	No	patient	in	either	group	had	TSH	deficiency	or	diabetes	insipidus.	(Figure	
3-2).	
	
Figure	3-2	Pie	Chart	showing	the	prevalence	of	pituitary	dysfunction	in	bTBI	vs.	
nbTBI	
	
	
The	3	soldiers	with	GH	deficiency	had	IGF-I	levels	in	the	low	normal	range	(Table	3-3)	
and	the	2	soldiers	with	ACTH	deficiency	had	normal	early	morning	cortisol	levels	on	
initial	assessment	of	287	to	292	nmol/L.	However,	on	subsequent	cortisol	day	curves,	
both	subjects	with	ACTH	deficiency	had	low	cortisol	levels	consistent	with	the	
diagnosis	that	was	then	confirmed	with	a	second-line	confirmatory	test	(Table	3-4).	
Prevalence of Pituitary Dysfunction:
nbTBI 2.6% bTBI 31.6%
Non-blast TBI                                                                                    Blast TBI
n=1 n=1
n=13n=38
n=2
n=1
n=1
GH Deficiency
Hyperprolactinemia
ACTH Deficiency
ACTH/GH/Gn Deficiency
Normal
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None	of	the	soldiers	with	ACTH	deficiency	had	any	history	of	hypotension,	
hypoglycaemia	or	hyponatraemia.	
	
Additional	endocrine	findings	included	the	finding	of	primary	hypogonadism	in	4	out	
of	19	soldiers	with	bTBI	(21.2%).	None	of	these	individuals	had	pituitary	dysfunction	
and	the	primary	nature	of	the	deficiency	was	likely	due	to	perineal/testicular	blast	
injury.	They	were	already	on	testosterone	at	the	time	of	testing	(Table	3-5).	
	
3.3.3 Comparison	of	soldiers	with	and	without	Pituitary	Dysfunction.	
		
There	was	no	significant	difference	in	age,	time	since	injury,	ISS,	abdominal	AIS,	BMI	
(but	could	not	be	adequately	assessed	in	n=8	who	had	limb	amputations),	major	
organ	damage,	prevalence	of	amputations,	seizures	and	use	of	opiates	or	
antidepressants	(Table	3-6).	The	medications	recorded	for	each	soldier	at	time	of	
research	visit	are	displayed	in	Table	3-7.	
	
There	were	trends	for	the	AIS	head	injury	scores	to	be	higher	(p=0.06)	and	duration	
of	PTA	to	be	longer	(15.5	vs.	3.0	days,	p=0.10)	in	those	soldiers	with	pituitary	
dysfunction	after	bTBI	than	in	those	without.	
	
There	was	a	significantly	higher	presence	of	skull/facial	fractures	in	the	soldiers	with	
pituitary	dysfunction	compared	to	those	without	(50	vs.	0%,	p=0.02)	(Table	3-6).	
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Table	3-3	Growth	hormone-IGF-I	axis	in	blast	traumatic	brain	injury		
	
GROWTH HORMONE / IGF-1 AXIS
Glucagon Stimulation Test GHRH-Arginine Test    Insulin Tolerance Test
ID Summary of Pituitary Dysfunction IGF-I 
IGF-I                      
age related NR
IGF-I             
median of NR
IGF-I                 
ratio to median Peak GH IGF-I BMI GH cut off Peak GH IGF-I Peak GH
Units nmol/L nmol/L nmol/L n/a µg/L nmol/L kg/m2 µg/L µg/L nmol/L µg/L
Normal range >5 >5
No Pituitary Dysfunction n=13
M02 Nil 22.6 14.2-36.9 22.9 0.72 6.55 n/a n/a n/a n/a 23.5 52.10
M04 Nil 58.0 15.2-42.8 25.5 1.84 13.10 n/a n/a n/a n/a n/a n/a
M05 Nil 19.9 15.2-42.9 25.5 0.63 11.60 n/a n/a n/a n/a n/a n/a
M09 Nil 29.0 18.3-62.8 33.9 0.62 0.98 18.7 n/a 11.7 17.20 n/a n/a
M11 Nil 31.9 16.5-55.1 30.2 1.01 1.56 31.9 26.6 11.7 37.80 n/a n/a
M12 Nil 38.1 15.2-42.8 25.5 1.21 0.64 38.1 n/a 8.1 13.50 n/a n/a
M13 Nil 74.5 15.1-46.5 26.4 2.37 0.69 ND n/a 11.7 17.30 n/a n/a
M15 Nil 27.4 15.2-42.8 25.5 0.87 2.84 30.0 n/a 8.1 23.30 n/a n/a
M16 Nil 31.3 14.2-36.9 22.9 0.99 3.17 29.8 28.7 8.1 27.00 n/a n/a
M17 Nil 19.9 15.2-42.8 25.5 0.63 8.66 n/a n/a n/a n/a n/a n/a
M18 Nil 17.9 15.2-42.8 25.5 0.57 2.65 19.9 n/a 8.1 10.00 n/a n/a
M19 Nil 29.6 15.2-42.8 25.5 0.94 5.96 n/a n/a n/a n/a n/a n/a
M20 Nil 17.2 15.0-39.9 24.4 0.55 7.96 n/a n/a n/a n/a n/a n/a
Median [IQR] 29.0 [19.9-35.0] 0.87 [0.63-1.11] 3.17 [1.27-8.31] 29.9 [19.6-33.5] 17.30 [13.50-27.00]
Range 17.2-74.5 0.55-2.37 0.64-13.10 19.0-38.0 10.0-38.0
Pituitary dysfunction n=6
M01 PRL 21.6 15.2-42.8 25.5 0.69 6.97 n/a n/a n/a n/a n/a n/a
M03 ACTH 26.7 15.2-42.8 25.5 0.85 0.19 32.1 31.6 8.1 15.40 n/a n/a
M07 GH 23.7 15.0-39.9 24.4 0.75 2.66 26.1 26.1 5.5 3.43 n/a n/a
M08 ACTH/GH/Gn 16.1 13.1-34.7 21.3 0.66 0.08 16.6 n/a 8.1 4.26 ND 0.18
M10 PRL 18.9 15.2-42.8 25.5 0.60 2.78 29.4 24.3 8.1 25.80 n/a n/a
M14 GH 18.2 15.2-42.8 25.5 0.58 0.05 21.8 33.7 5.5 2.70 n/a n/a
Median [IQR] 20.3 [17.7-24.5] 0.68 [0.60-0.78] 1.43 [0.07-3.83] 26.1 [19.2-30.8] 4.26 [3.07-20.6]
Range 16.1-26.7 0.58-0.85 0.05-6.97 16.6-32.1 2.70-25.80
P value 0.07 0.28 0.09 0.54 0.11
Abnormal	values	in	grey	shading	
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Table	3-4	ACTH-cortisol	axis	in	blast	traumatic	brain	injury		
	
	 	
ACTH CORTISOL AXIS
Glucagon Stress Test Day Curve Metyrapone Test (post levels) Insulin Tolerance Test
ID Summary of Pituitary Dysfunction Basal Cortisol 
a Peak Cortisol a Basal ACTH Cortisol a Cortisol a ACTH 11-DOC b Basal Cortisol a Peak Cortisol a CBG  
Units nmol/L nmol/L ng/L nmol/L nmol/L ng/L nmol/L nmol/L nmol/L µg/L
Normal Range 100-500 >350 <50 09, 12, 15, 18, 21h <200 >60 >200 100-500 >500 27.1-52.3
No Pituitary Dysfunction n=13
M02 Nil 230 230 6.0 304, 208, 226, 295, ND n/a n/a n/a 544 636 48.9
M04 Nil 283 378 27.4 395, 153, 136, 72, 54 123 247 244.5 n/a n/a n/a
M05 Nil 309 494 39.2 n/a n/a n/a n/a n/a n/a n/a
M09 Nil 335 389 15.3 n/a n/a n/a n/a n/a n/a n/a
M11 Nil 323 473 38.0 n/a n/a n/a n/a n/a n/a n/a
M12 Nil 192 478 17.2 n/a n/a n/a n/a n/a n/a n/a
M13 Nil 363 386 24.6 n/a n/a n/a n/a n/a n/a n/a
M15 Nil 376 497 ND n/a n/a n/a n/a n/a n/a n/a
M16 Nil 427 427 92.7 n/a n/a n/a n/a n/a n/a n/a
M17 Nil 207 626 20.0 n/a n/a n/a n/a n/a n/a n/a
M18 Nil 409 533 27.0 n/a n/a n/a n/a n/a n/a n/a
M19 Nil 220 435 19.7 n/a n/a n/a n/a n/a n/a n/a
M20 Nil 420 420 28.6 n/a n/a n/a n/a n/a n/a n/a
Median [IQR] 323.0 [225.0-392.5] 435.0 [387.5-495.5] 25.8 [17.8-35.7]
Range 192-427 230-626 6.0-92.7
Pituitary dysfunction n=6
M01 PRL 606 606 164.0 n/a n/a n/a n/a n/a n/a n/a
M03 ACTH 292 292 23.2 67, 50, <20, 28, <20 38 22 87.1 n/a n/a 63.0
M07 GH 419 419 24.8 n/a n/a n/a n/a n/a n/a n/a
M08 ACTH/GH/Gn 287 287 18.7 204, 86, 100, 44, 22 n/a n/a n/a 110 268 74.0
M10 PRL 109 350 20.6 422, 333, 200, 260, 79 ND 207 200.0 n/a n/a 55.7
M14 GH 88 445 32.2 200 at 13h n/a n/a n/a n/a n/a n/a
Median [IQR] 289.5 [103.8-465.8] 384.5 [290.8-485.3] 24.0 [20.1-65.2]
Range 88-606 287-606 18.7-164.0
P value 0.70 0.28 0.75
	
Abnormal	values	in	grey	shading	
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Table	3-5	Pituitary-gonadal	axis,	pituitary-thyroid	axis	and	prolactin	in	blast	traumatic	brain	injury	
	
GONADOTROPHIN / TESTOSTERONE AXIS THYROID PROLACTIN
ID Summary of 
Pituitary Dysfunction
LH                         FSH                     Testosterone SHBG                 Free Androgen Index 
Primary 
Hypogonadism Free T4            Free T3         TSH Prolactin                               
Units IU/L IU/L nmol/L nmol/L pmol/L pmol/L mU/L mU/L
Normal range 2.0-12.0 1.7-8.0 10.0-30.0 15-55 30-150 9.0-26.0 2.5-5.7 0.3-4.2 75-375
No Pituitary Dysfunction n=13
M02 Nil 2.4 1.1 23.7 55.0 43.1 No 15.6 4.4 0.46 97
M04 Nil 4.7 3.9 21.0 33.0 63.6 No 12.2 5.7 2.11 146
M05 Nil 4.4 2.5 15.5 18.0 86.1 No 15.3 3.2 1.78 118
M09 Nil 1.2 4.8 39.5 18.0 219.4 Yes 13.4 5.8 1.04 219
M11 Nil 1.6 0.7 12.5 18.0 69.4 No 14.0 4.4 1.43 285
M12 Nil 18.5 36.4 6.2 10.0 62.0 Yes 15.5 3.5 1.21 177
M13 Nil 5.8 9.6 13.1 10.0 131.0 No 13.2 5.2 1.33 240
M15 Nil 40.3 60.3 11.6 18.0 64.4 Yes 14.0 6.6 0.77 136
M16 Nil 5.5 4.9 22.3 24.0 92.9 No 13.4 4.4 0.96 200
M17 Nil 4.7 3.3 25.2 39.0 64.6 No 16.9 5.2 1.13 131
M18 Nil 0.0 0.1 12.3 19.0 64.7 Yes 18.5 4.8 1.25 312
M19 Nil 2.3 1.5 22.0 28.0 78.6 No 15.0 4.7 2.06 183
M20 Nil 3.8 3.6 28.8 32.0 90.0 No 13.2 4.6 0.70 330
Median [IQR] or n (%) 4.4 [2.0-5.6] 3.6 [1.3-7.3] 21.0 [12.4-24.5] 19.0 [18.0-32.5] 69.4 [64.0-91.5] 4 (30.8%) 14.0 [13.3-15.6] 4.7 [4.4-5.5] 1.21 [0.87-1.61] 183 [134-263]
Range 0-40.3 0.1-60.3 6.2-39.5 10.0-55.0 43.1-219.4 12.2-18.5 3.2-6.6 0.46-2.11 97-330
Pituitary dysfunction n=6
M01 PRL 1.8 2.5 21.7 27.0 80.4 No 17.3 4.6 4.18 619
M03 ACTH 1.5 1.2 23.8 35.0 68.0 No 16.0 5.5 1.11 126
M07 GH 3.7 2.4 13.1 24.0 54.6 No 14.4 4.9 1.81 172
M08 ACTH/GH/Gn 1.3 1.8 2.0 18.0 11.1 No 15.5 4.3 1.19 199
M10 PRL 2.6 1.3 22.8 26.0 87.7 No 10.8 4.7 2.29 439
M14 GH 6.5 3.9 22.4 33.0 67.9 No 12.9 4.0 0.90 216
Median [IQR] or n (%) 2.2 [1.5-4.4] 2.1 [1.3-2.9] 22.1 [10.3-23.1] 26.5 [22.5-33.5] 68.0 [43.7-82.2] 0 (0%) 15.0 [12.4-16.3] 4.7 [4.2-5.1] 1.50 [1.06-2.76] 208 [161-484]
Range 1.3-6.5 1.2-3.9 2.0-23.8 18.0-35.5 11.1-87.7 10.8-17.3 4.0-5.5 0.90-4.18 126-619
P value 0.37 0.28 0.97 0.42 0.47 0.26 0.90 0.70 0.31 0.47
Abnormal	values	in	grey	shading	
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Table	3-6	Characteristics	of	soldiers	with	blast	TBI	
	
	
Subjects Age at TBI  Age at GST Time since TBI ISS AIS Head AIS Chest AIS Abdo GCS PTA BMI at GST
PTA >24 
hrs
Limb 
amputation Major organ damage
Skull/facial 
fracture Opiate use
Antidepressant 
use Seizures
Units / Maximum score Years Years Months 75 6 6 6 15 Days kg/m
2
No pituitary dysfunction (n=13)
M02 36.3 37.6 15.2 20 4 0 2 3 1 25.4 No No No No Yes Yes No
M04 26.4 27.6 14.2 24 0 4 0 n/a 4 27.7 Yes No Lung/eye No No No No
M05 27.3 28.6 15.2 24 0 4 0 n/a 28 24.5 Yes No No No Yes No No
M09 19.0 19.6 6.7 45 4 0 2 n/a 4 n/a Yes Yes Perineum No Yes Yes * No
M11 19.3 20.9 16.6 25 5 0 0 3 84 26.6 Yes No No No No No Yes
M12 30.2 30.5 4.1 33 2 0 2 n/a 0 n/a No Yes Perineum No Yes Yes * No
M13 22.8 23.7 10.8 45 4 0 0 n/a 21 n/a Yes Yes Eye/Skin No No Yes * No
M15 26.4 26.8 4.1 45 4 0 2 15 0 n/a No Yes Eye/Skin/perineum No Yes Yes * No
M16 34.7 36.7 23.7 24 4 2 0 15 0 28.7 No No No No Yes Yes No
M17 26.6 28.0 16.6 9 3 0 0 14 0 23.6 No No No No No No No
M18 26.7 28.3 20.2 36 4 4 2 n/a 14 n/a Yes Yes Lung/colon/perineum No No No No
M19 26.6 27.7 13.6 9 3 0 0 n/a n/a n/a n/a Yes Skin No No No No
M20 30.9 32.2 15.4 9 3 0 0 n/a 2 29.4 Yes No No No No Yes No
median 26.6 28.0 15.2 24.0 4.0 0 0 3.0 26.6 7 (58.3%) 6 (46.1%) 7 (53.9%) 0 (0%) 6 (46.2%) 7 (53.8%) 1 (7.7%)
IQR [24.6-30.6]  [25.3-31.4] [8.8-16.6]  [14.5-40.5] [2.5-4.0]  [0-3] [0-2] [0-19.3]  [24.5-28.7]
Pituitary dysfunction (n=6)
M01 (PRL) 30.0 30.4 4.9 33 5 0 0 3 4 21.7 Yes No No Yes Yes Yes * Yes #
M03 (ACTH) 25.0 26.3 15.9 70 6 0 3 3 17 n/a Yes Yes Spleen/Liver Yes No Yes * No
M07 (GH) 34.3 36.2 21.9 38 5 3 0 3 7 26.7 Yes No Lung No No No No
M08 (ACTH/GH/Gn) 43.5 44.7 14.7 45 4 2 0 n/a 42 n/a Yes Yes No No Yes No No
M10 (PRL) 28.5 30.1 19.3 33 5 0 2 n/a 28 24.3 Yes No Eye/Liver/lung Yes No No No
M14 (GH) 26.1 27.7 19.6 9 0 1 0 3 14 33.7 Yes No Skin No Yes Yes No
median 29.3 30.3 17.6 35.5 5 0.5 0 15.5 25.5 6 (100%) 2 (33.3%) 4 (66.7%) 3 (50.0%) 3 (50%) 3 (50%) 1 (16.7%)
IQR [25.8-36.6] [27.4-38.3] [12.3-20.2] [27.0-51.3] [3.0-5.3]  [0-2.3]  [0-2.3]  [6.3-31.5] [22.4-32.0]
P value 0.48 0.32 0.32 0.24 0.06 0.83 0.97 0.10 0.79 0.11 1.00 1.00 0.02 1.00 1.00 1.00
All	data	expressed	as	median	[interquartile	range]	or	n	(%)
*	for	analgesia	only,	#	on	anti-epileptic	drug
Abbreviations:	AIS:	Abbreviated	Injury	Score,	BMI:	bodymass	index,	GCS:	Glasgow	Coma	Scale,	GST:	Glucagon	stimulation	test,	ISS:	Injury	Severity	Score,	n/a:	not	available,	PTA:	Post	traumatic	amnesia.
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Table	3-7	Medications	used	by	soldiers	with	blast	TBI	
	
	
3.3.4 Neuroimaging	Results		
Three	of	the	5	(50.0%)	soldiers	with	pituitary	dysfunction,	compared	to	only	1	of	the	
13	(7.7%)	soldiers	without	pituitary	dysfunction,	had	contusions	on	brain	MRI	scans	
(p=0.07).	However,	overall,	contusion	volume	was	small	(<10	cm3).	(Figure	3-3).	
	
Figure	3-3	Intracerebral	contusions	following	bTBI		
	
Subjects Medications
No pituitary dysfunction (n=13)
M02 Diclofenac, Sertraline, Tramadol
M04 Co-codamol
M05 Diclofenac, Tramadol
M09 Amitriptyline, MST, Nebido, Pregabalin
M11 None
M12 Amitriptyline, Diclofenac, Nebido, Pregabalin, Ranitidine, Sildenafil, Tramadol
M13 Amitriptyline, Baclofen, Pregabalin
M15 Amitriptyline, Nebido, Pregabalin, Tramadol
M16 Mirtazepine, Paracetamol, Pregabalin, Tramadol, Zopiclone 
M17 None
M18 Nebido
M19 Diclofenac, Pregabalin, Ranitidine
M20 Sertraline, Zopiclone
Pituitary dysfunction (n=6)
M01 (PRL) Amitriptyline, Diclofenac, MST, Phenytoin
M03 (ACTH) Amitriptyline, Erythromycin, Gabapentin
M07 (GH) None
M08 (ACTH/GH/Gn) Diclofenac, Lansoprazole, MST, Paracetamol, Pregabalin, Tramadol
M10 (PRL) Betnovate ointment, Co-codamol
M14 (GH) Amitriptyline, Diclofenac, Fluoxetine, Mirtazepine, MST, Paracetamol, Pregabalin, Salbutamol inhaler, Temazepam, Zopiclone
Abbreviations:	MST	morphine	sulphate
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High	resolution	T1	brain	scans	(axial	sections)	in	subject	space	showing	contusions	(arrows)	
in	soldiers	after	blast	TBI	(A)	without	pituitary	dysfunction,	and	(B-D)	with	pituitary	
dysfunction.	Total	contusion	volumes	for	these	patients	were:	(A)	0.2,	(B)	9.1,	(C)	0.6,	(D)	1.0	
cm3.	Produced	by	D	Baxter	
	
No	hypothalamic-pituitary	abnormalities	were	seen	on	MRI	brain	scans	in	any	
soldiers	in	the	bTBI	group.	There	were	also	no	abnormalities	detected	on	the	4/6	
soldiers	with	pituitary	dysfunction	who	had	dedicated	contrast-enhanced	MRI	
pituitary	scans.	The	prevalence	of	structural	abnormalities	in	soldiers	with	and	
without	pituitary	dysfunction	are	displayed	in	Table	3-8.	
	
Table	3-8	Prevalence	of	structural	abnormalities	in	soldiers	with	and	without	
pituitary	dysfunction	
	
	
DTI	FA	analysis	showed	a	reduction	in	FA	depending	on	the	ROI,	indicating	greater	
white	matter	damage,	in	those	soldiers	with	pituitary	dysfunction	after	bTBI	
compared	to	those	without	(p=0.14	effect	of	group,	p	=0.02	group	x	ROI	interaction).	
Planned	post	hoc	analysis	showed	significantly	lower	FA	values	for	those	soldiers	
with	pituitary	dysfunction	within	the	cerebellum	(p<0.05),	and	body/genu	(p	<	0.05)	
and	splenium	(p=0.01)	of	the	corpus	callosum	(Figure	3-4).	
	
No pituitary dysfunction Pituitary dysfunction P
 n 13 6
 Acute CT brain
Extra-dural hemorrhage 0 (0%) 0 (0%) n/a
Sub-dural hemorrhage 0 (0%) 0 (0%) n/a
Traumatic sub-arachnoid or 
intra-ventricular hemorrhage 0 (0%) 0 (0%) n/a
Diffuse swelling 1 (7.7%) 0 (0%) 1.00
 Study MRI brain
Contusion 1 (7.7%) 3 (50.0%) 0.07
Siderosis 3 (23%) 1 (16.6%) 1.00
Microbleeds 7 (53%) 3 (50%) 1.00
Gliosis 0 (0%) 1 (16.6%) 0.32
Hypo-pituitary damage 0 (0%) 0 (0%) n/a
 MRI pituitary with contrast ND 4 normal, 2 ND n/a
Data given as n (%)
Abbreviations: n/a: not applicable, ND: not done
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Figure	3-4	Pituitary	dysfunction	and	FA	measurements	in	various	WM	tracts	
	
Lower	fractional	anisotropy	was	seen	in	a	priori	white	matter	tract	regions	of	interest	in	
soldiers	with	pituitary	dysfunction	after	blast	traumatic	brain	injury	
(black,	n	5	6)	compared	to	those	without	pituitary	dysfunction	
(white,	n	5	13).	Data	are	expressed	as	mean+	standard	deviation.	
*p	<	0.05	(unpaired	t	test).	Ant=anterior;	CC=corpus	callosum;	Cap=capsule;	Int=internal;	
Post=posterior;WM=white	matter.	Produced	by	D	Baxter	
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3.3.5 Quality	of	Life	and	Cognitive	Function		
Soldiers	with	bTBI	appeared	to	have	worse	scores	for	physical	activity	and	daily	living	
problems	than	those	who	had	a	nbTBI.	There	were	trends	for	higher	reporting	of	
pain	and	deleterious	change	in	health	in	the	soldiers	vs.	civilians.	However	there	
were	no	differences	in	mood	or	sleep	disturbance	between	the	groups.	
	
Within	the	soldier	group	there	was	a	trend	towards	lower	mood	and	higher	AGHDA	
scores	(consistent	with	lower	mood)	in	those	subjects	with	pituitary	dysfunction	vs.	
those	without.	There	were	also	trends	towards	worse	measures	of	QoL	and	
symptom	scores	in	several	domains	relating	to	social	and	emotional	functioning	and	
fatigue	Table	3-9.	
	
The	bTBI	subjects	with	pituitary	dysfunction	had	significantly	worse	average	current	
verbal	intellectual	ability	than	those	without	pituitary	dysfunction	and	significantly	
worse	cognitive	impairment	in	the	domains	of	visual/naming/reading/processing	
speed,	verbal	fluency,	and	information	processing.	This	was	despite	there	being	no	
difference	in	premorbid	intelligence	between	the	two	groups	as	measured	by	the	
Wechsler	Test	of	Adult	Reading	Table	3-10.	
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Table	3-9	Quality	of	life	and	symptom	questionnaires	in	non-blast	and	blast	traumatic	brain	injury	 	
	
	
	
	
 Quality of Life / Symptom Assessment nbTBI All bTBI P value                 nbTBI vs. bTBI
bTBI: No Pituitary 
Dysfunction
bTBI: Pituitary 
Dysfunction
P  value                         
no pit dys vs. pit dys
n 38 18 h 12 h 6
Assessment of GH Deficiency in Adults (AGHDA)  9.5 [5.8-14.5] a  16.0 [4.0-18.5] b 0.22  14.0 [3.0-17.0]  17.5 [16.0-19.5] 0.10
Beck Depression Inventory Score (BDI-II)  11.0 [7.0-20.0] c  20.5 [4.0-24.5] 0.30  11.5 [1.8-21.8]  24.5 [20.3-26.3] 0.08
Epworth Sleepiness Scale  7.0 [2.0-12.0] d  7.0 [2.5-11.0] 0.89  6.0 [1.5-10.5]  10.0 [3.0-16.5] 0.25
Pittsburgh Sleep Index  ND  10.0 [2.8-16.0]  4.5 [2.0-16.3]  12.0 [8.0-15.5] 0.37
NHP Energy Levels         39.0 [0-100] e  49.0 [18.0-100] 0.63  49.0 [0-94.0]  68.5 [24.0-100] 0.39
NHP Pain                    0 [0-48] e  28.5 [9.7-52.5] 0.08  24.0 [14.0-51.0]  36.0 [0-54.5] 0.96
NHP Emotional Reactions  20.0 [10.0-47.0] e  32.5 [6.7-55.5] 0.71  15.0 [0-46.2]  54.0 [25.0-67.7] 0.10
NHP Sleep        22.0 [0-73.0] e  55.0 [0-100] 0.20  30.0 [0-93.2]  64.0 [31.7-100] 0.29
NHP Social Isolation   0 [0-45.0] e  21.0 [0-59.0] 0.52  0 [0-48.5]  29.0 [21.2-69.0] 0.13
NHP Physical Activity         0 [0-21.8] e  26.5 [11.0-42.0] 0.02  26.5 [13.2-42.0]  27.0 [0-60.7] 0.96
NHP Average              22.0 [5.4-41.0] e  41.5 [15.5-55.2] 0.09  28.5 [9.5-55.0]  48.5 [38.7-55.2] 0.25
NHP Daily Living Problems (0-7)  2.0 [0-5.0] f  5.0 [3.5-6.0] 0.04  4.5 [2.3-5.8]  4.5 [3.8-6.3] 0.62
SF-36 Physical functioning  85.0 [60.0-95.0] e  52.5 [27.5-81.3] 0.21  52.5 [41.3-58.8]  60.0 [27.5-88.8] 0.82
SF-36 Role limitations due to physical health  12.5 [0-62.5] g  12.5 [0-75.0] 0.94  25.0 [0-93.8]  0 [0-18.8] 0.10
SF-36 Role limitations due to emotional problems  67.0 [0-100] g  67.0 [24.8-100] 0.90  83.5 [33.0-100]  50.0 [0-100] 0.49
SF-36 Energy/Fatigue  50.0 [35-60] e  42.5 [33.8-66.3] 0.92  52.5 [36.3-70.0]  37.5 [26.3-47.0] 0.15
SF-36 Emotional well being  64.0 [52.0-80.0] e  60.0 [48.0-81.0] 0.57  68.0 [53.0-83.0]  58.0 [31.0-66.3] 0.34
SF-36 Social functioning  63.0 [38.0-75.0] e  50.0 [38.0-75.0] 0.66  56.5 [41.0-84.8]  44.0 [22.0-63.0] 0.18
SF-36 Pain  55.0 [33.0-88.0] e  45.0 [33.0-70.5] 0.68  68.0 [35.5-75.5]  33.0 [23.0-58.8] 0.21
SF-36 Health change  50.0 [38.0-75.0] e  32.5 [25.0-50.0] 0.06  25.0 [25.0-50.0]  45.0 [25.0-56.3] 0.49
SF-36 General health  50.0 [25.0-75.0] e  50.0 [25.0-61.3] 0.49  50.0 [27.5-63.8]  40.5 [18.8-61.3] 0.55
All	data	expressed	as	median	[IQR]				
Data	available	in	a	n=37,	b	n=17,	c	n=36,	d	n=31,	e	n=27,	f	n=25,	g	n=26	
Abbreviations:	bTBI:	blast	TBI,	NHP:	Nottingham	Health	Profile,	nbTBI:	non-blast	TBI,	SF-36:	Short	Form	36	Health	Survey,	TBI:	traumatic	brain	
injury	
Note:	AGHDA,	BDI-II,	Epworth	Sleepiness	Scale,	Pittsburgh	Sleep	Index	higher	score	equals	worse	symptoms;	NHP	higher	score	equals	worse	
health;	SF-36	lower	score	equals	worse	quality	of	life	
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Table	3-10	Cognitive	impairment	in	soldiers	with	pituitary	dysfunction	vs.	those	without	pituitary	dysfunction	
	
	
Cognitive domain Cognitive variable No pituitary dysfunction Pituitary dysfunction
n=13 n=6
Pre-morbid intelligence: reading ability WTAR raw score 35.9 ± 11.7 34.7 ± 14.6
Intellectual ability WASI similarities (verbal) 32.6 ± 6.2 27.0 ± 4.1 *
WASI matrix reasoning (non-verbal) 24.4 ± 7.5 24.2 ± 6.0
Memory: associative memory People test immediate recall 22.6 ± 8.1 25.0 ± 7.8
Processing speed: visual search/complex Trail Making Test Trail A (s) 23.1 ± 5.7 28.7 ± 5.2 *
Trail Making Test Trail B (s) 47.9 ± 14.5 53.8 ± 12.2
Processing speed: naming/reading Stroop Colour Naming (s) 32.5 ± 9.1 51.0 ± 29.7 *
Stroop Word Reading (s) 24.3 ± 6.7 37.2 ± 13.6 **
Executive function: alternating-switch cost Trail Making Test Trail B minus A (s) 24.8 ± 13.5 25.2 ± 9.0
Executive function: cognitive flexibility Color Word Stroop Inhibition/switching (s) 70.5 ± 24.2 86.3 ± 30.8
Inhibition/switching minus a baseline of 30.0 ± 18.8 26.5 ± 8.5
        color naming and word reading (s)
Word generation fluency DKEFS Letter Fluency F+A+S total 40.1 ± 12.9 28.8 ± 3.6 *
Information processing Choice reaction task median reaction time (ms) 413 ± 38 473 ± 31 *
Worse	cognitive	function	in	soldiers	after	blast	TBI	with	pituitary	dysfunction	(n=6)	compared	to	those	without	pituitary	dysfunction	(n=13).	Data	expressed	as	
mean	±	SD.	*P<0.05,	**P<0.005	(unpaired	t-test).	Abbreviations:	DKEFS:	Delis-Kaplan	Executive	Function	System,	WASI:	Wechsler	Abbreviated	Scale	of	
Intelligence	Similarities	and	Matrix	Reasoning	subsets,	WTAR:	Wechsler	Test	of	Adult	Reading.	Table	produced	by	D	Baxter		
	
	 123	
3.4 Discussion		
In	this	study,	we	report	that	nearly	one	third	of	soldiers	who	had	sustained	a	bTBI		
had	evidence	of	pituitary	dysfunction,		compared	to	only	2%	of	patients	who	had	a	
nbTBI.		The	most	common	pituitary	abnormality	was	GH	deficiency,	followed	by	
hyperprolactinaemia,	ACTH	and	gonadotrophin	deficiency.	One	soldier	had	three	
hormone	deficiencies	(GH,	ACTH	and	LH/FSH).	
	
We	used	conservative	and	stringent	methods	for	diagnosing	pituitary	dysfunction	for	
both	groups	and	followed	identical	protocols	for	each.	Our	algorithm	included	two	
stimulation	tests	rather	than	one	for	the	diagnosis	of	GH	and	ACTH	deficiency	(taking	
into	account	age	and	BMI	in	the	cut	offs	for	GH	deficiency	(Colao	et	al.,	2009),	we	
also	ruled	out	the	presence	of	macroprolactin	in	the	case	of	hyperprolactinaemia	
and	considered	the	effect	of	SHBG	on	the	diagnosis	of	gonadotrophin	deficiency.	
	
The	prevalence	of	pituitary	dysfunction	in	the	nbTBI	group	(1/39)	appears	to	be	
consistent	with	other	studies	that	have	also	reported	a	low	prevalence	(Kokshoorn	et	
al.,	2011;	Kokshoorn	et	al.,	2010).		We	therefore	feel	confident	that	we	have	neither	
under-	or	over-diagnosed	pituitary	abnormalities.		
	
We	could	not	find	any	clear	differences	between	the	patient	characteristics	of	the	
two	groups	that	may	explain	the	difference	in	prevalence	of	pituitary	dysfunction.	
There	was	a	higher	use	of	antidepressant	and	opiate	use	in	the	bTBI	group	overall	
but	not	between	those	with	and	without	pituitary	dysfunction.	The	time	to	
endocrine	testing	was	longer	in	the	bTBI	group	mainly	because	they	were	referred	to	
us	as	a	tertiary	rather	than	secondary	referral.	However	this	factor	is	not	likely	to	
account	for	an	increased	prevalence	of	pituitary	dysfunction	as	we	might	expect	
pituitary	abnormalities	to	recover	with	time	(Aimaretti	et	al.,	2005).		
	
PTA	was	longer	in	bTBI	vs.	nbTBI	hinting	at	more	severe	head	injury	as	a	group.	It	is	
possible	however	that	PTA	duration	could	have	been	complicated	by	the	use	of	
conscious	sedation.	Soldiers	did	have	greater	polytrauma	including	amputations	and	
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major	organ	damage	although	it	is	not	clear	how	this	may	lead	to	an	increased	rate	
of	pituitary	dysfunction	when	compared	with	civilians	and	there	was	no	difference	in	
these	factors	between	those	with	and	without	endocrine	abnormalities.	
	
Blast	appears	to	produce	a	specific	pattern	of	TBI	(Mac	Donald	et	al.,	2011),	although	
the	mechanisms	leading	to	this	are	not	completely	clear	as	blast	injury	is	often	a	
combination	of	primary,	secondary	and	tertiary	causes	(Cernak	&	Noble-Haeusslein,	
2010).	In	terms	of	the	effect	of	blast	injury	on	the	hypothalamus	and/or	pituitary	this	
could	be	explained	by	a	number	of	potential	mechanisms,	including	direct	damage	to	
cells	bodies,	hypophyseal	vessels	,	local	superficial	siderosis,	local/generalised	
inflammation	and	hypovolaemia/ischaemia.	There	was	no	evidence	radiographically	
however	of	these	type	of	injuries	at	the	hypothalamus-pituitary.	
	
There	were	however	important	differences	between	those	soldiers	with	and	without	
pituitary	dysfunction.	We	found	lower	FA	in	several	white	matter	tracts	(including	
the	body,	genu	and	splenium	of	the	corpus	callosum),	more	skull/facial	fractures	and	
a	trend	towards	more	cerebral	contusions	and	PTA	in	those	soldiers	with	pituitary	
dysfunction	vs.	those	without.	It	is	possible	that	these	factors	taken	together	are	
simply	more	indicative	of	a	more	severe	injury	overall	rather	than	a	specific	pattern	
of	injury	that	predisposes	to	hypothalamic-pituitary	damage.	
	
Our	focus	here	was	on	bTBI	that	was	defined	as	moderate-severe	in	severity	and	
caused	by	a	single	blast.	We	found	another	study	reporting	high	prevalence	of	
pituitary	abnormalities	in	soldiers	following	repeated,	mild	bTBI	(Wilkinson	et	al.,	
2012).	Although	the	methods	for	diagnosing	pituitary	dysfunction	were	considerably	
different	from	that	reported	here,	it	is	interesting	nonetheless	to	see	concordance	
with	our	results	even	in	milder	cases	of	bTBI.	
	
We	have	alluded	to	some	of	the	consequences	of	pituitary	dysfunction	in	this	study.	
The	trend	for	worse	fatigue,	mood,	social	and	emotional	problems	in	those	soldiers	
with	and	without	pituitary	dysfunction	may	be	a	direct	cause	of	the	pituitary	
deficiencies.	These	symptoms	are	well-recognised	features	of	GHD	and	fatigue	is	also	
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commonly	seen	in	cortisol	and	testosterone	deficiencies	(Cherrier,	2009;	Salvatori,	
2005;	Webb	et	al.,	2012).	The	greater	cognitive	impairment	in	soldiers	with	pituitary	
dysfunction	may	also	be	a	direct	consequence	of	the	hormone	deficiency	which	is	
well	reported	with	GH	(van	Dam,	2005).	However	it	is	also	important	to	bear	in	mind	
that	these	soldiers	may	have	worse	QoL	and	cognitive	impairment	due	to	greater	
brain	injury/axonal	damage	(Kinnunen	et	al.,	2011).	
	
In	the	clinical	setting,	the	diagnosis	of	treatable	pituitary	deficiency	in	these	
individuals	has	led	to	substantial	changes	in	their	clinical	care.	All	patients	with	GHD	
are	being	treated	with	daily	subcutaneous	recombinant	GH.	This	treatment	was	
started	>1	year	from	TBI	in	line	with	national	recommendations	and	has	been	
continued	due	to	symptomatic	improvement	at	6-9	months.	The	one	case	of	
testosterone	deficiency	is	being	treated	with	depot	testosterone	every	3	months	and	
the	two	soldiers	with	ACTH	deficiency	are	now	on	daily	hydrocortisone	replacement.	
The	cases	of	hyperprolactinaemia	have	not	required	treatment	due	to	absence	of	
secondary	hypogonadism.	Most	of	these	patients	have	been	referred	back	to	their	
local	endocrinologist	for	follow-up	as	many	of	these	soldiers	do	not	live	in	the	
locality	of	our	clinic.	
	
In	conclusion,	this	was	the	first	study	to	report	a	significantly	higher	prevalence	of	
pituitary	dysfunction	following	moderate-severe	bTBI	which	was	associated	with	
worse	QoL	and	cognitive	function.	It	is	not	clear	whether	the	mechanism	for	this	
higher	prevalence	is	due	to	greater	axonal	injury	overall	or	whether	blast	can	
specifically	predispose	to	pituitary	dysfunction	via	another	unknown	mechanism.	We	
recommend	that	all	individuals	who	have	had	a	moderate-severe	bTBI	should	have	
full	dynamic	pituitary	function	tests	as	part	of	their	routine	post	TBI	care.	The	
diagnosis	of	pituitary	dysfunction	may	warrant	hormone	replacement	which	is	likely	
to	have	diverse	benefits	for	these	patients.	
	
In	my	next	chapter,	I	will	be	examining	the	effect	of	GH	and	its	downstream	
mediator,	IGF-I	on	white	matter	recovery	following	TBI.	
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4 Association	of	serum	IGF-I	with	white	matter,	
neuropsychological	and	cognitive	recovery	following	
traumatic	brain	injury	
	
4.1 Introduction		
Hypopituitarism	is	a	recognised	consequence	of	TBI	(Agha	&	Thompson,	2006).	The	
reported	prevalence	of	anterior	pituitary	dysfunction	is	wide-ranging	and	this	is	likely	
to	be	due	to	differences	in	patient	populations	including	severity	of	injury,	time	since	
injury	and	methodology	used	for	diagnosis	(Bavisetty	et	al.,	2008;	Kokshoorn	et	al.,	
2010).	More	recent	larger	studies	using	gold-standard	dynamic	testing	have	reported	
a	prevalence	of	the	most	common	endocrinopathy,	growth	hormone	deficiency,	
(GHD)		of	2.7-11.8%	in	patients	more	than	1	year	after	TBI	(Bavisetty	et	al.,	2008;	
Klose	et	al.,	2014;	Kokshoorn	et	al.,	2011).	As	described	in	the	previous	chapter,	blast	
TBI	appears	to	be	a	particular	strong	risk	factor	for	developing	post-traumatic	
hypopituitarism.	We	found	an	overall	prevalence	of	pituitary	dysfunction	of	32.0%	
with	GHD	accounting	for	nearly	half	these	cases	(15.8%)	(Baxter	et	al.,	2013).	
	
GH	has	several	targets	within	the	brain	(Lobie	et	al.,	1993;	Nyberg	&	Hallberg,	2013),	
with	effects	either	direct	or	mediated	through	its	downstream	hormone	insulin-like	
growth	factor-I	(IGF-I).	In	non-TBI	related	GH	deficiency	(GHD),	there	is	impaired	
cognitive	function,	and	lower	FA	in	the	corpus	callosum	and	corticospinal	tract	in	
children	(Webb	et	al.,	2012),	and	GH	replacement	increases	serum	IGF-I	and	
improves	attention,	memory,	and	psychological	well-being(Arwert,	Deijen,	Muller,	&	
Drent,	2005;	Lasaite,	Bunevicius,	Lasiene,	&	Lasas,	2004;	Oertel,	Schneider,	Stalla,	
Holsboer,	&	Zihl,	2004).	Variations	in	serum	IGF-I	concentrations	are	also	related	to	
brain	structure	and	cognitive	function	(Nyberg	&	Hallberg,	2013).	In	stroke,	higher	
serum	IGF-I	concentrations	at	baseline	are	associated	with	better	neurological	and	
functional	outcomes	(N.	D.	Aberg,	Brywe,	&	Isgaard,	2006;	De	Smedt	et	al.,	2011).	
Mechanistically,	GH/IGF-I	deficiency	reduces	oligodendrocyte	turnover	in	the	corpus	
callosum	(Hua,	Forbes,	Lichtenwalner,	Sonntag,	&	Riddle,	2009),	whereas	GH/IGF-I	
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administration	increases	the	formation	of	new	neurons	in	the	hippocampus	(D.	
Aberg,	2010;	N.	D.	Aberg	et	al.,	2006;	De	Smedt	et	al.,	2011)	
	
In	TBI-related	GHD,	GH	replacement	also	improves	cognition,	psychological	function	
and	quality	of	life.	Improvement	in	WM	tract	recovery	after	TBI	might	be	a	
mechanism	by	which	GH	replacement	and	associated	increases	in	serum	IGF-I	
achieve	such	effects.	However	the	effects	of	GHD/IGF-I	status	on	WM	recovery	
following	TBI	are	unknown.	
	
TBI	is	a	disabling	disease	with	an	uncertain	prognosis,	although	a	significant	
proportion	of	individuals	improve	over	time	(McMillan	et	al.,	2012;	McMillan	et	al.,	
2011).	DTI	studies	have	previously	demonstrated	reductions	in	FA	throughout	
several	WM	tracts	after	TBI	that	correlate	with	functional	cognitive	deficits,	including	
memory	impairment	with	damage	in	the	fornices,	and	non-sustained	attention	with	
damage	in	the	cingulum	bundle	(Bonnelle	et	al.,	2011;	Kinnunen	et	al.,	2011;	Sharp	&	
Ham,	2011;	Sidaros	et	al.,	2008).	Furthermore,	dynamic	changes	in	FA	of	the	
splenium	of	the	corpus	callosum	(SPCC)	and	posterior	limb	of	the	internal	capsule	
(PLIC)	have	been	described	following	TBI	in	a	longitudinal	study	(Sidaros	et	al.,	2008).	
	
It	is	currently	unclear	what	inter-individual	factors	may	contribute	to	the	variability	
in	improvement	over	time	of	clinical	outcome	and	WM	tract	damage	after	TBI.	
Taking	into	account	the	prevalence	of	post-traumatic	hypopituitarism,	It	is	possible	
that	abnormal	hormone	levels	could	influence	brain	repair	following	TBI.	GH	
replacement	can	improve	cognition,	psychological	function	and	quality	of	life	in	TBI-
related	GHD	(Gardner	et	al.,	2015;	High	et	al.,	2010;	Maric	et	al.,	2010;	Moreau	et	al.,	
2013;	Reimunde	et	al.,	2011).	Improvement	in	WM	tract	recovery	after	TBI	may	be	a	
mechanism	by	which	GH	replacement	and	associated	increases	in	serum	IGF-I	
achieve	such	effects.	However	the	effects	of	GHD/IGF-I	status	on	WM	recovery	
following	TBI	are	unknown.	
	
The	aim	of	this	chapter	was	to	investigate	the	impact	of	GH/IGF-I	status	on	WM	
recovery	following	TBI.	We	hypothesised	that	IGF-I	status	would	impact	on	recovery	
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after	TBI	such	that	improvement	in	WM	tract	FA,	neuropsychological	and	cognitive	
measures	over	time	would	be	greater	in	those	with	a	higher	serum	IGF-I	at	baseline.	
Therefore	DTI	scans	were	performed	at	two	time	points	along	with	
neuropsychological	and	cognitive	testing	in	a	longitudinal	study	of	patients	after	TBI,	
and	improvements	compared	by	GH/IGF-I	status.	
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4.2 Methods		
4.2.1 Participants		
Thirty-nine	patients	with	persistent	neuropsychological	symptoms	were	recruited	in	
the	post-acute	phase	following	a	TBI	(>6	weeks).	All	patient	had	the	following	data	
recorded:	age,	gender,	BMI,	mechanism	of	injury,	date	and	severity	of	TBI	using	the	
Mayo	classification	(Malec	et	al.,	2007).	Research	ethics	committee	approval	(Ealing	
and	West	London	REC	09/H0707/82)	and	informed	written	consent	were	obtained,	
in	accordance	with	the	Declaration	of	Helsinki.	Participants	had	standard	structural	
brain	MRI,	and	DTI	at	baseline	and	follow-up	at	least	6	months	later.	Thirty-five	age	
and	gender-matched	healthy	volunteers	underwent	an	identical	neuroimaging	visit	
at	a	single	time	point	as	a	control	group.	
	
4.2.2 Endocrine	assessment			
Patients	had	full	endocrine	testing	at	baseline	as	part	of	their	routine	clinical	care	
(see	Table	3-1	page	104).	Measurements	of	anterior	pituitary	hormones	(serum	IGF-I,	
prolactin,	TSH,	free	thyroxine,	LH,	FSH,	testosterone/oestrogen,	SHBG)	were	taken	in	
the	late	morning/early	afternoon	in	the	non-fasted	state.	Serum	IGF-I	was	measured	
by	immunoassay	using	the	Immulite	2500	assay	(Siemens,	Erlangen,	Germany),	with	
reference	ranges	given	in	Table	4-1.	
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Table	4-1	Age-related	reference	ranges	for	serum	IGF-I	assay		
	
Median,	lower	(<5%	CI)	and	upper	(>95%	CI)	values	normal	range	for	serum	IGF-I	assay	
(Immulite	2500)	from	Dept.	of	Biochemistry,	University	College	London	Hospital,	London,	UK.	
	
	
Subsequently,	patients	had	initial	screening	for	GH	(and	ACTH)	deficiency	using	the	
glucagon	stimulation	test	(Gardner	et	al.,	2015).	The	diagnosis	of	GHD	was	confirmed	
using	the	GHRH-Arginine	test,	with	age	and	BMI-adjusted	cut-offs	(Colao	et	al.,	2009)	
and/or	insulin	tolerance	test,	in	all	patients.	The	protocol	for	diagnosis	of	other	
pituitary	dysfunction	e.g.	ACTH	or	gonadotropin	deficiency,	was	as	described	in	
Chapter	3.	Although	limited	by	the	low	prevalence,	an	exploratory	sub-group	
analysis	of	FA	recovery	was	made	for	those	patients	after	TBI	with	(n=4)	versus	
without	(n=35)	confirmed	GHD.	However	since	only	2	subjects	with	GHD	completed	
neuropsychological	and	cognitive	testing	at	both	time	points,	these	endpoints	were	
not	analysed	by	GHD	status.	
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4.2.3 Serum	IGF-I	status		
To	account	for	the	fact	that	IGF-I	level	decline	naturally	with	age,	an	age-adjusted	
IGF-I	ratio	was	calculated	for	each	patient.	Absolute	IGF-I	was	divided	by	the	median	
of	the	age-related	reference	range	Table	4-1.	Patients	were	then	assigned	to	an	
‘above	median’	or	‘below	median’	IGF-I	group	if	this	ratio	was	>=1	or	<1	respectively.	
Figure		shows	a	plot	of	IGF-I	ratio	values	for	those	in	above	and	below	median	IGF-I	
groups	
	
Figure	4-1	Scatter	plot	of	age-adjusted	IGF-I	ratios	in	above	and	below	median	IGF-I	
groups	
	
	
4.2.4 Structural	neuroimaging		
Each	patient	had	standard	high-resolution	T1	and	gradient-echo	T*	magnetic	
resonance	imaging	to	assess	focal	brain	injury	and	presence	of	microbleeds,	on	a	
Phillips	3T	Achieva	scanner	(Phillips	Medical	Systems,	Netherlands)	using	an	8-
channel	head	coil.	For	DTI,	diffusion-weighted	volumes	with	gradients	applied	in	16	
non-collinear	directions	were	collected	in	four	runs,	with	a	total	of	64	directions,	
using	the	following	parameters:	73	contiguous	slices,	slice	thickness	2mm,	field	of	
0
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view	224mm,	matrix	128 × 128	(voxel	size	1.75×1.75×2mm3),	b-value	1000s/mm2,	
four	images	with	no	diffusion	weighting	(b0).	DTI	images	were	registered	to	the	b0	
image	by	affine	transformations,	then	brain-extracted	and	FA	maps	generated	using	
the	FMRIB	Software	Library	image	processing	toolbox.	FA	diffusion	maps	were	
analysed	using	both	whole	brain	and	region-of-interest	voxelwise	analysis	
approaches	to	compare	those	with	vs.	without	GHD,	and	with	low	vs.	high	serum	
IGF-I	concentrations.	
	
4.2.5 	DTI	and	FA	analysis		
FA	was	analysed	specifically	in	the	two	a	priori	WM	tract	ROIs	that	have	previously	
shown	differences	in	FA	over	time	after	TBI,	namely	the	SPCC	and	the	PLIC	(Sidaros	
et	al.,	2008).	Bilateral	ROI	masks	were	defined	using	the	John	Hopkins	University	WM	
tractography	atlas	with	a	cut-off	threshold	>20%	(Figure	4.1),	averaging	mean	FA	
values	in	left	and	right	ROIs.	FA	differences	and	changes	over	time	were	also	
analysed	across	the	whole	brain	using	tract	based	spatial	statistics	(TBSS)	in	the	
FMRIB	Software	Library	using	threshold-free	cluster	enhancement	(TFCE)	to	correct	
for	multiple	comparisons	at	cluster-wise	threshold	P<0.05	(see	Methods:	Tract	based	spatial	statistics	(TBSS)	2.3.5	page	75).	
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Figure	4-2	Posterior	limb	of	internal	capsule	and	splenium	of	corpus	callosum	white	
matter	tract	regions	of	interest.	
	
Group	average	FA	skeleton	(green,	threshold	>0.2)	from	all	patients	after	TBI	(n=39)	and	
healthy	controls	(n=35),	overlaid	onto	standard	MNI152	1mm	T1	MRI	brain	scan.	White	
matter	(WM)	tract	defined	using	the	JHU	white	matter	tractography	atlas	with	a	cut-off	
threshold	of	20%	indicated	in	red.	Mean	fractional	anisotropy	(FA)	values	in	posterior	limb	of	
internal	capsule	and	splenium	of	corpus	callosum	WM	tract	regions	of	interest	were	
calculated	from	the	average	of	the	voxels	indicated	by	the	overlap	of	the	green	skeleton	and	
red	mask.	Co-ordinates	given	in	Montreal	Neurological	Institute	(MNI)	standard	space.	R	
indicates	right.	
	
4.2.6 FA	comparisons	by	group		
Analyses	and	design	matrices	were	constructed	to	compare	FA:	(i)	between	patients	
after	TBI	(baseline	scan	1)	versus	controls:	to	examine	effects	of	TBI	(ROIs,	whole	
brain);	and	in	patients	only:	(ii)	between	follow-up	scan	2	vs.	scan	1:	to	examine	
overall	recovery	over	time	after	TBI	(ROI,	whole	brain);	(iii)	using	a	longitudinal	
interaction	design	analysis:	to	examine	the	effect	of	GHD	and	IGF-I	status	at	baseline	
and	FA	recovery	over	time	(ROIs);	(iv)	in	a	cross-section	design	between	groups	at	
scan	1	only	to	examine	the	effects	of	GHD	and	IGF-I	status	at	baseline	only	(whole	
x= -22 y= -17 z= 6 
Posterior Limb of 
Internal Capsule  
R R 
x= -9 y= -31 z= 12 
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brain);	and	(v)	using	the	subtracted	FA	difference	between	scan	2	and	scan	1:	to	
examine	the	interaction	between	GHD	and	IGF-I	status	at	baseline	and	recovery	in	
FA	over	time	(whole	brain).	
	
	
4.2.7 Cognitive	and	Neuropsychological	Assessment		
Where	possible,	all	patients	underwent	detailed	cognitive	testing,	previously	found	
to	be	sensitive	to	impairments	after	TBI	(Baxter	et	al.,	2013;	Bonnelle	et	al.,	2012;	
Kinnunen	et	al.,	2011):	(i)	subsets	of	Weschsler	Memory	Scale-Third	edition	(WMS-II)	
to	test	immediate	and	delayed	verbal	recall	(Logical	Memory	I	and	II)	and	working	
memory	(Digit	Span);	(ii)	People	test	from	Doors	and	People	test	battery	to	measure	
associative	learning	and	recall;	(iii)	verbal	and	letter	fluency	and	Colour–Word	
(Stroop)	tests	from	Delis-Kaplan	Executive	Function	System	to	assess	cognitive	
flexibility,	inhibition	and	set-shifting;	(iv)	Trail	Making	Test	to	assess	executive	
function;	(v)	Wechsler	Test	of	Adult	Reading	and	Wechsler	Abbreviated	Scale	of	
Intelligence	Similarities	and	Matrix-Reasoning	subsets	to	assess	pre-morbid	verbal	
and	non-verbal	reasoning	ability	at	the	first	visit	only.	Please	see	Methods:	Neuropsychological	assessment	2.3.2	page	74	for	more	detailed	information.	
	
In	addition	patients	completed	the	following	psychological	and	quality	of	life	(QoL)	
questionnaires	at	both	visits	that	we	have	used	previously	in	TBI	(Baxter	et	al.,	2013):	
Beck	Depression	Inventory	Score	(BDI-II),	Epworth	Daytime	Sleepiness	Scale	and	
Assessment	of	GH	Deficiency	in	Adults	(AGHDA)	and	Short	Form	36	Health	Survey	
(SF-36)	QoL	questionnaires.	Please	see	Methods:	Quality	of	Life	(QoL)	assessments	
2.3.1	page	73	for	more	detailed	information.	
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4.2.8 Statistical	analyses		
Analysis	of	demographics	and	ROI	FA	values	was	performed	using	SPSS	(v21,	IBM).	
Comparison	between	groups	used	Mann-Whitney	U	test,	chi-squared	test,	2-way	
unpaired	or	paired	Student	t-test,	and	one-way	ANCOVA	or	one-way	repeated	
measures	ANCOVA	with	post-hoc	Fisher	LSD	test,	as	appropriate	with	statistical	
threshold	P<0.05.		
	
Comparison	of	FA	in	ROIs	between	controls	and	TBI	patients	at	baseline	using	
ANCOVA	included	age	and	gender	as	co-variates.	Comparison	of	FA	in	ROIs	between	
groups	in	TBI	patients	at	baseline	using	ANCOVA	included	age,	gender,	TBI	severity,	
time	since	TBI	as	co-variates.	Longitudinal	analyses	were	performed	both	without,	
and	with	addition	of	the	following	co-variates	that	might	influence	WM	tract	
recovery	over	time:	age,	gender,	TBI	severity,	time	since	TBI,	and	time	between	DTI	
scans.	Repeated	measures	ANCOVA	examined	improvement	in	FA	in	ROIs	over	time	
in	TBI	patients,	and	differences	between	groups	to	establish	effects	of	group,	time	
and	group	x	time	interaction.	Time	variables	were	log10-transformed	as	they	were	
not	normally	distributed.	
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4.3 Results		
4.3.1 Patient	characteristics		
Thirty-three	of	39	patients	(84.6%)	were	male	with	median	age	30.5y	(interquartile	
range	(IQR)	24.5-47.0).	Thirteen	patients	(33.3%)	had	sustained	their	TBI	as	a	result	
of	a	blast	exposure	from	an	improvised	explosive	device,	10	(25.6%)	road	traffic	
accident,	7	(17.9%)	assault,	6	(15.4%)	fall	and	3	(7.7%)	through	a	sporting	injury.	
Thirty-four	patients	(87.2%)	had	a	moderate-severe	TBI	by	Mayo	classification	35.	
The	median	time	between	TBI	and	first	scan	was	16.3	months	(IQR	3.6-24.5).	There	
was	no	significant	difference	in	prevalence	of	blast	TBI	or	moderate-severe	TBI,	or	
time	since	TBI	between	GH	status	or	IGF-I	groups.	Further	demographic	data	is	given	
in	Table	4-2.		
	
There	were	no	significant	differences	in	the	prevalence	of	contusions,	microbleeds,	
superficial	siderosis	and	diffuse	axonal	injury	between	IGF-I	groups.	Structural	
abnormalities	in	the	baseline	MRI	are	summarised	in	Table	1.	Although	dedicated	
pituitary	MRI	imaging	was	only	performed	in	those	with	GHD,	there	was	no	evidence	
of	hypothalamic-pituitary	damage	in	any	patient.	No	patients	had	craniotomy	as	
these	subjects	had	been	excluded	from	the	study.		
	
Thirty-five	healthy	controls	were	studied	with	the	following	demographics:	23	
(65.7%)	male	(P=0.11	vs.	TBI),	and	median	age	30.7y	(IQR	25.9-38.2,	P=0.22	vs.	TBI).	
Further	demographic	data	is	given	in	Table	4-2.	
	
4.3.2 GHD	and	pituitary	dysfunction		
Four	(10.2%)	patients	after	TBI	had	confirmed	untreated	GHD.	Overall,	7/39		(17.9%)	
had	pituitary	dysfunction	(3	isolated	GHD,	1	ACTH	deficiency,	2	hyperprolactinemia,	
1	combined	ACTH/GH/gonadotropin	deficiencies).	Six	were	soldiers	who	had	
sustained	blast	TBI(Baxter	et	al.,	2013).	None	of	these	patients	had	yet	started	any	
hormone	replacement	therapy	at	the	time	of	their	first	or	second	scan.	There	were	
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no	significant	differences	in	age,	gender,	TBI	severity,	time	since	injury,	time	
between	scans,	prevalence	of	blast	TBI,	or	prevalence	of	structural	MRI	
abnormalities	at	baseline,	between	patients	with	and	without	GHD	(Table	4-3).	
Absolute	serum	IGF-I	and	age-adjusted	IGF-I	ratio	tended	to	be	lower	(P=0.11)	in	
those	patients	with	vs.	without	GHD,	with	75%	of	GHD	subjects	having	serum	IGF-I	
below	the	age-related	median	Table	4-1.	
	
Table	4-2	Patient	characteristics	by	IGF-I	group	
	
	Data	given	as	n	(%)	or	median	[IQR]	and	range	(minimum-maximum).		
All Group Above Median IGF-I Below Median IGF-I
P Above vs 
Belowa
n 39 22 17
Age at first scan (yrs) 30.5 [24.5-47.0] 30.2 [24.3-47.6] 34.5 [25.2-48.8] 0.43
Range 19.6-66.9 19.6-62.2 21.3-66.9
Male Sex                               33 (84.6%) 17 (77.3%) 16 (94.1%) 0.21
Moderate-Severe Severity 34 (87.2%) 20 (90.6%) 14 (82.4%) 0.67
Time since Injury (months) 16.3 [3.6-24.5] 12.5 [4.-25.9] 17.2 [3.1-33.5] 0.89
                                   Range 1.47-571.0 1.5-571.0 1.5-102.9
Time between scans (months) 13.3 [12.1-14.9] 12.35 [10.81-13.4] 14.4 [13.1-15.1] 0.08
Range 6.3-24.6 6.3-24.6 8.87-17.8
Absolute IGF-1 nmol/Lb 23.8 [19.2-29.5] 28.2 [23.3.-35.1] 19.9 [16.8-23.7] 0.02
Range 12.8-74.5 19.2-74.5 12.8-29.0
Age-Adjusted IGF-1 Ratio 1.1 [0.9-1.2] 1.2 [1.1-1.5] 0.8 [0.8-0.9] <0.001
Range 0.6-3.0 1.0-2.9 0.6-1.0
GHD 4 (10.2%) 1 (4.5%) 3 (17.6%) 0.30
Any Pituitary Deficiency 7 (17.9%) 3  (13.6%) 4 (23.5%) 0.68
Blast Injury 13 (33.3% 8 (36.3%) 5 (29.4%) 0.74
Any structural brain abnormality 30 (76.9%) 19 (86.4%) 11 (64.7%) 0.14
≥ 1 contusion 20 (51.3%) 11 (28.2%) 9 (52.9%) 1.00
Average  no. of contusions* 1.7 2.8 2
≥ 1 microbleed 10 (25.6%) 8 (36.4%) 2 (11.8%) 0.14
Superficial siderosis 13 (33.3%) 6 (27.3%) 7 (41.2%) 0.50
Diffuse axonal injury (DAI) 5 (12.8%) 3 (13.6%) 2 (11.8%) 1.00
BMI 25.3 [23.1-29.8] 23.6 [19.6-29.0] 25.3 [24.4-30.2] 1.00
17.0-35.0 17.0-32.3 21.3-35.0
Post menopausal women 3 (7.7%) 2 (9.1%) 1 (5.9%) 1.00
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a	P	value	for	comparison	high	versus	low	serum	IGF-I	group	using	chi-squared	test	for	
categorical	variables	and	Mann-Whitney	U	test	for	continuous	variables.	b	To	convert	
nmol/L	to	ng/mL	divide	by	0.131.	
	
Table	4-3	Patient	characteristics	by	GH	deficiency	status	
	
Data	given	as	n	(%)	or	median	[IQR]	and	range	(minimum-maximum).		
a	P	value	for	comparison	high	versus	low	serum	IGF-I	group	using	chi-squared	test	for	
categorical	variables	and	Mann-Whitney	U	test	for	continuous	variables.	b	To	convert	nmol/L	
to	ng/mL	divide	by	0.131.	
	
4.3.3 IGF-I	status		
Seventeen	(43.6%)	patients	were	in	the	below	median	age-adjusted	IGF-I	group	and	
22	in	the	above	median	IGF-I	group.	In	the	below	median	IGF-I	group	1/17	(5.6%)	had	
All No GHD With GHD
P with vs 
without GHDa
n 39 35 4
Age at first scan (yrs) 30.5 [24.5, 47.0] 30.4 [24.1, 49.2] 39.4 [29.7, 44.4] 0.50
Range 19.6-66.9 19.6-66.9 27.8-44.7
Male Sex                               33 (84.6%) 29 (82.9%) 4 (100%) 1.00
Moderate-Severe Severity 34 (87.2%) 30 (85.7%) 4 (100%) 1.00
Time since Injury (months) 16.3 [3.6, 24.5] 11.4 [3.2, 25.7] 26.8 [7.7-34.3] 0.38
                                   Range 1.5-571.0 1.5-571.0 3.6-34.5
Time between scans (months) 13.3 [12.1, 14.9] 13.1 [12.1, 14.5] 14.6 [10.3-15.1] 0.58
Range 6.3-24.6 6.3-24.6 9.1-15.1
Absolute IGF-1 nmol/Lb 23.8 [19.2-29.5] 24.2 [19.5, 29.5] 19.6 [16.7, 23.2] 0.11
Range 12.8-74.5 12.8-74.5 16.5-23.7
Age-Adjusted IGF-1 Ratio 1.1 [0.9, 1.2] 1.1 [0.9, 1.3] 0.9 [0.8-1.0] 0.11
Range 0.6-3.0 0.6-2.9 0.8-1.0
Blast Injury 13 (33.3% 10 (28.6%) 3 (75.0%) 0.10
Any structural brain abnormality 30 (76.9%) 28 (80.0%) 2 (50.0%) 0.22
≥ 1 contusion 20 (51.3%) 19 (54.3%) 1 (25.0%) 0.34
Average  no. of contusions* 1.7 2.5 n/a
≥ 1 microbleed 10 (25.6%) 10 (28.6%) 0 (0.0%) 0.56
Superficial siderosis 13 (33.3%) 11 (31.4%) 2 (50.0%) 0.59
Diffuse axonal injury (DAI) 5 (12.8%) 4(11.4%) 1 (25.0%) 0.44
BMI 25.3 [23.1-29.8] 25.0 [21.7-28.6] 29.3 [21.7-28.2] 0.10
Range 17.0-35.0 17.0 -25.0 25.3-33.7
Post menopausal women 3 (7.7%) 3 (8.6%) 0 (0.0%) 1.00
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a	serum	IGF-I	<5th	percentile	(age-adjusted	normal	range),	and	in	the	above	median	
IGF-I	group	4/22	(18.2%)	had	a	serum	IGF-I	>95th	percentile.	There	were	no	
significant	differences	in	age,	gender,	TBI	severity,	time	since	injury,	prevalence	of	
blast	TBI,	of	structural	MRI	abnormalities	at	baseline	or	of	post-menopausal	females,	
or	BMI,	between	IGF-I	groups	(Table	4.1).	There	was	a	trend	towards	a	greater	length	
of	time	between	the	two	scans	in	the	below	median	IGF-I	group	compared	to	the	
above	median	IGF-I	group	(median	14.4	vs.	12.5	months,	P=0.08).		
	
Only	3/17	(17.6%)	of	patients	in	the	below	median	IGF-I	group	had	GHD	confirmed	
on	dynamic	testing,	compared	to	1/22	(4.5%)	in	the	above	median	IGF-I	group	
(P=0.15).	Of	the	4	patients	with	confirmed	GHD,	none	had	serum	IGF-I	<5th	
percentile,	3	had	IGF-I	between	5th	percentile	and	median,	and	one	had	IGF-I	
between	median	and	95th	percentile.	
	
4.3.4 Effect	of	TBI	on	WM	tracts		
(i)	 TBI	 patients	 show	 evidence	 of	 axonal	 injury:	 In	 whole	 brain	 analysis,	 FA	 was	
significantly	lower	in	many	WM	tracts	including	splenium,	body	and	genu	of	corpus	
callosum,	and	the	PLIC,	in	patients	following	TBI	at	baseline	scan	1	(n=39),	compared	
to	healthy	controls	(n=35)	(Figure	4-3).		
	
As	 expected,	 compared	 to	 the	 healthy	 control	 group,	 the	 TBI	 group	 overall	 had	
significantly	 lower	 FA	 in	 the	 a	 priori	 ROIs	 SPCC	 (effect	 size	mean	 ±	 SEM	 -0.021	 ±	
0.009,	 95%	CI	 [-0.003,	 -0.040],	 t(72)=-2.26,	 P=0.027)	 and	 PLIC	 (effect	 size	 -0.026	 ±	
0.006,	[-0.039,	-0.013],	t(72)=-3.90,	P<0.001)	(Figure	4-5).		
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Figure	4-3	Lower	white	matter	tract	FA	in	patients	after	TBI		
	
Voxels	displaying	lower	fractional	anisotropy	(FA)	in	patients	with	TBI	(n=39)	compared	to	
healthy	controls	(n=35)	displayed	in	red	(TFCE	P<0.05	corrected	and	correcting	for	age	and	
gender),	overlaid	on	combined	whole	group	FA	skeleton	(green),	displayed	on	standard	
MNI125	1mm	T1	MRI	brain	scan.	Co-ordinates	given	in	Montreal	Neurological	Institute	(MNI)	
standard	space.	R	indicates	right.	
	
4.3.5 Effect	of	time	on	WM	tract	recovery	over	time		
(ii)	Increased	FA	over	time	suggest	axonal	recovery	following	TBI:		Within	the	TBI	
patients,	FA	increased	over	time	from	scan	1	to	follow-up	scan	2,	suggesting	
recovery	of	axonal	over	time,	in	a	number	of	WM	tracts	including	splenium,	body	
and	genu	of	corpus	callosum,	subcortical	regions,	right	frontal	region	and	
widespread	ventral	regions	(Figure	4-4).		
	
As	expected,	in	the	TBI	group	there	were	significant	increases	in	FA	between	scans	in	
SPCC	(effect	size	0.015	±	0.007,	[0.001,	0.281],	t(38)=2.2,	P=0.035),	and	PLIC	(effect	
size	0.016	±	0.004	[0.003,	0.020],	t(38)=3.1,	P=0.005).	However	there	were	no	
significant	effects	of	age	(P=0.35-0.51),	gender	(P=0.14-0.60),	TBI	severity	(P=0.11-
0.23),	time	since	TBI	(P=0.33-0.73),	or	time	between	scans	(P=0.58-0.90)	on	the	
change	in	FA	over	time	(co-variate	x	time	interaction),	when	including	each	factors	
separately	as	a	within	subject	co-variate	in	a	repeated	measures	ANCOVA	model.	
x -9 z 22 y -34 
R R 
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Figure	4-4	White	matter	tract	FA	improvement	between	scans.		
	
Regions	displaying	higher	fractional	anisotropy	(FA)	in	TBI	patients	at	follow-up	scan	(in	red)	
compared	to	baseline	scan	overlaid	on	group	FA	skeleton	(green)	using	TFCE	P<0.05	
corrected	and	correcting	for	age,	time	since	injury,	gender,	TBI	severity	and	time	between	
scans.	Results	overlaid	on	standard	MNI125	1mm	T1	MRI	brain	scan.	Co-ordinates	given	in	
Montreal	Neurological	Institute	(MNI)	standard	space.	R	indicates	right.	
	
4.3.6 Effect	of	IGF-I	group	on	WM	tract	FA		
(v)	No	cross-sectional	influence	of	IGF-I	group	on	FA	at	baseline:	Within	the	TBI	
group,	there	was	no	significant	effect	of	IGF-I	group	on	FA	at	baseline	in	whole	brain	
analysis,	with	or	without	inclusion	of	co-variates.	
	
(vi)	Influence	of	IGF-I	group	on	recovery	in	FA	over	time:	Within	the	TBI	group,	there	
was	a	significantly	greater	increase	in	FA	in	SPCC	over	time	in	the	above	median	than	
below	median	IGF-I	group	(IGF-I	group	x	time	interaction	F(1,37)=4.62	P=0.038,	
above	median	IGF-I	group	effect	size	+0.027	±	0.008,	95%	CI	[0.009,	0.044],	
F(1,37)=9.82,	P=0.03;	below	median	IGF-I	group	effect	size	-0.001	±	0.100,	[-0.021,	
0.190],	F(1,37)=0.01,	P=0.92).	Similar	results	were	seen	when	including	co-variates	in	
the	repeated	measures	ANCOVA	(IGF-I	group	x	time	interaction	F(1,32)=5.66,	
P=0.023,	above	median	IGF-I	group	effect	size	+0.030	±	0.009,	[0.011,	0.048],	
x -9 y -34 z 22 
R R 
	 142	
F(1,32)=10.60,	P=0.003;	below	median	IGF-I	group	effect	size	0.011	±	0.010,	[-0.026,	
0.017],	F(1,32)=0.21,	P=0.65	(Figure	4-5B).	There	was	no	significant	difference	in	
SPCC	FA	between	IGF-1	groups	at	baseline.	
	
A	similar	interaction	was	seen	for	FA	improvement	in	SPCC	over	time	when	excluding	
4	subjects	without	moderate-severe	TBI	(IGF-I	group	x	time	interaction	(F(1,29)=3.74,	
P=0.063),	and	when	excluding	2	subjects	with	a	prolonged	time	since	TBI	>100	
months	(IGF-I	group	x	time	interaction	(F(1,31)=5.06,	P=0.032,	including	age,	gender,	
severity	and	time	between	scans).		
	
However,	there	was	no	significant	effect	of	IGF-I	group	on	increase	in	FA	over	time	in	
PLIC	either	without	any	covariates	(IGF-I	group	x	time	interaction	F(1,37)=0.57,	
P=0.46),	or	when	including	co-variates	(IGF-I	group	x	time	interaction	F(1,32)=1.31,	
P=0.26)	(Figure	4-5C).		
	
In	whole	brain	subtraction	analysis,	there	was	no	significant	effect	of	IGF-I	group	on	
the	change	in	FA	between	scans	2	and	1,	with	or	without	inclusion	of	co-variates.	A	
similar	lack	of	effect	of	IGF-I	group	was	also	seen	when	restricting	the	skeleton	in	
whole	brain	analysis	to	only	those	voxels	showing	a	significant	increase	in	FA	
between	scans	(Figure	4-4).	
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Figure	4-5	White	matter	tract	FA	in	regions	of	interest	in	patients	after	TBI	at	
baseline	and	recovery	over	time	by	IGF-I	group	
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(A)	Lower	FA	in	splenium	of	corpus	callosum	(SPCC)	and	posterior	limb	of	internal	capsule	
(PLIC)	ROIs	in	patients	after	TBI	(black	bar)	compared	to	controls	(white	bar)	at	baseline	scan,	
adjusting	for	age	and	gender	(*P<0.05,	ANCOVA	with	post-hoc	Fisher	LSD	test).		
(B)	Greater	improvement	in	FA	in	SPCC,	but	(C)	no	difference	in	improvement	in	FA	in	PLIC,	
between	scan	1	(dotted	bar)	and	scan	2	(striped	bar)	in	above	median	IGF-1	group	compared	
to	below	IGF-I	group,	adjusting	for	age,	gender,	TBI	severity,	time	since	TBI	and	time	between	
scans	(*P<0.05,	repeated	measures	ANCOVA	with	post-hoc	Fisher	LSD	test).	
All	data	given	as	mean	±	SEM.	
	
4.3.7 Effect	of	IGF-I	group	on	neuropsychological	and	cognitive	
variables		
	
Within	the	TBI	group,	there	was	a	significantly	greater	increase	in	the	logical	memory	
I	total	score	(measure	of	immediate	recall)	over	time	in	the	above	median	than	
below	median	IGF-I	group	(IGF-I	group	x	time	interaction	F(1,26)=4.38	P=0.046,	
above	median	IGF-I	group	effect	size	+4.19	±	2.01,	95%	CI	[0.06,	8.31],	F(1,26)=4.34,	
P=0.47;	below	median	IGF-I	group	effect	size	-2.42	±	2.22,	[-0.699,	2.15],	
F(1,26)=1.19,	P=0.29),	when	including	covariates	(age,	gender,	severity,	time	since	
injury	and	time	between	scans)	in	the	repeated	measures	ANCOVA,	despite	scores	
being	similar	between	groups	at	baseline	(F(1,26)=0.60,	P=0.45)	(Figure	4-6).		
	
There	was	no	significant	correlation	between	the	improvement	in	SPCC	FA	over	time	
and	the	improvement	in	logical	memory	I	total	score	over	time	in	patients	after	TBI,	
either	alone	(r=0.20,	P=0.28),	or	when	correcting	for	age,	gender,	severity,	time	since	
injury	and	time	between	scans	(partial	r=0.26,	P=0.18).	
	
There	was	no	significant	IGF-I	group	x	time	interaction	for	any	of	the	other	cognitive	
measures,	or	symptom	(BDI-II,	Epworth)	or	quality	of	life	(SF-36,	AGHDA)	
questionnaire	scores	(Table	4-4).	There	were	however	significant	improvements	
over	time	in	associative	memory	(People	Test)	and	cognitive	flexibility	(Color	Word	
Stroop)	independent	of	IGF-I	group.	
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Figure	4-6	Recall	memory	in	patients	after	TBI	at	baseline	and	recovery	
	
	
	
Greater	improvement	in	Logical	Memory	I	(LMI)	total	score	(immediate	recall)	in	above	
median	IGF-1	group	compared	to	below	IGF-I	group,	adjusting	for	age,	gender,	TBI	severity,	
time	since	TBI	and	time	between	scans	(*P<0.05,	repeated	measures	ANCOVA	with	post-hoc	
Fisher	LSD	test).	Significant	increase	in	LMI	score	between	scan	1	(dotted	bar)	and	scan	2	
(striped	bar)	for	IGF-I	group	above	but	not	below	median	at	baseline,	and	no	significant	
difference	between	IGF-I	groups	at	baseline.	Data	given	as	mean	±	SEM.
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Table	4-4	Neuropsychological	outcome	measures	in	patients	after	TBI	at	baseline	and	recovery	over	time	by	IGF	status.	
	
	 	
Symptom Domain  n
Max 
score First Visit n Second visit
Effect of 
Time*
Effect of 
IGF Group*
Time*Group 
Interaction*
Assessment of GH Deficiency in Adults (AGHDA-QoL)a 25 25 9 [2.5-16.5] 0-23 25 7.0 [1-12.5] 0-22 0.99 0.71 0.89
Beck Depression Inventory Score (BDI-II) 25 63 13.0 [4.0-23.0] 0-27 25 11.0 [2.5-18.5] 0-32 0.46 0.75 0.63
Epworth Sleepiness Scale 22 24 3.0 [0.9.5] 0-19 15 4.0 [1.0-10.0] 0-14 0.69 0.45 0.53
SF-36 QoL Physical functioning 16 100 70.0 [22.5-98.8] 0-100 24 87.5 [62.3-95.0] 0-100 0.32 0.82 0.53
Role limitations due to physical health 17 100 75.0 [0-100] 0-100 24 50.0 [6.25-100] 0-100 0.58 0.37 0.58
Role limitations due to emotional problems 16 100 100 [66.7-100] 0-100 24 100 [41.7-100] 0-100 0.88 0.59 0.77
Energy/Fatigue 16 100 45.0 [45.0-70.0] 15-85 24 67.5 [47.5-83.8] 5-100 0.41 0.41 0.12
Emotional well being 16 100 70.0 [54-83.0] 28.0-92.0 24 80.0 [61.0-92.0] 24.0-100 0.52 0.75 0.96
Social functioning 17 100 62.5 [50.0-75.0] 12.5-100.0 24 81.3 [50.0-100] 25-100 0.22 0.77 0.87
Pain 17 100 45.0 [39.0-83.8] 22.5-100 24 77.5 [55.6-100] 42.5-100 0.74 0.82 0.93
General health 17 100 60.0 [42.5-80.0] 20-100 24 65.0 [45.0-91.3] 15-100 0.27 0.59 0.18
Cognitive domain Cognitive variable
Pre-morbid intelligence: reading ability WTAR raw score 32 41.0 [35.3-45.0] 0-50 32 42.0 [31.8-46.8] 9-50 0.88 0.83 0.60
Intellectual ability WASI similarities (verbal) 33 36.0 [32.5-38.0] 21-46 33 39.0 [35.5-41.0] 23-46 0.61 0.96 0.42
WASI matrix reasoning (non-verbal) 32 26.5 [20.5-30.0] 9-34 32 28.5 [25.3-30.8] 12-35 0.08 1.00 0.20
Memory: associative memory People test (total score) 33 22.0 [14.5-29.0] 4-38 33 27.0 [18.0-31.0] 6-38 0.010 0.19 0.78
Immediate recall Logical memory I Total 33 28.0 [20.5-32.0] 10-40 33 43.0 [33.0-51.5] 19-62 0.26 0.12 0.046
Logical memory II Total 33 26.0 [18.5-32.5] 0-42 33 27.0 [19.5-33.0] 10-43 0.63 0.20 0.57
Delayed Recall Logical memory retention 32 86.7 [78.9-94.3] 33.3-107.7 33 90.3 [82.9-98.0] 45-190 0.41 0.34 0.93
Processing speed: visual search/complex Trail Making Test Trail A (s) 32 26.0 [21.0-32.0] 14-67 33 22.0 [16.5-28.5] 13-87 0.82 0.60 0.65
Trail Making Test Trail B (s) 32 52.0 [43.3-68.5] 22-192 33 47.0 [30.5-71.0] 25-166 0.62 0.32 0.81
Processing speed: naming/reading Stroop Colour Naming (s) 31 32.0 [28.0-41.0] 20-101 33 32.0 [30.0-35.0] 19-51 0.56 0.90 0.96
Stroop Word Reading (s) 31 23.0 [19.0-32.0] 15-62 32 23.0 [20.0-25.8] 14-43 0.53 0.25 0.34
Executive function: alternating-switch cost Trail Making Test Trail B minus A (s) 32 22.5 [13.0-38.8] 4-125 33 19.0 [15.0-42.5] 7-102 0.57 0.24 0.62
Cognitive flexibility Color Word Stroop Inhibition/switching (s) 32 66.0 [55.5-76.5] 38-128 33 57.0 [51.5-66.5] 37-119 0.003 0.33 0.50
Word generation fluency DKEFS Letter Fluency F+A+S total 33 36.0 [27.0-45.0] 11-65 33 41.0 [35.5-48.5] 15-60 0.15 0.57 0.59
*	=	correction	for	all	covariates	(time	since	injury,	time	between	scans,	gender,	age	at	first	scan,	TBI	severity)
Data	displayed	as	median,	[IQR],	range.
Note:	AGHDA,	BDI-II,	Epworth:	higher	scores	equals	worse	symptoms;	SF-36:	lower	score	equals	worse	quality	of	life,	WTAR,	Similarities,	Matrix	reasoning,	People	test,	Logical	memory:	higher	score	=	better	performance;	Trail-making,	Stroop,	letter	fluency;	lower	score=better	cognition
Abbreviation:	SF-36=Short	Form	36	Health	Survey,	WTAR	=Wechsler	Test	of	Adult	Reading,	WASI=Wechsler	Adult	Intelligence	Scale;	DKEFS=Delis-Kaplan	executive	function	system,	(s)=seconds
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4.3.8 Effect	of	GHD	on	WM	tract	FA		
(iii)	No	 cross-sectional	 influence	 of	 GHD	 on	 FA	 at	 baseline:	Within	 the	TBI	 group,	
there	was	no	significant	effect	of	GHD	on	FA	at	baseline	in	whole	brain	analysis,	with	
or	without	inclusion	of	co-variates	(age,	gender,	TBI	severity,	time	since	TBI).	
	
(iv)	No	longitudinal	influence	of	GHD	status	on	change	in	FA	over	time:	Within	the	
TBI	group,	there	was	no	significant	effect	of	GHD	on	the	increase	in	FA	over	time	in	
either	 the	 SPCC	 or	 PLIC	 ROIs	 (GHD	 status	 x	 time	 interaction	 P=0.29-0.45).	 This	
remained	non-significant	when	 including	 the	 co-variates:	 age,	 gender,	 TBI	 severity,	
time	since	TBI,	and	time	between	DTI	scans	(GHD	status	x	time	 interaction	P=0.22-
0.45)	(Figure	4-7).		
	
Similarly	 in	whole	brain	subtraction	analysis,	there	was	no	significant	effect	of	GHD	
on	the	change	in	FA	between	scans	2	and	1,	with	or	without	inclusion	of	co-variates.	
A	similar	lack	of	effect	of	GHD	was	also	seen	when	restricting	the	skeleton	in	whole	
brain	 analysis	 to	 only	 those	 voxels	 showing	 a	 significant	 increase	 in	 FA	 between	
scans	(Figure	4-4).	
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Figure	4-7	White	matter	tract	FA	in	regions	of	interest	in	patients	after	TBI	at	
baseline	and	recovery	over	time	by	GHD	status.	
	
	
No	significant	difference	in	improvement	in	FA	in	either	(A)	splenium	of	corpus	callosum	
(SPCC)	or	(B)	posterior	limb	of	internal	capsule	(PLIC)	between	scan	1	(dotted	bar)	and	scan	2	
(striped	bar)	in	patients	after	TBI	between	those	without	(n=35)	and	with	(n=4)	GH	deficiency	
(GHD),	adjusting	for	age,	gender,	TBI	severity,	time	since	injury	and	time	between	scans.	
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4.4 Discussion		
This	study	suggests	that	the	recovery	of	diffuse	axonal	injury	after	TBI,	measured	
using	DTI,	appears	dependent	on	serum	IGF-I	at	baseline.	A	greater	increase	in	FA	
over	time	in	the	SPCC,	indicative	of	WM	recovery,	was	seen	in	patients	who	had	IGF-I	
concentrations	above	the	median	for	their	age,	compared	to	those	with	IGF-I	below	
median.	This	supports	a	neuroendocrine	effect	on	brain	recovery	after	TBI	that	may	
have	important	therapeutic	implications.	GHD	at	baseline	did	not	influence	increase	
in	FA	in	either	ROI,	although	these	results	should	be	interpreted	with	caution	since	
only	4	patients	had	GHD	in	this	cohort.			
	
Human	serum	IGF-1,	a	70	amino	acid	polypeptide	is	thought	to	mediate	many	of	the	
trophic	effects	of	GH	through	both	hepatic	and	local	production.	The	effects	of	both	
systemic	IGF-I	and	GH	on	the	brain	are	not	completely	clear	or	disentangled,	
however	both	peptides	are	able	to	penetrate	the	blood	brain	barrier	and	peripheral	
IGF-I	and	GH	administration	can	improve	spatial	learning	and	memory	in	animal	
studies,	suggesting	that	similar	pathways	mediate	these	effects	(Le	Greves	et	al.,	
2006;	Nyberg	&	Hallberg,	2013).	
	
At	a	mechanistic	level,	GH	receptors	are	ubiquitous	throughout	the	brain	and	
GH/IGF-I	can	have	a	direct	neurogenic	effect	on	proliferation	of	neurons,	
oligodendrocytes	and	new	blood	vessels	(N.	D.	Aberg	et	al.,	2006).	Deficiency	of	
either	hormone	can	also	decrease	neuronal	survival	time	suggestive	of	a	
neuroprotective	effect	(Le	Greves	et	al.,	2006).	GH	also	influences	the	hippocampal	
NMDA	receptor	system	with	effects	on	memory	acquisition.	GH/IGF-I	may	also	
promote	brain	repair	through	the	local	induction	and	release	of	a	number	of	
neurotrophic	factors	such	as	VEGF,	EGF	and	BDNF	(Lichtenwalner,	Forbes,	Sonntag,	
&	Riddle,	2006).	Other	putative	mechanisms	may	be	directly	through	reduction	of	
neuroinflammation	or	improvement	in	peripheral	metabolic	factors	such	as	
metabolic	syndrome.	
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GHD	following	TBI	is	a	well-recognised	post-traumatic	phenomenon	but	appears	not	
be	as	common	as	initially	reported.	More	recent	larger	studies	have	reported	a	
prevalence	of	GHD	of	2.7-11.8%	of	112	patients	in	a	Dutch	cohort	(using	insulin	
tolerance	test,	or	GHRH-arginine	test	if	contra-indicated)	(Kokshoorn	et	al.,	2011)	
and	4.5-11.8%	of	439	patients	in	a	Danish	cohort	(using	insulin	tolerance	test	or	
GHRH-arginine/GHRH-pyridostigmine	test)	(Klose	et	al.,	2014),	both	including	
patients	more	than	1	year	after	TBI.	We	have	found	a	prevalence	of	GHD	in	5.7%	of	
163	patients	after	TBI	(median	0.47	years)	in	our	clinic	with	diagnosis	requiring	
inadequate	GH	response	to	both	glucagon,	and	GHRH-Arginine	testing	or	insulin-
induced	hypoglycaemia	(Carmen	Tenorio	Jimenez,	2012).	In	this	study	we	found	only	
4	of	39	patients	(10.3%)	had	GHD	using	these	criteria,	a	prevalence	enhanced	by	one	
third	of	patients	having	blast	TBI,	which	is	associated	with	a	particularly	high	risk	of	
pituitary	dysfunction	(Baxter	et	al.,	2013).	The	small	number	of	patients	with	GHD	in	
our	study	means	that	we	are	likely	to	have	significant	type	II	errors	in	examining	the	
effects	of	WM	tract	recovery.	
	
We	therefore	chose	to	also	study	serum	IGF-I	as	an	additional	biomarker	given	the	
potential	convergence	of	the	GH/IGF-I	axis	on	brain	recovery.	Indeed	serum	IGF-I	is	
the	biomarker	used	to	titrate	GH	replacement	therapy	in	subjects	who	are	GHD,	with	
a	target	IGF-I	in	the	upper	half	of	the	age-related	reference	range	being	the	usual	
target	for	dose	adjustment	(Drake,	Howell,	Monson,	&	Shalet,	2001).	We	were	not	
powered	to	look	for	effects	of	extremely	low	or	high	serum	IGF-I	concentrations	
since	only	5	of	39	patients	(12.8%)	had	serum	IGF-I	outside	the	95%	CI	for	their	age	
(1	above,	4	below).	Another	limitation	of	our	study	is	that	we	did	not	measure	serum	
IGF-binding	proteins	that	may	alter	free	IGF-I	concentrations,	though	none	of	our	
patients	were	malnourished.	
	
We	chose	to	focus	on	FA	as	a	measure	of	WM	tract	recovery	as	this	is	a	reliable	
measure	of	WM	integrity	(Bonnelle	et	al.,	2012;	Kinnunen	et	al.,	2011).	Given	DTI	
measures	water	diffusion	in	WM	tracts	and	FA	is	a	measure	of	diffusion	
directionality,	we	cannot	be	certain	that	this	specifically	relates	to	underlying	WM	
damage	and	repair	in	these	patients.	However	we	do	show	a	striking	reduction	in	FA	
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across	the	whole	brain	in	patients	after	TBI	compared	to	controls	and	that	FA	
increases	over	time	after	TBI.	We	have	previously	shown	that	after	TBI	FA	
measurements	in	particular	WM	tracts	relate	to	multiple	neuropsychological	
domains	(Bonnelle	et	al.,	2012;	Bonnelle	et	al.,	2011;	Kinnunen	et	al.,	2011)	and	
diffusivity	measures	in	the	SPCC	negatively	correlated	with	functional	connectivity	of	
the	posterior	cingulate	cortex	(Sharp,	Scott,	&	Leech,	2014).	Lower	FA	in	the	corpus	
callosum	also	predicts	worse	verbal	memory,	attention,	speed	of	information	
processing,	and	executive	function	over	five	years	in	patients	with	multiple	sclerosis	
(Bodini	et	al.,	2013).	Future	studies	will	need	to	address	whether	the	greater	
increase	in	SPCC	FA	seen	over	time	in	high	IGF-I	group	are	also	associated	with	
greater	improvements	in	neuropsychological	function,	including	domains	such	as	
memory,	attention,	planning,	mood,	and	whether	other	neuroimaging	markers	such	
as	brain	atrophy	are	also	influenced	by	IGF-I	status.	
	
Our	ROI	analysis	was	restricted	to	areas	expected	to	see	a	change	in	FA	based	on	
previous	studies	(Sidaros	et	al.,	2008;	Sidaros	et	al.,	2009).	Whole	brain	analyses	
using	TBSS	showed	a	striking	effect	of	time	on	FA	recovery	across	many	WM	tracts.	
However	we	did	not	find	any	significant	interaction	with	IGF-I	group.	This	may	be	
due	to	a	number	of	factors	including	small	numbers	given	the	need	for	robust	
statistical	correction	for	multiple	comparisons	in	whole	brain	analysis,	and	variability	
in	the	time	since	TBI	and	time	between	scans	in	our	cohort,	though	these	did	not	
appear	to	be	important	factors	influencing	FA	recovery	in	ROI	analysis.	Future	
studies	should	utilise	larger	cohorts	with	more	consistent	time	periods.	
	
In	conclusion	it	appears	that	higher	concentrations	of	serum	IGF-I	for	age	in	adults	
following	a	TBI	enhances	WM	recovery	in	the	SPCC,	irrespective	of	the	presence	of	
GHD.	As	there	are	limited	treatments	to	improve	recovery	from	TBI	and	relatively	
little	is	know	about	what	predicts	the	prognosis	for	patients,	this	raises	the	
possibility	that	GH	treatment	to	raise	serum	IGF-I	into	the	upper	part	of	the	age-
related	reference	range	might	aid	WM	recovery,	and	hence	neuropsychological	
function,	following	TBI,	regardless	of	whether	GHD	is	present	using	dynamic	tests.	
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5 The	effect	of	GH	replacement	therapy	on	the	recovery	
from	TBI		
	
5.1 Introduction	
	
In	the	last	chapter,	I	investigated	the	effect	of	GHD	and	serum	IGF-I	on	white	matter	
recovery	following	TBI.	I	was	not	able	to	study	the	effect	of	GHD	alone	as	at	the	time	
of	the	study	we	found	only	4/39	individuals	with	confirmed	GHD.	This	was	lower	
than	we	had	originally	expected	but	is	consistent	with	other	multi-centre	studies	
that	also	report	low	prevalence	(Kokshoorn	et	al.,	2011).	Instead	we	focussed	on	the	
principal	downstream	mediator	of	GH	i.e.	IGF-I	and	found	that	higher	levels	of	this	
hormone	were	associated	with	greater	WM	recovery	in	the	splenium	of	the	corpus	
callosum	(SPCC)	and	greater	improvement	in	logical	memory	scores.	
	
However	there	are	several	limitations	of	this	finding.	IGF-I	deficiency	is	not	generally	
considered	a	clinical	entity	in	adults,	although	in	children	the	diagnosis	is	sometimes	
made	and	treatment	with	recombinant	IGF-I	is	initiated	(Cohen	et	al.,	2014).	Serum	
IGF-I	can	also	be	affected	by	nutritional	status	and	other	factors	which	makes	it	an	
unreliable	diagnostic	test	for	GHD	although	useful	in	the	titration	of	GH	treatment	
(Drake	et	al.,	2001).	GHD	however	is	a	clinical	entity	which	is	usually	diagnosed	with	
dynamic	function	testing	and	is	amenable	to	treatment	with	daily	GH	injections.	GHD	
is	treated	in	adults	if	there	is	evidence	of	impaired	quality	of	life,	usually	assessed	by	
the	AGHDA-QoL	(QoL-AGHDA).	Reduced	bone	density	and	evidence	of	impaired	
adipocyte	metabolism,	reduced	lean	muscle	mass	and	other	markers	of	insulin	
resistance	can	also	support	the	use	of		growth	hormone	replacement	(GHR)	(Moller	
&	Jorgensen,	2009;	Rosen,	Hansson,	Granhed,	Szucs,	&	Bengtsson,	1993).	
	
Several	small	studies	have	reported	a	positive	effect	of	GHR	on	cognition	and	quality	
of	life	following	TBI	((Gardner	et	al.,	2015;	High	et	al.,	2010;	Maric	et	al.,	2010;	
Moreau	et	al.,	2013;	Reimunde	et	al.,	2011).	However	it	is	not	clear	what	effect	GH	
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has	on	microstructural	brain	recovery	following	TBI	in	cases	of	GHD.	This	could	have	
important	therapeutic	opportunities.	
	
The	purpose	of	this	chapter	is	to	investigate	the	effect	GHR	on	cognition	WM	
recovery	and	metabolism.	My	hypotheses	are	as	follows:		
	
1) GHR	improves	WM	recovery	in	the	SPCC	and	other	regions	that	relate	to	
areas	of	greater	density	of	GH	receptors	in	the	brain,	namely	the	anterior	
thalamic	radiculus	and	the	cingulum	hippocampus	(Lobie	et	al.,	1993).	
2) GHR	improves	cognitive	functions	such	as	working	memory	and	also	
improves	quality	of	life	compared	to	those	patients	who	had	not	received	GH	
injections	following	a	TBI.		
3) GHD	patients	exhibit	greater	insulin	resistance	compared	to	those	without.		
4) GHR	improves	insulin	sensitivity.	
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5.2 Methods		
5.2.1 Participants		
Ten	patients	with	confirmed	GHD	were	recruited	following	a	TBI	from	the	
multidisciplinary	TBI	clinic	at	Imperial	College	Healthcare	NHS	Trust.	All	patients	had	
the	following	data	recorded:	age,	gender,	date	of	TBI,	severity	of	TBI	(Mayo	
classification).	Research	ethics	committee	approval	was	obtained	(Ealing	and	West	
London	REC	09/H0707/82).	All	patients	gave	their	informed	consent.	Patients	had	a	
full	endocrine	and	metabolic	assessment	to	include	dynamic	function	testing,	a	
dedicated	pituitary	MRI	and	bone	densitometry	imaging	(DEXA).	Participants	had	
standard	structural	imaging	and	a	cognitive	and	psychological	assessment	following	
diagnosis	of	GHD	and	approximately	after	one	year	of	GH	replacement.		
	
The		treated	GHD	group	was	compared	against	23	age	and	gender-matched	TBI	
patients	without	GHD	and	who	had	not	received	GH	treatment.	They	underwent	
identical	imaging	and	cognitive	assessment	at	two	timepoints.		
	
35	age	and	gender	matched	healthy	volunteers	underwent	an	identical	
neuroimaging	visit	at	a	single	time	point,	but	no	cognitive	assessment.	
	
5.2.2	Endocrine	assessment	
	
Patients	had	full	endocrine	testing	at	baseline	as	part	of	their	routine	clinical	care	
(Table	3-1).	Measurements	of	anterior	pituitary	hormones	(serum	IGF-I,	prolactin,	
TSH,	free	thyroxine,	LH,	FSH,	testosterone/oestrogen,	SHBG)	were	taken	in	the	late	
morning/early	afternoon	in	the	non-fasted	state.	Subsequently,	patients	had	initial	
screening	for	GH	(and	ACTH)	deficiency	using	the	glucagon	stimulation	test	and	
confirmed	using	the	GHRH-Arginine	test	(with	age	and	BMI-adjusted	cut-offs).	A	
careful	medication	history	was	taken	to	exclude	any	confounding	factors	in	the	
interpretation	of	these	tests.	If	these	tests	confirmed	GHD	sooner	than	one	year	
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after	TBI,	then	a	further	test	was	performed	after	1	year	to	ensure	that	GHD	had	not	
recovered	spontaneously.	Please	refer	to	section	3.2.4	Tests	for	pituitary	dysfunction	on	page	102.	
	
Following	diagnosis	of	GHD,	a	gadolinium-enhanced	pituitary	MRI	was	obtained	
(where	possible)	to	exclude	any	other	cause	of	GHD	such	as	a	pituitary	adenoma.	
Given	that	GHD	can	have	deleterious	effects	on	bone	health,	and	given	that	this	is	an	
indication	for	GH	replacement,	a	DEXA	scan	was	performed	at	baseline.	Markers	of	
insulin	resistance	and	dyslipidaemia	were	also	measured	before	and	after	treatment	
and	these	included	fasting	insulin,	c-peptide,	glucose,	HbA1c,	fasting	cholesterol,	
LDL,	HDL	and	triglyceride	levels	and	BMI.	Please	see	section	2.5	Methods	for	assessing	insulin	resistance	(IR)	and	the	metabolic	syndrome	on	page	77.	Serum	
IGF-I	measurements	were	taken	at	baseline	and	follow-up.	An	age-adjusted	IGF-I	
ratio	was	calculated	using	the	median	of	age-adjusted	reference	ranges,	see	section	
4.2.3	Serum	IGF-I	status	on	page	131	for	more	details.		
	
If	patients	met	NICE	criteria	for	GH	replacement	(i.e.	>1	yr.	from	TBI	and	symptom	
score	on	AGHDA	of	11/25	or	above	((NICE),	2003)	then	patients	were	commenced	on	
0.2	mg	of	recombinant	GH	(Omnitrope®	or	Genotropin	®)	by	daily	subcutaneous	
injection.	Choice	of	GH	depended	on	local	prescribing	rules.	Each	individual	had	a	
target	IGF-I	in	the	upper	third	of	the	normal	reference	range.	Dose	of	GH	was	
titrated	every	month	for	the	first	three	months	to	achieve	an	IGF-I	in	the	desired	
range.	Patients	were	reviewed	approximately	every	three	months	for	the	first	year	
to	review	symptoms,	document	any	side	effects	and	alter	dose	if	necessary.	
Following	a	year	of	treatment,	patients	had	full	basal	pituitary	and	metabolic	profile,	
a	follow-up	structural	MRI	visit	and	cognitive/psychological/quality	of	life	
assessment.	
	
	
	
5.2.3	Structural	neuroimaging		
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Each	patient	had	standard	high-resolution	T1	and	gradient-echo	T2*	magnetic	
resonance	imaging	to	assess	focal	brain	injury	and	presence	of	microbleeds,	on	a	
Philips	3T	Achieva	scanner	(Philips	Medical	Systems,	Netherlands)	using	an	8-channel	
head	coil.	For	DTI,	diffusion-weighted	volumes	with	gradients	applied	in	16	non-
collinear	directions	were	collected	in	four	runs,	with	a	total	of	64	directions,	using	
the	following	parameters:	73	contiguous	slices,	slice	thickness	2mm,	field	of	view	
224mm,	matrix	128 × 128	(voxel	size	1.75×1.75×2mm3),	b-value	1000s/mm2,	four	
images	with	no	diffusion	weighting	(b0).	DTI	images	were	registered	to	the	b0	image	
by	affine	transformations,	then	brain-extracted	and	FA	maps	generated	using	the	
FMRIB	Software	Library	image	processing	toolbox.	FA	diffusion	maps	were	analysed	
using	both	whole	brain	and	region-of-interest	voxel-wise	analysis	approaches	to	
compare	those	pre-	vs.	post-	GH	replacement.	The	23	TBI	controls	(without	GHD)	
had	identical	imaging	visits	designed	to	be	1	year	apart.	
	
5.2.4	DTI	Analysis	
	
FA	was	the	principal	outcome	measurement.	For	details	on	DTI	analysis	and	TBSS	
please	refer	to	2.3.4	Generation	of	FA	maps	on	page	75	and	section	2.3.5	Tract	based	spatial	statistics	(TBSS)	also	on	page	75.	Identical	design	matrices	were	used	
for	chapter	4	(i.e.	an	interaction	and	subtraction	design).	Here	instead	of	IGF-I	groups	
patients	were	separated	into	GHD	(n=10)	and	no	GHD	(n=23)	groups.	Please	refer	to	
section	4.2.5	DTI	and	FA	analysis	on	page	132	for	more	details.	
	
Three	region	of	interest	were	selected.	The	SPCC	was	selected	as	this	region	is	
commonly	affected	following	a	TBI	and	baseline	serum	IGF-I	appears	to		predict	
recovery	in	the	region,	as	seen	in	Chapter	4	Association	of	serum	IGF-I	with	white	matter,	neuropsychological	and	cognitive	recovery	following	traumatic	brain	injury.	I	also	selected	two	other	a	priori	regions	from	the	JHU	atlas	that	relate	to	
region	of	increased	GH	receptor	density	in	the	brain,	namely	the	namely	the	anterior	
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thalamic	radiculus	and	the	cingulum	hippocampus	(Lobie	et	al.,	1993).	These	regions	
can	be	seen	below	in	Figure	5-1.	
	
Figure	5-1	Anterior	thalamic	radiculus,	cingulum	hippocampus	and	splenium	of	
corpus	callosum	white	matter	tract	regions	of	interest.	
	
Group	average	FA	skeleton	(green,	threshold	>0.2)	from	all	patients	after	TBI	(n=33)	and	
healthy	controls	(n=35),	overlaid	onto	standard	MNI152	1mm	T1	MRI	brain	scan.	White	
matter	(WM)	tract	defined	using	the	JHU	white	matter	tractography	atlas	with	a	cut-off	
threshold	of	20%	indicated	in	red/blue/yellow.	Mean	fractional	anisotropy	(FA)	values	in	
anterior	thalamic	radiculus,	cingulum	hippocampus	and	splenium	of	corpus	callosum	WM	
tract	regions	of	interest	were	calculated	from	the	average	of	the	voxels	indicated	by	the	
overlap	of	the	green	skeleton	and	red/blue/yellow	mask.	Co-ordinates	given	in	Montreal	
Neurological	Institute	(MNI)	standard	space.	R	indicates	right.	
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5.2.6	Neuropsychological	Assessment	
	
Each	patient	with	GHD	completed	a	standardised	battery	of	neuropsychological	tests	
previously	shown	in	our	group	to	detect	to	cognitive	impairment	following	TBI	
(Kinnunen	et	al.,	2011).	For	more	detailed	explanation	and	references	please	section	
2.3.2	Neuropsychological	assessment	on	page	74.	In	summary	these	tests	included:	
	
i) The	Wechsler	Test	of	Adult	Reading	(WTAR)	to	assess	pre-morbid	
intelligence			
ii) The	People	test	from	the	Doors	and	People	Test	to	measure	
associative	learning	and	memory	
iii) The	Trail	Making	Test		to	assess	executive	functions	of	set-shifting,	
inhibitory	control	and	cognitive	flexibility.	
iv) Verbal	and	non-verbal	reasoning	ability	via	the	Wechsler	Abbreviated	
Scale	of	Intelligence	Similarities	and	Matrix	Reasoning	subtests.	
v) The	Colour-Word	subtest	and	Letter	fluency	from	the	Delis-Kaplan	
Executive	Function	System.	
vi) Median	reaction	time	for	accurate	responses	on	a	simple	
computerised	choice	reaction	task.	
	
5.2.7	Quality	of	Life	(QoL)	assessments	
	
Quality	of	Life	(QoL)	assessments	were	carried	out	in	subjects	at	each	neuroimaging	
visit	and	periodically	during	GH	treatment.	These	assessments	included	the	
Assessment	of	GH	Deficiency	in	Adults	(AGHDA	scale),	Beck	Depression	Inventory	
Score	(BDI-II),	Epworth	Sleepiness	Scale,	Pittsburgh	Sleep	Index,	Nottingham	Health	
Profile	(NHP)	and	the	Short	Form	Survey	(SF-36).	Please	see	section	2.3.2	Neuropsychological	assessment	on	page	73	for	more	detailed	information	and	
references.	
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5.2.8	Statistical	analyses	
	
Analysis	of	demographics,	ROI	FA	values	and	cognitive	variables	was	performed	using	
SPSS	(v22,	IBM).	Comparison	between	groups	used	Mann-Whitney	U	test	or	chi-
squared	test	and	repeated	measures	ANCOVA	with	post-hoc	Fisher	LSD	test,	as	
appropriate	with	statistical	threshold	P<0.05.		
	
Comparison	of	FA	in	ROIs	between	controls	and	TBI	patients	at	baseline	using	
ANCOVA	included	age	and	gender	as	co-variates.	Comparison	of	FA	in	ROIs	between	
groups	in	TBI	patients	at	baseline	using	ANCOVA	included	age,	gender,	TBI	severity,	
time	since	TBI	as	co-variates.	Longitudinal	analyses	were	performed	both	without,	
and	with	addition	of	the	following	co-variates	that	might	influence	WM	tract	
recovery	over	time:	age,	gender,	TBI	severity,	time	since	TBI,	and	time	between	DTI	
scans.	Repeated	measures	ANCOVA	examined	improvement	in	FA	in	ROIs	over	time	
in	TBI	patients,	and	differences	between	groups	to	establish	effects	of	group,	time	
and	group	x	time	interaction.	
	
Analysis	of	metabolic	variables	and	QoL	before	and	after	GHR	treatment	was	
performed	in	SPSS	(v22,	IBM)	using	paired	Student	t-tests	with	a	statistical	
significance	threshold	of	<0.05.	
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5.3 Results		
5.3.1 Patient	characteristics		
Thirty-three	patients	in	total	were	studied	of	whom	10	(30.3%)	had	confirmed	GHD	
followed	by	GHR.		
	
5.3.1.1 TBI	group	who	received	GHR	at	baseline			
Nine	out	of	10	patients	(90%)	were	male	with	a	median	age	41.7	(IQR)	22.7-56.7	
years.	All	patients	has	suffered	a	moderate-severe	severity	TBI	with	the	exception	of	
the	one	female	participant	who	had	a	mild	injury.	Median	time	since	injury	was	23.5	
(IQR)	20.5-67.9	months	and	median	time	between	scans	17.1	(IQR)	13.9-18.9	
months.		
	
Seven	patients	(70%)	sustained	their	TBI	via	a	road	traffic	accident,	2	(20%)	from	a	
blast	explosion,	1	(10%)	from	a	fall	and	1	(10%)	following	an	assault.		
	
At	the	time	of	GHR	initiation,	4	patients	(40%)	had	post-traumatic	epilepsy,	1	(10%)	
had	type	2	diabetes	mellitus	and	1	patient	(10%)	also	had	confirmed	ACTH	and	
gonadotrophin	deficiency	in	addition	to	GHD.	This	patient	had	been	started	and	
stabilised	on	testosterone	treatment	prior	to	GHR	initiation.	The	medications	
recorded	at	the	start	of	GHR	treatment	and	other	demographics	data	pertaining	to	
the	GHR	group	are	displayed	in	Table	5-1	and	the	whole	group	displayed	in	Table	
5-2.	
	
Median	absolute	IGF-I	was	20.9	nmol/L	(IQR)	19.2-23.1	and	age	adjusted	ratio	1.1	
(IQR)	0.9-1.2.	GHD	was	diagnosed	using	a	glucagon	stimulation	test	(GST)	and	either	
a	GHRH-arginine	test	or	insulin	tolerance	test	(ITT)	as	a	confirmatory	test.	For	
patients	within	one	year	of	TBI,	a	3rd	confirmatory	test	was	performed	after	one	year	
to	confirm	the	persistence	of	GHD.	All	patients	were	started	on	0.2	mg	of	synthetic	
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GH,	irrespective	of	IGF-I	level	and	once	stable	titrated	at	3	monthly	intervals	
throughout	treatment.	
	
On	standard	structural	imaging	7	(70%)	of	patients	had	evidence	of	structural	
lesions,	although	structural	burden	was	low	and	no	patient	had	more	than	one	
contusion.	Nine	patients	also	had	dedicated	pituitary	imaging	on	confirmation	of	
GHD	and	two	of	these	had	reported	abnormalities	e.g.	small	volume	gland	and	
hypoplastic	stalk.	
	
5.3.1.2 TBI	group	without	GHR	at	baseline			
Twenty	of	the	23	patients	without	GHD	who	did	not	receive	GHR	were	male	(87%)	
with	median	age	30.5	(IQR)	26.8-47.0	years.	22/23	had	sustained	a	moderate	to	
severe	TBI	using	the	Mayo	classification	score.	Time	since	injury	was	19.2	months	
(IQR)	4.4-23.0	and	time	between	scans	11.8	months	(IQR)	9.0-14.8.	Median	absolute	
IGF-I	was	23.0	(IQR)	15.7-26.7	nmol/L	and	age-adjusted	ratio	0.9	(IQR)	0.8-1.0.	All	of	
these	patients	also	received	identical	endocrine	assessment	including	a	screening	
and	confirmatory	test	for	GHD.	Testing	was	complete	before	enrolment	in	the	study	
and	were	documented	to	have	no	evidence	of	GHD	in	the	clinical	notes.	
	
There	was	no	difference	in	the	age	at	first	scan,	gender,	severity	and	time	since	
injury	between	the	group	that	did	and	did	not	receive	GHR	(P	0.21-0.87).	The	time	
between	scans	was	significantly	lower	in	the	group	who	did	not	receive	GHR	(11.8	vs.	
17.1	months	P=0.04).	There	was	a	trend	towards	a	lower	absolute	IGF-I	in	the	GHR	
group	at	baseline	(20.9	vs.	23.0	nmol/L,	P=0.08),	but	no	difference	in	the	age-
adjusted	IGF-I	ratio.	Demographic	data	are	displayed	in	Table	5-2.	
	
5.3.1.3 GHR	group	at	follow-up			
All	patients	self-administered	their	GHR	subcutaneously	throughout	the	duration	of	
treatment	and	all	attended	their	regular	follow-up	visits	at	the	multidisciplinary	TBI	
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clinic.	Median	duration	of	GHR	(i.e.	time	from	GH	start	to	2nd	scan)	was	14	months	
(range	7-20).	However	of	note,	two	patients	(patient	2	and	9,	median	duration	18	
and	20	months	respectively,	Table	5-1)	had	an	interruption	to	treatment	due	to	
possible	allergic	reaction	and	patient	discomfort	(patient	2)	and	another	was	asked	
to	temporarily	stop	treatment	to	confirm	ACTH	deficiency	and	re-initiate	
hydrocortisone	treatment	(patient	9).		
	
GHR	was	well	tolerated	by	all	patients.	There	were	no	reports	of	headache	or	
arthralgia	on	starting	treatment.	Patient	2	intermittently	stopped	his	GHR	due	to	
experiencing	pruritus.	However,	following	review	by	an	experienced	endocrine	
consultant	it	was	felt	that	GH	injections	were	not	responsible	for	this	symptom.	
	
5.3.2 Effect	of	TBI	on	WM	tracts	
	
In	whole	brain	analysis,	FA	was	significantly	lower	in	several	WM	tracts	including	the	
superior	longitudinal	fasciculus,	superior	region	of	the	internal	capsule	and	
cerebellar	peduncles	in	patients	following	TBI	at	baseline	scan	(n=33),	compared	to	
healthy	controls	(n=35)	(Figure	5-2A).	
	
5.3.3 Effect	of	time	on	WM	recovery		
	
Within	the	TBI	group	as	a	whole,	FA	increased	over	time	from	scan	1	to	scan	2	in	a	number	
of	WM	tracts	including	the	splenium	and	body	of	corpus	callosum	and	posterior	limb	of	the	
internal	capsule	and	other	subcortical	regions	(n=33)	(Figure	5-2B).	There	was	a	trend	
towards	an	effect	of	time	in	the	anterior	thalamic	radiculus	F(1,31)=0.39,	P=0.06	Figure	5-3.	
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Table	5-1	Baseline	characteristics	of	the	10	patients	who	had	confirmed	GHD	and	went	on	to	receive	GHR	
	 	
	
	
	
	
	
			
	
PARTICIPANT
MODE	OF	
INJURY SEVERITY	(MAYO) GENDER MEDICATIONS	AT	INITIATION	OF	GHR
OTHER	PITUITARY	
DEFICIENCES/DIABETES/EPILEPSY STRUCTURAL	MRI	LESIONS PITUITARY	MRI
1 cyclist moderate-severe male levetiracetam,	escitalopram,	venlafaxine,	rampril,	vitamin	D epilepsy siderosis	left	parietal	lobe small	vol	of	pituitary	tissue
2 RTA-pedestrian moderate-severe male carbamazepine,	fluoextine,	quetiapine,	omeprazole epilepsy nil	 hypoplastic	stalk	
3 RTA-pedestrian moderate-severe male phenytoin,	temazepam,	sertralline,	quietapine,	lansoprazole,	codydramol,	ramipril epilepsy cystic	encephalomalacia normal
4 assault moderate-severe male vitamin	D nil left	frontal	haemorrhagic	contusion normal
5 RTA-motorbike moderate-severe male citalopram,	modafinil,	omeprazole nil contusion normal
6 Fall moderate-severe male carbamezpine,	fluoextine,	lorazepam,	zopiclone epilepsy gliosis,	microbleed not	performed
7 RTA-car mild female metformin,	lisinopril,	rosuvastatin,	gliclazide,	bendroflumethiazide,	atenolol,	aspirin type	2	diabetes nil normal
8 RTA-cyclist moderate-severe male vitamin	D nil microhaemorrhages,	contusion,	siderosis normal
9 blast moderate-severe male nebido,	pregabalin,	amitriptyline,	sodium	docusate,	hydrocortisone ACTH	and	gonadotrophin nil normal
10 blast moderate-severe male fluxetine,	morphine	sulphate,	amitryptilline,	zopiclone,	mirtazapine,	sodium	docusate nil microbleed normal
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Table	5-2	Patient	characteristics	and	markers	of	insulin	resistance	at	baseline		 	
	
																															Data	given	as	n	(%)	or	median	[IQR]	and	range	(minimum-maximum).		
a	P	value	for	comparison	no	GHR	vs.	with	GHR	groups	using	chi-squared	test	for	categorical	variables	and	
Mann-Whitney	U	test	for	continuous	variables.	b	To	convert	nmol/L	to	ng/mL	divide	by	0.131.	
	
n No GHR With GHR
P with vs. 
without 
GHR a
n 33 23 10
Age at first scan (yrs) 33 30.5 [26.8-47.0] 41.7 [26.8-45.4] 0.62
Range 23.1-55.0 22.7 -56.7
Male Sex                               33 20 (87.0%) 9 (90%) 0.74
Moderate-Severe Severity 33 22 (95.7%) 9 (90%) 0.87
Time since Injury (months) 33 19.2 [4.4-23.0] 23.5 [20.5-67.9] 0.21
                                   Range 1.5-25.5 17.6-292.8
Time between scans (months) 33 11.8 [9.0-14.8] 17.1 [13.9-18.9] 0.04
Range 6.3-16.4 11.5-19.4
Absolute IGF-1 nmol/Lb 33 23.0 [15.7-26.7] 20.9 [19.4-23.1] 0.08
Range 12.8-27.0 15.9-31.7
Age-Adjusted IGF-1 Ratio 33 0.9 [0.8-1.0] 1.1 [0.9-1.2] 0.21
Range 0.7-1.1 0.7-1.3
Blast Injury 33 9 (39.1%) 2 (20%) 0.50
Any structural brain abnormality 33 10 (43.4%) 6 (60%) 0.62
BMI (kg/m2) 27 24.9 [21.6-29.5] 28.8 [27.5-33.1] 0.12
Range 20.9-31.6 26.1-33.7
Fasting blood glucose 32 5.2 [4.7-5.2] 5.2 [4.9-7.0] 0.70
Range 4.5-5.4 4.0 -17.0
HbA1c 32 32.5 [30.3-35.2] 38.0 [32.0-43.5] 0.25
Range 4.4-39.0 29.0-53.0
Fasting C-peptide 31 665.0 [381.5-818.3] 861.0 [526.-1167.0] 0.20
Range 247.0-923.0 217.0-2552.0
Fasting insulin 29 6.0 [3.8-8.7] 10.0 [8.5-13.7] 0.02
Range 0.8-83.3 2.5-44.3
HOMA-IR 24 0.9 [0.5-1.1] 1.4 [1.1-1.9] 0.002
Range 0.4-2.0 1.0-5.9
SHBG 33 25.5 [18.2-39.5] 25.0 [14.0-35.5] 0.97
Range 18.0 - 91.0 11.0 - 38.0
Total cholesterol (mmol/L) 33 5.1 [4.4-5.5] 4.9 [4.1-5.7] 0.97
Range 4.1-7.2 3.2-6.2
Low density lipoprotein (LDL) mmol/L 32 3.2 [2.9-3.7] 3.0 [2.0-3.5] 0.70
Range 2.6-5.3 1.4-4.0
High density lipoprotein (HDL) mmol/L 32 1.1 [0.9-1.4] 1.0 [0.9-1.3] 0.70
Range 0.8-1.4 0.8-1.4
Triglycerides (TG) mmol/L 33 1.3 [1.0-2.0] 2.0 [1.2-3.1] 0.21
Range 0.7-2.4 0.8-5.1
Systolic BP (SBP) 30 126.0 [108.0-139.3] 141.0 [125.0-144.5] 0.70
Range 104.0-150.0 107.0-150.0
Diastolic BP (DBP) 30 84.0 [70.0-87.0] 87.0 [74.0-91.5] 0.25
Range 64.0-90.0 68.0-94.0
Average metabolic score (out of 4) 33 1.5 (1.4) 3.3 (1.0) 0.001
Range 0.0-4.0 1.0-4.0
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Table	5-3	Endocrine,	metabolic,	bone	and	QoL	before	and	after	GHR	
	
Data	given	as		mean	+SD	and	range	(minimum-maximum).		
a	P	value	for	comparison	before	GHR	vs.	after	GHR	groups	using	paired	Student’s	t-test	(two-tailed)	
n Before GHR After GHR
P before 
vs. after 
GHR a
Absolute IGF-I 10 21.9 ± 4.1 37.1 ± 13.3 0.008
Range 15.9-31.7 23.0-68.1
Age-adjusted IGF-I ratio 10 1.1 ± 0.2 1.7  ± 0.6 0.016
Range 0.7-1.3 0.9-2.8
Dose of GH (mg) 10 0.2 ± 0.0 0.3 ± 0.2 0.049
Range 0.2-0.2 0.1-0.8
BMI (kg/m2) 10 29.4 ± 3.1 30.0 ± 3.6 0.38
Range 24.9-33.7 25.9-35.8
Fasting blood glucose (mmol/L) 10 6.3 ± 3.9 5.5 ± 1.5 0.41
Range 3.2-17.0 4.0 -9.1
HbA1c (mmol/mol 10 37.9 ± 7.4 39.0 ±  8.0 0.36
Range 29.0-53.0 26.0-52.0
Fasting insulin (ug/L) 10 13.1 ± 11.4 12.0 ± 11.8 0.43
Range 2.5-44.3 1.0-43.0
Fasting C-peptide (ug/L) 10 911.0 ±  667.6 915.0 ± 483.7 0.97
Range 814.5-2552.0 256.0-2115.0
HOMA-IR 8 1.9 ± 1.6 1.9 ± 1.8 0.62
Range 1.0-5.9 0.7-6.0
SHBG (mmol/L) 10 27.3 ± 12.5 29.0 ± 11.6 0.31
Range 11.0-48.0 10.0-42.0
Total Cholesterol (mmol/L) 10 4.9 ± 1.0 5.2 ± 0.9 0.08
Range 3.2-6.2 3.4-6.1
Low density lipoprotein (mmol/L) 10 2.8 ± 0.9 3.1 ± 0.9 0.10
Range 1.3-4.0 1.5-4.2
High density lipoprotein (mmol/L) 10 1.1 ± 0.2 1.1 ± 0.2 0.18
Range 0.8-1.4 0.8-1.5
Triglycerides (mmol/L) 10 2.2 ± 1.3 2.3  ± 0.8 0.83
Range 0.8-5.1 1.0-4.2
Systolic BP (mmHg) 10 133.5 ± 14.0 128.2  ± 17.6 0.27
Range 107.0-150.0 107.0-155.0
Diastolic BP (mmHg) 10 81.0 ± 12.1 79.0 ± 11.1 0.43
Range 58.0-94.0 60.0-95.0
Metabolic score (out of 4) 10 3.0 ± 1.4 2.2 ± 0.9 0.07
Range 0.0-4.0 1.0-4.0
AGHDA (out of 25) 10 18.4 ± 5.0 12.0 ± 8.7 0.004
Range 10.0-25.0 1.0-25.0
BDI (out of 63) 10 33.4  ± 16.1 20.7 ± 18.4 0.001
Range 15.0-60.0 3.0-56.0 
Epworth (out of 24) 8 11.0 ± 8.1 10.5 ± 6.8 0.47
Range 0.0-20.0 0.0-18.0
T-score Hip 9 -0.03 ± 1.2
Range -1.2 - +2.5
T-score Spine 9 0.08 ± 1.2
Range -1.5 - +2.5
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Figure	5-2	White	matter	tract	fractional	anisotropy	in	patients	following	TBI		
	
A)	Lower	white	mater	tract	fractional	anisotropy	in	patients	after	TBI.	Voxels	displaying	
lower	fractional	anisotropy	(FA)	in	patients	with	TBI	(n=33)	compared	to	healthy	controls	
(n=35)	displayed	in	red	(TFCE	P<0.05	corrected	and	correcting	for	age	and	gender),	overlaid	
on	combined	whole	group	FA	skeleton	(green),	displayed	on	standard	MNI125	1mm	T1	MRI	
brain	scan.	Co-ordinates	given	in	Montreal	Neurological	Institute	(MNI)	standard	space.	R	
indicates	right.	
B)	White	matter	tract	FA	improvement	between	scans.	Regions	displaying	higher	fractional	
anisotropy	(FA)	in	TBI	patients	at	follow-up	scan	(in	red)	compared	to	baseline	scan	overlaid	
on	group	FA	skeleton	(green)	using	TFCE	P<0.05	corrected	and	correcting	for	age,	time	since	
injury,	gender,	TBI	severity	and	time	between	scans.	Results	overlaid	on	standard	MNI125	
1mm	T1	MRI	brain	scan.	Co-ordinates	given	in	Montreal	Neurological	Institute	(MNI)	
standard	space.	R	indicates	right.	
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5.3.4 Effect	of	GHD	and	GHR	on	white	matter	FA	
	
i) No	cross-sectional	influence	of	GHD	on	FA	as	baseline:	Within	the	TBI	
group,	there	was	no	significant	effect	of	GHD	on	FA	at	baseline	in	whole	
brain	analysis,	with	or	without	the	inclusion	of	co-variates	(age,	gender,	
TBI	severity,	time	since	TBI).	
ii) Using	the	subtraction	and	interaction	TBSS	design,	there	was	no	
significant	effect	of	GHR	group	or	GHR*time.	This	remained	non-
significant	when	including	the	co-variates:	age,	gender,	TB	severity,	time	
since	TBI	and	time	between	scans.	
There	was	no	effect	of	GHR	on	the	increase	in	FA	over	time	in	either	the	anterior	thalamic	
radiculus	(ATR),	cingulum	hippocampus	(CH)	or	the	splenium	of	the	corpus	callosum	(SPCC)	
(GHR	group	x	time	interaction	P=0.29-0.66)	when	including	all	co-variates	and	or	including	
none.	Figure	5-3.	
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Figure	5-3	White	matter	tract	FA	in	regions	of	interest	in	patients	after	TBI	at	
baseline	and	recovery	over	time	by	GHR	status	
	
No	difference	in	improvement	in	FA	in	ATR,	CH	and	SPCC	between	scan	1	(dotted	bar)	and	
scan	2	(striped	bar)	in	the	group	that	received	growth	hormone	replacement	(GHR)	and	those	
that	did	not.	(P	results	using	a	repeated	measures	ANOVA).	
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5.3.5 Effect	of	GHR	group	on	cognitive	variables	and	QoL	
5.3.5.1 Cognitive	variables		
	
Complete	cognitive	data	was	available	in	all	patients	who	received	GHR	(n=10)	and	
20/23	who	did	not	receive	GHR	and	who	were	not	GH	deficient.	
	
There	was	a	significant	effect	of	time	on	the	Colour	Word	Stroop	
Inhibition/Switching	task,	median	time	61.0	s	at	scan	1	vs.	52.0	s	at	scan	2,	P=0.006	
(table).	Lower	time	score	on	this	task	relates	to	better	performance.	There	were	
trends	towards	greater	performance	scores	over	time	in	the	domains	of	WTAR,	WASI	
matric	reasoning,	People	test,	and	Stroop	(colour	naming)	(P=0.054-0.091).	(Table	
5-4).	
	
There	were	no	significant	GHR	x	time	interactions	in	any	of	the	cognitive	variables	
tested	when	including	no	co-variates	and	when	correcting	for	all	co-variates	(time	
since	injury,	time	between	scans,	gender,	age	at	first	scan	ad	TBI	severity)	(P	>0.108).	
(Table	5-4).	
	
5.3.5.2 Quality	of	life	variables		
	
There	was	a	significant	decrease	in	the	AGHDA-QoL	score	following	GHR	treatment	
indicating	greater	improvement	in	QoL	(t=-3.8,	df	=9,	P=0.004,	two-tailed).	A	similar	
significant	reduction	in	the	BDI-II	score	was	aloes	observed	indicating	fewer	
symptoms	of	depression	following	treatment	(t=-5.2,	df	=	9,	P=0.001,	two-tailed).	
These	results	are	displayed	in	Figure	5-4.	There	was	no	significant	change	in	the	
Epworth	sleepiness	scale	following	treatment.	These	data	are	displayed	in	Table	5-3.	
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Table	5-4	Cognitive	outcome	measures	in	patients	after	TBI	at	baseline	and	recovery	over	time	by	GHR	status	
	
	
	
	
	
	
a	=	correction	for	all	covariates	(time	since	injury,	time	between	scans,	gender,	age	at	first	scan,	TBI	severity)	 	 	 	 	
Data	displayed	as	median	[IQR]	range.	 Group,	time	and	group*time	analysis	performed	using	a	repeated	measures	ANOVA.	 	 	 	
Note:		Matrix	reasoning,	People	test,	Logical	memory:	higher	score	equals	better	performance;	Trail-making,	Stroop,	letter	fluency:	lower	score	equals	better	
cognition	 	 	 	 	
Abbreviations:	DKEFS,	Delis-Kaplan	executive	function	system;	(s),	seconds;	SF-36;	WASI,	Wechsler	Adult	Intelligence	Scale;	WTAR,	Wechsler	Test	of	Adult	
Reading.	 	 	 	 	
	
Cognitive domain Cognitive variable n (no GHR)
n (with 
GHR) First Visit Second visit
Effect of 
Timea
Effect of 
GH group a
Time*Group 
Interactiona
Pre-morbid intelligence: reading ability WTAR raw score 20 10 41.0 [36.0-46.0] 43.0 [34.5-47.8] 0.091 0.939 0.943
Intellectual ability WASI matrix reasoning (non-verbal) 20 10 29.0 [24.0-30.0] 29.0 [26.3-31.0] 0.054 0.317 0.741
Memory: associative memory People test (total score) 20 10 24.0 [20.0-28.0] 27.5 [20.3-31.0] 0.067 0.922 0.218
Memory: immediate recall Logical memory I Total 20 10 41.0 [36.0-49.5] 45.0 [34.5-51.0] 0.552 0.107 0.108
Logical memory II Total 20 10 26.0 [20.5-34.0] 26.5 [22.3-36.0] 0.666 0.635 0.629
Memory: delayed recall Logical memory retention 20 10 86.7 [78.4-96.1] 90.8 [83.4-100.0] 0.667 0.632 0.630
Processing speed: visual search/complex Trail Making Test Trail A (s) 20 10 24.0 [18.0-31.0] 20.5 [16.3-23.8] 0.188 0.224 0.261
Trail Making Test Trail B (s) 20 10 47.0 [35.0-67.0] 44.0 [31.0-60.0] 0.275 0.170 0.803
Processing speed: naming/reading Stroop Colour Naming (s) 20 10 31.0 [27.5-40.5] 30.5 [26.5-35.0] 0.068 0.382 0.135
Stroop Word Reading (s) 20 10 22.0 [18.5-26.0] 22.0 [19.0-24.8] 0.837 0.326 0.254
Executive function: alternating-switch cost Trail Making Test Trail B minus A (s) 20 10 23.0 [15.5-37.0] 19.0 [14.3-35.5] 0.846 0.296 0.466
Cognitive flexibility Colour Word Stroop Inhibition/switching (s) 20 10 61.0 [51.0-74.0] 52.0 [46.0-57.0] 0.006 0.712 0.871
Word generation fluency DKEFS Letter Fluency F+A+S total 20 10 37.0 [31.5-46.5] 41.0 [33.0-49.0] 0.810 0.626 0.532
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Figure	5-4	AGHDA-QoL	and	BDI-II	scores	pre-	and	post-	GHR		
			
Significant	reduction	in	AGHDA-QoL	score	(t=-3.8,	df	=9,	P=0.004,	two	tailed)	and	BDI-II	score	
(t=-5.2,	df	=	9,	P=0.001,	two-tailed),	indicating	improvement	in	QoL	and	symptoms	of	
depression	following	GHR.	(AGHDA	score	out	of	25,	BDI-II	out	of	63).	Line	label	1-10	equates	
to	patient	no.	see	Table	5-1.	
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5.3.6 Effect	of	GHD	and	GHR	on	markers	of	metabolism	
5.3.6.1 Effect	of	GHD	on	metabolism	
	
There	were	significantly	higher	levels	of	fasting	insulin	in	patients	with	GHD	compared	to	
those	without	(median	values	10.0	vs.	6.0	ug/L	P=0.02).	Insulin	resistance	as	measured	by	
the	HOMA-IR	was	significantly	higher	in	those	with	GHD	compared	to	those	without	
(median	value	1.4	vs.	0.9	P=0.002).	Total	metabolic	score	(One	point	for	each	of	raised	
fasting	blood	glucose	(FBG),	HDL,	LDL	and	BP)	was	significantly	higher	in	patients	with	GHD	
vs.	those	without	3.3	vs.	1.5	(P=0.001),	although	on	the	individual	measures	of	FBG,	lipids	
parameters	and	BP	there	were	no	significant	differences	between	groups.	BMI	was	higher	
in	those	with	GHD	(median	28.8	(IQR)	27.5-33.1)	than	those	without	(median	24.9	(IQR)	
21.6-29.5),	although	this	did	not	reach	significance	at	P=0.12.	The	same	was	true	for	
glycosylated	haemoglobin	(HbA1c)	which	was	higher	in	the	GHD	group	(median	38.0	IQR	
32.0-43.5)	vs.	those	with	no	GHD	(median	32.5	IQR	30.3-35.2)	but	was	significantly	
different	between	the	two	groups.	There	was	no	difference	in	SHBG	(another	marker	of	
insulin	resistance)	between	those	with	and	without	GHD	(P=0.97).	Data	are	displayed	in	
Table	5-2.	
	
Bone	densitometry	(DEXA)	was	performed	only	at	baseline	in	those	with	GHD	only	(Table	
5-3).	Data	were	available	in	9/10	patients.	No	patient	had	evidence	of	osteoporosis	(T	
score	<	-2.5).	Three	out	of	10	patients	had	osteopenia.	One	patient	had	osteopenia	of	the	
hip	(T	score	-1.5)	and	the	spine	(T	score-1.1),	another	patient	had	osteopenia	of	the	spine	
only	(T	score	-1.2)	and	another	of	the	hip	only	(T	score	-1.3).	Median	T	score	at	the	hip	was	
-0.05	(IQR)	-1.1-0.7	and	at	the	spine	-0.1	(IQR)	-1.0-0.8.		
5.3.6.2 Effect	of	GHR	on	metabolism			
All	patients	started	GH	treatment	at	a	dose	of	0.2	mg	but	this	had	significantly	increased	
at	the	end	of	the	study	period	to	a	mean	dose	of	0.3	mg	(range	0.1-0.8)	to	ensure	patients	
were	kept	in	the	upper	third	of	the	age-related	IGF-I	reference	range.	Absolute	IGF-I	was	
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significantly	higher	at	the	end	of	the	study	period	(t=3.4,		df=9,	P=0.08,	two-tailed)	as	was	
the	age-adjusted	IGF-I	ratio	(t=2.9,	df	=9,	P=0.016,	two-tailed).	
	
There	was	a	trend	towards	a	lower	metabolic	score	following	treatment	from	mean	score	
3.0	(±	1.4)	to	2.2	(±	0.9)	t=0.93,	df=9,	P=0.07,	two-tailed.	However	there	were	no	other	
significant	differences	in	BMI,	SHBG,	HOMA-IR,	HbA1c,	lipids	and	blood	pressure	following	
treatment	with	GHR	in	the	study	period.			
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5.4 Discussion		
The	aim	of	this	chapter	was	to	build	on	work	in	the	previous	chapter	which	describes	an	
effect	of	baseline	serum	IGF-I	on	WM	recovery	and	memory	following	TBI.	IGF-I	is	the	
main	downstream	mediator	of	pituitary-derived	GH	and	is	therefore	considered	a	proxy	
measurement	of	GH	reserve.	However	the	gold	standard	for	assessing	GH	reserve	is	a	
diagnosis	of	GHD	via	dynamic	pituitary	function	testing,	irrespective	of	the	level	of	IGF-I.	
This	chapter	examined	the	effects	of	GH	replacement	(GHR)	on	WM,	cognitive	and	QoL	
measures	and	metabolism	in	10	patients	who	were	diagnosed	with	GHD	and	underwent	
GH	replacement	for	a	median	duration	of	14	months.		
	
The	patients	with	and	without	GHR	were	fairly	well	matched	in	terms	of	age	at	first	scan,	
severity,	gender,	and	mode	of	injury.	We	did	include	patients	who	had	sustained	a	bTBI	
which	is	not	surprising	as	bTBI	appears	to	be	a	particular	risk	factor	for	GHD	(Baxter	et	al.,	
2013)	but	there	was	no	significant	difference	in	the	number	of	soldiers	in	each	group.		
	
There	was	no	significant	difference	in	the	time	since	injury	but	there	was	an	outlier	in	the	
GHR	group	who	sustained	his	injury	24	years	ago.	Given	that	there	were	relatively	few	
patients	on	GHR	in	the	multidisciplinary	TBI	clinic	who	were	also	happy	to	take	part	in	the	
study,	we	decided	on	balance	to	include	this	patient.	There	was	a	significantly	greater	
time	period	between	the	two	scans	in	patients	on	GHR	compared	to	those	who	were	not.	
There	could	be	a	number	of	reasons	for	this	including	the	desire	of	the	physician	to	ensure	
appropriate	dose	titration	and	accommodating	any	interruptions	to	treatment	prior	to	
returning	for	the	second	study	scan.	GHR	interruptions	occurred	in	two	patients	and	it	was	
difficult	to	estimate	exactly	how	much	time	was	spent	off	GHR,	although	was	not	thought	
to	account	for	more	than	2	months	in	both	cases.	
	
Four	of	the	patients	with	GHD	had	post-traumatic	epilepsy	for	which	they	were	treated	
with	anti-epileptic	agents	including	phenytoin,	carbamazepine	and	levetiracetem.	It	is	
unlikely	that	these	medications	or	the	underlying	condition	interfered	with	the	diagnosis	
of	GHD.	One	study	found	minor	abnormalities	in	stimulated	GH	in	patients	who	were	
taking	these	drugs	for	epilepsy	compared	to	healthy	controls	(Franceschi	et	al.,	1984).	
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However	given	our	stringent	protocol	for	diagnosing	GHD	in	our	patients	that	included	a	
second	and	sometimes	a	third	dynamic	confirmatory	test,	I	think	it	is	unlikely	that	these	
medications	interfered	with	the	test	results	sufficiently	to	alter	the	final	diagnosis.	The	
same	is	likely	to	be	true	for	the	one	patient	(patient	7)	who	had	type	2	diabetes.	The	GST	
can	be	an	unreliable	test	in	type	2	diabetes	(Yuen,	2011),	however	this	patient	also	had	
two	abnormal	GHRH-arginine	tests	and	was	therefore	very	likely	to	have	GHD.	We	also	
used	BMI	and	age	cut	offs	for	the	GHRH-Arginine	tests	to	account	for	these	factors	(Colao	
et	al.,	2009).	
	
One	patient	had	combined	GH/ACTH	and	gonadotrophin	deficiency.	That	patient	was	
commenced	on	testosterone	replacement	at	least	one	year	prior	to	commencing	GHR.	It	is	
unlikely	therefore	that	testosterone	replacement	was	responsible	for	improved	QoL	as	is	
sometimes	reported	(Moncada,	2006).	
	
Structural	brain	abnormalities	were	common	in	both	groups	i.e.	contusions,	superficial	
siderosis,	microbleeds,	diffuse	axonal	injury,	and	there	was	no	particular	difference	in	the	
pattern	of	injury	in	both	group.	Overall,	no	one	had	grossly	abnormal	anatomy	in	this	
study.	One	patient	with	GHD	had	cystic	encephalomalacia	which	is	softening	of	the	brain	
parenchyma	with	a		cystic	component	that	is	usually	a	late	manifestation	following	a	TBI.	
Of	the	4	patients	with	GHD	with	normal	anatomy,	3	were	defined	to	have	a	moderate-
severe	injury	based	on	GCS,	LOC	and/or	PTA	duration	and	1	had	evidence	of	a	mild	injury	
only.	Severity	of	injury	was	not	significantly	different	between	the	two	groups.		
	
Nine	out	of	10	patients	with	GHD	had	a	dedicated	pituitary	MRI	imaging.	Two	abnormal	
findings	of	a	hypoplastic	stalk	and	a	small	volume	of	pituitary	tissue	were	reported	in	two	
individuals.	These	reports	were	made	by	an	experienced	consultant	neuroradiologist.	The	
significant	of	these	findings	is	uncertain.	They	could	represent	previous	ischaemic/hypoxic	
injury	resulting	from	TBI	or	could	be	a	normal	variant.		
	
In	terms	of	WM	recovery,	we	found	widespread	increases	in	FA	in	several	WM	tracts	
across	the	whole	brain	not	only	in	healthy	controls	vs.	patients	but	also	at	scan	2	vs.	scan	
1.	This	confirms	that	patients	have	microstructural	evidence	of	TBI	and	this	appears	to	
improve	following	TBI.	This	result	was	also	reported	in	the	previous	chapter.	There	was	
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however	no	effect	of	GHR	on	WM	recovery.	There	could	be	several	reasons	why	this	could	
be	false	negative	result.	It	is	possible	that	patients	were	not	treated	long	enough	with	GHR	
and	at	a	high	enough	IGF-I	level.	It	is	also	possible	that	this	study	was	underpowered	to	
detect	a	difference	between	the	two	groups	and	with	a	larger	sample	size	differences	may	
emerge	especially	at	the	cingulum	hippocampus.	I	also	had	not	accounted	for	lesions	in	
this	study,	however	no	patient	had	distinctly	abnormal	anatomy	and	the	pattern	of	injury	
was	similar	between	the	two	groups.	
	
The	same	can	be	said	for	the	apparent	lack	of	effect	of	GHR	on	cognition.	The	study		may	
have	been	too	small	to	detect	a	difference	or	patients	should	have	been	studied	at	a	later	
time	point,	especially	as	there	appears	to	be	a	strong	effect	of	time	alone	particularly	in	
the	domains	of	cognitive	flexibility.	In	addition,	patient	comorbidity	may	also	be	an	
important	factor	to	consider	here.	At	least	four	patients	had	significant	psychiatric	and	
psychological	comorbidity	that	may	have	affected	their	performance	on	the	cognitive	
tests.	One	patient	had	significant	psychomotor	retardation	and	was	heavily	involved	with	
the	psychiatric	team.	Sequentially	removing	these	patients	from	the	cognitive	analysis	
made	no	difference	to	the	overall	results.		
	
However,	GHR	in	this	study	appeared	to	significantly	improve	QoL	and	reduce	symptoms	
of	depression.	The	QoL	improvement	is	consistent	with	other	studies	of	GHR	outside	of	
TBI	and	a	recent	study	in	patients	following	TBI	(Deijen	&	van	der	Veen,	1999;	Gardner	et	
al.,	2015).	I	could	not	find	any	literature	supporting	a	reduction	of	depressive	symptoms	
following	TBI	in	those	who	had	received	GHR	and	this	could		be	an	important	novel	
finding.	Nine	out	of	10	of	our	patients	had	a	reduction	in	their	BDI-II	score	(average	point	
reduction	12.7)	and	one	patient	showed	no	change.	This	could	potentially	dramatically	
improve	functioning	for	these	individuals	especially	as	depression	is	considered	one	of	the	
most	burdensome	consequences	of	TBI	(Fann,	Hart,	&	Schomer,	2009).	However	it	is	
important	to	point	out	that	6/10	of	these	patients	were	on	medication	to	treat	depression	
following	TBI	and	further	investigations	are	required	to	determine	whether	the	reduction	
in	depression	scores	could	be	attributable	to	any	other	intervention	or	medication	dose	
change.		
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GHD	patients	in	this	study	appeared	to	have	a	worse	metabolic	profile	at	baseline	with	an	
increase	in	insulin	resistance	(HOMA-IR)	and	a	higher	average	metabolic	score.	Formal	
assessment	for	metabolic	syndrome	could	not	be	made	as	we	had	not	collected	waist	
circumference	measurements.	BMI	was	higher	in	the	GHD	group	with	all	patients	in	the	
overweight	or	obese	categories	although	BMI	was	not	significantly	different	between	the	
two	groups.	Ideally	we	should	have	taken	a	measurement	of	lean	muscle	mass	and	
abdominal/visceral	adiposity	as	adipose	metabolism	impairment	is	the	best	recognised	
metabolic	impairment	of	GHD.	However	after	GHR	there	was	no	significant	improvement	
in	any	of	the	metabolic	variables	we	measured.	There	was	a	trend	however	towards	a	
lower	metabolic	score	following	GHR.	Bone	health	appeared	to	be	lower	than	a	healthy	
age	matched	reference	group	with	3	patients	having	osteopenia	at	either	the	hip/spine	or	
both.	It	would	have	been	useful	to	examine	the	effects	of	GHR	on	DEXA	imaging	at	follow-
up,	however	there	was	no	clinical	indication	to	do	this.	
	
In	conclusion,	we	found	no	effect	of	GHR	on	WM	recovery	or	cognition	following	TBI.	
However	we	did	find	a	striking	improvement	in	QoL	and	depressive	symptoms	following	
injury.	Larger	studies	examining	different	lengths	of	GHR	treatment	duration	are	required	
to	determine	if	GHR	has	any	effect	on	WM	and	cognitive	recovery	from	TBI	both	in	GH	
deficient	and	GH	replete	individuals.				 	
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6 Neuroinflammation	in	TBI:	A	kinetic	analysis	of	the	
translocator	protein	(TSPO)	positron-emission	tomography	
ligand	[18F]GE-180	in	the	human	brain	
	
6.1 Introduction		
The	translocator	protein	(TSPO)	is	a	mitochondrial	transporter	involved	in	varied	
intracellular	processes,	but	its	expression	in	the	central	nervous	system	(CNS)	is	relatively	
low	under	normal	physiological	conditions	(Cosenza-Nashat	et	al.,	2009).	However,	
activation	of	microglial	cells	caused	by	inflammatory	stimuli	results	in	significant	
upregulation	of	TSPO	expression	(M.	K.	Chen	&	Guilarte,	2008). TSPO	quantification	with	
positron	emission	tomography	(PET)	provides	a	measure	of	intrinsic	neuroinflammation	in	
a	variety	of	CNS	diseases.	Early	PET	studies	used	the	isoquinoline	[11C]PK-11195	to	
measure	TSPO	binding	and	detected	elevations	across	a	range	of	conditions	including	
multiple	sclerosis	(Banati	et	al.,	2000),	Huntington’s	disease	(Pavese	et	al.,	2006),	
Alzheimer’s	disease	(Cagnin	et	al.,	2001;	Edison	et	al.,	2008),	traumatic	brain	injury		
(Ramlackhansingh	et	al.,	2011),	and	ischaemic	stroke	(Gerhard,	Schwarz,	Myers,	Wise,	&	
Banati,	2005).	However,	the	ligand	can	be	limited	by	a	high	non-specific	signal,	making	
non-standard	approaches	to	data	analysis	necessary	(Kropholler	et	al.,	2006).	In	addition,	
[11C]PK-11195	is	a	carbon-11	compound,	with	a	half-life	of	20.3	minutes,	restricting	its	use	
to	locations	with	an	on-site	cyclotron.	
	
A	number	of	second	generation	TSPO	ligands	have	been	developed	recently	with	the	
promise	of	improved	signal	to	noise	and	greater	specific	binding.	[18F]GE-180	is	a	novel	
fluorinated	radiotracer	that	binds	to	the	TSPO	with	high	affinity	(Wadsworth	et	al.,	2012).	
Developed	from	a	series	of	tricyclic	indoles,	[18F]GE-180	has	demonstrated	superior	
specific	binding	affinity	to	[11C]PK-11195	in	animal	models	of	acute	neuroinflammation	
(Dickens	et	al.,	2014)	and	stroke	(Boutin	et	al.,	2015).	The	fluorine-18	radiolabelling,	with	a	
half-life	of	109.8	minutes,	also	makes	[18F]GE-180	more	suitable	than	carbon-11	based	
compounds	for	long-distance	distribution	enabling	widespread	clinical	use.		
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Other	second	generation	TSPO	radiotracers	(e.g.	[11C]PBR-28,	[18F]PBR-06,	[11C]-DAA1106,	
[11C]-DPA713,	[18F]	FEPPA)	show	binding	affinities	influenced	by	a	TSPO	polymorphism	
expressed	by	individuals	which	have	been	classified	as	high-affinity	binders	(HABs),	mixed	
affinity	binders	(MABs)	and	low	affinity	binders	(LABs)	(Owen	et	al.,	2011).	Expression	of	
the	TSPO	Ala147Thr	polymorphism	results	in	MAB	or	LAB	depending	on	whether	one	or	
two	copies	are	present	(Owen	et	al.,	2012).	
	
In	this	chapter	I	present	a	study	in	healthy	participants	using	[18F]GE-180	PET	imaging.	The	
primary	objective	here	was	to	study	the	tracer	kinetics	and	quantification	in	the	healthy	
human	brain.	The	secondary	objective	was	to	investigate	whether	there	were	differences	
in	binding	between	HABs	and	MABs.	Work	in	this	chapter	forms	the	foundation	for	the	
next	chapter	where	this	tracer	is	used	to	quantify	TSPO	inflammation	in	patients	following	
TBI	and	to	investigate	a	link	between	the	metabolic	syndrome	and	central	
neuroinflammation.	
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6.2 Methods		
6.2.1 Participants	
	
This	study	was	approved	by	the	Westminster	Research	Ethics	Committee,	London	
(13/LO/1596),	the	Riverside	Research	Ethics	Committee	(13/LO/1916),	and	the	
Administration	of	Radioactive	Substances	Advisory	Committee	(no.	631/336/30788).	
Research	was	conducted	in	accordance	with	the	Helsinki	Declaration.	All	participants	gave	
written,	informed	consent.		
	
Ten	healthy	volunteers	(7	males),	mean	age	41	±	9,	28–56	years,	mean	weight	81.8	±	13	
kg,	were	included	in	the	study.	A	screening	assessment	was	carried	out	that	included	full	
medical	and	drug	history,	blood	pressure,	height,	weight,	Allen’s	test	for	patency	of	the	
ulnar	anastomosis,	and	the	Structured	Clinical	Interview	for	DSM	disorders	(SCID).	Blood	
samples	were	taken	for	analysis	of	full	blood	count,	renal	profile,	clotting	screen	and	TSPO	
genotyping.	Exclusion	criteria	included	pregnancy,	a	history	of	prior	or	current	psychiatric	
or	neurological	disease,	abuse	of	alcohol	or	drugs	or	contraindication	to	arterial	line	
placement.	
	
6.2.2 TSPO	Genotyping	
	
DNA	was	extracted	using	the	Qiagen	QIAmp	DNA	blood	mini	kit.	TSPO	genotyping	of	the	
c.439A>G	(p.Thr147A1a)	(SNP	rs6971)	was	performed	using	a	TaqMan	Allelic	
Discrimination	assay.	Low	affinity	binders	(n=1)	were	excluded	from	the	imaging	
component	of	the	study.	During	the	study	design	it	was	felt	that	on	ethical	and	
economical	grounds	we	should	not	expose	LABs	to	this	novel	tracer	and	instead	focus	on	
MABs	and	HABs.	Of	the	10	participants	eligible	for	imaging,	5	were	high-affinity	binders	
and	5	were	mixed	affinity	binders.	
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6.2.3 Synthesis	of	[18F]GE-180	
	
[18F]	fluorine	was	produced	by	the	18O(p,n)18F	nuclear	reaction	on	a	GE	PETtrace	8	
cyclotron	(The	Grove	Centre,	Amersham,	UK).	All	radiochemistry	was	performed	on	the	GE	
FASTlab	synthesizer	with	single	use	cassettes.	Average	synthesis	time	was	43	mins,	
radiochemical	yield	43%	and	purity	was	greater	than	95%	(Wickstrom	et	al.,	2014).	The	
radiotracer	was	manufactured	by	GE	Healthcare	(The	Grove	Centre,	Amersham,	UK),	
transported	to	Hammersmith	Hospital,	London,	and	used	within	12	hours	of	manufacture.	
	
6.2.4 Positron	Emission	Tomography	(PET)	Scanning	and	Image	
Reconstruction	
	
All	participants	were	scanned	at	the	Clinical	Imaging	Facility,	Imperial	College	London,	
Hammersmith	Hospital.	Prior	to	PET	scanning,	an	arterial	cannula	was	inserted	under	local	
anaesthetic	(2%	lidocaine)	into	the	radial	artery	to	allow	arterial	blood	sampling.	An	
antecubital	venous	cannula	was	inserted	for	radiotracer	administration.	
	
PET	studies	were	performed	on	a	Biograph	6	(6	slice	CT)	scanner	after	administration	of	
182	±	3.1	MBq	via	intravenous	bolus	injection	given	over	ten	seconds	followed	by	a	10	mL	
saline	flush.	A	low	dose	CT	scan	preceded	the	PET	acquisition	to	allow	correction	for	tissue	
attenuation.	Emission	data	were	then	acquired	over	90	minutes	in	list	mode	and	
reconstructed	as	24	temporal	frames	(6x15,	3x60,	5x120,	5x300,	5x600	seconds)	using	
filtered	back	projection	(matrix	size	168x168,	zoom	2.6,	5mm	Gaussian	filter,	pixel	size	
1.56x1.56,	slice	thickness	3mm)	with	and	without	attenuation	correction.	Standard	
corrections	for	scatter,	decay	and	random	counts	were	applied.		
	
6.2.5 Whole	Blood,	Plasma	Activity	and	Parent	Fraction	of	[18F]GE-180	
	
Arterial	blood	activity	was	measured	every	second	for	the	first	15	minutes	of	the	90	
minute	scan	using	an	automated	blood	sampling	system	(ABSS	Allog,	Mariefred,	Sweden)	
connected	to	the	participant	via	a	1.5	m	x	1.0	mm	diameter	polytetrafluoroethylene	
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(PTFE)	line	(blood	withdrawal	rate	2.5	ml/min).	In	addition,	manual	blood	samples	(10mL)	
were	collected	from	the	radial	artery	at	0,	5,	10,	15,	30,	50,	70,	90	mins	to	assay	whole	
blood	and	plasma	activity.	Plasma	was	obtained	by	centrifugation	over	3	minutes	at	1800	
g.	Activity	of	whole	blood	and	plasma	was	measured	in	a	Well	Counter	(CAPRAC	-®T/Well	
Counter)	over	10-60	seconds.	The	first	15	minutes	of	continuous	whole	blood	activity	was	
combined	with	the	discrete	samples	to	generate	the	whole	blood	activity	curve	for	use	in	
data	modelling.	The	continuous	plasma-over-blood	ratio	was	estimated	using	a	constant	
model	and	a	total	plasma	activity	curve	was	obtained	by	correcting	the	whole	blood	curve	
for	this	partition	between	plasma	and	blood.	
	
The	parent	fraction	of	[18F]GE-180	was	measured	by	high-performance	liquid	
chromatography	(HPLC)	(Agilent	1100	and	1260	series)	of	discrete	plasma	samples	(3.5	
mL).	The	parent	fraction	was	fitted	to	a	single	exponential	plus	a	constant	model.	The	total	
plasma	activity	was	multiplied	by	this	parent	fraction	and	then	smoothed	post	peak	by	
fitting	to	a	tri-exponential	function	to	generate	an	arterial	parent	plasma	input	function.	A	
delay	correction	of	up	to	+30	seconds	was	applied	to	the	input	function	to	prior	to	fitting	
the	kinetic	modelling	stage.	This	was	performed	to	account	for	delay	in	the	1.5	m	tube	and	
delay	between	the	radial	artery	and	the	brain.	
	
6.2.6 Magnetic	Resonance	Imaging	(MRI)	
	
To	provide	additional	anatomical	information	to	aid	analysis	of	the	PET	data,	each	subject	
had	a	structural	T1-weighted	MRI	scan	on	a	Siemens	Verio	3T	scanner	(matrix	size	
256x256,	1x1x1	mm	voxel	size,	TR	9.63	ms,	TE	4.74	ms,	flip	angle	9	degrees).	
	
6.2.7 Data	Analysis		
A	high	level	overview	of	the	data	analysis	is	provided	in	Figure	6-1.	We	used	the	PET	data	
analysis	and	kinetic	modelling	toolkit,	MIAKATTM	(www.miakat.org),	which	incorporates	
software	from	SPM5	(Wellcome	Trust	Centre	for	Neuroimaging)	and	FSL	(FMRIB,	
University	of	Oxford)	(Searle	et	al.,	2014).	
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Figure	6-1	Overview	of	PET	data	analysis	
We	used	 the	MIAKATTM	 analysis	 toolkit	 for	 image	 processing	 (A),	 blood	 data	 processing	 (B)	 and	
kinetic	modelling	(C)	of	PET	data.  
	
The	brain	was	initially	extracted	from	the	T1-weighted	MR	image.	The	CIC	
neuroanatomical	atlas	was	non-linearly	registered	to	the	individual's	extracted	brain	in	
order	to	generate	a	personalised	set	of	anatomically	parcellated	regions	(Tziortzi	et	al.,	
2011).	Frame-by-frame	motion	correction	of	the	dynamic	(non	attenuated-corrected)	PET	
data	was	performed	using	mutual	information	co-registration	of	the	individual	frames	to	a	
reference	frame.	An	average	motion-corrected	PET	image	was	generated	and	used	for	co-
registration	with	the	T1-weighted	MR	image.	Finally,	regional	tissue	time	activity	curves	
(TACs)	were	generated	for	each	region	of	interest	(ROI)	defined	from	the	CIC	atlas	that	
had	been	transformed	into	each	individual’s	image	space.		
	
Datasets	were	analysed	with	one-	and	two-tissue-compartment	models	and	the	Logan	
graphical	method,	using	the	metabolite-corrected	plasma	input	function	as	previously	
described	(Fujita	et	al.,	2008) with	a	fixed	5%	blood	volume	correction.	
	
The	primary	outcome	measures	were	the	radioligand	delivery	rate	constant	(K1;	mL	cm	-3	
min	-1),	total	distribution	volume	(VT:	mL	cm	-3),	and	standardised	uptake	values	(SUV).	The	
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SUV	ratio	and	distribution	volume	ratios	(DVR)	were	estimated	using	cortical	grey	matter	
as	a	pseudo	reference	region,	since	previous	studies	reported	this	area	as	having	one	of	
the	lowest	levels	of	TSPO	binding	(Owen	et	al.,	2014)	
	
6.2.8 Time	Stability	Analysis	
	
To	investigate	the	stability	of	VT	over	different	scan	durations,	a	time	stability	analysis	was	
performed	by	analyzing	data	for	total	time	windows	that	ranged	between	40-90	minutes	
in	10	minute	increments.	
	
6.2.9 Statistical	Analysis	
	
To	determine	the	most	appropriate	compartmental	model	the	Akaike	information	
criterion	(AIC)	was	used	for	model	selection	(Akaike,	1974),	where	lower	AIC	was	
indicative	of	a	more	parsimonious	model.		To	compare	characteristics	between	genetic	
groups	(HAB/MAB),	Fisher’s	exact	test	(gender)	and	the	Mann	Whitney	U	test	(age	weight,	
injected	dose)	were	used.	To	evaluate	differences	between	genetic	groups	in	time	activity	
curves	for	blood	data,	a	repeated	measures	analysis	of	variance	(ANOVA)	was	used,	with	
time	as	the	within-subjects	factor	and	genotype	as	the	between-subjects	factor.	A	
repeated	measures	ANOVA	was	also	used	to	compare	outcome	measures	across	multiple	
ROIs,	where	ROI	was	used	as	the	within-subjects	factor.	
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6.3 Results		
6.3.1 Patient	characteristics	and	drug	safety		
Injection	of	[18F]GE-180	caused	no	pharmacological	effects	based	on	patient	reports,	
blood	pressure,	pulse,	respiration	rate	and	oxygen	saturation	after	radioligand	
administration.	There	were	no	significant	differences	in	gender,	age	or	weight	between	
HABs	and	MABs.	We	looked	for	correlations	between	age	and	our	principal	outcome	
measure.	We	found	no	significant	correlations	between	age	and	VT	in	both	HABs	and	
MABs	in	any	of	the	ROIs	studied	(HABS:	Spearman’s	rho	=	-0.3-0.7	p=0.188-0.873,	MABs:	
Spearman’s	rho	0.1-0.8,	p=0.104-0.94).	There	was	also	no	significant	relationship	between	
age	and	outcome	measures	when	added	as	a	covariate	in	the	repeated	measures	
ANCOVAs	performed.	Demographic	data	are	displayed	here	in	Table	6-1.	
	
Table	6-1	Patient	characteristics	of	the	ten	healthy	volunteers	enrolled	in	study		
Subject	 Genotype	 Age	(yrs.)	 Gender	 Weight	(kg)	
1	 HAB	 47.9	 M	 97.9	
2	 HAB	 35.5	 M	 72.1	
3	 HAB	 34.4	 M	 94.6	
4	 HAB	 48.1	 F	 69.7	
5	 HAB	 28.4	 M	 96.6	
6	 MAB	 49.2	 M	 87.5	
7	 MAB	 39.8	 F	 70.3	
8	 MAB	 31.0	 F	 74.2	
9	 MAB	 56.2	 M	 65.4	
10	 MAB	 39.7	 M	 90.4	
HAB=high	affinity	TSPO	binders	and	MAB=mixed	affinity	TSPO	binders	
	
6.3.2 Plasma	Data		
In	plasma,	the	concentration	of	[18F]GE-180	peaked	at	about	45	seconds	and	was	followed	
by	a	rapid	decrease	(Figure	6-2).	The	fraction	of	unchanged	[18F]GE-180	over	time	is	
shown	in	Figure	6-2B.	The	parent	compound	accounted	for	65.0-81.7%	(min-max	across	
participants)	of	the	total	concentration	in	plasma	at	30	minutes,	and	57.3-78.3%	at	90	
minutes.	Three	polar	radioactive	metabolites	were	identified	over	the	course	of	the	90	
minute	scanning	window	(<10%	of	parent	compound).	The	plasma	to	blood	ratio	
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remained	constant	at	≈1.69	(Figure	6-2C)	across	individuals.	There	were	no	significant	
differences	in	profiles	of	plasma	over	blood	There	were	no	significant	differences	in	
profiles	of	plasma	over	blood	(F(1,48)=0.407,	p=0.541),	parent	fraction	(F(1,48)=	0.871,	
p=0.378)	or	parent	in	plasma	between	genetic	groups	(F(1,48)=0.130,	p=0.728).	There	was	
no	interaction	of	genotype	with	time	for	any	of	these	profiles	(p>0.204).	The	parent	in	
plasma	profile	for	HABs	and	MABs	is	shown	in	Figure	6-3.	
		
Figure	6-2	[18F]GE-180	Blood	data:	whole	blood,	plasma,	parent	fraction	and	
plasma:blood	ratio	
	
 
 
 
	
(A)	Whole	blood	(red)	and	parent	in	plasma	(black)	curves	for	one	subject.	(B)	The	fraction	
of	unchanged	parent	compound	over	time,	for	high	affinity	binders	(HAB,	red)	and	medium	
affinity	binders	(MAB,	blue).	(C)	Plasma	to	blood	ratio	over	time,	for	HAB	and	MAB	groups.	
Values	plotted	for	B	and	C	are	mean	+/-	standard	error	of	the	mean.	
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Figure	6-3	[18F]GE-180	Blood	data:	parent	in	plasma	(HABs	vs.	MABs)	
	
Parent	in	plasma	for	groups	HABs	and	MABs	over	time	
	
6.3.3 Tissue	Data		
The	concentration	of	the	ligand	in	the	brain	peaked	at	around	one	minute	followed	by	
rapid	washout	for	all	participants.	Group-averaged	tissue	TACs	for	frontal	grey	matter	and	
thalamus	are	shown	in	Figure	6-4A	and	B.	A	60-90	minute	SUV	image	for	a	
representative	MAB	subject	are	shown	in	Figure	6-4C.	Overall,	there	was	low	uptake	of	
the	tracer	in	brain	with	images	being	dominated	by	signal	from	blood	vessels.	There	were	
no	significant	differences	in	SUV	curves	between	genetic	groups	(F(1,48)=1.396,	p=0.271).	
There	was	no	interaction	of	genotype	with	time	(P=0.684).	
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Figure	6-4	Example	of	[18F]GE-180	imaging		
	
Time	activity	curves	(TACs)	are	shown	for	high	affinity	binders	(HAB)	and	medium	affinity	binders	
(MAB),	in	frontal	grey	matter	(A)	and	thalamus	(B).	Standardised	uptake	values	(SUV)	are	plotted	
as	mean	 +/-	 standard	 error	 of	 the	mean.	 (C)	 SUV	 image	 calculated	 from	 the	 60-90	minute	 PET	
frames,	superimposed	on	the	co-registered	T1-weighted	MR,	for	a	representative	MAB	subject.		
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6.3.4 Kinetic	Analysis	
	
The	results	of	the	kinetic	modeling	are	shown	in	Figure	6-5.	The	two-tissue-
compartment	(2TC)	model	was	superior	to	the	one-tissue-compartment	model	(1TC),	as	
judged	by	a	lower	AIC,	in	all	ROIs	except	the	striatum.	Example	model	fits	for	1TC	and	2TC	
are	shown	in	Figure	6-5A	for	a	representative	MAB	subject.	The	first	10	minutes	of	
Figure	6-5A	and	C	are	shown	in	more	details	in	Figure	6-6.		
	
The	2TC	generally	showed	a	good	fit	to	the	data	excepting	an	initial	small	mismatch	in	the	
blood	volume	peak,	which	should	not	impact	on	VT	estimates.	When	we	included	the	2TC-
fit	model,	it	did	not	outperform	the	2TC-fix	based	on	the	AIC.	Blood	volume	estimates	
ranged	from	6.3-10.5%	(mean	8.4%)	across	all	ROIs.	Therefore	the	2TC-fix	was	selected	as	
the	model	to	use	for	further	analysis	and	gave	average	rate	constants	(across	all	regions	
and	participants)	of	K1=0.013	mL	cm−3	min−1,	k2=0.229	min−1,	k3=0.035	min−1,	and	k4=0.010	
min−1,	resulting	in	VT=0.311	mL	cm−3	Table	6-2.		
	
The	delivery	rate	constant,	K1,	was	low	across	all	ROIs	in	all	participants,	indicating	low	
extraction	across	the	blood-brain	barrier.	This	is	consistent	with	the	low	tissue	uptake	
observed	in	the	images	and	the	predominance	of	the	vasculature	structures.	There	was	no	
significant	effect	of	genetic	group	on	any	of	the	four	rate	constants.		The	Logan	graphical	
method	was	also	used	to	estimate	the	VT	in	each	ROI	Table	6-2.	A	representative	plot	is	
shown	in	Figure	6.4B.	Pooled	VT	estimates	from	the	2TC	were	positively	correlated	with	VT	
Logan	(Pearson’s	r=0.630	p<0.0001,	regression	equation	VT	Logan	=	0.3	*	VT-2TC	+	0.19).	
Tissue	TAC	minus	whole	blood	radioactivity	demonstrates	that	approximately	20%	of	the	
activity	in	a	typical	ROI	comes	from	blood	(Figure	6-5B).	
	
6.3.5 Time	Stability	Analysis	and	Outcome	Measures		
The	time	stability	analysis	of	the	2TC	model	demonstrated	an	increasing	VT	for	each	
successive	time	window	analysed	(shown	for	two	ROIs	in	Figure	6-5D.	A	comparison	of	
six	outcome	measures	for	a	number	of	ROIs	is	shown	in	Figure	6-7.	For	all	six	outcome	
measures,	no	significant	effect	of	genetic	group	was	found	(p>0.186),	nor	any	interaction	
between	genetic	group	and	ROI	(p=0.468).	
	 190	
	
Figure	6-5	Kinetic	modelling	and	time	stability	analysis		
(A)	
Model	fits	are	shown	for	one-tissue	compartmental-model	(reversible	1TC)	black	dashed	line	and	
two-tissue	compartmental-model	(reversible	2TC),	red	solid	line)	against	a	time	activity	curve	(TAC)	
(black	dots)	for	the	Parietal	Lobe.	(B)	Logan	plot	(black	dashed	line	for	most	linear	portion	of	curve)	
for	the	same	time	activity	curve	as	(A)	(black	dots).		(C)	Parietal	Lobe	TAC	(solid	black	line),	5%	
whole	blood	activity	curve	(red	solid)	and	difference	of	the	two	curves	(black	dashed)	highlights	the	
significant	contribution	of	blood	signal	to	the	TAC.	(D)	Estimates	of	two-tissue	compartmental-
model	VT	calculated	for	40-90	minute	scan	windows	in	10	minute	increments	are	plotted	as	the	
absolute	percentage	difference	compared	to	the	final	90	minute	VT,	for	parietal	lobe	(A)	and	
cerebellum	(B)	grey	matter	regions	of	interest.	Values	plotted	are	mean	percentage	+/-	standard	
error	of	the	mean.  
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Figure	6-6	First	10	minutes	of	Figure	6.5A	and	6.5C	in	more	detail	
	
	
(A)	Model	 fits	 are	 shown	 for	 one-tissue	 compartmental-model	 (reversible	 1TC)	 black	 dashed	 line	
and	two-tissue	compartmental-model	(reversible	2TC),	red	solid	line)	against	a	time	activity	curve	
(TAC)	 (black	 dots)	 for	 the	 Parietal	 Lobe.	 (C)	 Parietal	 Lobe	 TAC	 (solid	 black	 line),	 5%	whole	 blood	
activity	curve	(red	solid)	and	difference	of	the	two	curves	(black	dashed)	highlights	the	significant	
contribution	of	blood	signal	to	the	TAC.	
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Figure	6-7	Group	outcome	measures	(VT/Logan	VT/DVR/Logan	DVR/SUV/SUVR)	
	
Six	outcome	measures	are	plotted	for	seven	regions	of	interest,	coloured	separately	for	high	
affinity	binders	(HAB,	red)	and	medium	affinity	binders	(MAB,	blue).	(A)	Two-tissue-compartmental	
model	(2	TC)	volume	of	distribution	(VT).	(B)	VT	estimated	using	Logan	plot.	(C)	Distribution	volume	
ratio	(DVR)	from	2TC	using	cortical	grey	matter	as	a	reference	region.	(D)	DVR	estimated	using	
Logan	plot	and	cortical	grey	matter	as	a	reference	region.		(E)	60-90	minute	standardised	uptake	
values	(SUV)		(F)	60-90	minute	SUV	ratios	(SUVR)	using	cortical	grey	matter	as	a	reference	region.		
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Table	6-2	Parameter	estimates	and	model	fits	
	
Parameter	estimates	and	model	fits	are	shown	for	the	one	tissue	compartment	(1-TC),	two	tissue	
compartment	(2-TC)	model	and	Logan	graphical	method.	Data	are	presented	as	median	(interquartile	range,	
IQR).	For	1-TC	versus	2-TC,	the	right-most	column	shows	the	proportion	of	the	ten	participants	for	which	the	
model	was	the	more	parsimonious	(defined	as	having	the	lower	akaike	information	criterion,	AIC). 
	 	
Model Region K1 (mL/min) k2 (/min) k3 (/min) k4 (/min) VT 
(mL/cm3) 
DVR AIC 
wins 
1-TC  Frontal 
Lobe 
0.00472(0.00
41-0.006) 
0.0271(0.023
-0.028) 
  0.171(0.15
-0.22) 
0.939(0.94
-0.95) 
2/10 
 Parietal 
Lobe 
0.00513(0.00
4-0.0061) 
0.027(0.024-
0.028) 
  0.19(0.16-
0.22) 
0.969(0.96
-1) 
1/10 
 Temporal 
Lobe 
0.00514(0.00
48-0.006) 
0.0266(0.025
-0.028) 
  0.182(0.17
-0.24) 
1.04(1-1) 0/10 
 Occipital 
Lobe 
0.00621(0.00
57-0.0074) 
0.03(0.025-
0.032) 
  0.214(0.19
-0.25) 
1.12(1.1-
1.2) 
0/10 
 Thalamus 0.00555(0.00
46-0.0058) 
0.0261(0.024
-0.028) 
  0.182(0.17
-0.24) 
1.03(0.96-
1.1) 
0/10 
 Striatum 0.00358(0.00
3-0.0046) 
0.0241(0.021
-0.025) 
  0.155(0.14
-0.2) 
0.826(0.78
-0.89) 
8/10 
 Cerebellum 0.00656(0.00
54-0.0076) 
0.0339(0.034
-0.034) 
  0.178(0.16
-0.22) 
0.968(0.91
-1) 
0/10 
2-TC  Frontal 
Lobe 
0.0102(0.008
9-0.013) 
0.195(0.15-
1.6) 
0.0301(0.0
24-0.15) 
0.00653(0.0
04-0.017) 
0.346(0.26
-0.5) 
0.984(0.96
-1.2) 
8/10 
 Parietal 
Lobe 
0.0116(0.011
-0.014) 
0.192(0.15-
0.25) 
0.0334(0.0
25-0.039) 
0.00873(0.0
045-0.014) 
0.33(0.31-
0.42) 
1.01(0.98-
1.1) 
9/10 
 Temporal 
Lobe 
0.0143(0.012
-0.032) 
0.217(0.16-
1.3) 
0.0348(0.0
3-0.15) 
0.00927(0.0
063-0.016) 
0.306(0.27
-0.42) 
0.958(0.93
-1) 
10/10 
 Occipital 
Lobe 
0.0238(0.019
-0.031) 
0.385(0.2-
0.62) 
0.0395(0.0
36-0.054) 
0.0101(0.00
62-0.014) 
0.35(0.3-
0.52) 
1.07(0.97-
1.1) 
10/10 
 Thalamus 0.0118(0.011
-0.014) 
0.16(0.14-
0.2) 
0.0315(0.0
26-0.042) 
0.00881(0.0
062-0.012) 
0.376(0.28
-0.41) 
0.922(0.81
-1.1) 
10/10 
 Striatum 0.00413(0.00
33-0.0088) 
1.14(0.66-
1.7) 
4.89(0.62-
9.1) 
0.14(0.027-
0.21) 
0.155(0.14
-0.22) 
0.451(0.41
-0.71) 
2/10 
 Cerebellum 0.0224(0.016
-1.3) 
0.319(0.23-
78) 
0.0331(0.0
29-0.091) 
0.0113(0.00
84-0.018) 
0.281(0.25
-0.33) 
0.916(0.69
-0.98) 
10/10 
Logan Frontal 
Lobe 
    0.265(0.23
-0.33) 
0.931(0.92
-0.97) 
 
 Parietal 
Lobe 
    0.284(0.23
-0.35) 
0.996(0.93
-1) 
 
 Temporal 
Lobe 
    0.312(0.24
-0.36) 
1.01(0.95-
1.1) 
 
 Occipital 
Lobe 
    0.34(0.3-
0.39) 
1.14(1.1-
1.2) 
 
 Thalamus     0.3(0.26-
0.31) 
0.991(0.98
-1) 
 
 Striatum     0.25(0.21-
0.29) 
0.844(0.7-
0.92) 
 
 Cerebellum     0.29(0.24-
0.3) 
0.99(0.91-
1) 
 !
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6.4 Discussion	
	
In	this	chapter	we	have	described	the	characterization	and	quantification	of	the	novel	
TSPO	tracer	[18F]GE-180	for	the	first	time	in	the	normal	healthy	human	brain.	We	
generated	arterial	parent	plasma	and	whole	blood	input	functions	and	fitted	brain	TACs	to	
one-	and	two-tissue	compartmental	kinetic	models	and	Logan	graphical	analysis	to	
generate	outcome	measures	across	regions	and	individuals.	The	following	key	outcome	
measures	were	generated	from	the	analysis:	delivery	(K1),	volume	of	distribution	(VT),	
standardised	uptake	values	(SUV),	distribution	volume	ratios	(DVR)	and	SUV	with	cortical	
grey	matter	as	a	pseudo	reference	region	(SUVR).	In	addition,	we	investigated	whether	
the	TSPO	Ala147Thr	polymorphism	in	the	TSPO	binding	site	influenced	these	outcome	
measures	(Q.	Guo	et	al.,	2013;	Owen	et	al.,	2011).	
	
There	was	consistent	and	stable	metabolism	of	[18F]GE-180	parent	compound	across	all	
individuals.	There	was	no	difference	in	blood	or	plasma	activity	between	the	two	
genotypes	and	there	were	only	moderate	levels	of	detectable	metabolites	in	all	
individuals	with	70%	of	the	intact	parent	tracer	remaining	at	90	min.	SUV	images	across	all	
individuals	demonstrated	low	uptake	of	the	tracer	in	brain	tissue	with	significant	tracer	
activity	apparent	in	the	blood	compartments	of	the	brain.	The	low	brain	uptake	could	
reduce	the	signal	to	noise	ratio	for	this	tracer	and	might	mean	that	variation	in	the	activity	
within	the	blood	across	the	groups	could	bias	results.	In	addition,	the	low	uptake	might	
make	the	tracer	more	susceptible	to	showing	increased	uptake	when	there	is	BBB	
breakdown.	
 
Analysis	of	the	tracer	compartmental	modelling	showed	that	the	reversible	two	tissue	
compartment	model	provided	the	best	overall	fit	in	the	majority	of	cases.	There	was	a	
small	discrepancy	in	the	model	fit	at	the	initial	sharp	peak	of	the	curve	i.e.	<5	mins	of	data	
acquisition.	It	is	possible	that	this	may	be	due	to	increased	dispersion	of	[18F]GE-180	in	the	
vascular	bed,	although	this	is	difficult	to	quantify	precisely.	In	addition,	the	1.5m	line	that	
was	used	from	the	radial	artery	to	the	arterial	blood	detection	machine	may	have	
impacted	the	model	fit.	However,	this	discrepancy	should	not	impact	in	a	significant	way	
on	the	estimation	of	VT	as	this	is	based	on	the	integral	of	the	impulse	response	function	
(i.e.	integral/area	under	curve	of	plasma	input	function)	(Gunn,	Gunn,	&	Cunningham,	
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2001).	K1	could	be	affected	by	dispersion	but	would	still	remain	small	after	any	correction	
and	therefore	the	interpretation	of	low	brain	delivery	of	this	tracer	is	still	valid.	
	
Using	the	2TC	model,	the	initial	rate	constant	K1	was	consistently	low	suggesting	a	low	
extraction	fraction	and	delivery	into	brain	tissue.	Theoretically	this	could	be	due	to	a	
number	of	reasons:	(1)	low	lipophilicity	-	however	pre-clinical	work	has	suggested	that	this	
tracer	is	relatively	lipophilic	(logD	at	pH	7.4	is	2.95),	making	this	unlikely;	(2)	[18F]GE-180	
could	be	a	substrate	for	xenobiotic	pumps	at	the	blood	brain	barrier	such	as	the	three	
major	ABC	transporters,	p-glycoprotein-ABCB1	and	ABCC1,	ABCG2	as	can	be	seen	with	
other	tracers	with	low	BBB	penetration;(Toth	et	al.,	2014)	(3)	the	low	K1	could	be	due	to	
increased	plasma	protein	binding	although	the	relationship	here	is	complex	and	high	
plasma	protein	binding	does	not	always	lead	to	low	brain	penetration.	Most	molecules	to	
a	greater	or	lesser	extent	bind	to	human	serum	albumin	and	some	tracers	also	bind	to	
alfa1-acid	glycoprotein	(Lockhart	et	al.,	2003).	However	in	the	case	of	[18F]GE-180,	the	
binding	affinity	to	these	or	other	plasma	proteins	may	be	considerable.	A	limitation	of	this	
study	is	that	the	protein	binding	of	[18F]GE-180	was	not	measured.	However	in	vitro	work	
suggests	that	in	humans	the	plasma	free	fraction	is	approximately	3%.	
 
The	median	volume	of	distribution	of	[18F]GE-180	using	the	2TC	model	across	all	subjects	
and	brain	regions	ranged	from	0.16-0.38	mL	cm-3.	There	was	little	variability	across	brain	
regions.	VT	estimates	were	lower	than	those	observed	for	some	other	second	generation	
TSPO	tracers	(e.g.	[11C]-PBR-28:	4.1	±		1.6	mL	cm-3		in	grey	matter	(Park	et	al.,	2015)	and	
[11C]PK-11195:	0.72-1.06	mL	cm-3)	(Jucaite	et	al.,	2012).	
 
Our	time	stability	analysis	demonstrated	that	VT	did	not	reach	a	stable	estimate	during	our	
90	minute	scan,	continually	increasing	over	the	90	minute	scanning	window.	This	might	
lead	to	an	underestimation	of	VT.		A	scan	time	of	90	minutes	was	originally	selected	based	
on	pre-clinical	studies	and	consideration	of	what	would	be	acceptable	for	individuals.	
However,	our	results	suggest	that	a	longer	scanning	duration	might	give	a	more	‘stable’	VT	
estimate.	This	on-going	increase	in	VT	could	have	been	caused	by	the	accumulation	of	
radiometabolites	in	brain.	However,	only	modest	levels	of	metabolites	were	detected	in	
the	blood	and	earlier	pre-clinical	work	demonstrated	very	low	penetration	of	any	
metabolite	into	the	brain	with	94%	parent	at	60	minutes	(Chau	et	al.,	2015).	Metabolites	
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have	not	formally	been	identified	but	all	those	observed	in	this	study	have	been	more	
polar	than	the	parent.		It	is	believed	that	the	2	main	routes	of	metabolism	are	O-
demethylation	and	hydroxylation	of	the	aliphatic	ring	(Chau	et	al.,	2015).		Other	
metabolites	could	be	a	combination	of	the	2	processes	or	hydroxylation	at	different	sites.	
The	question	of	accumulation	of	metabolites	in	the	brain	is	most	relevant	when	brain	
uptake	is	high,	which	is	not	the	case	here.		It	is	also	worth	noting	that	these	time	stability	
results	are	consistent	with	other	TSPO	tracers	which	also	do	not	achieve	a	stable	estimate	
within	a	2-hour	scanning	window	e.g.	[11C]PBR28	(Fujita	et	al.,	2008)	
 
We	did	not	find	evidence	of	an	effect	of	TSPO	genotype	on	any	of	our	outcome	measures.	
We	observed	no	difference	in	K1,	VT,	DVR,	SUV	or	SUVR	between	MABs	and	HABs.	This	was	
an	unexpected	finding	as	in	vitro	work	with	cold	GE-180	displacing	[3H]PK11195	has	shown	
a	binding	affinity	of	15:1	between	HABs	and	LABs	(D	Owen,	personal	communication).	
Although	we	did	not	acquire	PET	scans	on	LABs	we	would	still	have	expected	to	see	an	
effect	of	HABs	vs.	MABs	on	our	outcome	measures.	Our	expectation	was	that	MABs	would	
show	an	intermediate	binding	between	HABs	i.e.	around	50%	of	the	HAB	binding	(Owen	et	
al.,	2012).	The	fact	that	we	did	not	observe	this	difference	in	vivo	may	be	a	consequence	
of	the	low	uptake	seen	with	this	tracer.	Genotype	effects	may	emerge	in	other	groups,	for	
example	older	individuals	or	diseased	individuals	where	we	may	expect	microglial	TSPO	
expression	to	be	higher.	We	did	consider	the	affect	that	increasing	age	of	our	participants	
could	have	on	TSPO	binding	as	has	been	shown	previously	(Schuitemaker	et	al.,	2012)	
however	we	did	not	find	any	correlations	between	age	and	VT	in	all	ROIs.	
	
In	summary,	we	report	the	first	PET	studies	of	[18F]GE-180	in	humans.	Administration	of	
the	tracer	was	used	safely	and	the	scan	was	tolerated	well	by	all	participants.	A	reversible	
2TC	model	fitted	the	data	well	and	determined	that	the	tracer	has	a	low	first	pass	
extraction	(~1%)	and	low	VT	estimates	in	healthy	volunteers.	There	was	no	observable	
dependency	on	the	rs6971	polymorphism	as	compared	to	other	2nd	generation	TSPO	PET	
tracers.	A	low	first	pass	extraction	combined	with	a	tissue	signal	with	a	relatively	large	
blood	component	suggests	similarities	to	[11C]PK-11195	in	vivo.	However	more	human	
work	with	[18F]GE-180	would	be	informative	including	studies	in	patients	with	
neuroinflammatory	conditions,	subjects	of	varying	ages	and	a	competition	study	to	more	
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clearly	delineate	specific	binding	and	in	disease	states	to	assess	signal	in	the	presence	of	
upregulated	TSPO.	
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7 Analysis	of	neuroinflammation	in	TBI	using	the	novel	PET	
radioligand	[18F]GE-180	and	its	relationship	with	the	metabolic	
syndrome	
	
7.1 Introduction	
	
In	the	previous	chapter	I	presented	the	kinetic	analysis	of	this	novel	TSPO	radioligand	in	10	
healthy	human	brains.	The	aim	of	the	last	study	was	to	determine	which	kinetic	model	
best	fitted	the	data	and	this	was	determined	to	be	the	2TC	compartmental	model	with	a	
5%	fixed	blood	volume.	This	was	important	to	establish	as	this	was	one	of	the	first	studies	
in	the	world	to	use	[18F]GE-180	and	its	kinetics	were	not	known.	We	also	investigated	
whether	the	tracer	binding	was	dependent	on	the	rs6971	TSPO	polymorphism	which	has	
been	seen	with	other	tracers	e.g.	[11C]PBR28.	We	examined	5	high	affinity	binders	(HABs)	
and	5	mixed-affinity	binders	(MABs)	but	found	no	significant	difference	in	outcome	
measures.	
	
One	of	the	major	limitations	of	this	tracer	was	low	tracer	uptake.	Approximately	1%	of	the	
tracer	was	extracted	into	the	brain	circulation,	resulting	in	very	low	VT	values	ranging	from	
0.1-0.4	mL/cm3	across	multiple	regions.	This	suggests	that	[18F]GE-180	could	be	a	
substrate	for	pumps	in	the	BBB	in	the	human,	but	not	in	rats.	This	already	is	a	serious	
limitation	to	the	use	of	this	tracer	to	quantify	TSPO	neuroinflammation	as	we	had	
originally	hoped.	However,	the	work	of	this	chapter	is	to	present	the	[18F]GE-180	data	in	
TBI	patients,	again	by	HAB	and	MAB	status	and	to	examine	for	an	influence	of	the	
metabolic	syndrome	in	these	patients.	
	
TSPO	neuroinflammation	has	been	demonstrated	in	TBI	patients	using	the	tracer	[3H]PK-
11195	(Ramlackhansingh	et	al.,	2011).	Tracer	binding	was	apparent	even	at	very	long	
times	since	injury	and	the	greatest	signal	was	found	in	subcortical	areas	such	as	the	
thalamus	i.e.	not	at	the	original	site	of	injury.	The	aim	of	this	study	was	to	evaluate	
[18F]GE-180		uptake	in	TBI	patients	in	the	subacute	phase	and	at	two	time	points	designed	
to	be	6	months.	My	second	aim	was	to	evaluate	if	there	was	a	difference	in	signal	
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between	HABs	and	MABs.	My	final	aim	was	to	establish	whether	a	TSPO	signal	is	related	
to	the	presence	of	the	metabolic	syndrome	(MetS).	For	more	introductory	material	for	
this	chapter	please	to	refer	to	sections	1.5	Neuroinflammation	following	TBI	on	page	48	
and	section	1.6	The	Metabolic	Syndrome	(MetS)	on	page	58.	
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7.2 Methods		
7.2.1 Participants	
	
This	study	was	approved	by	the	Westminster	Research	Ethics	Committee,	London	
(13/LO/1596)	and	the	Administration	of	Radioactive	Substances	Advisory	Committee	(no.	
631/336/30788).	All	participants	gave	written,	informed	consent.		
	
Eighteen	patients	with	TBI	were	initially	recruited	into	the	study.	Sixteen	of	these	patients	
were	recruited	from	the	multidisciplinary	TBI	clinic	at	St	Mary’s	hospital	and	the	remaining	
2	were	recruited	from	Dr	Greenwood’s	private	TBI	clinic.	All	patients	attended	for	a	
screening	assessment	at	the	Imperial	College	Clinical	Research	Facility	(ICCRF).	Patients	
underwent	a	full	clinical	interview	and	examination	including	a	Structured	Clinical	
Interview	for	DSM	disorders	(SCID),	BP,	ECG	and	Allen’s	test	(to	check	for	patency	of	the	
ulnar	anastomosis).	Patients	also	had	a	fasting	metabolic	assessment	(see	section	2.5	Methods	for	assessing	insulin	resistance	(IR)	and	the	metabolic	syndrome	on	page	77	
and	section	2.1.5	Recruitment	for	Chapter	7	on	page	69)	to	investigate	for	presence	of	
MetS.	To	summarise,	all	patients	had	height,	weight,	%	body	fat,	waist	circumference	
measurements	in	addition	to	BP	and	fasting	lipid	assessment	to	diagnose	MetS.	Fasting	
blood	samples	were	also	taken	for	analysis	of	full	blood	count,	renal	profile,	clotting	
screen	and	TSPO	genotyping.	Exclusion	and	inclusion	criteria	following	the	screening	visit	
are	outlined	in	2.1.5	Recruitment	for	Chapter	7	on	page	69.	
	
Of	the	18	patients	who	attended	the	screening	visit,	12	patients	were	included	in	the	
study.	Two	patients	were	excluded	because	they	had	two	alleles	for	the	rs6971	TSPO	
polymorphism	making	them	low-affinity	binders	(LABs).	Two	were	excluded	due	to	taking	
a	drug	that	could	have	an	effect	on	the	brain	(1,	minocycline,	1,	internet	purchased	
steroids)	and	two	were	excluded	due	to	language	barriers	that	could	have	affected	
informed	consent	and	also	affected	the	cognitive	assessment.		
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Of	the	12	patients	that	were	included,	8	were	high-affinity	binders	(HABs).	Details	on	the	
assay	used	for	TSPO	genotyping	can	be	found	in	6.2.2	TSPO	Genotyping	on	page	180.	Five	
of	these	patients	had	confirmed	MetS	following	metabolic	assessment.	
	
Of	the	12	TBI	patient	recruited	into	the	study,	10	attended	for	the	follow-up	study	visit	
designed	to	be	6	months	later.	One	patient	was	lost	to	follow-up	and	the	other	was	not	
able	to	attend	on	several	other	occasions	due	to	intercurrent	illness.	
	
Eleven	healthy	controls	were	also	recruited	into	the	study.	Ten	of	these	controls	were	the	
same	healthy	participants	used	in	Chapter	6	Neuroinflammation	in	TBI:	A	kinetic	analysis	of	the	translocator	protein	(TSPO)	positron-emission	tomography	ligand	[18F]GE-180	in	the	human	brain.	Another	single	control	(male,	MAB,	age	42	yr.)	was	
recruited	following	the	previous	chapter	work	and	included	in	this	study.	No	healthy	
control	had	evidence	of	MetS.	Healthy	controls	were	not	invited	for	a	follow-up	PET	visit	
at	6	months.	
	
7.2.2 PET	acquisition	
	
Following	the	screening	visit	and	final	recruitment	into	the	study,	patients	were	invited	
back	for	a	PET	and	MRI	scanning	visit.	For	details	on	synthesis	of	[18F]GE-180	and		PET	
acquisition	please	refer	to	sections	6.2.3		Synthesis	of	[18F]GE-180	on	page	181	and	
2.7	PET	scanning	visit	on	page	80.	To	summarise	patients	had	an	arterial	line	inserted	
for	continuous	and	discrete	arterial	blood	sampling	and	were	injected	with	~	185	Mbq	of	
[18F]GE-180	via	a	venous	cannula	followed	by	a	10	mL	saline	flush	prior	to	90	minute	
dynamic	PET	acquisition.	Prior	to	injection,	a	low	dose	CT	Head	was	performed	to	allow	
attenuation	correction.		
	
Continuous	blood	monitoring	was	performed	throughout	and	discrete	samples	taken	at	
specific	intervals.	Plasma	and	whole	blood	radioactivity	measurements	were	taken	as	well	
as	estimates	of	parent	compound	using	HPLC	and	metabolites.	For	details	on	acquisition	
of	blood	data	please	refer	to	section	6.2.5	Whole	Blood,	Plasma	Activity	and	
Parent	Fraction	of	[18F]GE-180	on	page	181.	Blood	sampling	and	recording	of	data	
	 202	
was	performed	by	the	CIF	biochemist	Gokul	Kolipaka.	A	senior	PET	radiographer	was	in	
attendance	with	the	study	investigator	throughout	the	duration	of	the	scan.	
	
On	termination	of	the	scan,	patients	were	asked	to	rest	for	thirty	minutes	prior	to	vital	
signs	being	recorded	and	brief	consult	with	the	study	physician.	Arterial	and	venous	lines	
were	removed	with	a	compression	bandage	applied	to	the	radial	artery	site.	Patients	were	
encouraged	to	urinate	to	maximise	excretion	of	[18F]GE-180	prior	to	leaving	the	building.	
Advice	leaflet	and	emergency	contact	number	was	given	regarding	the	arterial	line	site	
and	precautions	advised	re.	minimising	radioactive	exposure	to	others.	Patients	were	sent	
home	by	taxi	and	called	by	the	study	physician	the	following	day	to	address	any	concerns.	
	
PET	data	were	reconstructed	as	23	temporal	frames	using	filtered	back	projection	with	
and	without	attenuation	correction.	Standard	correcting	for	scatter,	decay	and	randoms	
were	applied.	
	
7.2.3 MRI	acquisition	and	cognitive	assessment		
	
In	all	cases,	PET	acquisition	was	preceded	by	a	standard	T1	MPRAGE	brain	MRI	scan	as	
well	as	other	MRI	sequences,	data	from	which	is	not	presented	here.	For	more	details	on	
MRI	acquisition	please	refer	to	6.2.6	Magnetic	Resonance	Imaging	(MRI)	on	page	
182.	If	MRI	was	not	acquired	prior	to	PET	scanning,	patients	were	brought	back	for	an	MRI	
scan	within	two	weeks	of	the	PET	scan.	A	full	cognitive	(both	paper	and	ipad)	and	QoL	
assessment	were	performed	prior	to	scanning	as	well	as	the	choice	reaction	time	task	
(CRT)	and	sustained	attention	to	response	task	(SART).	
	
7.2.4 PET	data	analysis	
	
Imaging	and	blood	data	were	all	decay	corrected	to	time	of	injection	prior	to	any	further	
processing.	I	used	MIAKATTM	v.2,	a	PET	data	and	analysis	and	kinetic	modelling	toolkit,	
that	was	downloaded	from	(www.miakat.org).	In	the	kinetic	modelling	stage,	the	2TC	
model	was	applied	as	this	appeared	to	be	the	most	parsimonious	model	in	healthy	
controls	(see	previous	chapter).		When	applicable,	cortical	grey	matter	was	selected	as	a	
pseudoreference	region	as	TSPO	is	reported	to	be	relatively	lower	in	this	region	and	has	
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been	used	in	previous	studies	(Tziortzi	et	al.,	2011).		Please	refer	to	sections	2.14		PET	analysis	pipeline	on	page	91	and	6.2.7	Data	Analysis	on	page	182.	
	
The	primary	outcome	measures	were	the	radioligand	delivery	rate	constant	(K1;	mL	cm	-3	
min	-1),	total	distribution	volume	(VT:	mL	cm	-3),	and	standardised	uptake	values	(SUV),	
with	and	without	a	reference	region	for	each	of	the	anatomical	regions	described	in	the	
previous	chapter.		
	
Comparative	analyses	were	i)	HABs	vs.	MABs	in	TBI	patients	at	baseline	ii)	TBI	vs.	healthy	
controls	(HABs	and	MABs	separately)		iii)	Baseline	vs.	follow-up	in	TBI	only	(iv)	Effect	of	
MetS	as	an	additional	within	subject	factor	for	the	above	analyses.	
	
7.2.5 Statistical	analyses	
	
To	compare	characteristics	between	genetic	groups	(HAB/MAB),	Fisher’s	exact	test	
(gender)	and	the	Mann	Whitney	U	test	(age	weight,	injected	dose)	were	used.	To	evaluate	
differences	between	genetic	groups	for	blood	data,	tissue	data	and	outcome	measures,	a	
repeated	measures	analysis	of	variance	(ANOVA)	was	used,	with	time	as	the	within-
subjects	factor	and	genotype	as	the	between-subject	factor.	A	repeated	measures	ANOVA	
was	used	to	compare	outcome	measures	across	multiple	ROIs	by	binding	status	and	by	
the	presence	of	MetS		
	
Only	6	patients	had	complete	baseline	and	follow-up	imaging	and	for	these	subjects,	
blood	data	and	outcome	measures	for	these	subjects	are	plotted	individually.	
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7.3 Results		
7.3.1 Patient	characteristics	
	
Twelve	patients	were	included	in	the	study	(10	male,	11	moderate-severe	severity,	
median	time	since	injury	9.1	months,	8	HABs,	median	weight	79.0	kg,	median	injected	
dose	183.0	MBq).	Five	out	of	12	patients	had	confirmed	MetS.	Ten	patients	attended	for	
their	follow-up	visit	and	for	these	patients	the	median	time	between	scans	was	6.0	
months.	Data	are	displayed	in	Table	7-2	and	Table	7-3.		
	
Of	the	12	patients,	6	(50%)	sustained	their	injury	as	a	result	of	an	RTA,	5	(42%)	via	a	fall	
and	1	(8%)	from	an	assault.	All	patients	had	reported	abnormalities	on	acute	imaging	(CT	
or	MRI)	and	9/12	had	on-going	evidence	of	structural	lesions	on	the	baseline	research	
MRI.	These	abnormalities	included	superficial	siderosis,	contusions,	microbleeds	and	
gliosis.	Details	of	the	injury	and	imaging	findings	are	displayed	in	Table	7-4.	
	
Almost	all	patients	had	cognitive	and/or	psychological	symptoms	following	TBI	and	at	the	
time	of	assessment.	4	(33.3%)	patients	had	stopped	work	completely	as	a	result	of	their	
TBI.	In	terms	of	additional	medical	problems,	3/12	patients	had	a	pituitary	abnormality	
confirmed	following	their	TBI	(1	SIADH,	1	ACTH	deficiency,	1	combined	GH	and	
gonadotrophin	deficiency)	and	were	on	appropriate	treatment		at	the	time	of	assessment.	
Data	regarding	symptoms,	other	medical	problems,	medication	and	occupational	status	
are	displayed	in	Table	7-5.	Results	from	the	baseline	metabolic	assessment	are	displayed	
in	Table	7-6	and	values	in	red	contributed	to	the	final	diagnosis	of	MetS	which	is	based	
on	waist	circumference,	fasting	blood	glucose,	BP,	high-density	lipoprotein,	triglycerides	
and	medications	for	raised	BP	and	dyslipidaemia.	Please	refer	to	2.5.1	Criteria	for	diagnosing	the	metabolic	syndrome	in	this	study	on	page	77.	
	
In	terms	of	patient	characteristics	by	TSPO	genotype,	there	were	no	significant	differences	in	age,	
gender,	severity,	structural	lesions,	time	since	injury,	presence	of	MetS,	weight	and	injected	dose	
of	tracer	between	HABs	and	MABs	(	P	0.15-0.78).	Figure	7-2	
.	
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Eleven	healthy	volunteers	were	also	included	in	the	study	for	comparison	(8	male,	5	HABs,	
median	age	39.8	yrs.,	median	weight	87.5	kg	and	median	injected	dose	181.3	MBq).	There	
were	no	significant	differences	in	age,	gender,	TSPO	status,	weight	or	injected	dose	of	
tracer	between	TBI	patients	and	healthy	controls	(see	Table	7-1)	
	
7.3.2 Drug	safety	and	adverse	events		
The	tracer	was	well	tolerated	and	there	were	no	serious	adverse	events	or	drug	reactions.	
One	patient	developed	some	cardiac	symptoms	one	week	after	the	first	scan	but	he	was	
fully	investigated	and	no	cause	found.	Another	patient	fell	and	fractured	her	radius	
between	baseline	and	follow-up	scan.	Both	of	these	were	filed	in	the	notes	as	adverse	
events	and	a	copy	kept	in	trial	master	file.	There	were	no	reported	complications	from	the	
arterial	line	insertion.	
	
Table	7-1	Baseline	characteristics:	healthy	controls	vs.	TBI	patients		
	
Data	displayed	as	median	[IQR]	or	n%.	Tests	of	statistical	significance:	Mann	Whitney	U	test	for	
continuous	variables	and	Yates’	test	for	categorical	variables.				
Controls TBI P	Controls	
vs	TBI
n 11 12
Age 39.8	[34.4-48.1] 46.0	[38.9-56.4] 0.41
Range 28.4-56.2 35.0-65.7
Males	(n	%) 8	(72.7%) 10	(83.3%) 0.91
HABs	(n	%) 5	(45.5%) 8	(66.7%) 0.55
Weight	(kg) 87.5	[70.3-94.6] 79.0	[69.3-86.5] 0.68
Range 65.4-97.9 66.8-100.6
Injected	dose	(MBq) 181.3	[180.0-184.3] 183.0	[181.0-185.0] 0.41
Range 176.8-1888.0 178.3-188.6
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Table	7-2	Baseline	characteristics	in	TBI	patients:	HABs	vs.	MABs	
		
Data	displayed	as	median	[IQR]	or	n%.	Tests	of	statistical	significance:	Mann	Whitney	U	test	for	
continuous	variables	and	Yates’	test	for	categorical	variables.		 	
HABs MABs
P	HABs	vs	
MABs
n 8 4
Age 41.4	[37.9-52.6] 52.6	[45.0-63.6] 0.15
Range 35.0-59.7 44.0-65.7
Males	(n	%) 7	(87.5%) 3	(75%) 0.78
Moderate-to-severe	severity	(n	%) 7	(87.5%) 4	(100%) 0.71
Any	structural	lesion	(n%) 6	(75%) 3	(75%) 0.48
Time	since	injury 7.1	[4.5-11.2] 15.6	[9.6-25.6] 0.15
Range 2.9-152.0 8.9-67.7
MetS	(n	%) 2	(25%) 3	(75%) 0.30
Weight 75.3	[69.3-80.5] 90.3	[72.1-98.5] 0.15
Range 66.8-81.0 66.8-100.6
Injected	dose 183.3	[181.1-184.9] 182.7	[179.3-186.5] 0.57
Range 179.6-188.6 178.3-187.7
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Table	7-3	Baseline	characteristics	of	12	TBI	patients	enrolled	in	study	 		
	
	
HAB=high	affinity	binders,	MAB=mixed	affinity	binders,	n/a	=not	applicable	(pt.	did	not	return	for	follow-	up	
scan)	
	 	
Participant	
no. Gender
Age	at	
PET	scan Ethnicity
Highest	
qualification
Injury	Severity	
(Mayo)
Time	since	
injury	(m)
Time	between	
scans	(m) TSPO
Metabolic	
syndrome	
(MetS)
1 male 38.6 White	caucasian Doctorate moderate-severe 9.2 0.51 HAB Yes
2 male 43.0 White	caucasian A	Level probable 152.0 0.49 HAB No
3 male 37.7 South	asian NVQ moderate-severe 11.9 0.50 HAB Yes
4 male 35.0 White	caucasian Masters moderate-severe 7.4 0.52 HAB No
5 male 59.7 White	caucasian MBA moderate-severe 4.4 0.50 HAB No
6 female 57.2 White	caucasian None moderate-severe 27.6 0.51 MAB Yes
7 female 54.0 White	caucasian O	level moderate-severe 4.8 0.54 HAB No
8 female 48.2 White	caucasian BA moderate-severe 2.9 0.50 HAB No
9 male 44.0 White	caucasian Degree moderate-severe 19.5 0.51 MAB Yes
10 male 48.0 White	caucasian Degree moderate-severe 11.7 0.50 MAB No
11 male 39.8 Chinese None moderate-severe 6.8 n/a HAB No
12 male 65.7 White	caucasian Degree moderate-severe 8.9 n/a MAB Yes
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Table	7-4	Baseline	characteristics:	Injury	details	and	structural	imaging	reports		
NK=not	known,	L=left,	R=right		
Participant	
no. Mode	of	injury PTA GCS LOC Other	Injuries	at	TBI Acute	clinical	imaging	findings Baseline	MRI	Report	
1 Fall 24-48	hrs 4 1-24	hrs R	6th	nerve	palsy
L	subdural	haemorrhage,	
contusions	frontal	lobe,	R	
temporo-	and	L	parieto-
occipital	lobes
Superficial	siderosis
2 RTA:	motorcylist <24	hrs NK nil R	tibia	fracture ?Bifrontal	hyperintensity Normal
3 RTA:	ped	vs	car 4	days NK 1-24	hrs
Rib	fractures,	
pneumothorax
Haemorrhagic	contusion	
involving	L	inferior	frontal	lobe	
and	inferior	operculum
L	inferior	and	opercular	contusion
4 Fall 4-6	hrs NK 1-24	hrs superficial	injuries
Long	bilateral	occipital	
fracture,	R	extradural	
haematoma,	some	SAH
normal
5 RTA	cyclist 7	days 8 1-24	hrs superficial	injuries
Small	white	matter	
bihemispheric	haemorrhages
Frontal	and	temporal	microbleeds,	superfical	
siderosis	R	parietal	lobe
6 Fall 1-7	days NK nil Rib	fractures
Occipital	fracture,	R	temporal	
contusion,	possible	frontal	
operculum	contusion
Gliosis	R	temporal	lobe,	microbleeds,	contusions	R	
superior	middle	temporal	gyri
7 Fall 24-48	hrs 5 <1	hr superficial	injuries
basal	skull	fracture,	contusion	
temporal	horn,	SAH	
Contusion	L	frontal	and	temporal	lobes,	shear	injury	
occipital	lobe,	small	scattered	foci	deep	cerebral	
white	matter
8 Fall 24-48	hrs NK <1	hr superficial	injuries
R	temporal	lobe	fracture,	
orbitofrontal	contusion Gliosis	R	orbit	and	R	temporal	lobe
9 RTA:	ped	vs	car 6	days 12 1-24	hrs superficial	injuries
R	occipital	fracture	and	
haematoma,	R	frontal	
contusion
Contusions	overlying	both	orbits,	microbleeds	R	
parietal	lobe
10 Assault 48	hrs 15 NK nil
R	occipital,	R	medial	maxillary,	
L	zygomatic	arch	and	nasal	
bone	fractures,	small	SDH
Normal
11 RTA:	ped	vs	car NK 14 NK
knee	dislocation,	
4th	nerve	palsy Contusion	occipital	lobe
Parafalcine	microbleeds	more	marked	on	R	than	L,	
medial	temporal	lobes,	right	thalamus,	DAI	thalamus
12 RTA:	ped	vs	car <24	hrs NK <1	hr superficial	injuries
R	frontal	and	subdural	blood,	
small	R	frontal	contusion,	SAH	
R	temporal	sulci,	L	occipital	
fracture
Extensive	R	cortical	damage,	small	microbleed	R	
parietal	lobe	and	R	inferior	frontal	lobe,	superficial	
siderosis	R	frontal	cortex.	Small	area	of	mature	
gliotic	damage	L	inferior	cerebellum	?old	infarct
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Table	7-5	Baseline	characteristics:	symptoms	following	TBI,	past	medical	history	and	
medications	at	first	visit		
	
BPPV=Benign	paroxysmal	positional	vertigo,	SIADH=syndrome	of	inappropriate	ADH	production,	
GORD=gastro-oesophageal	reflux	disease,	CKD=chronic	kidney	disease		
Participant	
no. Symptoms	following	TBI Other	PMH
Medication	at	time	of	first	research	
visit	
Stopped	
working	after	
injury
1 Diplopia Nil Vitamin	D	1000	units yes
2
Attention,	memory	,	switching,	planning,	
disinhibition,	depression,	anxiety,	social	
withdrawal,	sleep	disturbance,	microsomia,	fatigue,	
GHD,	testosterone	
deficiency,	osteopenia
GH	0.2	mg	sc	last	3.5	years,	modafinil	
20mg,	citalopram	20mg	od,	nebido	1g	
12	weeks
no
3
Attention,	information	processing,	fatigue,	
headaches,	sleep	disturbance,	anosmia,	irritability,		
hearing	loss,	
GORD
Gabapentin	900mg		od,	omeprazole	
40mg	od,	Vit	D	1000	units no
4 Attention,	fatigue,	memory,	labile	mood,	BPPV Renal	colic nil yes
5
Slowed	thinking,	memory,	lack	of	insight,	
personality	change Nil Nil no
6 Memory,	sleep	disturbance
SIADH,	hypertension,	
dyslipidaemia,	Vitamin	
D	deficiency,	COPD
demeclocycline	300mg	bd,	ramipril	5mg	
od,	simvastatin	40mg	od,	salbutamol	2-
3	times	pw,	vit	D	1000	units/day	
yes
7 BPPV nil nil no
8
Slowed	thinking,	impaired	attention,	memory	
impairment,	headaches,	anosmia,	 Back	pain	 Regular	neurofen	 no
9
Single	seizure,	memory,	attention,	anosmia,	
anxiety,	sleep	disturbance
ACTH	deficiency,	TMJ	
dysfunction,	dyspepsia Hydrocortisone	20mg	od no
10
Absence	seizures,	irritability,	sleep	disturbance,	
memory,	executive	dysfunction knee	OA
Carbamazepine	200	mg	bd,	vit	d	1000	
units,	ibuprofen/paracetamol	2-3	times	
per	week
no
11 Possible	mood	disturbance nil nil yes
12
BPPV,	fatigue,	anosmia,	mood	disturbance,	sleep	
disturbance,	sexual	dysfunction
CKD,	hypertension,	
diabetes
Ramipril	2.5	mg,	metformin	500mg	bd,	
gliclazide	20	mg	od,	fybogel,	senna no
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Table	7-6	Baseline	characteristics:	metabolic	variables	in	TBI	patients		
			
					Values	in	red=abnormal	values	meeting	criteria	for	MetS	 	
Participant	
no.
BP	
systolic
BP	
Diastolic
Waist	
circumference	
(cm)
BMI Height	(cm) Weight	(kg) %body	fat Insulin	(ug/L)
C-peptide	
(ug/L)
SHBG	
(mmol)
HBA1c	
(mmol/mol)
Glucose	
(mmol/L) HOMA-IR
Cholesterol	
(mmol/L)
High	
density	
lipoprotein	
(mmol/L)
Low	
density	
lipoprotein	
(mmol/L)
Triglycerides	
(mmol/L) BP	meds Lipid	meds
Type	2	
diabetes MetS
1 131 75 94 28.7 168 81.0 24.7 11.8 857 26 38 5.6 1.56 6.5 1.21 4.68 1.34 no no no yes
2 114 67 93 25.8 174 78.2 20.2 7.9 690 13 37 5.2 1.04 5.2 0.94 3.25 2.22 no no no no
3 116 67 95 23.7 185 80.8 23.3 20.4 1731 23 36 5.0 2.59 6.0 0.81 4.17 2.25 no no no yes
4 114 65 76 23.0 177 72.1 14.6 6.0 436 38 34 4.7 0.77 7.4 1.33 5.62 1.00 no no no no
5 109 66 86 25.1 163 66.8 22.4 3.2 269 ND 38 5.1 0.42 7.1 1.34 5.20 1.23 no no no no
6 139 70 100 28.9 152 66.8 42.0 3.2 740 104 44 6.3 0.44 4.7 1.62 2.50 1.27 yes yes no yes
7 122 76 85 24.8 171 72.4 23.0 5.1 502 62 36 4.7 0.65 5.6 1.43 3.67 1.11 no no no no
8 116 64 85 29.6 164 79.7 35.4 6.0 553 155 33 4.7 0.77 5.4 1.47 3.54 0.86 no no no no
9 133 77 112 33.1 167 92.3 33.9 29.8 1464 13 53 8.0 4.13 5.4 0.83 3.41 2.55 no no yes yes
10 133 91 110 32.1 177 100.6 29.2 13.2 1089 27 33 5.4 1.73 5.4 1.05 3.89 1.02 no no no no
11 138 90 90 27.7 157 68.3 21.3 4.0 264 31 42 5.0 0.52 7.9 1.38 5.87 1.42 no no no no
12 158 64 101 30.9 169 88.3 30 5.9 694 49 43 7.3 0.84 6.0 1.96 3.36 1.49 yes no yes yes
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7.3.3 Blood	data		
	
One	patient	(Patient	4,	HAB,	see	Table	7-3)	was	excluded	from	this	analysis	as	it	was	not	
possible	to	place	an	arterial	line.	Therefore	11	TBI	patients	were	included	in	this	analysis	
(7	HAB,	4	MAB).	
	
For	the	whole	group,	median	parent	fraction	of	unchanged	tracer	was	0.72	[IQR	0.71-
0.77],	range	0.61-0.82.	There	was	no	difference	in	parent	fraction	between	HABs	and	
MABs	(P=1.0,	all	time	points)	and	there	was	no	significant	difference	in	weight	(P=0.24)	or	
injected	dose	(P=1.0)	between	HABs	and	MABs.		
	
For	the	whole	group,	median	plasma	radioactivity	of	[18F]GE-180	ranged	from	22.1	[IQR	
18.7-29.4]	range	14.4-51.7	KBq/mL	at	5	minutes	to	median	5.1	[IQR	4.4-8.8]	range	2.9-
16.0	KBq/mL	at	the	end	of	the	scan.	There	was	no	significant	difference	between	HABs	
and	MABs	at	all	time	points	(P=0.24).	
	
For	the	whole	group,	median	whole	blood	radioactivity	ranged	from	11.5	[IQR	10.2-16.8]	
range	8.5-28.2	KBq/mL	at	5	minutes	to	median	2.7	[IQR	2.3-4.5]	range	1.7-8.7	KBq/mL	at	
the	end	of	the	scan.	There	was	no	statistically	significant	difference	between	HABs	and	
MABs	(P=0.24).Figure	7-1.	
	
Plasma	over	blood	(POB)	ratio	is	also	presented	as	this	was	one	of	final	inputs	into	the	
arterial	input	function.	Median	whole	group	POB	ranged	from	1.75-1.85	at	all	time	points	
and	there	was	no	significant	difference	between	HABs	and	MABs.	Figure	7-2.	
	
Six	patients	had	arterial	blood	monitoring	at	baseline	and	follow-up.	Arterial	line	insertion	
was	not	possible	in	the	4	other	patients	at	follow-up	scan.	Data	are	displayed	by	individual	
patients	in	Figure	7-3	&	Figure	7-4.	
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Figure	7-1	Parent	fraction,	plasma	and	whole	blood	radioactivity	of	[18F]GE-180	in	11	
TBI	subjects	(Scan	1)		
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Figure	7-2	Plasma	over	blood:	whole	group	at	baseline	and	by	genotype	
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Figure	7-3	Comparison	of	blood	parameters	at	baseline	and	follow-up	scan	(patients	
2,3&5)		
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Figure	7-4	Comparison	of	blood	parameters	at	baseline	and	follow-up	scan	(patients	
6,9&10)	
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7.3.4 Tissue	Data			
SUV	images	for	a	representative	HAB	and	MAB	subject	are	shown	in	Figure	7-5	and	Figure	7-6.	
Tracer	uptake	appears	to	dominate	in	the	venous	sinuses.	Uptake	elsewhere	in	the	brain	appears	
to	be	low	and	symmetrical.	None	of	the	subjects	had	any	specific	foci	of	increased	uptake.					
Figure	7-5	Representative	HAB	subject	(Patient	1).	SUV	images	superimposed	on	T1	MRI	
brain	
	
	
	
	
Add	image	(30-end)	Add	image	(10-end)	 Add	image	(0-10)	 Add	image	(0-end)	 Add	image	(60-end)	
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Figure	7-6	Representative	MAB	subject	(Patient	10).	SUV	images	superimposed	on	T1	
MRI	brain	
			
7.3.5 Model	Fit		
From	the	previous	chapter,	the	2TC	(5%	fit	BV)	compartmental	model	was	deemed	the	
best	fit.	For	this	study,	the	2TC	(Fit	and	fix	BV)	and	the	1TC	(fit	and	fix	BV)	were	compared	
at	the	kinetic	modelling	stage.	The	2TC	(Fix	BV)	was	considered	the	best	fit.	There	was	a	
slight	discrepancy	in	the	model	fit	at	the	beginning	of	the	scan	as	was	seen	in	healthy	
controls.	The	2TC	model	fit	is	shown	for	each	patient	below.	Model	fit	is	applied	to	the	
whole	brain	tissue	TAC	generated	from	MIAKAT	(Figure	7-7).	
	
Add	image	(10-end)	 Add	image	(0-10)	 Add	image	(0-end)	 Add	image	(30-end)	 Add	image	(60-end)	
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Figure	7-7	2TC	(fix	BV)	model	fit	for	whole	brain	tissue	TAC	for	each	patient	for	duration	
of	scan		 	
Patient	1		
Patient	2	
	
Patient	3	
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Patient	5	
	
Patient	6	
	
	
Patient	7	
	
	
	
	
	
	
Patient	8	
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Patient	9	
	
Patient	10		
	
	
	
	
	
	
Patient	11	
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Patient	12	
	
	
	
	
7.3.6 Tracer	uptake	
	
Within	TBI	patients,	K1	ranged	from	0.008-2.39	ml/min	across	all	regions.	There	was	a	
trend	towards	MABs	having	a	lower	K1	than	HABs	in	the	striatum	(P=0.06)	but	there	was	
no	other	effect	of	genotype	or	metabolic	syndrome	on	K1	across	other	ROIs	Table	7-7	and	
Figure	7-8.	Within	HABs	only	there	was	no	difference	in	K1	between	HABs	and	MABs	
Figure	7-13.			
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Table	7-7	Table	demonstrating	2TC	rate	constants	K1-K4	in	TBI	patients	by	genotype		
	
	
	
	
	
	
	
	
	
HABs K1
P	HABs	
vs	MABs
K2
P	HABs	vs	
MABs
K3
P	HABs	vs	
MABs
K4
P	HABs	vs	
MABs
n 7 7 7 7
Frontal	Lobe 0.0087 0.55 0.1102 0.02 0.0276 0.02 0.0094 0.02
[0.0079-0.0113] [0.0948-0.1596] [0.0244-0.0329] [0.0053-0.0144]
Parietal	Lobe 0.0104 0.06 0.1335 0.24 0.0293 0.24 0.0066 0.24
[0.0096-0.0133] [0.1191-0.1770] [0.0245-0.0323] [0.0051-0.0127]
Temporal	Lobe 0.0129 0.06 0.1822 1.00 0.0478 1.00 0.0168 0.55
[0.0098-0.0194] [0.1476-0.2301] [0.0301-0.0646] [0.0121-0.0175]
Occipital	Lobe 0.0141 0.55 0.2528 0.24 0.0472 1.00 0.0162 0.55
[0.0161-0.4665] [0.2003-31.7664] [0.0362-0.0979] [0.0096-0.0186]
Thalamus 0.0142 1.00 0.1353 0.24 0.0417 0.24 0.0149 1.00
[0.0094-0.0745] [0.1210-21.6753] [0.0307-0.1652] [0.0101-0.0182]
Striatum 0.0081 0.06 1.7700 1.00 2.8427 0.24 0.0854 0.24
0.0044-0.0422 [0.6328-7.1387] [0.3940-4.8181] [0.0234-0.1304]
Cerebellum 0.0179 0.06 0.2220 1.00 0.0302 1.00 0.0142 0.55
[0.0142-0.5333] [0.1647-31.7753] [0.0267-0.0848] [0.0078-0.0172]
Hypothalamus	grey 0.0037 0.55 0.7070 0.24 6.0323 1.00 0.1620 1.00
[0.0033-0.0082] [0.6508-1.6766] [4.6810-7.0465] [0.1387-0.1689]
MABs K1 K2 K3 K4
n 4 4 4 4
Frontal	Lobe 0.0028 7.1624 5.9343 0.1436
[0.0010-0.0792] [1.0090-14.0856] [2.8968-6.6064] [0.0663-0.7196]
Parietal	Lobe 0.0030 0.5739 6.4566 0.0853
[0.0013-0.0058] [0.1708-1.4901] [2.6549-12599.4987] [0.0214-0.1374]
Temporal	Lobe 0.0048 0.7848 3.5199 0.0080
[0.0016-0.0076] [0.1473-7.3992] [0.0304-15304.2525] [0.0036-0.0770]
Occipital	Lobe 0.0237 5.4155 0.0627 0.0121
[0.0061-0.6691] [0.2756-36.2639] [0.0393-533.3176] [0.0010-0.1682]
Thalamus 0.0845 12.9516 3.4038 0.0206
[0.0019-0.4232] [3.7036-49.3591] [0.2325-12728.5189] [0.0093-0.0599]
Striatum 0.0013 1.7550 7.3367 0.2158
[0.0006-0.0026] [1.030-2.2570] [2.7557-25.5438] [0.1613-0.7595]
Cerebellum 0.0080 0.2414 0.0288 0.0056
[0.0039-0.0090] [0.1707-7.1481] [0.0239-4349.6958] [0.0020-0.6344]
Hypothalamus	grey 0.0017 6.1179 6.9653 0.1756
[0.0008-2.3905] [1.3386-222.3930] [1.6717-21.1234] [0.0829-0.9847]
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Figure	7-8	Rate	constant	K1	in	TBI	subjects	by	genotype	
				
7.3.7 Outcome	measures		
SUV	
Standardised	uptake	values	(SUV)	were	calculated	from	the	60-90	minute	add	image.	SUV	
values	ranged	from	0.3-0.8	and	there	was	no	difference	between	HABs	and	MABs	or	an	
interaction	of	binding	status	across	ROIs.	SUVR	was	calculated	using	CGM	and	again	there	
was	no	difference	in	SUVR	between	regions,	between	HABs	and	MABs	nor	was	there	an	
interaction	of	binding	on	Vt.	There	was	no	main	effect	of	metabolic	syndrome	for	either	
outcome	measure	and	no	group*ROI	interaction.	Figure	7-9.	
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Volume	of	distribution	(VT)	
Median	VT	ranged	from	0.12-0.33	mL/cm3	across	all	regions.	There	was	no	difference	in	
VT	across	regions	(P=0.20),	no	main	effect	of	binding	status	(p=0.20)	or	interaction	of	
binding	status	on	VT	(0.20).		There	was	no	main	effect	of	metabolic	syndrome	on	VT	
(P=0.48)	or	a	group*ROI	VT	interaction	(P=0.47).	Figure	7-10.	
	
DVR	and	SRTM	
There	was	no	difference	in	DVR	or	SRTM	across	regions,	no	main	effect	of	binding	status	
or	interaction	of	binding	status	on	either	outcome	measure.		There	was	no	main	effect	of	
metabolic	syndrome	on	either	outcome	measure	or	a	group*ROI	interaction.	Figure	
7-11.		
	
Longitudinal	analyses	
Individuals	VT	plots	are	shown	in	Figure	7-12.	There	was	no	significant	difference	
between	VT	at	follow	up	compared	to	baseline	scan	across	all	regions.	
	
Comparison	of	VT	in	Patients	vs.	controls	
For	this	analysis	11	controls	and	11	patients	were	analysed.	There	was	no	difference	in	K1	
between	ROI,	no	main	effect	of	binding	status	(P=0.45)	and	no	interaction	of	binding	
status	on	K1	(P=0.42).	For	VT,	there	was	no	difference	in	VT	between	region	(P=0.33),	no	
main	effect	of	binding	status	(P=0.33)	and	no	genotype	group*VT	interaction	(P=0.33).	
Figure	7-13.	
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Figure	7-9	SUV	and	SUVR	(from	60-90	min	summed	image)	in	TBI	patients	by	genotype	 	
	
Figure	7-10	Volume	of	distribution	in	TBI	patients	by	genotype	
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Figure	7-11	Distributed	volume	ratio	(DVR)	and	simplified	reference	tissue	model	
(SRTM)	in	TBI	patients	by	genotype	
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Figure	7-12	Comparison	of	VT	between	scan	1	and	scan	2	(patients	2,3,5,6,9,10)	
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Figure	7-13	Comparison	of	VT	and	K1	in	Patients	vs.	Controls		
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8 Discussion		
This	preliminary	work	describes	the	behaviour	of	the	novel	tracer	[18F]-GE-180	in	11	
patients	following	a	TBI.	The	work	here	follows	on	from	the	previous	chapter	where	the	
kinetic	behaviour	of	the	tracer	was	described	in	10	healthy	volunteers.	The	main	aims	of	
this	chapter	were	to	investigate	whether	the	2TC	compartmental	model	provided	the	best	
fit	to	the	data,	whether	the	TSPO	polymorphism	affected	outcome	measures	and	whether	
patients	had	higher	TSPO	binding	compared	to	controls.	The	secondary	aims	were	to	
determine	whether	the	metabolic	syndrome	influenced	outcome	measures	and	whether	
binding	measures	changed	over	time.		
	
The	2TC	model	did	provide	the	best	fit	to	the	data	as	was	found	in	healthy	volunteers.	
Again	there	was	a	minor	discrepancy	in	model	fit	at	the	start	of	the	scan	and	this	is	likely	
due	to	effects	of	dispersion	of	the	tracer.	However	early	discrepancies	are	unlikely	to	have	
an	effect	of	outcome	measures	which	are	generally	speaking	calculated	from	the	later	
portion	of	the	curve	or	is	an	integral	of	the	area	under	the	curve.	
	
In	the	blood,	[18F]-GE-180	appears	to	have	favourable	kinetics	in	that	the	parent	fraction	
of	tracer	ranges	from	0.9-0.7	throughout	the	duration	of	the	scan	and	the	plasma	over	
blood	ratio	of	approximately	1.8	suggests	good	availability	of	plasma	bound	tracer.	
However	we	did	not	measure	plasma	proteins	so	cannot	be	certain	of	the	availability	of	
bound	vs.	unbound	tracer.	There	were	up	to	4	identifiable	metabolites	as	was	seen	in	
healthy	subjects,	however	I	cannot	report	on	their	polarity	as	this	was	not	tested.	There	
was	no	difference	between	HABs	and	MABs	in	blood	kinetics.	In	the	individuals	who	have	
two	scans	6	months	apart	(6	patients)	there	was	noticeable	variability	between	the	
plasma	over	blood	ratios	at	both	time	points.	This	could	be	due	to	a	number	of	factors	
including	patient	factors	but	also	factors	relating	to	the	tracer	i.e.	tracer	mass,	purity	etc.	
Given	the	variability,	this	suggests	that	blood	data	should	be	sought	at	every	time	point	
within	an	individual.			
Late	SUV	images	(i.e.	60-90	mins)	demonstrate	generalised	low	uptake	of	tracer	and	a	
high	blood	signal	volume	as	was	seen	in	healthy	volunteers.	The	time	stability	analysis	in	
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the	previous	study	suggested	that	a	90	minute	scanning	window	may	not	be	sufficient	to	
derive	reliable	outcome	measures	at	90	mins,	and	therefore	this	should	be	born	in	mind	
when	considering	tissue	data	and	outcome	measures	at	90	mins.	
	
The	rate	constants	K1-K4	were	derived	from	the	2TC	model.	K1,	the	first	rate	constant	and	
measure	of	tracer	uptake	was	low	(i.e.	<0.01	ml/min)	throughout	all	ROIs	irrespective	of	
genotype.	K1	was	not	different	between	patients	and	controls.	This	was	surprising	given	
that	I	anticipated	that	there	may	be	some	BBB	breakdown	in	patients	which	would	
increase	K1.	The	majority	of	patients	I	selected	had	had	a	moderate	to	severe	injury	but	
perhaps	their	injury	was	not	severe	enough	or	recent	enough	to	predispose	to	BBB	
breakdown.	It	is	also	not	clear	from	the	literature	whether	TBI	can	lead	to	BBB	breakdown	
in	the	subacute	phase.	
	
Volume	of	distribution	was	<1	mL/cm3	throughout	all	regions.	This	is	an	extremely	low	VT	
and	questions	the	ability	of	[18F]-GE-180	to	quantify	TSPO	concentrations	in	the	brain.	
There	was	no	significant	effect	of	binding	status	on	VT	but	this	was	a	very	small	sample	of	
patients	(n=11).	There	was	no	difference	in	VT	between	patients	and	controls	in	this	study.	
The	likely	reason	for	this	is	that	[18F]-GE-180	is	a	substrate	for	a	BBB	transporter	affecting	
uptake	and	VT.	Another	explanation	is	that	TSPO	expression	in	the	healthy	brain	and	in	
these	TBI	patients	is	truly	low	and	other	diseases	that	elicit	a	more	powerful	TSPO	
response	e.g.	active	MS,	should	be	studied	with	this	tracer	before	we	draw	any	further	
conclusions.	
	
In	the	subset	of	patients	of	had	two	scans	6	months	apart	there	appeared	to	be	no	
dynamic	change	in	VT	and	this	is	not	surprising	given	the	known	limitations	of	the	tracer.	
	
My	original	hypothesis	was	to	study	the	effect	of	metabolic	syndrome	on	
neuroinflammation	following	TBI.	Whilst	the	appropriate	analyses	were	performed	to	
investigate	this,	the	now	known	limitations	of	this	tracer	mean	that	the	original	
hypothesis	was	premature	and	may	have	been	better	investigated	using	an	alternative	
TSPO	tracer	such	as	[12C]PBR-28.	However,	other	tracers	are	extremely	expensive	and	this	
may	not	be	appropriate	either.	
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In	conclusion,	the	2TC	compartmental	model	best	describes	the	kinetic	behaviour	of	[18F]-
GE-180	in	vivo.	Uptake	and	distribution	of	the	tracer	is	low	in	both	healthy	subjects	and	in	
this	small	study	of	TBI	patients.	There	appeared	be	no	effect	of	the	TSPO	polymorphism	of	
or	the	metabolic	syndrome	on	outcome	measures.	The	most	likely	explanation	for	low	
uptake	and	distribution	is	due	to	[18F]-GE-180	being	a	substrate	for	a	BBB	transporter.	
Therefore	the	tracer	may	still	be	suited	to	diseases	with	significant	BBB	breakdown.		
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9 Main	discussion	
9.1 Results	summary	
	
TBI	is	major	public	health	problem	and	one	which	is	often	under-represented	amongst	the	
medical	community.	Cognitive	and	psychological	disability	following	TBI	leads	to	
occupational	loss,	relationship	breakdown	and	huge	impairment	in	quality	of	life	for	these	
individuals.	Given	the	relative	lack	of	targeted	treatments	for	the	deficits	following	TBI,	
one	management	approach	would	be	to	identify	the	predictors	of	good	recovery	and	
adjust	modifiable	risk	factors	leading	to	a	poorer	prognosis.		
	
Pituitary	dysfunction	following	TBI	has	attracted	a	lot	of	attention	in	the	last	decade	
especially	due	to	the	wide	prevalence	(at	least	reported	initially)	and	the	prospect	of	
offering	hormonal	replacement	as	treatment	options.	GHD,	the	most	commonly	reported	
abnormality	(likely	due	to	somatotroph	cells	being	located	on	the	outside	of	the	pituitary	
gland)	can	be	treated	with	GH	injections.	This	treatment	option	not	only	has	the	
advantage	of	treating	the	underlying	condition	but	also	potentially	has	a	positive	effect	on	
cognition	and	quality	of	life	as	is	seen	outside	of	TBI.	
	
Several	studies	have	reported	a	prevalence	of	pituitary	dysfunction	to	be	in	the	region	of	
10%	and	this	is	consistent	with	our	own	(unpublished)	experience	in	the	multidisciplinary	
TBI	clinic	at	St	Mary’s	Hospital.	However,	in	the	third	chapter	of	this	thesis,	we	have	
identified	as	special	group	of	patients	who	have	a	particularly	high	prevalence	of	pituitary	
dysfunction.		Soldiers	who	have	been	exposed	to	an	IED	blast	explosion	during	warfare	
appear	to	have	a	much	higher	prevalence	of	pituitary	dysfunction	than	those	individuals	
who	have	been	exposed	to	non-blast	TBI	as	a	result	of	assaults	or	road	traffic	accidents	for	
example.		In	a	group	of	19	soldiers,	6	had	evidence	of	pituitary	dysfunction	compared	to	
1/39	with	nbTBI.	
	
Focussing	specifically	on	the	GH/IGF-1	axis	as	this	is	the	most	commonly	affected	pituitary	
abnormality	following	TBI,	I	report	some	interesting	results	in	chapters	4	and	5.	Baseline	
serum	IGF-I	appears	to	predict	white	matter	recovery	in	the	splenium	of	the	corpus	
callosum	and	higher	levels	of	IGF-I	at	baseline	lead	to	a	greater	improvement	in	memory	
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function	over	time.	In	patients	who	received	GH	replacement	to	treat	GHD	over	a	period	
of	approximately	one	year,	there	was	no	observable	effect	on	white	matter	recovery	and	
cognition	but	there	was	a	highly	significant	improvement	in	depression	scores	and	quality	
of	life	following	treatment.	
	
The	second	half	of	this	thesis	addresses	neuroinflammation	following	TBI.	The	original	
hypothesis	was	that	the	metabolic	syndrome	which	fuels	a	low	grade	systemic	
inflammatory	environment	may	modulate	inflammation	in	the	CNS.	Microglia,	the	
resident	macrophage	in	the	CNS	express	TSPO	when	in	the	activated	state.	TSPO	
expression	by	microglia	is	exploited	by	many	PET	tracers	designed	to	bind	to	the	TSPO		
receptor	and	is	therefore	considered	to	be	a	reliable	marker	of	neuroinflammation.	
	
In	chapter	6,	I	used	the	novel	fluorinated	tracer	[18F]GE-180	to	measure	TSPO	
inflammation	in	the	healthy	brain.	This	study	was	performed	with	two	aims	in	mind,	to	
evaluate	the	kinetics	of	this	new	tracer,	which	were	not	known	prior	to	this	study	and	to	
determine	whether	there	was	a	difference	in	binding	between	individuals	who	expressed	
a	genetic	polymorphism	for	TSPO.		The	2TC	compartmental	model	provided	the	best	fit	for	
the	data.	Overall	uptake	of	the	tracer	was	very	low	with	an	extraction	rate	of	~1%	which	
was	also	reflected	in	a	low	volume	of	distribution	throughout	many	brain	regions.	There	
was	no	significant	difference,	in	this	study,	in	outcome	measures	between	high-affinity	
and	mixed	affinity	binders.	
	
Despite	the	limitations	of	this	tracer,	in	the	final	chapter	I	evaluate	[18F]GE-180	in	TBI	
patients	using	the	2TC	model.	First	pass	extraction	remained	low	and	there	was	no	
difference	in	outcomes	measures	between	HABs	and	MABs.	There	was	no	effect	of	the	
metabolic	syndrome	on	outcome	measures	in	this	small	study.	
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9.2 Main	findings		
9.2.1 Prevalence	of	pituitary	dysfunction	is	significantly	higher	in	blast	TBI	
compared	to	non-blast	TBI			
The	prevalence	of	pituitary	dysfunction	is	significantly	higher	in	bTBI	than	nbTBI	(31.6%	vs.	
2.6%,	P=0.004).		There	was	a	trend	toward	greater	PTA	(P=0.10)	and	higher	AIS	head	injury	
scores	(P=0.006)	in	soldiers	who	did	vs.	those	who	did	not	have	pituitary	dysfunction.	
There	was	a	significantly	higher	prevalence	of	skull/facial	fractures	in	those	with	pituitary	
dysfunction	(P=0.02)	and	this	could	be	an	important	predictor	of	the	condition	however	
half	the	soldiers	who	had	pituitary	dysfunction	had	no	evidence	of	facial/skull	fractures.	
On	cross-sectional	analysis	there	was	significantly	lower	FA	in	the	body,	genu	and	
splenium	of	the	corpus	callosum	in	soldiers	with	and	without	pituitary	dysfunction.	In	
addition	soldiers	with	the	condition	fared	worse	in	multiple	cognitive	domains	and	
trended	towards	worse	QoL	than	those	who	did	not	have	the	condition.	
	
This	novel	finding	which	has	now	been	published	highlights	a	important	group	of	patients	
who	have	potentially	treatable	conditions.	This	study	was	not	able	to	answer	about	why	
bTBI	appears	to	pre-dispose	to	pituitary	dysfunction	more	than	nbTBI	so	we	can	only	
speculate.	The	blast	wave	may	predispose	to	increased	acceleration-deceleration	forces	
which	could	precipitate	shear	injury	in	the	region	of	the	hypothalamus-pituitary	gland.	
Vascular	damage	could	lead	to	hypoxic/ischaemic	damage	and	BBB	breakdown	which	
could	also	lead	to	pituitary	autoimmunity.	
	
Given	the	high	prevalence	of	the	condition	our	recommendation	was	to	fully	investigate	
all	people	with	moderate	to	severe	bTBI	and	to	comprehensively	screen	for	the	condition	
in	those	with	lower	severity	categories	of	bTBI.	Following	this	finding	we	disseminated	this	
information	to	our	colleagues	at	the	Defence	Medical	Rehabilitation	Centre	(DMRC)	at	
Headley	Court	and	the	multidisciplinary	TBI	clinic	at	St	Mary’s	Hospital	continue	to	receive	
referrals	via	this	route.		
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9.2.2 FA	is	greater	in	the	SPCC	and	logical	memory	scores	are	higher	at	
follow-up	in	those	patients	with	a	higher	IGF-I	at	baseline		
In	this	longitudinal	DTI	study	of	39	TBI	patients,	FA	was	greater	at	follow-up	in	the	SPCC	in	
those	who	had	a	baseline	IGF-I	level	above	the	median	of	the	age-adjusted	reference	
range	(IGF-I	group	x	time	interaction	F(1,37)=4.62	P=0.038).	Logical	memory	score	at	visit	
2	was	also	significantly	higher	in	these	individuals	(IGF-I	group	x	time	interaction	
F(1,26)=4.38	P=0.046).	This	result	appears	to	be	consistent	with	studies	in	stoke	where	a	
higher	IGF-I	at	baseline	leads	to	better	neurological	and	functional	outcomes	at	follow-up.	
Mechanistically	this	seems	plausible	as	well	given	that	IGF-I	is	a	trophic	factor	involved	in	
the	turnover	of	oligodendrocytes.		
	
Although	IGF-I	above	and	below	the	median	of	the	age-adjusted	reference	range	is	a	fairly	
crude	categorisation	and	one	which	has	no	real	clinical	meaning,	we	felt	it	was	a	good	
surrogate	for	examining	the	effect	of	GHD	as	at	the	time	of	carrying	out	the	study	only	4	
patients	had	confirmed	GHD.	In	a	sub-analysis	of	GHD=4,	the	presence	of	GHD	appeared	
to	have	no	influence	on	FA	or	cognition.		
	
This	chapter	also	highlighted	two	other	important	findings	unrelated	to	endocrine	
variables.	I	reported	that	TBI	patients	have	widespread	reductions	in	FA	throughout	the	
whole	brain	compared	to	healthy	controls.	I	also	report	that	over	time	(i.e.	Between	the	
two	study	visits),	FA	does	increase	throughout	many	regions	of	the	brain.	This	is	important	
as	demonstrating	that	recovery	from	TBI	on	a	microstructural	level	is	a	dynamic	process	
and	one	that	is	reflected	in	cognitive/psychological	recovery	and	one	that	may	be	
amenable	to	manipulation.	Increasing	IGF-I	may	be	one	potential	factor	that	could	
improve	white	matter	recovery	in	key	areas	of	the	brain	which	are	commonly	affected	in	
TBI.		
		
9.2.3 GH	replacement	appears	to	have	no	effect	on	FA	and	cognition	
following	TBI	but	does	significantly	improve	QoL	and	reduce	
symptoms	of	depression	
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This	small	study	of	10	patients	diagnosed	with	GHD	following	TBI	who	were	then	treated	
with	GH	replacement	for	a	median	duration	of	14	months	were	compared	to	group	of	23	
TBI	patients	who	had	no	evidence	of	GHD	and	who	did	not	receive	and	GH.	There	
appeared	to	be	no	influence	of	group	on	FA	over	time	in	three	key	regions	including	the	
SPCC	and	no	effect	either	on	cognitive	variable	including	logical	memory.	This	was	
surprising	as	given	IGF-I	group	appears	to	affect	FA	in	the	SPCC	and	memory	we	were	
expecting	that	raising	GH/IGF-I	levels	with	exogenous	treatment	would	influence	these	
factors.	However	a	group	of	10	patients	may	be	too	small	a	sample	to	expect	to	see	a	
significant	effect	of	GH	replacement.	Encouragingly,	from	visually	looking	at	the	data,	it	
did	appear	that	the	group	who	received	GH	replacement	appeared	to	be	going	in	the	
direction	of	FA	improvement	rather	than	reduction.	Increasing	the	sample	size	and/or	
performing	scans	at	later	time	points	e.g.	after	2-3	years	on	GH	replacement,	may	be	the	
basis	for	future	studies	and	may	be	warranted	before	we	conclude	that	GH	replacement	
has	no	beneficial	effects	on	cognition	or	white	matter	recovery	following	TBI.		
However	there	was	a	significant	improvement	in	QoL	as	measured	by	AGHDA-QoL	
following	GHR	(t=-3.8,	df	=9,	P=0.004,	two-tailed)	and	an	even	more	impressive	reduction	
of	depressive	symptoms	(mean	point	reduction	12.7)	following	GHR	(t=-5.2,	df	=	9,	
P=0.001,	two-tailed).	This	probably	justifies	the	use	of	GHR	treatment	in	patients	with	
GHD	following	TBI	and	could	have	far-reaching	effects	on	occupational	status,	preserving	
relationships	and	increasing	motivation	to	engage	with	rehabilitation	services.	
	
In	keeping	with	what	is	seen	outside	of	TBI,	patients	with	GHD	had	greater	insulin	
resistance	and	worse	metabolic	score	compared	to	those	who	did	not.	There	was	a	trend	
towards	improvement	in	metabolic	score	following	GHR	but	insulin	resistance	did	not	
appear	to	improve	with	GHR.	This	again	may	be	due	to	a	too	short	a	study	period	but	it	
may	be	that	any	metabolic	amelioration	with	GHR	may	be	outweighed	by	a	potentially	
more	sedentary	environment	in	the	initial	recovery	period	following	TBI.	
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9.2.4 The	kinetics	of		[18F]GE-180	are	best	described	by	the	2TC	model	and	
there	is	no	effect	of	the	TSPO	Ala147Thr	polymorphism	on	
distribution	volume	outcome	measures	in	the	healthy	human	brain		
This	chapter	presents	one	of	the	first	studies	using	the	novel	TSPO	ligand	[18F]GE-180	in	
the	healthy	human	brain.	This	study	has	now	been	published	in	the	European	Journal	of	
Nuclear	Medicine	and	Molecular	Imaging	(Feeney	et	al.,	2016).	This	purpose	of	the	study	
was	to	evaluate	the	kinetics	of	this	tracer	in	the	healthy	human	brain	prior	to	its	
evaluation	in	TBI.	
	
Several	compartmental	models	were	applied	to	the	data	and	the	2TC	model	with	a	5%	
fixed	blood	volume	was	the	most	parsimonious.	There	was	a	slight	discrepancy	in	model	
fit	at	the	start	of	the	scan	and	this	may	have	been	due	to	effects	of	dispersion.	There	was	
a	very	low	first	pass	extraction	of	the	tracer	in	the	region	of	1%	and	this	is	likely	to	be	due	
to	[18F]GE-180	being	a	substrate	for	an	as	yet	unknown	BBB	transporter.	Within	the	brain	
the	blood	component	of	tracer	distribution	was	particularly	high	at	around	20%.	Volume	
of	distribution	was	<1	throughout	all	brain	regions.	These	characteristics	of	the	tracer	
were	disappointing	findings	and	could	not	have	been	predicted	from	pre-clinical	work	
where	[18F]GE-180	appeared	to	have	greater	specific	binding	and	less	non-specific	binding	
compared	to	PK[11195].	
	
There	was	no	significant	effect	of	the	TSPO	polymorphism	(between	HABs	and	MABs,	not	
LABs)	on	distribution	volume	measures	in	this	study.	However,	given	that	VT	was	very	low,	
it	would	be	difficult	to	say	with	certainty	that	there	is	no	effect	of	TSPO	genotype	as	in	
disease	states	or	where	there	is	greater	uptake	of	the	tracer	due	to	BBB	breakdown,	
differences	between	genotype	may	emerge.	
	
Another	important	finding	was	the	time	stability	analysis	that	showed	that	VT	was	still	
rising	throughout	the	90	minute	duration	of	the	scan	and	too	short	a	scan	duration	may	
also	be	contributing	factor	to	low	distribution	volumes.	
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9.2.5 There	is	no	difference	in	the	volume	of	distribution	of	[18F]-GE-180	in	
TBI	patients	compared	to	controls		
In	this	preliminary	small	study	of	TBI	patients,	[18F]-GE-180	uptake	and	volume	of	
distribution	was	no	different	between	patients	and	controls	and	there	was	no	effect	of	
genotype	or	of	metabolic	syndrome	on	the	outcome	measures	studied.		
	
The	2TC	model	provided	the	best	model	fit	to	the	data	as	was	seen	in	healthy	volunteers	
and	there	were	favourable	blood	kinetics.		
	
More	work	in	needed	in	a	larger	TBI	sample	and	in	other	diseases	known	to	cause	
significant	BBB	breakdown	to	further	evaluate	this	tracer.		
	
9.3 Limitations		
There	are	several	limitations	to	the	interpretation	of	the	data	presented	in	this	thesis.	
Firstly,	the	study	in	Chapter	3,	Pituitary	Dysfunction	after	Blast	Traumatic	Brain	Injury	(bTBI)	was	by	its	design	a	retrospective	case-control	study	which	means	that	although	
every	effort	was	made	to	match	the	groups	as	much	as	possible,	there	were	factors	
(mainly	environmental)	that	could	not	be	controlled	for.	For	this	reason,	although	we	
make	an	interesting	observation,	it	was	not	made	in	the	context	of	a	randomised	
controlled	trial.		
	
The	major	limitation	to	Chapter	4	Association	of	serum	IGF-I	with	white	matter,	neuropsychological	and	cognitive	recovery	following	traumatic	brain	injury,	was	that	I	
could	not	find	an	association	with	IGF-I	and	FA	using	the	whole	brain	analysis	approach	
and	neither	was	there	a	correlation	between	delta	FA	at	the	corpus	callosum	and	IGF-I.	
This	potentially	undermines	the	association	we	found	between	FA	at	the	SPCC	and	IGF-I.	
	
For	the		Chapters	5	&	7,	the	major	limitations	relate	to	the	small	numbers	enrolled	in	the	
two	studies	with	the	potential	for	there	to	be	significant	type	II	errors.	We	hope	to	
address	this	by	adding	to	these	datasets	and	re-analysing	the	data	prior	to	publication.	
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9.4 Conclusion		
The	aim	of	this	thesis	was	to	investigate	the	role	of	hormones	and	metabolic	factors	in	the	
recovery	from	TBI.	The	findings	that	pituitary	dysfunction	(mainly	GHD)	has	a	high	
prevalence	in	blast-TBI,	that	a	high	IGF-I	at	baseline	may	enhance	recovery	following	TBI	
and	that	GH	replacement	improves	QoL	and	reduces	depression	all	highlight	the	
importance	of	endocrine	factors	following	TBI.	The	work	here	provides	some	foundation	
for	future	studies	investigating	the	role	of	hormone	replacement	on	recovery	from	TBI	
and	other	neurological	conditions.			
I	had	hoped	to	also	explore	the	role	of	the	metabolic	syndrome	in	the	recovery	from	TBI	
and	on	neuroinflammation	per	se.	However	the	novel	TSPO	tracer	[18F]-GE-180	which	had	
promising	pre-clinical	results	appears	to	be	limited	by	low	uptake	and	distribution	
volumes.	Instead,	this	thesis	has	detailed	one	of	the	first	kinetic	analyses	of	this	tracer	in	
healthy	brain	and	in	a	preliminary	study	of	TBI	patients.	This	work	will	be	of	use	to	
researchers	using	or	planning	to	use	[18F]-GE-180	in	their	studies.		
	
10 Future	Directions			
Arising	from	this	thesis,	there	are	several	datasets	that	I	would	like	to	expand	upon	and	
interrogate	further.	I	would	like	to	work	more	on	the	data	presented	in	Chapter	5	(The	effect	of	GH	replacement	therapy	on	the	recovery	from	TBI).	In	particular	I	would	like	to	
analyse	repeated	QoL	measurements	in	patients	taking	GH	to	establish	whether	the	
positive	effect	on	QoL	is	sustained.	Ideally	I	would	like	to	add	more	people	to	this	study	as	
n=10	may	be	too	small	to	answer	the	question	about	GH	replacement	on	WM	recovery.	In	
addition	I	would	like	to	do	additional	analyses	such	as	voxel	based	morphometry	
especially	as	data	is	available	to	do	this.	Time	permitting,	I	would	like	to	publish	this	work,	
(even	if	we	find	no	effect	on	WM	recovery)	as	there	is	little	in	the	literature	that	answers	
questions	about	GH	replacement	in	adults	following	TBI.	
	
Regarding	the	TSPO	PET	chapters,	I	hope	to	continue	to	work	closely	with	other	
researchers	using	this	tracer	to	determine	whether	there	is	increased	TSPO	signal	in	brain	
injured	patients.	Unfortunately	I	was	not	able	to	specifically	answer	the	question	about	
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whether	the	metabolic	syndrome	influences	the	recovery	from	TBI.	However	I	do	think	
body/brain	interactions	are	an	important	area	of	research	and	ideally	I	would	set	about	
answering	this	question	in	different	ways	e.g.	designing	a	large	observational	study	to	look	
for	correlations	between	markers	of	insulin	resistance	and	functional	outcome	from	TBI.			
	
More	broadly,	I	hope	I	am	able	to	apply	the	skills	learnt	during	my	PhD	and	utilise	them	
during	my	return	to	clinical	training	in	Endocrinology	and	Diabetes	with	a	view	to	paving	
new	research	avenues	in	the	field	of	clinical	neuroendocrinology.		 	
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Dear	Editors,	
	
The	possibility	of	human-human	transmission	of	Alzheimer’s	disease	(AD)	has	never	been	
considered	until	recently.	A	landmark	study,	published	in	September	2015	in	Nature,	
reports	the	probable	seeding	of	β-amyloid	(a	pathological	hallmark	of	AD)	from	cadaveric	
human	growth	hormone	(c-hGH)	pituitary	preparations	who	also	developed	iatrogenic	
Creutzfeldt-Jakob	Disease	(iCJD)	from	the	same	source	(Jaunmuktane	et	al.,	2015).	Here,	
we	argue	that	c-hGH	was	historically	used	to	treat	rare	neuroendocrine	disease	and	that	
these	diseases	or	treatment	with	GH	could	result	in	β-amyloid	pathology	per	se.	Without	a	
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control	group	of	the	same	patient	cohort	who	neither	received	c-hGH	nor	developed	iCJD,	
we	believe	that	the	authors	are	premature	to	infer	an	iatrogenic	source	of	AD.	
	
Cadaveric-hGH	was	previously	used	to	growth	hormone	deficiency	(GHD)	in	children.	In	
the	UK,	GH	was	extracted	from	a	cadaveric	pool	of	approximately	400,000	pituitary	glands	
and	offered	as	an	intramuscular	treatment	to	selected	patients.	Given	scarce	resources	
and	laborious	extraction,	its	use	was	coordinated	in	the	UK	by	a	Medical	Research	Council	
working	party	in	1959	that	was	superseded	by	the	Health	Services	Human	Growth	
Hormone	Committee	in	1977	(Milner	et	al.,	1979).	In	the	UK,	1,908	people	were	registered	
as	having	received	c-hGH	from	1959	to	1985	when	it	was	withdrawn	worldwide	after	an	
initial	report	documenting	three	deaths	from	CJD	in	the	US	and	one	in	the	UK.	This	
number	rose	to	226	incidences	worldwide	in	2012	(Stagnaro,	2015).	From	1985	onwards	
c-hGH	became	obsolete	after	being	superseded	by	synthetic	recombinant	forms.	
	
The	diverse	clinical	indications	for	c-hGH	treatment	until	1985	are	clearly	presented	in	a	
comprehensive	epidemiological	review	which	utilised	data	from	the	Health	Services	
Human	Growth	Hormone	Committee	records	in	the	UK	(Buchanan,	Preece,	&	Milner,	
1991).	Of	the	1908	patients	registered	as	having	received	c-hGH	in	the	UK,	1004	(52.6%)	
had	‘idiopathic’	isolated	GHD,	188	(10%)	‘idiopathic’	panhypopituitarism,	230	(12.1%)	
craniopharyngioma,	194	(10.2%)	other	intracranial	tumour,	62	(3.3%)	other	neurological	
disease	e.g.	hydrocephalus,	post	meningitis	and	62	(3.3%)	genetic	short	stature	and	
growth	delay	or	both	and	44	(2.3%)	Turner’s	Syndrome.	The	remaining	causes	included	
Prader-Willi	syndrome,	low	birth	weight,	haematological	disease,	histiocytosis	and	septo-
optic	dysplasia.	These	well-recorded	historical	data	demonstrate	the	heterogeneity	and	
severity	of	neuroendocrine	disease	necessitating	c-hGH	treatment	in	the	UK	prior	to	1985.	
	
Supplementary	material	from	the	article	in	question	reports	the	clinical	details	of	all	8	
patients	and	the	indication	for	c-hGH	treatment,	summarized	in	Table	1.	All	patients	
received	c-hGH	as	children	or	adolescents	and	duration	of	treatment	was	for	2-12	years.	
From	an	etiological	perspective,	3/8	subjects	had	panhypopituitarism	(one	also	with	
mental	retardation	and	microcephaly),	1/8	craniopharyngioma	and	4/8	are	reported	to	
have	been	treated	for	short	stature	alone.	This	is	surprising	as	short	stature	alone	was	an	
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uncommon	indication	for	c-hGH	prior	to	1985,	although	trials	were	starting	to	emerge	for	
this	indication	just	prior	to	the	withdrawal	of	c-hGH(Poidvin	et	al.,	2014).	Short	stature	
should	not	be	confused	with	GHD	as	the	former	can	be	constitutional	and	the	latter	is	a	
neuroendocrine	disease	which	can	lead	to	short	stature.	It	is	therefore	likely	that	the	
‘short	stature’	group	disguises	a	more	complicated	clinical	picture.		
	
At	the	other	end	of	the	clinical	spectrum,	one	of	the	4	patients	reported	as	having	
moderate	to	severe	gray	matter	and	vascular	β-amyloid	pathology	had	a	
craniopharyngioma.	These	unusual	pituitary	tumours	can	be	large,	often	require	
neurosurgery	and/or	cranial	radiation	and	are	prone	to	recurrence	and	multiple	pituitary	
hormone	deficiencies.	Interestingly,	the	one	patient	in	the	sporadic	CJD	control	group	
(aged	65	yrs.	approx.)	who	also	had	similar	levels	of	cerebral	amyloid	angiopathy	(CAA)	to	
the	iCJD	group	was	labelled	as	an	outlier	and	it	was	commented	that	the	subject	had	a	
surgical	intervention	40	years	before	death	(Jaunmuktane	et	al.	Extended	Data	Figures	
2&3).	
	
Jaunmuktane	and	colleagues’	article	was	preceded	by	a	case	series	from	the	same	
research	group	of	the	clinical,	imaging,	molecular	and	autopsy	findings	of	the	whole	iCJD	
cohort	(n=22)(Rudge	et	al.,	2015).	One	patient	had	a	history	of	long	term	cognitive	
problems	and	additional	MRI	findings	included	one	patient	with	septo-optic	dysplasia	and	
partial	agenesis	of	the	corpus	callosum.	It	is	not	clear	whether	these	particular	patients	
were	the	ones	included	in	the	current	article,	but	together	with	the	historical	records	and	
the	supplementary	clinical	details	provided,	highlight	our	argument	that	these	patients	
had	complex,	rare	and	potentially	severe	neuroendocrine	disease.	
	
With	this	in	mind,	an	alternative	hypothesis	contributing	to	the	findings	is	that	these	pre-
existing	and	underlying	conditions	could	by	themselves	lead	to	β-amyloid	pathology	and	
abnormal	brain	structure.	GH	is	known	to	have	various	cognitive	effects	on	the	brain	and	
isolated	GHD	in	children	can	lead	to	lower	IQ,	impaired	cognition,	reduction	brain	volumes	
and	white	matter	abnormalities	(Nyberg	&	Hallberg,	2013;	Webb	et	al.,	2012).	If	GHD	
continued	into	adulthood	(as	it	usually	does)	and	was	untreated	then	significant	cognitive	
impairments	are	likely	to	have	persisted	(Rinderknecht	&	Humbel,	1978).		
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Traumatic	brain	injury	(TBI)	we	now	know	is	a	common	cause	of	GHD	in	children(Rose	&	
Auble,	2012)	and	this	may	not	have	been	widely	acknowledged	prior	to	1985.	TBI	has	
been	associated	with	widely	distributed	Aβ	deposition	in	post-mortem	brain	tissue	(Le	
Tissier	et	al.,	2012).	Other	neurological	diseases	including	epilepsy,	fragile	X	syndrome,	
Down’s	syndrome	and	Parkinson’s	disease	have	all	been	linked	with	significant	increased	
levels	of	amyloid	precursor	protein	(APP)	and	β-amyloid	protein	questioning	the	specificity	
of	this	neuropathology	to	AD.	Aβ	deposition	may	result	from	common	underlying	
processes	such	as	neuroinflammation,	microglial	activation	and	genetic	factors(Kokshoorn	
et	al.,	2010).	
	
The	authors	comment	on	the	striking	CAA	in	this	patient	group	and	hypothesize	that	these	
individuals	‘would	be	at	increasing	risk	of	cerebral	haemorrhages	had	they	lived	longer’.	
However,	large	long-term	follow	up	studies	of	children	who	received	recombinant	GH	
from	1985	onwards	(i.e.	no	risk	of	human-human	transmission)	were	found	to	have	a	5-7	
fold	increased	risk	of	cerebrovascular	disease	and,	in	particular,	subarachnoid	
haemorrhage,	suggesting	that	this	cohort	have	predisposing	factors	leading	to	increased	
risk	of	intracranial	haemorrhage,	irrespective	of	having	received	c-hGH(Carel	et	al.,	2012;	
Poidvin	et	al.,	2014).	
	
In	conclusion,	the	authors	present	an	interesting	finding	worthy	of	further	investigation,	
but	we	feel	that	caution	must	be	exercised	in	interpreting	the	result,	especially	in	the	
absence	of	an	appropriate	control	group.	We	believe	it	is	also	important	to	present	a	
neuroendocrinological	perspective	and	consider	plausible	alternative	hypotheses	to	offer	
a	balanced	view	on	this	high	profile	communication.	
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Table	1	
Patient		 Sex	 History	
Substantial	
Aβ	
Focal	
Aβ	
Aβ	
angiopathy	
1	 M	 GH	as	a	child	for	~5	years	for	panhypopituitarism	 No	 Yes	 No	
2	 F	
GH	as	a	child	for	~10	years	for	panhypopituitarism,	
mental	retardation	and	microcephaly	
No	 No	 No	
3	 M	 GH	as	a	child	for	~5	years	for	short	stature	 No	 Yes	 No	
4	 M	 GH	as	a	child	for	short	stature	from	~7	for	~12	years	 Yes	 No	 Yes	
5	 F	
Craniopharyngioma	aged	~10	years,	GH	from	11	
years	for	~8	years	
Yes	 No	 No	
6	 M	 GH	for	short	stature	from	~9	years	for	~5	years	 Yes	 No	 Yes	
7	 M	
GH	as	an	adolescent	for	~3	years	for	
panhypopituitarism	
No	 No	 No	
8	 M	
GH	for	restricted	growth	
from	16	years	for	~2	years	
Yes	 No	 Yes	
	
Summary	table	of	the	clinical	indications	for	c-hGH	treatment	in	childhood	and	incidence	of	
β-amyloid	for	each	patient	(adapted	from	article	text	and	supplementary	information)	
	
